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SLC12A3 Solute carrier family 12 (Na/K/Cl transporter),member 3 
SLC16A1 Solute carrier family 16 (monocarboxylate transporter), 
member 1 
SLC16A9 Solute carrier family 16 member 9 
SLC39A8 Solute carrier family 39 (metal ion transporter), member 8 
SLC4A7 Solute carrier family 4, sodium bicarbonate co-transporter, 
member 7 
SNPs Single nucleotide polymorphisms 
SOLAR Sequential Oligogenic Linkage Analysis Routines 
SOX6 Sex Determining Region Y-box 6 
SRMs Self-reported medications 
ST7L Suppression of tumorigenicity 7 like 
STK39 Serine threonine kinase 39 
TAL Thick ascending limb of Henle  
TBX3 T-Box 3 
TBX5 T-box 5 
TDT Transmission disequilibrium test  
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Tm Melting temperature  
TMEM133 Transmembrane protein 133 
TNNT3 Troponin T type 3 
ULK3 Unc-51 Like Kinase 3 
ULK4 Unc-51 like kinase 4 
UMOD Uromodulin gene  
VCL Vinculin  
VHL von Hippel-Lindau tumour suppressor 
WHO World Health Organization  
WNK1 Lysin deficient protein kinase 1 
WNK4 Serine-threonine protein kinase WNK4 
WTCCC Wellcome Trust Case Control Consortium  
YLD Years lived with disability  
YLS Years of life lost  
ZNF652 Zinc finger protein 652 
α Statistical significance level 
β Effect size 
κ Cohen’s Kappa Coefficients Statistics 
  
λR Relatives recurrence risk ratio 
λS Siblings recurrence risk ratio 
µl Microlitre 
σ2A Additive genetic component 
σ2E Environmental component 
σ2G Total genetic component 
σ2p Total phenotypic variance 
ρE Environmental correlation 
ρG Additive genetic correlation 
ρP Phenotypic correlation 
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Abstract+
Hypertension is a major risk factor for cardiovascular disease and mortality, and 
a growing global public health concern, with up to one-third of the world’s 
population affected. Despite the vast amount of evidence for the benefits of 
blood pressure (BP) lowering accumulated to date, elevated BP is still the 
leading risk factor for disease and disability worldwide. It is well established 
that hypertension and BP are common complex traits, where multiple genetic 
and environmental factors contribute to BP variation. Furthermore, family and 
twin studies confirmed the genetic component of BP, with a heritability 
estimate in the range of 30-50%. Contemporary genomic tools enabling the 
genotyping of millions of genetic variants across the human genome in an 
efficient, reliable, and cost-effective manner, has transformed hypertension 
genetics research. This is accompanied by the presence of international 
consortia that have offered unprecedentedly large sample sizes for genome-wide 
association studies (GWASs). While GWAS for hypertension and BP have 
identified more than 60 loci, variants in these loci are associated with modest 
effects on BP and in aggregate can explain less than 3% of the variance in BP.  
The aims of this thesis are to study the genetic and environmental factors that 
influence BP and hypertension traits in the Scottish population, by performing 
several genetic epidemiological analyses. In the first part of this thesis, it aims 
to study the burden of hypertension in the Scottish population, along with 
assessing the familial aggregation and heritialbity of BP and hypertension traits. 
In the second part, it aims to validate the association of common SNPs reported 
in the large GWAS and to estimate the variance explained by these variants. 
In this thesis, comprehensive genetic epidemiology analyses were performed on 
Generation Scotland: Scottish Family Health Study (GS:SFHS), one of the largest 
population-based family design studies. The availability of clinical, biological 
samples, self-reported information, and medical records for study participants 
has allowed several assessments to be performed to evaluate factors that 
influence BP variation in the Scottish population. Of the 20,753 subjects 
genotyped in the study, a total of 18,470 individuals (grouped into 7,025 
extended families) passed the stringent quality control (QC) criteria and were 
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available for all subsequent analysis. Based on the BP-lowering treatment 
exposure sources, subjects were further classified into two groups. First, 
subjects with both a self-reported medications (SRMs) history and electronic-
prescription records (EPRs; n =12,347); second, all the subjects with at least one 
medication history source (n =18,470). In the first group, the analysis showed a 
good concordance between SRMs and EPRs (kappa =71%), indicating that SRMs 
can be used as a surrogate to assess the exposure to BP-lowering medication in 
GS:SFHS participants. Although both sources suffer from some limitations, SRMs 
can be considered the best available source to estimate the drug exposure 
history in those without EPRs. The prevalence of hypertension was 40.8% with 
higher prevalence in men (46.3%) compared to women (35.8%). The prevalence 
of awareness, treatment and controlled hypertension as defined by the study 
definition were 25.3%, 31.2%, and 54.3%, respectively. These findings are lower 
than similar reported studies in other populations, with the exception of 
controlled hypertension prevalence, which can be considered better than other 
populations. Odds of hypertension were higher in men, obese or overweight 
individuals, people with a parental history of hypertension, and those living in 
the most deprived area of Scotland. On the other hand, deprivation was 
associated with higher odds of treatment, awareness and controlled 
hypertension, suggesting that people living in the most deprived area may have 
been receiving better quality of care, or have higher comorbidity levels 
requiring greater engagement with doctors. These findings highlight the need for 
further work to improve hypertension management in Scotland.  
The family design of GS:SFHS has allowed family-based analysis to be performed 
to assess the familial aggregation and heritability of BP and hypertension traits. 
The familial correlation of BP traits ranged from 0.07 to 0.20, and from 0.18 to 
0.34 for parent-offspring pairs and sibling pairs, respectively. A higher 
correlation of BP traits was observed among first-degree relatives than other 
types of relative pairs. A variance-component model that was adjusted for sex, 
body mass index (BMI), age, and age-squared was used to estimate heritability 
of BP traits, which ranged from 24% to 32% with pulse pressure (PP) having the 
lowest estimates. The genetic correlation between BP traits showed a high 
correlation between systolic (SBP), diastolic (DBP) and mean arterial pressure 
(MAP) (ρG: 81% to 94%), but lower correlations with PP (ρG: 22% to 78%). The 
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sibling recurrence risk ratio (λS) for hypertension and treatment were calculated 
as 1.60 and 2.04 respectively. These findings confirm the genetic components of 
BP traits in GS:SFHS, and justify further work to investigate genetic 
determinants of BP. 
Genetic variants reported in the recent large GWAS of BP traits were selected 
for genotyping in GS:SFHS using a custom designed TaqMan® OpenArray®. The 
genotyping plate included 44 single nucleotide polymorphisms (SNPs) that have 
been previously reported to be associated with BP or hypertension at genome-
wide significance level. A linear mixed model that is adjusted for age, age-
squared, sex, and BMI was used to test for the association between the genetic 
variants and BP traits. Of the 43 variants that passed the QC, 11 variants showed 
statistically significant association with at least one BP trait. The phenotypic 
variance explained by these variant for the four BP traits were 1.4%, 1.5%, 1.6%, 
and 0.8% for SBP, DBP, MAP, and PP, respectively. The association of genetic risk 
score (GRS) that were constructed from selected variants has showed a positive 
association with BP level and hypertension prevalence, with an average effect of 
one mmHg increase with each 0.80 unit increases in the GRS across the different 
BP traits. 
The impact of BP-lowering medication on the genetic association study for BP 
traits has been established, with typical practice of adding a fixed value (i.e. 
15/10 mmHg) to the measured BP values to adjust for BP treatment. Using the 
subset of participants with the two treatment exposure sources (i.e. SRMs and 
EPRs), the influence of using either source to justify the addition of fixed values 
in SNP association signal was analysed. BP phenotypes derived from EPRs were 
considered the true phenotypes, and those derived from SRMs were considered 
less accurate, with some phenotypic noise. Comparing SNPs association signals 
between the four BP traits in the two model derived from the different 
adjustments showed that MAP was the least impacted by the phenotypic noise. 
This was suggested by identifying the same overlapped significant SNPs for the 
two models in the case of MAP, while other BP traits had some discrepancy 
between the two sources 
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1+ Introduction+
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1.1+Cardiovascular+disease+
The global burden of disease (GBD) has substantially shifted from communicable 
diseases in children to non-communicable diseases in adults. This was 
highlighted in the GBD Study 2010, which clearly stated in the executive 
summary:  
“Infectious diseases, maternal and child illness, and malnutrition now 
cause fewer deaths and less illness than they did twenty years ago. As 
a result, fewer children are dying every year, but more young and 
middle-aged adults are dying and suffering from disease and injury, as 
non-communicable diseases, such as cancer and heart disease, 
become the dominant causes of death and disability worldwide. Since 
1970, men and women worldwide have gained slightly more than ten 
years of life expectancy overall, but they spend more years living with 
injury and illness”.1  
The GBD 2010 study collated and analysed global data to estimate the deaths 
and disability-adjusted life years (DALYs; sum of years lived with disability 
[YLDs] and years of life lost [YLLs]). The above quotation reflects the finding 
that high blood pressure (BP) has shifted from being the fourth-highest cause of 
DALYs in 1990 to be the leading risk factor for disease in 2010, an estimated 
7.0% [95% CI: 6·2–7.0] of global DALYs.1 For instance, the number of people 
around the world with hypertension was estimated to be nearly one billion in 
2000, resulting in more than seven million premature deaths and ninety-two 
million DALYs worldwide.2,3 This shift is due to the aging population and the 
lower mortality rate in children below five years of age, as well as other factors, 
such as changes in cause-of-death composition and risk factor exposure. Yet, the 
extent of this shift varies greatly across the world, as it is not applied in much of 
sub-Saharan Africa, where the leading risk factors are still related to infectious 
diseases.1 
The mortality rate from non-communicable diseases has increased from 60% in 
2000, to 68% of global death in 2012. According to the World Health 
Organization (WHO) 2012 statistical report, cardiovascular disease (CVD) was the 
highest cause of death with an estimated 17.5 million deaths a year (that is 3 in 
every 10 deaths); of these, complications of hypertension are responsible for 9.4 
million deaths, and hypertension accounts for at least 45% of deaths due to 
heart disease and 51% of deaths due to stroke.4 The risk of stroke for middle-
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aged individuals (40 to 60 years) is doubled for each increment of 20/10 mmHg 
blood pressure.5 Furthermore, even high-normal values of BP were associated 
with an increased risk of CVD.6 Consequently, evaluation of the current practice 
of hypertension management with rigorous research to expand our knowledge of 
the pathogenesis and risk factors of hypertension are fundamental for future 
treatment and prevention of the disease.  
1.2+Blood+pressure+
1.2.1+ BP+physiology+and+its+regulation+
BP is the pressure exerted by circulatory blood on the walls of blood vessels. The 
principal function of circulation is to deliver nutrients to and remove wastes 
from tissue; this is achieved through blood flow effected by the difference in 
pressure that occurs during the pumping action of the heart. The relationship 
between pressure and blood flow is analogous to Ohm’s law, which can be 
clinically represented as BP being directly proportionate to the product of the 
blood flow [i.e. cardiac output (CO)] and total peripheral vascular resistance 
(PVR) [mean arterial pressure (MAP) =CO x PVR]. One way to control BP is by 
regulating CO and PVR in three anatomic sites: arterioles, postcapillary venules 
(capacitance vessels), and heart. The kidney is the fourth anatomic site that 
controls BP by regulating the volume of intravascular fluids. These four anatomic 
sites are under the control of baroreflexes, which are mediated by autonomic 
nerves to accommodates acute change in BP, and humoral mechanisms such as 
the renin-angiotensin-aldosterone system (RAAS) that affects volume 
homeostasis and vascular tone, and the adrenergic receptor system that affects 
heart rate, vascular tone, and cardiac contraction, and kinin-kallikrein system 
that influences vascular tone and renal salt handling.7 In addition, vascular 
endothelium may also release local vasoactive substances to regulate the 
vascular resistance, such as the vasodilator nitric oxide, or a vasoconstrictor 
endothelin-1. All of these multiple physiological systems act in an integrated 
complex manner to ensure homeostasis of BP in all metabolizing tissue.  
RAAS has a central role in regulation of BP, and is supported by various 
pharmacological agents that lower BP by blocking its activity, such as renin 
inhibitors, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin 
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receptors blockers (ARBs). RAAS begins with the biosynthesis of renin in the form 
of prorenin, the inactive precursor of renin, by the juxtaglomerular cells in the 
kidney. Renin converts angiotensinogen, which is mainly released from the liver, 
to form the biologically inert angiotensin I that is rapidly hydrolysed by ACE 
enzyme to angiotensin II. Angiotensin II is a potent vasoconstrictor that increases 
BP by several mechanisms: it binds to angiotensin II-type 1 receptor to stimulate 
several tyrosine kinases, which in turn phosphorylate the tyrosine residues in 
several proteins, causing vasoconstriction, cell growth, and cell proliferation.8 In 
addition, it raises BP by increasing blood volume directly by inducing water and 
sodium reabsorption, and indirectly by stimulating the release of aldosterone 
which further raises BP.9,10 The degree of RAAS activity is variable between 
individuals and it depends on several factors such as sex, ethnicity, salt intake, 
genetic components, and the uses of medication.11 Particularly, BP-lowering 
medication that acts on RAAS are less effective in people with low level of RAAS, 
for example, Blacks and elderly. 
The second system that has an important role in regulating BP is the 
sympathetic nervous system, which can cause both arteriolar constriction and 
arteriolar dilation. Higher activity of this system can increase BP by acting on 
the heart, peripheral vasculature, and kidneys, leading to increased cardiac 
output, vascular resistance, and fluid retention.8 The roles of this system in 
regulating BP are complex and include alteration in both baroreflex and 
chemoreflex at central and peripheral level, that mainly affect the short-term 
changes in BP in response to stimuli such as physical exercise or stress. The 
potent BP lowering effect of pharmacological drugs such as alpha- and beta-
sympathetic blockers highlights its role in controlling BP. Importantly, it was 
found that stimulation of beta-adrenergic receptors leads to reduced kidney 
expression of the serine-threonine protein kinase WNK4, which is a regulator of 
the sodium-chloride cotransporter, a target of thiazide diuretics.12,13  
Vascular endothelial cells have also been implicated in BP regulation and CVD, 
by releasing potent local vasoactive substances, including the vasodilator nitric 
oxide (NO) and the vasoconstrictor peptide endothelin. Endothelial dysfunction 
is a phenotypical alteration of endovascular lining of blood vessels that is 
characterized by a pro-thrombotic, pro-inflammatory, and pro-constrictive 
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phenotype.14 It occurs over time from aging and hypertension, leading to 
increased arterial stiffness and structural abnormality that may be irreversible 
once established.8,9 Though, deficiency of NO can be restored by 
antihypertensive therapy such as nitrates, which increases arterial compliance 
and dispensability and lowering systolic blood pressure (SBP) but not diastolic 
blood pressure (DBP).8,9 Other vasoactive substances that may act on different 
systems are also important in regulation of BP, an example is bradykinin that is a 
potent vasodilator which is inactivated by ACE enzyme, meaning ACE inhibitors 
(ACEIs) may also lower BP by blocking bradykinin inactivation.9,10 Atrial 
natriuretic peptide (ANP) is a cardiac hormone that is secreted from the atria of 
the heart in response to increased blood volume; ANP has a natriuretic, diuretic 
and vasodilatory properties, where deficiency of this hormone may cause fluid 
retention and hypertension.  
1.2.2+ BP+components++
The two components of blood pressure are SBP and DBP. SBP is the maximum 
pressure exerted against arteries and vessels during contraction of the left 
ventricle, thus SBP mainly depends on the CO. DBP is the minimum pressure on 
the walls of arteries during the time that the left ventricle is relaxing and 
refilling, and just before the ventricle ejects blood into the aorta. The mean of 
SBP and DBP during the cardiac cycle is the time-weighted average arterial 
pressure, and is called MAP, which represents the steady components of BP that 
reflects CO, vascular resistance, elasticity averaged over time, and heart rate.15-
17 MAP can be determined directly by catheterization or can be calculated by 
the formula (DBP + ⅓ x [SBP-DBP]). This is because ventricles spend 
approximately one-third (⅓) of their time in systole, and two-thirds (⅔) in 
diastole in each cardiac cycle. The pulsatile components of BP are represented 
by pulse pressure (PP), which occurs as a result of the outward and inward 
movements of the arterial walls during the SBP and DBP. PP is the difference 
between SBP and DBP, and reflects the large artery stiffness, ventricular 
ejection, and the timing of wave reflection. It is influenced by other 
haemodynamic mechanisms such as the change in ventricular ejection, large 
artery compliance, and timing of reflected waves.15-17. 
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The relative importance of these four components have established a continuing 
debate in the field of hypertension in regard to which one should be used to 
estimate CVD risk. DBP has historically been considered the most important 
components of BP, as it was determined by pooled data from 420,000 individuals 
that showed a log-linear association between DBP and risk of stroke and 
myocardial infarction.18 The importance of SBP over DBP has been later 
recognized with the publication of a series of epidemiologic studies showing that 
SBP is the best predictor of risk in the elderly, and that low DBP is also 
associated with higher risk of CVD. The Framingham Heart Study was the first 
study to show that there is a decline in importance of DBP and a corresponding 
increase of importance of SBP with age.19 Since then, several studies have shown 
the superiority of either SBP or PP in the elderly, whereas DBP is a better 
predictor in subjects younger than 50 years old.20 PP has also been reported to 
have a possible additional prognostic role, as it was found that patients with 
high SBP and low or normal DBP (i.e. isolated systolic hypertension) have a 
higher risk of CVD.21 Generally, age plays an important factor in determining 
which BP component is a better predictor of CVD, with findings from the 
Framingham Heart Study suggesting that with increasing age there is a gradual 
shift from DBP to SBP and then to PP as predictor of CVD risk, and that 
combining two components such as DBP and SBP, or MAP and PP provides a 
better prediction than any single BP component.20,22 
1.2.3+ BP+measurements+
BP is traditionally measured by non-invasive methods using the auscultatory 
technique (Korotkoff sounds) with a mercury sphygmomanometer that depends 
on the transient occlusion of the brachial artery by an appropriately sized cuff 
inflated over the upper arm. Although this may be considered the “gold 
standard”, it is no longer applied in most of the European countries due to 
concerns regarding mercury toxicity. The advancement of technologies has 
allowed automated devices, which should be carefully used after validation and 
calibration to ensure accurate measurements.23 Currently, two types of BP 
measurements are used: office-BP measurement and out-of-office 
measurement. While the office measurement is always performed by a 
specialized person in the clinic and involves single or multiple readings, out-of-
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office provides larger number of observations and it performed in less stressful 
environments and may represent a more reliable estimate of the actual BP.+
The out-of-office BP measurement can be performed by either ambulatory BP 
monitoring (ABPM) or home BP monitoring (HBPM). ABPM is performed by using a 
portable device that measures BP at frequent intervals for 24 hours, where the 
cuff is attached to a small electric recording device. The HBPM can be 
considered as a cost-effective alternative to the ABPM, which has the advantage 
of not interfering with a patient’s daily activity. The process of measuring BP 
with HBPM is exactly the same as office BP measurement. Although ABPM 
provides more complete information of BP than HBPM, both of them are superior 
to office measurements in regard to predicting CVD risk.24,25 
1.2.3.1+ BP+measurements+errors+
The presence of these different BP monitoring methods highlights the 
importance of taking accurate BP measurements. The challenge of obtaining a 
correct measurement of BP is due to the considerable variability of BP because 
of issues involving the observer (measurement variation), or biological factors 
within the patient that may occur from moment to moment with respiration, 
emotion, smoking, temperature, pain, meals, and bladder distension.26 Factors 
that are related to variation in the measurement include white-coat effect, 
suboptimal measurement procedures such as inappropriate cuff size, or rounding 
bias (Table 1-1).27 Obtaining an accurate measurement of BP is of great clinical 
importance as inaccuracy could expose normotensive patients to unnecessary 
treatments, or it may deprive hypertensive patients of a useful treatment. It has 
been estimated that a systematic error of underestimating of true BP by 5 
mmHg would mislabel 20 million persons as having normal BP, disqualifying them 
from receiving treatment. On the other hand, a systematic error of 
overestimated BP by 5 mmHg could misclassify 27 million people as being 
hypertensive.28  
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Table+1G1+Factors+affecting+the+accuracy+of+BP+measures+
Factor+ Magnitude+of+SBP/DBP+discrepancy+(mmHg)+
Talking!or!active!listening! 10/10!
Distended!bladder! 15/10!
Cuff!over!clothing! 5–50/!
Cuff!too!small! 10/2–8!
Smoking!within!30!minutes!of!measurement! 6–20/!
Paralyzed!arm! 2–5/!
Back!unsupported! 6–10/!
Arm!unsupported,!sitting! 1–7/5–11!
Arm!unsupported,!standing! 6J8/!
Table!is!reproduced!from!29!
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1.3+Hypertension+
The current agreement of the quantitative nature of hypertension has resulted 
from a large number of epidemiological studies, which showed that BP is 
normally distributed in the population. However, this agreement was not always 
accepted especially during the 1950s, with competing views expressed by Sir 
Robert Platt and Sir George Pickering, known later as the “Platt versus Pickering 
debate”.30-32 Platt examined BP in normotensive and hypertensive probands and 
their relatives, and concluded that hypertension is a qualitative disease that 
follows a bimodal distribution, and that the hypertensive subpopulation can be 
distinguished from the normotensive majority. On the other hand, Pickering 
believed that BP is normally distributed in the population with a unimodal 
distribution, in which there is no discernible separation between normotensive 
and hypertensive subjects. Hence, those people in the extreme top of the 
distribution can be classified as having hypertension, but it does not exist as a 
separate entity. Pickering view was supported with the observation that BP is 
normally distributed in the first-degree relatives of normotensive and 
hypertensive probands; he concluded that BP was inherited as a “graded 
character” with a polygenic nature. At the beginning, Platt’s qualitative model 
was much preferred, but it was only changed with mounting evidence from 
epidemiological studies showing the benefit of reducing BP. Despite the 
rejection of the Platt model, evidence from the rare monogenic forms of 
hypertension do indicate that there exists a small sub-population of people with 
hypertension where the cause of hypertension is due to a single gene defect and 
thus existing as a separate entity. 
The consensus that hypertension is a quantitative disease implies that any blood 
level used to define hypertension is arbitrary. Basically, hypertension is defined 
based on a cut-off at the upper extreme of the BP distribution at which 
investigation and treatment do more good than harm. In practical terms, a 
conventional cut-off of 140/90 mmHg are used to simplify the diagnostic 
approach and to facilitate the decision about starting treatment.23,33,34 The 
threshold for hypertension diagnosis and classification is slightly different 
between different guidelines; the most common classifications are based on the 
Seventh Report of the Joint National Committee (JNC7), and the European 
Society of Hypertension (ESH) guidelines 2013 (Table 1-2).23,35 It must be noted 
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that “JNC8” was published during the writing of this thesis, and it differs from 
the earlier version in that it no longer addresses the old definition of 
hypertension but it only states the threshold for treatment intervention.36 
 
Figure+1G1+Illustration+of+the+PlattGPickering+debate.+
(a)+Platt+argued+that+hypertensive+population+represents+a+discrete+subpopulation,+appeared+
due+to+a+single,+heritable+genetic+mutation.+(b)+Pickering+debated+that+hypertensive+
population+represents+the+extreme+top+of+the+normally+distributed+population,+with+no+clear+
separation+line+between+hypertensive+and+normotensive,+suggesting+that+hypertension+is+a+
polygenic+disease.+Figure+is+reproduced+with+permission+from+37.+
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Table+1G2+Definition+and+classification+of+hypertension+based+on+ESH2013+and+JNC7+
1.!Definition!of!hypertension!based!on!ESH2013!and!JNC7!
Category! SBP! ! DBP!
Office!BP! ≥!140! and/or! ≥!90!
ABPM!(awake)! ≥!135! and/or! ≥!85!
ABPM!(asleep)! ≥!120! and/or! ≥!70,!(≥!75!in!
JNC7)!
ABPM!(24Jhr)! ≥!130! and/or! ≥!80!
HBPM!! ≥!135! and/or! ≥!85!
!
2.!Classification!of!hypertension!!
A.!Based!on!ESH2013!
Optimal! <120! and! <80!
Normal!! 120–129! and/or! 80–84!
High!normal! 130–139! and/or! 85–89!
Grade!1!hypertension! 140–159! and/or! 90–99!
Grade!2!hypertension! 160–179! and/or! 100–109!
Grade!3!hypertension! ≥!180! and/or! ≥!110!
Isolated!systolic!hypertension! ≥!140! and! <90!
!
B.!Based!on!JNC7!
Normal!! <120! and! <80!
Prehypertension! 120–139! or! 80–89!
Stage!1!hypertension! 140–159! or! 90–99!
Stage!2!hypertension! ≥!160! or! ≥!100!
Table!is!produced!based!on!information!from!ESH201323!and!JNC735!
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1.3.1+ Pathophysiology+of+hypertension+
The pathophysiology of hypertension involves complex interacting systems and 
pathways that maintain BP homeostasis (some of these system were described in 
Section 1.2.1 -p22). These interactions may even involve unknown pathways yet 
to be discovered. Primary or essential hypertension is the most common type of 
hypertension, estimated to cause 90% of the cases, where the patient has high 
BP without an obvious secondary cause. The remaining cases are classified as 
secondary hypertension (<10%), which is an elevation in BP that is due to 
specific causes such as renovascular disease, hyperaldosteronism, 
phaeochromocytoma, monogenic disorders, or medication-induced. The 
enormous advances made in the genetic studies of hypertension and BP 
regulation affirms the multifactorial polygenic nature of hypertension as 
represented by the Mosaic Theory of hypertension proposed by Paige in 1960, 
who indicated that hypertension is due to an interaction of genetic, 
environmental, adaptive, neural, mechanical, and hormonal perturbations 
(Figure 1-2).38 
There is clear evidence that the kidney plays an important role in the 
pathogenesis of hypertension, especially with its capacity to rapidly reduce BP 
by increasing urinary sodium execration, a phenomenon known as “pressure 
natriuresis”; this mechanism plays an important role to balance BP, regardless of 
the initiating cause.13 The concept of pressure natriuresis was suggested by 
Arthur Guyton and his colleagues in the 1970’s, who proposed that the kidney 
controls the level of BP through regulating extracellular fluid volume, by 
matching urinary excretion of salt and water with dietary intake.39 In addition, 
the presence of different BP-lowering agents that target pathways in the kidney, 
such as RAAS; or that inhibit sodium reabsorption such as thiazide diuretics 
affirm the role of kidney in hypertension pathogenesis. Lastly, the majority of 
the identified Mendelian forms of hypertension are due to mutations that alter 
renal hemodynamics or tubular reabsorption.38,40 This hypothesis of the central 
role of the kidney is supported by experimental kidney cross-transplantation 
studies, where long-term BP level followed the kidney donor.13 These studies 
showed that long-term BP level is elevated in the genetically normotensive 
recipient controls, after transplanting a kidney from genetically hypertensive 
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donor; whereas, BP level is reduced when a genetically hypertensive recipient 
receives a kidney from a genetically normotensive donor. 
 
Figure+1G2+The+Paige+mosaic+model+of+BP+regulation+and+the+updated+mosaic+2014.+
A.+Paige+mosaic+model+of+BP+regulation+in+1960,+B.+The+updated+BP+mosaic+of+BP+regulation+
which+shows+the+several+types+of+monogenic+hypertension.+Figure+is+reproduced+with+
permission+from+38.+
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1.3.2+ Hypertension+risk+factors+
Although the aetiology of essential hypertension remains unclear, some of the 
main risk factors that elevate BP are known, including obesity and overweight,41 
family history,42 race (more common in black people until the age of 75 years),43 
excess sodium intake (e.g. >3000 mg/day),44 insulin resistance, aging,23 stress, 
sedentary lifestyle, low potassium intake,44 and low calcium intake.45 The 
influence of these risk factors on BP and hypertension risk will be briefly 
explained in this section, except for the monogenic forms of hypertension, 
which will be explained in a separate section. 
Advancing age is associated with hypertension, particularly an increase in SBP in 
both genders. Women tend to have lower SBP than men before the menopause 
by around 6/3 mmHg, but slightly higher than men after the menopause. Yet, 
women tend to have greater pulsatile load with increasing age.46 The 
differences in hypertension prevalence between genders may be explained by 
this differences in BP level, in addition to differences in other factors related to 
awareness, treatment, and control of hypertension (see also Section 1.3.3).47 
Ancestry has a major impact on blood pressure. BP level tends to be higher in 
people of African descent, who have a more severe and higher prevalence of 
hypertension and an earlier onset of hypertension. This difference is particularly 
observed between Blacks and Whites in the 45 to 74 year age-range, but not 
after age 75 years.43 Effects of stressors were found to be greater in Blacks, 
especially during childhood, leading to greater long-term variability in BP in 
Blacks.48 A study that used a 24-hour ABPM showed a significant ethnic 
difference, even after adjusting for height, body mass index (BMI), 
socioeconomic status, and stress-related coping styles. This study demonstrated 
that Blacks had higher BP levels during both night and day, but the differences 
were significantly greater at night than during the day.49 That is, Blacks had 
higher nocturnal BP and smaller difference between daytime BP, a terminology 
that is called “nondipping” and it is associated with higher risk of vascular 
disease.50 The difference between Whites and Asians is controversial with most 
studies reporting similar prevalence of hypertension and BP level.51 
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The impact of obesity and overweight on BP and hypertension is well established 
for both children and adults. For instance, the Framingham Heart Study showed 
that obesity and overweight accounted for about 26% and 28% of hypertension 
cases in men and women, respectively; and the risk of new onset of 
hypertension was 1.5 for overweight men (BMI, 25–29.9 kg/m2) and 2.2 for obese 
men (BMI, >30 kg/m2).41 It was also estimated that there is a 20–30% higher risk 
of developing hypertension for every 5% increment in weight gain.52 Obesity 
increases the risk of hypertension through the interaction of several factors 
including dietary, genetic, epigenetic, and environmental factors. The elevation 
of BP in obese subjects is initially associated with raising cardiac output, which 
would also be the same in normotensive obese people. However, the systemic 
vascular resistance tends to be relatively normal in hypertensive obese patients, 
and lower than normal in normotensive obese people.53 Vascular and systemic 
insulin resistance is usually a result of adipocyte dysfunction in the obese 
patients, which is accompanied with dysfunction in sympathetic nervous system 
and RAAS. Also, structural and functional changes in the kidney such as 
activation of intrarenal angiotensin II are important factors in pathogenesis of 
obesity induced hypertension.52 Possible other mechanisms that link obesity to 
hypertension include diet, sodium retention, metabolic factors, neuroendocrine 
imbalances, proteinuria, endothelial and vascular dysfunction, glomerular 
hyperfiltration, and maladaptive immune and inflammatory responses.52 
Importantly, the combination of these two conditions has two implications; first, 
that affected people are at a higher risk of morbidity and mortality from CVD. 
Second, they are at higher risk of treatment-resistance and may require multiple 
medications.54 
Dietary factors have received much attention for their contribution in 
hypertension risk. The dietary factors can also be influenced by genetic factors, 
as the association between salt intake and BP is mediated by the subject’s salt 
sensitivity, which is partly genetically determined. A diet that is high in sodium 
salt intake has been shown to increase BP; the Dietary Approaches to Stop 
Hypertension study showed that reduction in sodium intake resulted in a 
stepwise decrease in BP, in subjects who were allocated to receive food with 
high, intermediate, and low level of sodium for 30 consecutive days.55 A meta-
analysis of long-term trials (at least four weeks duration) showed that reducing 
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sodium intake by 3 gram per day decreased BP by an average 4/2.5 mmHg in 
hypertensive, and 2/1 mmHg in normotensive individuals.56 The diet of isolated 
populations tends to be rich in potassium with a low level of sodium, and their 
hypertension prevalence is less than 1%; on the other hand, people of 
industrialized countries on average consume more processed food, which is 
sodium-rich and potassium-poor, and approximately one-third are affected by 
hypertension.44  
Excessive alcohol consumption is associated with the development of 
hypertension and higher levels of BP and BMI, and reduction of alcohol 
consumption was associated with a significant reduction in BP by an average of 
3.3/2.04 mmHg.57,58 The risk factors listed above can themselves be 
multifactorial, affected by genetic and environments factors, even though some 
of them would be considered predominantly environmental factors that can be 
minimized by lifestyle modification. For instance, alcohol intake would be 
determined by consumption; yet, some individuals may inherit a genetic variant 
in the aldehyde dehydrogenase 2 gene (ALDH2), which influences the rate of 
alcohol degradation and metabolism. Individuals homozygous for this variant 
experience severe adverse symptoms of alcohol consumption and are less likely 
to drink. Through the concept of “Mendelian randomization” it was found that 
men homozygous for the slow metabolism variant are less likely to develop 
hypertension, and their SBP is lower by 4.24 mmHg and 7.44 mmHg than those 
heterozygous or homozygous for the other variant, respectively.59 Furthermore, 
factors such as alcoholism and obesity tend to be influenced by both genetic and 
environmental factors, leading to more confounding factors in studying the 
proportion of BP variability that is caused by inheritance, and that they may 
vary in different populations. 
1.3.3+Distribution+of+BP++
Studies of the BP distribution with age showed a trend of steadily increasing SBP 
with age in both sexes, and an increase of DBP with age until the fifth decade 
and then progressively reduction in both sexes. MAP increases steadily with age 
and reach a relative plateau in the seventh decade, whereas PP remained 
relatively constant until the fifth decade, after which it steeply increases in men 
and women (Figure 1-3).46 The age-related increase of SBP was observed in a 
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sub-group of a German study after including only participants with no 
antihypertensive usage and no CVD risk factors (n =22,550), suggesting that this 
increase is part of the normal ageing process that occurs independently of 
known risk factors.60 The distribution of BP between genders shows that women 
tend to have lower SBP than men before the menopause by around 6/3 mmHg, 
but slightly higher than men after the menopause.46 Average SBP differs widely 
between world regions with a difference up to 16.8 mmHg and 19.4 mmHg 
between the lowest and highest regions for men and women, respectively 
(Figure 1-4).61 During the last 30 years, the global age-standardized SBP has 
declined by 1 mmHg per decade from 1980 to 2008, but trends varied 
significantly across regions and countries. SBP is currently highest in low-income 
and middle-income countries.61 
 
Figure+1G3+Distribution+of+unadjusted+mean+of+the+four+BP+components+with+age+for+men+and+
women.+
Figure'is'reproduced'with'permission'from'46.''
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Figure+1G4+Distribution+of+mean+SBP+across+the+world+for+men+and+women+in+2008.+
Figure'is'reproduced'with'modification'from'61.'
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1.3.4+Prevalence+of+hypertension++
Estimation of the global prevalence of hypertension in the year 2000 
demonstrated that more than a quarter of the world’s adult population had 
hypertension, nearly one billion cases, and it was expected that this would 
increase to 29%, or 1.56 billion, by 2025.3 The prevalence of hypertension varies 
widely across populations and regions of the world. For instance, mean 
prevalence of hypertension among men in developing countries was statistically 
lower by 6.5% than those in developed countries.62 Moreover, a study that 
pooled data from different regions of the world showed that regions with the 
highest estimated prevalence of hypertension had roughly twice the rate of 
regions with the lowest estimated prevalence.3 Moreover, an international 
comparison showed that hypertension is substantially higher in European 
countries than North American countries; for instance, England had higher 
prevalence of hypertension in 2006 (30%) than both Canada (19.5%) and USA 
(29%).47,63 Variation in the prevalence of hypertension within the country was 
also documented. For instance, the prevalence of hypertension was significantly 
higher among blacks compared to whites in USA,64 and among Afro-Caribbeans 
than Caucasians in England.51 Furthermore, rural populations had significantly 
higher prevalence of hypertension than urban populations in high-income 
countries (HIC), middle-income countries (MIC), and low-middle income 
countries (LMIC), with low-income countries (LIC) the exception, where rural 
population had significantly lower rate of hypertension than urban populations.65 
1.3.5+Prevalence+of+hypertension+in+Scotland+
Prevalence of hypertension in Scotland was 28.4% in 2012/2013, as reported by 
the Scottish Health Survey (SHeS) 2013 for adults aged 16 years and over.66 Men 
had marginally higher prevalence of hypertension than women (28.6% vs. 28.3%). 
The trend in prevalence of hypertension over the ten-year period between 2003 
and 2013 showed a stable prevalence between 2003 and 2010/2011, before a 
statistically significant decline to 28.4% in 2012/2013 (Figure 1-5); this 
observation was similar for both men and women. In 2012/2013, 25% of 
hypertensive participants were receiving treatment for hypertension but still 
having high BP, and only 20% of the hypertensive participants were controlled by 
the treatment and maintained BP levels below 140/90 mmHg (i.e. controlled 
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hypertension). Moreover, more than half of the hypertensive interviewees were 
untreated; particularly, no participants under the age of 35 years were being 
treated for hypertension. Importantly, identifying people with BP >140/90 
mmHg who are not on treatment may provide an estimate of the prevalence of 
potentially undiagnosed hypertensive. Yet, it must be considered carefully as a 
clinical diagnosis of hypertension is defined as “sustained raised of BP” that is 
not based on a single measurement. 
1.3.6+Global+management+of+hypertension+
The global importance of hypertension treatment and control is now recognized, 
leading to frequent epidemiological studies and community surveillance to 
evaluate the effort of treating and controlling hypertension. These surveys 
mainly report the prevalence of hypertension along with three important 
indices- ratios of treatment, control, and awareness of hypertension. In the case 
of comparable measurements between surveys, an international comparison 
between countries and regions can help devise potential ways to improve public 
health strategies. Although the benefits of lowering blood pressure are robustly 
evident and there are several classes of antihypertensive medication available, 
the proportion of awareness, treatment, and control of hypertension are still 
low. For instance, more than half of the individuals defined as hypertensive in 
the Prospective Urban Rural Epidemiology study (PURE) were unaware of their 
conditions, and only 41% of them received antihypertensive therapy (Table 
1-3).65 The proportion of treated and controlled hypertension with target BP 
level of <140/90 mmHg was only 33%. Similar to hypertension prevalence, the 
proportion of hypertension management indices varied widely between countries 
and within sub-populations of the same country. For example, the proportion of 
awareness, treatment, and control of hypertensive individuals in England were 
65.3%, 51.3%, and 53% for the year 2006, compared to 83.4%, 79.9%, and 82%, 
respectively, in Canada for the year 2007/2009.47 In addition, Table 1-3 shows 
the variation in hypertension management indices between the different country 
categories from the PURE study. Similarly, the Study on Global Ageing and Adult 
Health examined these hypertension indices in six countries and reported lower 
proportion of control and awareness in LICs.67 Consequently, there is a 
substantial shortfall in the effective management of hypertension worldwide, 
with a wide gap between different countries. Nevertheless, the proportion of 
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hypertension management indices have shown improvement. A cross-sectional 
study of five Health Survey for England (HSE), conducted between 1994 and 
2011, showed an improvement of the mean BP level in treated hypertensive 
from 150/80 mmHg in 1994 to 135.4/73.5 mmHg in 2011.68 There was also 
significant improvement in the proportion of awareness, treatment and control, 
the proportion of control among treated hypertensive almost doubling from 33% 
in 1994 to 63% in 2011. 
 
 
Figure+1G5+Trends+in+hypertensionGrelated+ratio+between+2003+and+2013+in+Scotland.+
Figure+is+produced+based+on+data+from+the+Scottish+Health+Survey+2013+for+adults+aged+16+
years+and+over.+In+the+2012/2013+survey,+BP+measurements+were+taking+by+the+interviewer,+
replacing+the+previous+method+of+nurseGcollected+BP+measurements.+However,+the+
prevalence+stated+in+this+graph+is+the+equivalent+to+the+nurseGcollected+BP+measurements,+
which+was+reported+in+the+survey+as+“nurse+/+nurse+equivalent”.+Data'available'in'
http://www.gov.scot/Publications/2014/12/9982/20#t8.6.+
+
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Table+1G3+Prevalence+of+hypertension,+awareness,+treatment,+and+control+in+PURE+Study+
Variables! Total!
No.!(%)!of!Participants!
Prevalence!of!
hypertensiona!
Awarenessb!
among!
hypertension!
Treatedc!
among!
hypertension!
Controlledd!
among!
treated!
Country!by!income!level!
HIC! 15,418! 6,263!(40.7)! 3,070!(49.0)! 2,924!(46.7)! 1189!(40.7)!
UMIC! 36,463! 18,123!(49.7)! 9,516!(52.5)! 8,761!(48.3)! 2833!(32.3)!
LMIC! 58,476! 23,269!(39.9)! 10,134!(43.6)! 8,595!(36.9)! 2314!(26.9)!
LIC! 31,685! 10,185!(32.2)! 4,157(40.8)! 3,230!(31.7)! 1,298!(40.2)!
Sex!
Women! 82,607! 32,649!(39.5)! 16,440!(50.4)! 14,491(44.4)! 4,891!(33.8)!
Men! 59,435! 25,191(42.4)! 10,437!(41.4)! 9,019!(35.8)! 2,743!(30.4)!
Overall!
All! 142,042! 57,840!(40.8)! 26,877!(46.5)! 23,510!(40.6)! 7,634!(32.5)!
a.!hypertension!is!defined!as!selfJreported!hypertension,!receiving!treatment,!or!BP!
≥140/90!mmHg!
b.!awareness!is!defined!as!answering!“yes”!to!the!question!whether!they!had!a!medical!
diagnosis!of!hypertension!!
c.!treatment!is!defined!as!answering!“yes”!to!the!question!whether!they!receiving!BPJ
lowering!medications.!
Abbreviations:!!
HIC,!highJincome!country;!includes!(Canada,!Sweden,!and!United!Arab!Emirates)!
LIC,!lowJincome!country;!includes!(Argentina,!Brazil,!Chile,!Malaysia,!Poland,!South!
Africa,!and!Turkey)!
LMIC,!low–middleJincome!country;!includes!(China,!Colombia,!and!Iran)!
UMIC,!upper–middleJincome!country;!includes!(Bangladesh,!India,!Pakistan,!and!
Zimbabwe)!
Table!is!derived!from!data!in!Chow!et!al.65!
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1.3.7+The+public+health+importance+of+blood+pressure+
High BP ranked as the leading single risk factor for global disease burden in 
2010, above tobacco smoking and household air pollution from solid fuels.1 
Moreover, high BP was one of the five leading risk factors for GBD in all world 
regions, except the Western sub-Saharan Africa where it was ranked as number 
six.1 It was estimated that hypertension affected nearly one billion people in the 
year of 2000, leading to more than seven million premature deaths and ninety-
two million disability-adjusted life years in worldwide.2,3 Generally, more than 
80% of the attributable burden of high BP (SBP >115 mmHg) occurred in LIC and 
MIC regions, and over 50% occurred in people aged 45-69 years, and just over 
half occurred in people with mean SBP less than 145 mmHg.2 This suggests that 
the relative risk of CVD events start to rise at this level of BP (>115 mmHg), and 
restricting prevention and treatment strategies to only people identified as 
hypertension by the current guidelines may miss much of BP-related disease.  
High BP has been found to be positively and progressively related to the risk of 
stroke and coronary heart disease. For instance, the risk of CVD for people aged 
40-60 years is doubled for each incremental increase of 20/10 mmHg of BP 
above the usual BP level of 115/75 mmHg.5 Moreover, a stepwise increase in the 
rate of CVD events was observed in persons with higher BP categories.6 
Consequently, adequate management of hypertension can effectively protect 
against high BP-related complications, and reduction in mean BP was associated 
with reduced chronic heart disease (CHD) and stroke events, even for individuals 
without a history of cardiovascular diseases.69,70 In addition, healthcare costs 
attributed to sub-optimal BP was estimated to be at least US$370 billion, which 
represents nearly 10% of the world healthcare expenditures, highlighting the 
fact that both lifestyle and pharmacological interventions are more cost-
effective options.71 
Several epidemiological studies have consistently demonstrated the benefit of 
BP lowering through population-wide and individual intervention (i.e. 
behavioural or pharmacological). A meta-analysis of 147 randomized trials of BP 
lowering and 464,000 participants showed that a 10 mmHg reduction in SBP is 
associated with 22% reduction in CHD and 41% reduction in stroke.70 Moreover, 
each 10 mmHg reduction in mean population SBP was associated with 46% and 
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41% reduction in cardiometabolic mortality for men and women, respectively.72 
Consequently, developing a strategy to lower BP in everyone above a certain age 
is a superior method than measuring it in everyone and treating it in some. This 
can be achieved by implementing effective primary prevention strategies to 
reduce exposure to behavioural risk factors. Remarkably, the degree of exposure 
to such risk factors are influenced by the lifestyle in the society, which 
necessitate developing healthy public health policies and environmental 
interventions that make healthy lifestyle options much easier for people. An 
example of primary prevention program for hypertension includes two strategies 
that can be applied at a population-level and high-risk individual level, to 
maintain a BMI between 18.5–24.5 kg/m2, reduce dietary sodium intake, regular 
aerobic exercise, limit alcohol consumption, and adequate diet that is rich of 
potassium, fruit, and vegetables.73 
Despite the overwhelming benefits of lowering BP, the rates of awareness and 
controlled-hypertension remain low (see Section 1.3.6 –p39). This highlights the 
importance of more intensive and cost-effective strategies that are applicable 
even to population of LIC, which may have major challenges to adopt the 
international guidelines due to a poor healthcare infrastructure or insufficiency 
of antihypertensive medications. Nevertheless, medication availability, 
affordability, adherence, and acceptability are important barriers that need to 
be considered carefully in each setting to improve the control rate of 
hypertension. The difficulty in attaining a high rate of controlled hypertension 
can be extending to inadequate response to monotherapy, and difficulties in 
adopting healthy lifestyle. Improving our understanding of the biological 
mechanisms of BP regulation with identifying new pathways for antihypertensive 
medications, along with early identification of people at higher risk of BP-
related complication may offer hope that some of these problems will be 
surmounted in the future.!
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1.4+Principles+of+basic+genetics+
The human genome consists of deoxyribonucleic acid (DNA), which is made up 
from a long sequence of four nucleotide bases; adenine (A), cytosine (C), 
guanine (G), and thymine (T). Two strands of DNA are held together by hydrogen 
bonds to form a double helix, in which each two of the complementary base 
pairs are linked together based on Watson-Crick rules; (A) pairs with (T), and (C) 
pairs with (G). Each nucleotide base is linked to its neighbours in the same 
strand by phosphodiester bonds, that links carbon atoms number 3’ and number 
5’ of successive sugar residues. Hence, the two single strands can be identified 
by their ends, which are the 3’ and 5’, pronounced as 3 prime and 5 prime, 
respectively. During replication, the DNA double strand is first unwound by the 
action of the helicase enzyme and each strand serves as a template for 
synthesizing a new complementary DNA strand by the action of different types 
of DNA polymerases. A single strand of DNA can also serve as a complementary 
strand for ribonucleic acid (RNA) during the transcription process when certain 
segments of coding DNA (exons) that are spaced at irregular intervals by non-
protein coding regions (introns) are transcribed to make initial primary RNA, 
which then undergoes post-transcriptional processing to cut out the introns and 
splices the exons to make a mature RNA (mRNA), or messenger RNA that will in 
turn serve as a template to make a polypeptide in the translation process. 
The double helix DNA in the human genome is divided into 46 chromosomes; 22 
homologous pairs of autosomes and one pair of sex chromosomes (XY in males, 
and XX in females). One copy of the homologous chromosome is maternally 
inherited and the other is paternally inherited. Although the two homologues 
share the same sequence of genes in the same positions, they usually can be 
distinguished by the presence of sequence variations at several loci. The term 
“locus or loci for plural” refers to a unique chromosomal location that defines 
the position of an individual gene or DNA sequence; if this locus has a different 
version of DNA sequence in the population, then each version is called an 
“allele”. The alleles present at a specific locus is called the genotype; for 
instance, for three loci, A, B, and C that lie in one chromosome and take alleles 
A1-B1-C1 along one homologous chromosomes and A2-B2-C1 along the other, 
then the genotype of this subject for the three loci is, respectively, A1A2, B1B2, 
and C1C1. This subject would be called as homozygous at locus “C”, as it 
45 
 
consists of the same allele, and heterozygous at loci “A” and “B” as they contain 
two different alleles at the same locus. The haplotype refers to the allelic 
configuration along the same single DNA strand, thus in the above example it 
would be A1-B1-C1 and A2-B2-C1. This haplotype can be rearranged by a 
recombination process during meiosis; in which the pairs of the two non-sister 
chromatids of chromosome homologues are aligned at meiosis I, resulting in 
recombined chromosomes that have a portion of DNA from both mother and 
father. This one source of genetic variability during meiosis is then further 
expanded by the independent assortment of chromosomes and random 
fertilization. 
The concept of recombination is very important for gene mapping, as the 
probability of an odd number of crossovers (recombination) between two genes 
(or loci) is highly dependent on the physical distance between them; that is, if 
the two segments of DNA are close together, the chance of recombination is 
very small, and the probability of!recombination!increases as the distance 
between them increases, up to a maximum of 50%. The physical distance in 
chromosome is expressed in “centimorgans”, which refers to the region of DNA 
within which a crossover is expected once in every 100 meiosis events. The size 
of this region in base pair depends on the gender and place in the genome, but a 
rule of thumb is that one centimorgan corresponds to about one million bases.74 
When a variant is introduced into a population by mutation, it is perfectly 
correlated with nearby variants and is said to be in linkage, which is the 
tendency of genes at specific loci to be inherited together as a consequence of 
their physical proximity on a single chromosome. If two particular alleles at two 
different loci are found together more often than expected by chance, they are 
said to be in linkage disequilibrium (LD), which is defined as the non-random 
association of alleles in adjacent loci. The new variant perfect LD with its 
neighbouring loci tends to break up (“LD decay”) over successive generations 
due to several reasons such as mutation rates, admixture, gene conversion, 
genetic drift, population growth, population structure, and natural selection.75  
The LD between two markers within the same genomic region is commonly 
measured by the absolute value of D’ and r2. The concept of these measures is 
to calculate the difference between the observed allele frequencies, i.e. a two 
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marker haplotype, and the frequencies if the two alleles are independent. The 
higher the value of D’, the lower the possibility that a recombination event 
occurred between these two loci (D’ =1 means that the two markers have not 
been separated by a recombination event). The absolute value of r2 is more 
commonly used to quantify and compare LD in the context of mapping. When 
r2 =1, the two markers have not been separated by recombination and have the 
same allele frequency. In this case of perfect LD, the two markers are 
completely linked and observation at one marker provide complete prediction 
about the other. If the alleles D and A are in complete LD, the power to detect 
the association between allele A and the disease requires no change in sample 
size. However, if the r2 value is less than one, the sample size must be increased 
by 1/r2 of the sample size required for detecting the direct association with the 
disease’s allele.  
The human haploid genome is very large as it consists of more than 3 billion 
base-pairs; of which, about 3% contains coding sequences with an estimated 
21,000 distinct protein-coding genes.74,76 While the vast majority of the genome 
is identical between any two unrelated individuals, there are DNA sequence 
variants that contribute to genetic differences within and between populations, 
which are responsible for human diversity in expressing traits such as eye or hair 
colour, and even disease susceptibility. These genetic variants vary between 
populations and have arisen over time as a result of several factors, such as 
positive natural selection, which is the increase in prevalence of a specific 
genetic variant that improves survival and fertility. An example is the mutation 
that protect against malaria by disrupting expression of the Duffy antigen gene 
(DARC), which encodes the receptor used by the parasite to enter blood cells.77 
The types of genetic variation within the human genome are diverse, ranging 
from a single base pair alteration such as in single nucleotide polymorphisms 
(SNP) to structural variants, which are any change that involves more than a 
single nucleotide such as insertion-deletion (indels), block substitutions, 
inversions of DNA sequences, and copy number variants (CNVs). These variants 
can be also classified by the frequency of the minor allele to rare and common 
variants; common variants or polymorphisms are defined as genetic variants with 
a minor allele frequency (MAF) of at least 1% in the population, and rare variants 
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have a MAF of less than 1%.78 It is estimated that the human genome contains at 
least 11 millions SNPs, with about 7 million SNPs that have MAF over 5%, and the 
remaining have MAF between 1 and 5%.78 Despite the huge number of these 
variants, the vast majority of SNPs with MAF of at least 5% tend to be in LD with 
each other in different regions (known as LD bins). Hence, a limited set of about 
500,000 to 1,000,000 “tagging” SNPs from each LD bin could capture more than 
90% of genetic variation in the population.76 Most of these SNPs are catalogued 
in the public database SNPs and designated by a reference number.  
There are four main factors that make SNPs more preferable than other type of 
genetic variation for dissecting the genetic basis of common diseases. First, they 
are the most common type of variant and can be found throughout the genome, 
in exons, introns, promoters, enhancers, and intragenic regions. Thus, some of 
these polymorphisms might themselves be functional. Second, adjacent SNPs 
can be used for gene mapping by examining the correlation pattern between 
them, which may underline recombination hot-spots. Third, SNP frequency 
differences between different populations can be used in population-based 
trans-ethnic genetic studies. Fourth, SNPs are more stable than other types of 
genetic variation, which allow more consistent estimates from association 
studies. 
1.5+Fundamental+of+complex+trait+genetics+and+
association+studies+
Dissecting the genetics architecture of a trait (i.e. all the genetic and 
environmental factors that contribute to the trait, as well as their magnitude 
and their interactions) requires knowledge of the epidemiology and genetics, 
which are combined together in the field of genetic epidemiology. Traditionally, 
these two fields were independent disciplines with minimal interaction. Yet, 
advancements in molecular genomic applications technology have enabled the 
integration of epidemiological methods in human genetics. While epidemiology 
can be defined as the study of the distribution and determinants of health 
related states and events in specified populations, the term genetic 
epidemiology is less clearly defined and has been used to describe different 
aspects such as familial aggregation, inherited disease in populations, genetic 
structure of populations, and gene-environment interaction.79 A comprehensive 
48 
 
definition for genetic epidemiology is given by Morton as “ a science which deals 
with the aetiology, distribution and control of disease in groups of relatives and 
with inherited causes of disease in populations”.79 These two definitions of 
epidemiology and genetic epidemiology emphasize that both disciplines aim to 
draw inferences at the level of population rather than at the level of an 
individual. For instance, genetic epidemiology aims to pool information across 
families or subset of individuals to draw inferences about potentially weak 
effects at the level of a population. Importantly, the definition of genetic 
epidemiology used the term “inherited” but not “genetic” to also considers non-
genetic factors of traits clustering within families, which may includes cultural 
and environmental factors.74 Hence, genetic epidemiology incorporates several 
analytical approaches to discover the action and transmission of genes, and the 
potential mechanisms of non-genetic factor contributions in familial 
aggregation. 
An illustrative example of approaches used by genetic epidemiologists to dissect 
the genetic basis of a trait was provided by Burton et al., and depicted in Figure 
1-6. These methods can be used to establish if the trait of interest is likely to be 
influenced by one or more genes. However, important considerations need to be 
applied to this flowchart. First, it was not meant to be a guideline about how to 
conduct the study but rather just an overview of the broad range of process and 
its complexity, Second, a detailed descriptive analysis about the population 
should be performed first to prioritise the subsequent methods, which may be 
expensive and requires collaboration with other research groups. Finally, it is 
not necessarily to follow these steps in sequence, for instance, the presence of 
supporting evidence of a specific locus can justify doing an expensive genotyping 
experiment without performing all the previous steps. This is especially true 
with the advance of genomic technology and reducing cost of genotyping. 
Moreover, obtaining a sample of related individuals (i.e. family) with proper 
phenotyping data is one of the most expensive parts of many contemporary 
studies, which in many cases tempt scientists to jump directly to the association 
analysis without investing time and resources to examine the familial 
distribution of the phenotype. Nevertheless, such procedures are still important 
to refine the genetic model and risk estimates.  
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Figure+1G6+Flowchart+of+a+systematic+approach+to+dissect+the+genetic+basis+of+complex+
disease.+
*+Absence+of+significant+results+from+segregation+analysis+does+not+exclude+the+possibility+
of+genetic+disease.+Figure+is+reproduced+with+permission+from+74.++
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1.5.1+ Definition+of+phenotype+
The term “phenotype” refers to a measurable and observable characteristics of 
individuals;74 this term will be used interchangeably with the term “trait” 
throughout this thesis. This definition generally covers two types of traits – 
discrete or binary, and continuous. Discrete or simple binary traits are those 
where only two phenotypes are observed, such as hypertension or not (yes/no). 
Continuous or quantitative traits are those where the phenotype has a range of 
continuous values such as SBP. Choosing to study the phenotype quantitatively 
or qualitatively is usually motivated by the balance of maximizing the statistical 
power and reducing heterogeneity, i.e. showing similar phenotypic 
characteristics that are due to a different genetic background. Examining 
complex phenotypes quantitatively can greatly enhance the statistical power, 
help to uncover biological pathways from gene to disorder, explore the genetic 
overlap among quantitative traits that contribute to the complex disease, and 
chart the relative contributions of particular genetic variants to build up 
aetiological profiles that may be influenced by different factors such as age or 
environment.80 For instance, defining someone as hypertensive based on 
arbitrary BP values is of clinical importance but it is generally unclear if this 
definition is genetically relevant. Essentially, what is considered as a distinct 
disease on the clinical scale may be a heterogeneous group of potentially 
overlapping diseases on a genetic aetiology scale, leading to both challenges and 
opportunities in discovering genes for such heterogeneous disorders. For 
instance, phenotypic variation due to locus heterogeneity (i.e. different genes 
contribute to one phenotype) can affects all the methods of gene localizations; 
nonetheless, allelic heterogeneity (i.e. different alleles in the same locus cause 
a similar phenotype) can also affect the association methods. In both cases, 
statistical power is reduced by phenotypic complexity due to heterogeneity.81 
The complexity of the clinical definition may be minimized by using 
intermediate phenotypes or “endophenotypes”, which are phenotypes 
correlated with disease that might be closer to gene action than the overall 
disease definition. The term “endophenotype” was coined in 1966 to distinguish 
between exophenotype (external) and endophenotype (internal). In general, an 
endophenotype must meet the following criteria: (1) it is linked to an illness in a 
population; (2) it is heritable; (3) it manifests itself whether or not the illness is 
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active; and (4) it co-segregates with an illness in families.75 Separate analysis of 
the underlying quantitative traits (i.e. SBP, DBP, MAP, and PP) instead of an 
overall clinical phenotype (i.e. hypertension) can be a more powerful approach. 
The qualitative approach may be relevant in certain instances, especially to 
reduce the heterogeneity by studying extreme phenotype. For example, 
Padmanabhan et al. reported a novel locus in the promoter region of the 
Uromodulin gene (UMOD) by using cases and controls drawn from the extremes 
of the BP distribution.82 This approach can increase the statistical power of the 
study by achieving the maximum possible phenotypic separation between the 
cases and controls. 
1.5.1.1+ Phenotype+error+
The accuracy of phenotype is important for the outcome of genetic studies; that 
is, “even the most precise molecular-genetic data cannot be useful if the 
phenotypes are not well defined”.83 In general, reduction of phenotype accuracy 
can lead to lower statistical power and increases the likelihood of a type II 
error, or failure to identify true genetic signals, resulting in findings that are 
less likely to be replicated in future studies. However, it is possible to 
compensate for the attenuation of estimates towards the null from random 
measurement error by increasing the sample sizes using standard phenotypes. It 
is important recognise that large sample sizes are obtained usually by combining 
data from different studies. Thus adequate phenotyping performed similarly 
across large samples is a valid strategy as sample size factor mitigates the need 
for expensive hi-fidelity phenotyping strategies to resolve a phenotype that is 
reasonably captured by standard methods more economically.  
For case-control GWAS, several studies have showed that an increase in 
diagnostic or classification errors are associated with a substantial reduction in 
statistical power, particularly for lower allele frequencies and genotype relative 
risks.84-86 For quantitative traits, however, the impact of measurement errors on 
the statistical power is much smaller compared to misclassification errors in 
case-control studies.85 This was shown in a study that examined two traits 
(nuclear cataract and BP) using different measurements methods.85 In this study, 
two phenotypes were used for testing the effect of measurement errors for SBP 
and DBP in a Chinese cohort- the first phenotype derived from the average of 
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the two closest readings, which was assumed to be the “true” values, and the 
second phenotype derived from the third reading only. For DBP, the same 
significant signal was replicated in both phenotypes (i.e. true phenotype and its 
error counterpart); for SBP, however, three significant signals were reported for 
each phenotype but only two signals were in common. For the cataract trait, no 
overlapping signals were identified between the two measurement methods, 
suggesting that the impact of phenotypic errors on statistical power is much 
smaller for quantitative traits than binary traits (i.e. misclassification errors), 
and that small phenotypic measurement errors in BP phenotype is likely to have 
only a little impact on genetic association signals.85  
The issue of phenotype accuracy can also be exacerbated in the presence of 
other confounders such as treatment effect, where other adjustment need to be 
performed to account for the medication effect.87,88 The effect of treatment on 
the genetic association and epidemiological studies was demonstrated by Tobin 
et al. who showed by simulation and real sample data that inappropriate 
adjustment for BP-lowering medication can lead to substantial shrinkage in the 
estimated effect of the examined parameters and a marked reduction in 
statistical power.87 A proposed method to offset this effect was by adding a 
fixed value to the observed BP values, such as 15 mmHg and 10 mmHg for the 
observed SBP and DBP, respectively. Later, an extended method was developed 
to apply a step-wise adjustment based on the class and number of medication 
along with the subject’s ethnicity.88 
1.5.2+ FamilyG+or+populationGbased+sample+
Family-based studies were the sine que non in the field of genetics. Following 
the Human Genome Project, family-based linkage studies supported by accurate 
genome map information, greatly expanded the discovery of genes for 
monogenic diseases. However, linkage analysis was less fortunate in the setting 
of complex diseases, such as hypertension. Advances in technology along with a 
reduction in the cost of genotyping has shifted the focus of gene mapping from 
family based linkage analysis to association studies using sample of unrelated 
individuals. This is currently performed on the scale of genome-wide association 
studies (GWAS) by genotyping a huge number of SNPs in large sample size of 
unrelated individuals. The association studies are believed to have greater 
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statistical power compared to linkage analysis, especially for disease variants 
with weak effect.89 However, variants identified by GWAS explain little of the 
heritability of common diseases, which has led to a renewed interest in linkage 
and other family-based methods.89-92 In particular, the current GWAS approaches 
are less effective in detecting rare risk variants that are in LD with common 
SNPs, but such variants can be detected by family-based studies (the comparison 
between linkage and association approaches are discussed in more details in the 
next section). Essentially, the availability of exome and whole-genome sequence 
data has reinforced the importance of linkage analysis in detecting rare variants 
involved in complex disease using family-based data. 
Family-based design offers some advantages over population-based designs, and 
can be performed using several possible designs, which range from simple trios 
(two parents and one affected child) to a large extended pedigree with multiple 
generations. The main advantage of family-based design is its robustness to the 
effect of population stratification, a phenomenon that can lead to discovery of 
spurious genetic signals due to differences of genotype frequency between cases 
and controls that are only present because of differences in the ethnic 
background. The issue of population stratification is acknowledged in 
population-based studies and there are several methods to account for it, either 
during the study design stage or statistical analysis stage, for instance by 
computing genomic control (λ).93 A family-based design can test within-family 
and between-family information; while the former is protected against the 
stratification issue, the later is still susceptible to stratification (more details 
about method to test for association in family design studies are provided in 
Section 1.5.7 – p67).93 The family-based design can also offer the opportunity to 
test for the effect of imprinted or parent-of-origin effect, which occurs when 
the expressed phenotype is dependent on whether the risk allele was inherited 
from the father or mother. The importance of parent-of-origin effect is usually 
ignored because of the unavailability of this information. However, its 
importance as a potential contributor to complex disease is highlighted in one 
study from Iceland which reported five variants with parental-origin-specific 
association; one allele of the variant rs2334499 is protective against type 2 
diabetes if it was inherited from the mother and confers risk when inherited 
from the father.94 Furthermore, a survey of 97 complex traits measured in 
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outbred mice showed that 91 of 97 (93%) of these traits have measureable 
parent-of-origin effects 95 The family-based design also offers the possibility to 
examine whether a particular variant was inherited or has arisen as a de novo 
mutation. This has greater importance for examining CNVs where de novo 
mutation appear to occur with greater frequency in individuals with a 
neurodevelopmental disorders than in individuals without such disorders.96,97 
Family-based designs can offer the ability to perform more quality control (QC) 
by detecting genotyping errors in the form of Mendelian inconsistencies, by 
checking that genotypes between relatives such as parent-offspring follow 
Mendelian rules. The proportion of genotypic error that can be detected in trios 
family ranges between 25% to 30%, which can be increased by adding more 
relatives that would highlight unlikely genotypes within the family.98 Another 
advantage of family-based design is the possibility of imputing missing genotypes 
in relatives, and include the imputed genotypes scores and phenotypes in the 
total association test; this would increase the power of the study when 
genotyping resources are limited or when obtaining DNA sample for some 
relatives is not possible.99  
The possibility to carry out a combined test for linkage and association is only 
applicable in a family-based design where linkage analysis tests the presence of 
linkage between a genomic locus and the disease, followed by fine-mapping this 
linked region through association test by using several genetic markers that span 
this genomic region. These markers will be evaluated if they account for the 
linkage signal to determine if they can explain all of the genetic contribution 
that can be detected from this region. The simultaneous evaluation of linkage 
and association by using data from pedigrees with different relationship 
structures is likely to be the most powerful and useful approach to detect 
genetic variants that cannot be detected using traditional GWAS.89,100 However, 
it requires complex computation and statistical methods to account for family 
relationship and avoid false discovery, as the power to detect association is 
maximized with association test that incorporates data on related 
individuals.89,101 
The family-based design does however suffer from some disadvantages, similar 
to any other study design. The recruitment of individuals (i.e. probands) and 
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their relatives is more difficult than recruitment of unrelated individuals, and 
requires more resources in terms of time and cost. Furthermore, the family-
based design has less power per genotype than population-based study, 
especially in the methods that test the within-family effect, which has been 
attributed to the fact that these markers were used to test for the association 
and guard against population stratification.99 This reduction in power can be 
gained by considering the total association effect rather than within-family 
effect only.97 Furthermore, Visscher et al. have argued that the advantages of 
using related individuals in GWAS for quantitative traits may well outweigh the 
small disadvantage in terms of statistical power, by providing a more robust and 
flexible strategy for analysis.100 The analysis of family-based association studies 
requires special software to account for relatedness and usually cannot be 
performed using classical statistical tools.!
1.5.3+ Descriptive+genetic+epidemiology+
Familial aggregation of disease is an important factor that has its own clinical 
and epidemiological meaning, and these two meanings need to be carefully 
distinguished. Whilst the clinical meaning relies on the fact that extended 
families tend to have multiple individuals with the disease, the epidemiological 
meaning relies on the fact that relatives of affected individuals tend to have 
greater frequency of the disease than the general population. Furthermore, 
simple analyses of familial aggregation aims to find if the disease clusters within 
this cluster unit, and no attempt is made to attribute this aggregation to a 
specific causes (i.e. genes or environment). However, as most non-genetic 
factors associated with complex traits are weakly correlated in relatives and 
have only modest effects, the magnitude of familial aggregation can be 
considered to have a predominantly genetic basis.75,102 Different metrics are 
used to quantify familial aggregation and heritability of the traits, which will be 
discussed separately in the next sections.  
1.5.3.1+ Familial+aggregation+
For a binary phenotype (disease/health), one of the simplest metrics of familial 
aggregation is the recurrence risk ratio in relatives of affected individuals.103 
This risk ratio is defined as the recurrence risk ratio in relatives (λR), which is 
56 
 
the prevalence of the disease in relatives, compared with disease prevalence in 
the general population. ΛR can be estimated across different types of relatives, 
for example λS for siblings, which is the most common form. Measuring λR 
provides valuable information about the mode of the transmission of the 
disease, and is an important determinant of the power of affected relative pair 
studies to detect linkage. Three points need to be considered about the value of 
λS; first, it only reflects aggregation between siblings without explaining the 
source (i.e. either genetic or environmental). Second, the value of λS can be 
distorted by the presence of systematic differences of ages between the study 
sample population (i.e. siblings) and the general population sample from which 
the disease prevalence is calculated, which is a particular concern for diseases 
of late onset. Third, the value of λS is specific to the studied population and it 
should be carefully interpreted in different populations, especially for diseases 
with prevalence that may differ across populations.79 
Familial aggregation for continuous traits can be assessed using a covariance-
based method, for instance the intra-family correlation (i.e. intraclass 
correlation coefficient [ICC]) is one way to describe the correlation of 
quantitative trait for units that are clustered on groups (families). The ICC 
statistic indicates the proportion of the total variability in the trait that can be 
attributed to real variability between families. For a predominantly genetic 
trait, the within-family variability is expected to be small, resulting in higher 
estimates of between-family variability and higher ICC. Hence, non-random 
ascertainment can seriously bias the ICC estimate leading to inflated estimates 
of familial aggregation, as the full range of the trait values in the total 
population is not well-represented across families.104 
1.5.3.2+ Heritability++
The heritability of a continuous trait is defined as the proportion of its total 
phenotypic variance (σ2P) attributable to genetic factors in a specific 
population. Narrow sense heritability (h2) is defined as σ2A/σ2P, and broad sense 
heritability (H2) is defined as σ2G/σ2P, where σ2A includes the additive genetic 
components of variance and σ2G includes all genetic components of variance.105 
For binary traits, heritability is usually calculated by invoking a hypothetical 
construct, known as liability, and applying a version of variance components 
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modelling. Liability is an underlying, unobservable, normally distributed trait 
that is assumed to determine the probability that an individual will develop the 
disease of interest. The main point to note here is that the numerator has a 
simple genetic meaning, but the denominator σ2P captures the variance 
attributable to genes and shared environment as well as residual variance 
attributable to unshared and unmeasured determinants and measurement error. 
For a given trait, heritability can vary quite substantially from study to study 
depending on the population being investigated as a result of varying 
environmental exposures between populations, the structure of the analytic 
model, and measurement error. If a disease process is entirely dependent on the 
presence of a particular allele of a particular gene, but all individuals in the 
population are homozygous for that allele, variation at that locus does not exist 
and hence plays no role in variation in disease phenotype, therefore making no 
contribution to heritability. On the other hand, the gene is clearly implicated in 
the causal architecture of the disease. Equivalently, a near ubiquitous 
environmental exposure makes little or no contribution to the denominator σ2P. 
The power of most studies for discovering genes is positively associated with the 
heritability of the trait of interest. Thus, all else being equal and if the option 
exists, analytic efficiency may be enhanced by selecting a study population in 
which heritability of the trait of interest is thought to be high. Whilst the 
proportion of variance explained by genetic factors can provide insight into the 
value of genetic studies, it is important to note that heritability estimates do 
not provide information on the direction of effect of these factors nor insight 
into their utility in prediction.  
To estimate the magnitude of familial aggregation of a phenotype that is due to 
genes requires statistical modelling of how the phenotype is modulated by the 
effect of one or more genes. One of the most common methods is the additive 
genetic effects model, which adds or subtracts a constant value from the 
expected value of a trait for each copy of an allele at a locus.80 The amount 
added or subtracted varies in an unknown way from allele to allele and from 
locus to locus. The additive model assumes that the effect of any one allele is 
independent of other alleles, and uses probabilities of alleles that are shared 
identical by descent (IBD) as a measure of allele sharing among different classes 
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of relatives. Under these assumptions, the additive model captures much of the 
genetic effect on the phenotype, and this can be quantified by estimating the 
variance components in families or pedigree using mixed linear models.105 
Crucially, variance components analyses require no information about genotypes 
or measured environmental determinants. This approach can be extended to 
include the covariance or correlation patterns (or both) that would be expected 
for other more complex models of genetic determination (for example, genetic 
dominance) due to unmeasured environmental determinants that are shared by 
a whole family, those that are shared just by siblings, and those which wax and 
wane as individuals spend time living together or living apart. Finally, many 
environmental and lifestyle exposures are unique to an individual. These 
unshared determinants contribute nothing to the tendency for relatives to be 
more similar than non-relatives (i.e. they do not contribute to the covariance 
between relatives), but they do affect the total variability of a quantitative 
trait. Other genetic and non-genetic models might also be consistent with the 
data, so a good fit of any one model does not prove that that model is right.80,105  
1.5.4+ Linkage+analysis+
The purpose of linkage analysis is to search for alleles or chromosomal segments 
shared by affected relatives that are more than expected by random Mendelian 
segregation. These segments are passed entirely from the parents to the 
offspring without recombination at meiosis (Figure 1-7). The number of 
crossover sites in the human genome is thought to follow a Poisson distribution 
(averaging around 35 crossover points), and their locations are generally random 
and independent of each other. Co-segregation should therefore be detectable 
for marker loci quite far away from the disease-causing variant. Because linkage 
operates over long genetic distances, a positional mapping approach based on 
linkage can cover the entire genome by using a relatively small number of highly 
polymorphic markers. Standard marker sets for whole-genome linkage scans, 
based on 200–800 microsatellite polymorphisms, which became available in the 
1990s, enabled the successful mapping of hundreds of rare single-gene 
disorders. Linkage analysis is carried out only in families with affected relatives 
and involves genotyping of several markers that spread over the entire genome. 
Markers that flank the disease gene or mutation tend to highly segregate with 
disease status in families. Identifying markers within such a segment that 
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consistently accompany the disease may indicate the presence of susceptibility 
genetic factors near them. The power to detect small effect size increases with 
decreasing relatedness of subjects (for example by recruiting extended family), 
however, higher numbers of markers are required as the likelihood of 
recombination also increases (i.e. shorter segments are shared).  
Linkage studies were the predominant method for gene mapping and were 
successful in uncovering genes for monogenic Mendelian disease. However, 
linkage analysis has achieved only limited success for most of the common 
complex diseases. This has made the field of common complex disease to shift 
to apply genetic association methods that analyse common variants, which have 
a modest effect. For such variants, association methods are more powerful than 
linkage analysis. 
1.5.5+ Association+studies++
The goal of population association studies is to identify patterns of 
polymorphisms that vary systematically between individuals with different 
disease states and can therefore represent the effects of risk-enhancing or 
protective alleles. This implies that traits are still linked to the surrounding 
genetic sequence of the original evolutionary ancestor through linkage 
disequilibrium, or that they are found more often in a given haplotype than 
outside of it. Association mapping is based on the idea that genetic variants 
underlying complex traits occur with a relatively high frequency (>1%), have 
undergone little or no selection in earlier populations, and are likely to date 
back >100,000 years (the common disease/common variant hypothesis). 
Association analysis potentially has far greater power than linkage analysis for 
detecting variants with a modest effect on disease risk, provided that the 
genetic marker is close enough to exhibit strong LD with the functional variant 
(Figure 1-8).  
A direct association study tests the association between a known functional 
variant and disease. Indirect association studies are more commonly performed 
and rely on the principle of LD, by testing the association between the disease 
and a marker locus that lies close enough for the disease locus to be in LD with 
it; they may be enhanced by examining multiple markers simultaneously using 
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haplotypes. The association study can be performed by two main approaches; 
the first is the candidate-gene approach where it examines the association 
between a trait of interest and selected markers, based on an a priori 
hypothesis about their relationship to the trait. The second is a genome-wide 
approach, where a survey of most of the genome is performed to find the 
associated genetic variants without previous hypothesis or assumptions about 
the location of the causal variant. 
Finding an association between a marker and a trait does not necessarily 
indicate a genetic causation. Other factors related to the studied population can 
also result in an association signal. In general, an association between a genetic 
marker and a trait might be a result of (a) direct causation, where this marker 
does affect the trait status, or this marker is in LD with an ancestral 
chromosomal segment that carries a functional variant, or (b) due to an 
epistatic effect, where the trait status is more likely to be affected in the 
presence of specific genotypes of this marker along with other markers, or (c) 
due to chance or other factors related to the study design and the studied 
population such as population stratification or type 1 error. Confirming that an 
association is a direct association is a challenging process that may include re-
sequencing the target region, dense genotyping of all the available markers, or 
functional studies to confirm the role of a putative mutation in the disease 
pathophysiology.  
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Figure+1G7+Linkage+and+linkage+disequilibrium.+
Within+a+family,+a+recombination+occurs+during+meiosis+in+the+germ+cell+between+the+
paternal+chromosome+(blue)+and+the+maternal+chromosome+(yellow).+The+offspring+carry+a+
recombinant+chromosome,+which+undergoes+further+recombination+in+the+next+generation.+
In+generation+3,+the+two+markers+(red+triangles)+in+the+ancestral+(yellow)+region+are+said+to+
be+in+linkage.+Within+a+population,+the+stretches+from+the+ancestral+chromosomes+are+
decayed+by+recombination+events+over+time.+At+some+point,+a+recombination+event+occurs+
between+every+possible+point+in+the+chromosome,+which+leads+the+population+to+move+from+
LD+to+linkage+equilibrium.+Reproduced'with'permission'from'75.++
+
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Figure+1G8+Direct+and+indirect+association.+
LD+is+the+key+factor+in+an+association+study+because+it+induces+correlation+in+short+regions+
of+the+genome+and+underlines+the+susceptibility+factors+that+have+been+inherited+from+
ancient+common+ancestors.+The+d+allele+is+associated+with+the+disease.+The+a+allele,+on+the+
other+hand,+is+always+associated+with+the+d'allele+due+to+close+physical+proximity.+Thus,+an+
association+with+the+disease+can+be+directly+found+by+genotyping+the+disease+allele+d+(A),+or+
indirectly+found+by+genotyping+the+a+allele+that+is+in+LD+with+the+disease+allele+(B).+Finding+
the+direct+association+always+results+in+higher+association+power,+but+indirect+association+
should+result+in+a+significant+association+when+the+r2+of+alleles+a+and+d+is+high+and+an+
adequate+sample+size+has+been+used.+Reproduced+with+permission+from+75.+
+
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1.5.6+ GenomeGwide+association+study+(GWAS)+
GWAS offer a hypothesis-free approach that systematically tests hundreds of 
thousands or more variants in the genome without prior knowledge of the 
location of the causal variants. Essentially, GWAS are dependent on three 
critical factors; (1) sufficiently large sample size drawn from a population of 
appropriate genetic background, (2) efficient genotyping panel that adequately 
covers the whole genome, and (3) powerful statistical methods that can reveal 
genuine association signals. The rapid developments in these three areas over 
the last ten years has led to more than 2000 GWAS, reporting more than 15,000 
SNPs as of February 20, 2015. Regarding the first factor, several consortia and 
collaborations were established combining samples from multiple cohorts to 
conduct GWAS meta-analyses, such as the International Consortium for Blood 
Pressure (ICBP).107 These consortia have resulted in discovery and replication 
cohorts of large size that are sufficient to detect variants of moderate to small 
effect sizes; for instance, a reasonable statistical power to detect a variant with 
effect size typically observed for complex traits such as BP can only be achieved 
by recruiting a large sample size of at least 10,000 or preferably 100,000 or 
more.108 As expected, a common finding from all GWAS is the very modest 
effects on risk of the trait, typically with odds ratio (OR) ranging from 1.1 to 1.3 
and thus explaining a very small amount of the examined trait’s heritability. For 
instance, all the reported SNPs for association with BP have a very modest effect 
on BP, and the collective effect of all loci identified through GWAS explain only 
2% of BP heritability,38,107 compared to an estimated heritability from family 
studies that varies from 30% to 50%.109-111 Regarding the second factor, 
cataloguing SNPs in projects such as the international HapMap Project and more 
recently the 1000 Genome Project have identified and mapped a substantial 
number of SNPs that are easily and publically accessed. These were used by 
companies to develop several types of commercial genotyping “chips” that can 
assay up to 5 million SNPs with coverage down to 1% MAF. For the third factor, 
the large number of statistical tests performed in GWAS increases the chance of 
type I error, thus the high number of false-positive results is addressed by QC 
procedures, stringent multiple testing correction and seeking evidence from 
multiple replication and validation studies of the top signals. For instance, a 
genome-wide significant p-value for GWAS that tested one million markers 
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would be set at 5x10-8 or lower (Bonferroni-corrected alpha of 0.05). 
Furthermore, rigorous QC steps are always performed before the association test 
to minimize the possibility of errors.  
The important insight from GWAS of complex traits can be summarised in two 
points: (1) complex traits are more likely influenced by very large number of 
genetic variants, at least in the hundreds if not thousands. For example, the 
ICBP GWAS used a multi-stage design of almost 200,000 individuals, and 
discovered 16 novel loci for association with BP, and estimated that there are 
potentially 116 (95% confidence interval 57–174) independent BP variants with 
similar effect size to be discovered.107 (2) The statistical power of GWAS to 
detect a genetic variants depends on its effect size and MAF. Thus, it is possible 
that many variants may have been missed because of either a small effect size 
(OR <1.2), or low MAF (<5%). It is now possible to have a genotyping array that 
simultaneously genotypes up to 5 million SNPs including variants with MAF down 
to 1% such as the HumanOmni5Exom array by Illumina. (3) Other structural 
variants such as CNVs may play a role in disease aetiology112, but accurate 
calling of such structural variants remains problematic in standard GWAS.113 (4) 
Several variants were reported in association with multiple traits, highlighting 
the presence of pleiotropy in complex traits.114 For instance, a non-synonymous 
SNP rs3184594 in SH2B3, which introduces the amino acid substitution W262R in 
a plekstrin homology domain on exon 3, has showed significant association with 
chronic kidney disease, celiac disease, type 1 diabetes, coronary artery disease, 
cholesterol, haemoglobin, retinal vascular calibre, plasma eosinophil count and 
rheumatoid arthritis, SBP, and DBP.37,115 (5) Most trait-associated SNPs lie within 
non-coding sequence, of which 43% were intergenic region and 45% were intronic 
regions, suggesting a greater than anticipated role for non-coding SNPs in 
complex traits.116 Several studies have consistently reported patterns of 
enrichment among genic regions, where GWAS SNPs were enriched in function-
rich regions and depleted in function-poor regions.117-119  
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Figure+1G9+Traits+examined+by+GWAS+and+functional+distribution+of+GWAS+variants.+
(A)+A+pie+chart+the+shows+the+percentage+of+GWAS+SNPs+by+disease/trait+class,+including+a+
total+of+6,011+traitGSNP+associations+(5,386+SNPs)+from+920+different+studies+as+of+January+4,+
2012.+(B)+Location+of+GWAS+SNPs+relative+to+genic+features,+showing+that+only+4.9%+of+
GWAS+SNPs+lie+in+coding+region+sequence.+Figure'is'reproduced'with'permission'from'119.'
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1.5.6.1+ GWAS+quality+control+
QC is an essential procedure for GWAS to reduce the possibility of systematic 
bias. This is carried out by performing several QC procedures to exclude 
individuals or markers with particularly high error rates. Although it is possible 
to start by performing QC for markers to exclude ones with poor quality, it is 
generally advised to start by excluding individuals with poor quality data before 
conducting QC on markers.120,121 This is because the association signal may be 
lost if it was tagged by one of the removed SNPs. Hence, performing individual 
QC first prevents markers from being erroneously removed because of poorly 
genotyped samples. Essentially, the question of which procedure to start with is 
of relative importance and based on study design, sample size, and SNP panel. 
Several procedures and protocol for performing GWAS QC are already available 
120-123, such as the Nature protocol for case-control GWAS.120 However, a brief 
listing of the QC method is explained in the next paragraph to emphasize the 
stringency of the procedure. 
QC for individuals starts by (1) checking sex inconsistencies to identify issues 
that typically result from sample handling errors; (2) checking sample 
relatedness by comparing the estimated kinship coefficient based on the 
pedigree to the one calculated based on the markers, this would identify 
possible non-paternity, adoption, sample mix-up, or duplicate process of a single 
individual.122 For a population-based GWAS, individuals with greater relatedness 
would be excluded to ensure that sample includes only unrelated individuals; (3) 
checking population stratification to ensure that study sample is drawn from a 
relatively homogenous population, for instance this can be done by principal 
component analysis; (4) checking the sample genotyping call rate that may be 
indicative of individuals with a poor quality DNA sample. 
QC for markers starts by (1) checking the marker genotyping efficiency or call 
rate to exclude marker with poor quality, as marker assays that fail on a large 
number of individuals are poor assays, and are likely to result in spurious results; 
(2) checking Mendelian inconsistencies to identify genotyping error if pedigree 
information is correct; (3) filtering SNP based on MAF because statistical power 
is extremely low for rare SNPs; (4) checking for Hardy-Weinberg Equilibrium 
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(HWE) as departure from HWE can be indicated of potential genotyping errors, 
population stratification, or even actual association signal.122 
1.5.7+ Power+considerations 
Several factors influence the power of the study and many of them are beyond 
the control of the investigators, such as the degree of complexity of the trait or 
phenotype, the allele frequency and its effect size, and the genetic and 
historical characteristics of the study populations. However, other factors that 
can be addressed by investigators include selection of a homogeneous study 
sample, obtaining the maximum statistically powered sample size, using 
appropriate methods to measure the phenotype and genotypes, and applying 
correct methods to ensure high data QC, and performing the right statistical 
analyses to increase the statistical power within the constraints of available 
resources. For instance, the statistical power is influenced by the hypothesis for 
which the test is designed; for a variant with additive effects, a test that 
assumes additive effects would have greater power than a test that also allows 
dominance, and the opposite is also true as the statistical power is lost by 
carrying out an analysis that assumes additivity for a variant with a recessive 
effect.124 
The power of a study is generally a function of the sample size (n), the effect 
size of the gene or locus, and the significance level threshold (α). Typically, 
genetic association studies are performed under the null hypothesis (H0) that the 
effect size of the genetic marker is zero, and the alternative hypothesis (H1) is 
that the genetic marker has non-zero effect size. The observed results are 
considered significant if the p-value is lower than the p-value of the significance 
threshold (α =0.05). However, due to the large size of the dataset and analysing 
very large number of markers it is necessary to choose a more realistic 
significance threshold. For instance, keeping the value of α at 0.05 in a study 
that test 1,000,000 markers would reveal about 50,000 significant markers (i.e. 
5% of the tested markers) just by chance when the H0 is in fact true. Hence, 
more stringent significance thresholds (α) are usually considered for GWAS to 
allow for multiple testing penalties. For GWAS of a European population, a 
genome-wide significance threshold of 5x10-08 has been widely adopted 
regardless of the actual SNP density of the study.124 An alternative approach has 
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also been widely used to adjust for multiple testing in studies that use custom 
SNP arrays, or candidate-gene studies where the traditional Bonferroni 
correction has been used to define the significant threshold (α), by dividing 0.05 
by the number of tests.124 
Genetic studies can be performed using two approaches; either by recruiting 
related participants as in the family-based studies, or using unrelated individuals 
as in the population-based studies. These two approaches can be considered as 
complementary as each has its own strengths and limitations. Furthermore, the 
two approaches can be performed using several methods and generally the 
differences between them in terms of statistical power is small, when using the 
necessary sample size. For instance, a case-control study of 200 cases and 200 
controls were slighlt powerful than a study of 200 trios (of an affected offspring 
plus parents) in the context of common disease with a prevalence of 14%.90 
However, family-based studies require more resources and are time consuming, 
leading to greater popularity of population-based study designs.  
One of the best advantages of the family-based studies is their robustness to the 
population stratification issues, provided that the performed test was to assess 
within-family information. This can be applied using the transmission 
disequilibrium test (TDT), as both of the transmitted and untransmitted alleles 
came from the same ancestral source. These tests can be performed using 
family-bases association test (FBAT) or quantitative transmission disequilibrium 
test (QTDT). However, these kinds of tests ignore the between-family 
information, which can increase the power of gained information. Performing 
between-family association test in a family-based study make them similar to 
the population-based studies in terms of importance to test for population 
stratification issues. Hence, several methods were developed to incorporate the 
linear-mixed models (LMMs) in the genetic association studies that involve 
multiple sub-populations or family data (Figure 1-10).93,125 Basically, the concept 
of LMM is to model the trait using a mixture of fixed effects and random-effects 
in which fixed effects include the genotypic markers and any covariates such as 
age or sex, and random-effects include the phenotypic covariance matrix which 
is based on kinship matrix. Originally, the kinship matrix was proposed to be 
constructed using the information from pedigree.126 However, more advanced 
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methods were developed to be used with unrelated individuals using genome-
wide genotypic data rather than being fixed at their known theoretical values.127 
 
 
 
Figure+1G10+Statistical+association+methods+for+different+type+of+samples.+
The+figure+shows+the+suggested+statistical+methods+to+be+used+in+genetic+association+
studies+to+control+for+population+structure+and+relatedness.+The+yGaxis+represents+the+
population+structures+among+the+sample+that+may+include+major+subGpopulations.+The+xG
axis+represents+the+familial+relatedness+that+may+reflect+a+relationship+among+individuals+
from+recent+ancestry.+In+the+first+part+(leftGbottom),+the+sample+contains+minimal+familial+
relatedness+and+population+structures+resulting+in+greatest+statistical+power,+provided+that+
the+trait+is+well+distributed.+The+second+area+(rightGbottom)+represents+familyGbased+sample+
that+can+be+assessed+using+QTDT.+Studies+of+larger+sample+size+can+include+a+mixture+of+
these+two+samples+to+include+population+structure+as+in+the+rightGtop+area,+or+include+
familial+relationship+as+in+the+topGleft+area.+Figure+is+reproduced+with+modification+from+Yu+
et+al.125+
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1.6+Genetics+of+BP+and+hypertension+
The importance of genetics factors in the aetiology of hypertension has been 
established in several ways. Firstly, the presence of monogenic forms of 
hypertension has proved that gene mutations that affect gene function can 
influence BP, and lead to either hypertension or hypotension. The success in 
identifying these mutations has expanded our understanding of the physiological 
pathways that contribute to BP regulation. The single gene variants that cause 
monogenic forms of hypertension are rare, have large effect sizes, and affect a 
single pathway, which primarily involves renal electrolyte balance; Table 1-4 
shows a summary of the important monogenic forms of BP dysregulation. 
Secondly, family and twin studies have shown that BP is heritable trait, with 
heritability that ranging from 15% to 40% for the clinic SBP, and 15% to 30% for 
clinic DBP; a higher heritability was noted for the ABPM (sleep) around 69% and 
51% for SBP and DBP, respectively.109-111 Additionally, the risk of hypertension is 
about the double in subjects with one or two hypertensive parents, and BP 
levels correlate more in monozygotic twins than dizygotic twins.42,128 The last 
section introduced the concept and some approaches that are used to dissect 
the genetic of complex disease. This section reports the findings of these 
approaches in identifying some types of monogenic forms of hypertension, or 
revealing common genetic variants that are associated with BP traits.  
1.6.1+Monogenic+forms+of+hypertension+
Studying the genetic architecture of BP and hypertension started with 
identifying monogenic Mendelian forms of hypertension, by first using a linkage 
analysis approach and more recently exome sequencing methods. This has led to 
identification of several causal mutations in genes, which are primarily related 
to sodium homeostasis through renal and adrenal mechanisms. Discovering these 
specific causal pathways has expanded our understanding of the complex 
mechanisms underlying BP regulation and highlighted how this can be translated 
into targeted therapy, for instance Gordon’s syndrome patients can be treated 
by thiazides diuretics, and Familial Hyperaldosteronism (FH) type 1, or 
“glucocorticoid remediable aldosteronism” with steroid therapy. Hence, finding 
the genetic mutation that causes the monogenic hypertension is a classical 
example of directing the therapy based on the information of the culprit genetic 
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mutations, and the underlying perturbed pathway. The presence of strong family 
history of hypertension, especially early onset with Mendelian pattern of 
inheritance indicates monogenic forms. Though, this can sometimes be 
misleading, as essential hypertension is a highly prevalent disease. Other 
indications include abnormality in serum potassium level, and aldosterone, 
suppressed renin, and presence of metabolic acidosis or alkalosis. 
Discovery of the monogenic Mendelian forms of hypertension has mainly been 
through positional cloning using large family pedigrees, with multiple members 
of the family showing a clear inheritance pattern. This is usually performed by a 
linkage analysis approach (discussed in Section 1.5.4 - p58), which is based on 
genotyping highly polymorphic markers across the genome. This approach can 
reveal the chromosome, and the position of the locus, or even the genes that 
are most likely to be involved. This is then followed by fine-mapping to identify 
the culprit variants. Patients with these types of disorders represent less than 
1% of patients of essential hypertension and are considered to have secondary 
hypertension. The contribution of identifying these types of variants is great, as 
they represent the clearly definable genetic influence on BP. 
Mutations causing monogenetic hypertension are characterized by being rare 
with a major defect that usually disrupts a single pathway. Given the complexity 
and the presence of several systems and physiological pathways that control BP, 
it is surprising that most of the identified monogenic hypertension are due to 
mutation in genes that play key roles in renal-sodium handling. These mutations 
can be categorized based on their mechanisms, though all of which lead to 
common pathways related to increased sodium reabsorption, volume expansion, 
and low plasma renin activity.7 First, gain of function mutations that increase 
sodium and chloride reabsorption in the distal tubular, or mutations of 
mineralocorticoid receptors that resemble mineralocorticoid excess, leading to 
volume expansion and hypertension, such as in Liddle syndrome, Gordon’s 
syndrome and hypertension exacerbated by pregnancy. Second, mutations that 
reduce regulatory enzymes of adrenal steroid synthesis and deactivation, leading 
to accumulation of precursors with mineralocorticoid activity such as congenital 
adrenal hyperplasia and apparent mineralocorticoid excess. Third, mutations 
that causes excessive aldosterone synthesis that escape regulatory mechanisms, 
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leading to volume-dependent hypertension that suppresses renin release, such 
as in FH types I and II.7 Table 1-4 summaries the different forms of monogenic 
hypertension based on the affected pathway. 
It is important to differentiate between the impact of rare variants that cause 
monogenic forms of hypertension, and common variants that are assumed to 
play a role in essential hypertension. As discussed before, monogenic 
hypertension is caused by rare variants that often cluster within families, and 
have a large effect size. On the other hand, common variants are assumed to 
have very small effect with unequivocal association with BP, and the functional 
effects of these variants are obscure. Tobin et al. studied the common variants 
in genes associated with monogenic forms in the general population, with the 
aim to evaluate comprehensively the effect of common variants as potential 
contributors to BP variation in the general population.129 The study examined 
the association of 298 SNPs across 11 loci, in 2018 individuals from 520 families 
unselected for BP, using mean 24-hr SBP and DBP as primary phenotypes. The 
key findings were for association of five variants in the KCNJ1 gene (potassium 
inwardly-rectifying channel, subfamily J), which encodes the renal outer 
medullary potassium channel (ROMK), which is associated with Bartter syndrome 
type 2. Evidence of nominal associations were also found for variants in CASR, 
NR3C2, SCNN1B, and SCNN1G. This study showed that common variants in genes 
causing monogenic forms of hypertension may also play a role in regulating BP in 
general population. 
+ +
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Table+1G4+Monogenic+forms+of+hypertension+
No+
Condition+
(mode+of+
inheritance)+
Phenotypes/treatment+ Gene,+locus+ Features+
Renal!ion!channels!
Mutations!in!this!pathway!affect!the!renal!net!salt!homeostasis,!by!disruption!of!the!normal!regulatory!mechanisms!
of!ion!channel!transporters,!such!as!the!epithelial!Na+!channel!(ENaC),!the!thiazideJsensitive!Na/Cl!coJtransporter!
(NCC),!and!the!NaJKJ2Cl!coJtransporter!(NKCC2).!Normally,!60%!of!sodium!is!reabsorbed!in!the!proximal!convoluted!
tubule!(PCT)!of!the!nephron!by!Na+/H+!exchange.!Then,!30%!is!reabsorbed!in!the!thick!ascending!limb!of!Henle!
(TAL)!by!the!NKCC2!coJtransporter.!Then,!7%!is!reabsorbed!in!the!distal!convoluted!tubule!(DCT)!by!NCC!coJ
transporter.!Finally,!3%!is!reabsorbed!in!the!cortical!collecting!tubule!(CCT)!by!ENaC.7!
1.! Liddle!Syndrome!MIM!177200!(AD)!
↑↑BP,!↓↓serum!aldosterone,!
↓↓K+,!↓↓!plasma!renin!activity,!
metabolic!alkalosis.!
Treated!with!amiloride!or!
triamterence.!
SCNN1B&
SCNN1G(
16p12.2!
Gain!of!function!mutations!in!
the!genes!coding!βJ!or!γJ
subunits!of!ENaC,!leading!to!
increased!ENaC!activity!due!to!
constitutive!expression!of!
sodium!channels!and!
prolongation!of!the!halfJlife,!
which!result!in!net!renal!salt!
balance.!
2.! Gitelman!syndrome!MIM!263800!(AR)!
↓↓BP,!↑↑!plasma!renin!activity,!
↓↓K+,!↓↓Mg2+,!↓Ca2+.!
SLC12A3(
16q13!
LossJof!function!mutation!in!
the!NCC!coJtransporter,!
leading!to!lower!sodium!
reabsorption.!!
3.
!B
ar
tt
er
!sy
nd
ro
m
e!
!
Type!1!“antenatal”!
MIM!601678!(AR)!
↓↓BP,!↑↑!plasma!renin!activity,!
↑↑aldosterone,!↓↓K+,!metabolic!
alkalosis!and!hypercalciuria.!
SLC12A1(
15q21.1!
Loss!of!function!mutation!in!
the!NKCC2!coJtransporter,!
leading!to!impaired!salt!
reabsorption!in!TAL.!
Type!2!“antenatal”!
MIM!241200!(AR)!
KCNJ1(
11q24.3!
KCNJ1!belongs!to!the!
potassium!channel!gene!(KCN)!
family!that!encodes!
potassium!channels.!A!loss!of!
function!mutation!in!KCNJ1,!
which!encodes!the!apical!
ROMK,!leads!to!a!disruption!in!
the!normal!activity!of!NKCC2.!!
Type!3!
MIM!607364!(AR)!
CLCNKB(
1p36.13!
Homozygous!or!compound!
heterozygous!mutation!in!the!
kidney!chloride!channel!B!
gene!(CLCNKB).!
Mineralocorticoid!Pathway:!
This!pathway!regulates!homeostasis!of!blood!volume!and!pressure!by!promoting!renal!sodium,!chloride,!and!water!
reabsorption!through!releasing!mineralocorticoid!hormones,!of!which!aldosterone!represents!90%.!The!
mineralocorticoid!receptor!(MR)!is!a!major!regulator!of!ENaC!activity,!which!is!normally!activated!by!aldosterone!in!
CCT.!Genetic!mutation!in!this!pathway!causes!abnormalities!in!aldosterone!secretion!or!production!of!other!steroids!
that!activate!MR,!leading!to!increases!sodium!and!chloride!reabsorption!in!the!distal!nephron,!or!enhances!the!
effects!of!hormones!with!mineralocorticoid!activity!leading!to!low!plasma!renin!activity,!thus!the!elevation!in!BP!is!
more!likely!to!be!salt!sensitive.!
4.
!F
am
ili
al
!H
yp
er
al
do
st
er
on
ism
!(F
H)
!
!
FH!Type!1,!or!
glucocorticoid!
remediable!
aldosteronism!
MIM!103900!(AD)!
↑↑BP,!↑↑!aldosterone,!↓K+,!
↓↓plasma!renin!activity.!
Treated!by!dexamethasone.!
CYP11B1!
8q24.3!
Chimeric!CYP11B1/CYP11B2!
gene,!which!encodes!a!
protein!with!aldosterone!
synthase!activity,!but!it!is!
regulated!by!
adrenocorticotropic!hormone!
(ACTH),!rather!than!normal!
hormonal!regulator.!Thus,!
higher!aldosterone!is!secreted!
to!maintain!normal!level!of!
cortisol,!leading!to!expanded!
plasma!volume!and!
suppressed!renin!activity.!!
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FH!Type!2!
MIM!605635!(AD)!
7p22.3J
7p22.1!
Hyperaldosteronism!because!
of!adrenocortical!hyperplasia;!
not!suppressible!by!
dexamethasone.!
FH!Type!3!
MIM!613677!(AD)!
KCNJ5(
11q24.3!
Severe!hypertension!due!to!
massive!mineralocorticoid!
production,!that!only!can!be!
treated!by!adrenalectomy.!
5.!
Apparent!
Mineralocorticoid!
Excess!(AME)!
MIM!218030!(AR)!
↑↑BP,!↓↓plasma!renin!activity,!
↓↓serum!aldosterone,!↓↓K+.!
Onset!in!infancy!or!childhood.!
HSD11B2(
16q22.1!
A!congenital!defect!in!11J
betaJhydroxysteroid!
dehydrogenase!type!II!
(HSD11B2)!activity,!resulting!
in!decreased!conversion!of!
biologically!active!cortisol!to!
inactive!cortisone;!this!defect!
allows!cortisol!to!act!as!a!
ligand!for!the!MR,!resulting!in!
sodium!retention!and!volume!
expansion.!
!6
.!P
se
ud
oh
yp
oa
ld
os
te
ro
ni
sm
!(P
HA
)!
PHA1A!
MIM!177735!(AD)!
↓↓BP,!↓Na+,!↑↑K+,!↑↑serum!
aldosterone,!↑↑!plasma!renin!
activity,!metabolic!acidosis.!
Onset!in!infancy.!
NR3C2(
4q31.2!
Loss!of!function!mutation!in!
MR!that!impairs!maximal!salt!
reabsorption,!with!reduced!
ENaC!activity,!leading!to!salt!
wasting!despite!elevated!
aldosterone!levels.!!
PHA2B!“Gordon!
syndrome”!
MIM!614491!(AD)!
↑↑BP,!↓↓!plasma!renin!activity,!
↑K+,!↑↑ClJ,!↑!aldosterone.!
Treated!by!thiazide!diuretics.!
WNK4(
17q21.2!
LossJofJfunction!mutations!in!
WNK4,!or!WNK1(which!
encode!proteins!involved!in!
electrolyte!homeostasis,!
leading!to!reduced!potassium!
excretion!from!the!kidney,!
despite!normal!renal!
glomerular!filtration.!The!
pathogenic!sequence!is!
similar!to!PHA1A;!despite!the!
high!level!of!aldosterone,!the!
normal!target!for!MR!
activation,!ENaC,!is!missing.!
PHA2C!“Gordon!
syndrome”!
MIM!614492!(AD)!
↑↑BP,!↓↓!plasma!renin!activity,!
↑K+,!↑↑ClJ,!↑!aldosterone.!
Treated!by!thiazide!diuretics.!
WNK1(
12p12.3!
PHA2D!
MIM!614495!(AD/AR)!
↑K+,↑Cl,!metabolic!acidosis.!Age!
at!diagnosis!24!+/J!18!years!for!
AD.!
Age!at!diagnosis!26!+/J!14!years!
for!AR.!
KLHL3(
5q31.2!
Loss!of!function!missense!
mutations!in!KLHL3!that!
disrupt!binding!to!WNK4,!
WNK1,!or!CUL3,!leading!to!
decreased!ubiquitination!and!
increased!levels!of!WNK4.!
PHA2E!
MIM!614496!(AD)!
↑↑BP,!↓!plasma!renin,!↑K+,!↑↑Cl,!
metabolic!acidosis.!
Age!at!diagnosis!18!+/J!6!years.!
CUL3(
2q36.2!
Loss!of!function!mutations!
that!disrupt!ubiquitination!of!
at!least!a!subset!of!KLHL3!
targets.!Patient!affected!with!
PHA2E!have!the!worst!
symptoms!of!PHA.!
7.!
!
Sporadic!aldosteroneJ
producing!adenoma!
(APA),!or!primary!
aldosteronism!(AD)!
!
!
!
↑↑BP,!↑↑!aldosterone,!↓K+,!
↓Na+,!↓↓plasma!renin!activity,!
metabolic!alkalosis.!
!
KCNJ5(
11q24.3!
Gain!of!function!mutations!in!
and!near!the!selectivity!filter!
of!the!potassium!channel!
KCNJ5!produces!increased!
sodium!conductance!and!cell!
depolarization,!triggering!
calcium!entry!into!
glomerulosa!cells,!the!signal!
for!aldosterone!production!
and!cell!proliferation.!
ATP1A1(
1p31.1!
Mutations!in!ATP1A1!that!
encodes!Na+/K+!ATPase!α!
subunit!that!is!expressed!in!
adrenal!cells!and!control!Na+,!
K+,!Ca2+!homeostasis.!
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CACNA1D(
3p21.3!
Mutation!in!CACNA1D,!which!
encodes!voltageJsensitive!Ca2+!
channels!that!regulates!
hormone!and!
neurotransmitter!release.!!
ATP2B3(
Xq28!
Mutations!in!ATP2B3(that!
encodes!Ca2+!ATPase,!which!is!
expressed!in!adrenal!cells!and!
control!Na+,!K+,!Ca2+!
homeostasis.!
8.!
Hypertension!
exacerbation!
in!pregnancy!
MIM!605115!(AD)!
↑↑BP,!↓K+,!↓↓plasma!renin!
activity,!↓↓aldosterone.!
NR3C2(
4q31.2!
Gain!of!function!mutation!in!
the!ligand!binding!domain!of!
MR!that!causes!increased!
renal!reabsorption!and!
hypertension.!
Glucocorticoid!Pathway:!Defects!in!enzymes!of!cortisol!biosynthesis!result!in!a!group!of!autosomal!recessive!
disorders!collectively!called!congenital!adrenal!hyperplasia.!In!some!of!these!syndromes,!plasma!ACTH!will!increase!
in!an!attempt!to!produce!cortisol,!and!the!some!of!the!aberrant!products!that!accumulate!can!result!in!
hypertension.!
9.! 11βJhydroxylase!MIM!202010!(AR)!
↑↑BP,!↑↑ACTH,!↓↓aldosterone,!
↓↓renin,!↓↓cortisol,!↓↓K+,!
↑↑FSH,!↑↑deoxycorticosterone.!
Treated!by!glucocorticoid!
therapy.!
!
CYP11B1(
8q21!
Loss!of!function!mutation!in!
CYP11B1,!leading!to!
decreased!conversion!of!11J
deoxycortisol!and!11J
deoxycorticosterone!to!
cortisol!and!corticosterone,!
respectively;!resulting!in!
accumulation!of!11J
deoxycortisol!and!11J
deoxycorticosterone;!which!is!
a!potent!saltJretaining!
mineralocorticoid!that!leads!
to!arterial!hypertension.!
10.!
3βJhydroxysteroid!
dehydrogenase!(AR)!
OMIM!613890!
HSD3B2(
1p12!
Genetic!mutation!in!HSD3B2,!
which!is!important!for!
production!of!all!classes!of!
steroid!hormones.!
11.!
17αJhydroxylase!
deficiency!
MIM!202110!(AR)!
CYP17A1(
10q24.3!
Loss!of!function!mutation!in!
CYP17A1,!which!encodes!
steroid!17αJhydroxylase,!
leading!to!an!excessive!
amount!of!corticosterone!and!
deoxycorticosterone!resulted!
in!hypertension!and!
hypokalemic!alkalosis.!
12.!
21JHydroxylase!
deficiency!
MIM!201910!(AR)!
CYP21A2(
Genetic!mutation!in!CYP21A2,!
that!encodes!21Jhydrozylase!
enzyme,!which!is!essential!for!
adrenal!steroidgenesis.!
Sympathetic!pathway!
Monogenic!forms!of!hypertension!that!result!from!disruption!of!the!sympathetic!pathways!is!caused!by!genetic!
mutations!that!leads!to!rare!neuroendocrine!tumours!in!the!form!of!phaeochromocytomas!and!paragangliomas.!
This!is!accompanied!with!higher!level!of!catecholamines!that!increases!the!sympathetic!activity.!
13
.!P
ar
ag
an
gl
io
m
as
!(P
GL
)!
Paragangliomas!1!
MIM!168000!(AD)!
Tumours!or!extraadrenal!
paraganglia!associated!
pheochromocytoma,!
↑↑catecholamines!level,!↑↑BP,!
and!↑↑heart!rate.!
SDHD(
11q23.1!
Rare!tumours!diffuse!
paraganglionic!tissues!that!
are!located!internally!and!
centrally!around!the!major!
arteries,!nerves,!within!
organs.130!PGL!is!
characterized!by!genetic!
mutation!in!any!of!the!four!
subunits!of!the!mitochondrial!
succinate!dehydrogenase!
enzyme!complex!(SDH),!which!
catalysed!the!conversion!of!
succinate!to!fumarate!in!the!
Krebs!cycle!and!serves!as!
Paragangliomas!2!
MIM!601650!(AD)!
SDHAF2(
11q12.2!
Paragangliomas!3!
MIM!605373!(AD)!
SDHC(
1q23.3!
Paragangliomas!4!
MIM!115310!(AD)!
SDHB(
1p36.13!
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Paragangliomas!5!
MIM!614165!(AD)!
SDHA(
5p15.3!
complex!II!of!the!electron!
transport!chain.!SDHAF2!
encodes!a!protein!that!is!
necessary!for!SDH!function.!
These!are!collectively!known!
as!the!SDHx(genes.!
14.!
von!Hippel–Lindau!
syndrome!!
MIM!193300!(AD)!
↑↑BP,!retinal,!cerebellar,!and!
spinal!hemangioblastoma,!renal!
cell!carcinoma,!
pheochromocytoma,!and!
pancreatic!tumours.!
VHL(
3p25.3!
Genetics!mutation!in!VHL,!
that!encodes!protein!
important!in!tumour!
suppression!mechanisms.!
15.!
Multiple!endocrine!
neoplasia,!type!IIA!
MIM!171400!(AD)!
!
Multiple!endocrine!neoplasms,!
including!medullary!thyroid!
carcinoma,!pheochromocytoma,!
and!parathyroid!adenomas.!
↑↑BP.!
RET(
10q11.2!
Genetic!mutation!in!the!RET!
oncogene,!that!produce!
constitutively!activated!
receptors,!leading!to!several!
endocrine!and!neuralJcrestJ
derived!tumour.!
16.!
NOS3JpregnancyJ
induced!hypertension!
(AD)!
MIM!+163729!
Hypertension!that!is!exacerbated!
during!pregnancy.!
NOS3(
7q36.1!
Genetic!mutation!in!NOS3,!
leading!to!dysfunction!
releases!of!NO,!which!an!
important!role!in!the!
maintenance!of!
cardiovascular!and!renal!
homeostasis.!
Table!is!compiled!from!information!in!these!reviews!37,38,40,!direction!of!the!arrow!indicates!either!low!level!or!high!
level.!
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1.6.2+ Overview+of+GWAS+for+BP+and+hypertension+
Several GWAS have been conducted using BP as a quantitative trait, or by using 
a binary definition of hypertension. The first GWAS was a case-control design 
from the Wellcome Trust Case Control Consortium (WTCCC), published in 
2007.131 The study examined seven complex diseases of major public health 
importance using 2,000 cases in each, and 3,000 shared control. The study 
genotyped approximately 500,000 SNPs using the 500 K Affymetrix SNP chip, and 
reported a total of 24 significant SNPs (p<5.0x10-7) that were associated with the 
six examined diseases, apart from hypertension, which was the only trait 
without any significant signal even in the regions that previously showed 
evidence of association. This failure in identifying significant SNPs also extended 
to the first GWAS that analysed BP as a quantitative trait in the Framingham 
Heart Study, in which almost 71,000 SNPs were genotyped in about 1,400 related 
individuals.132 The study used six primary phenotypes for BP that were derived 
from single and long-term averaged (LTA) SBP and DBP, in which all the analysed 
phenotypes failed to produce significant association signals. These two studies 
represent the first attempts at applying the GWAS approach for hypertension 
and BP. Although no association signals were reported for hypertension, 
important lessons were taken from these two attempts. For instance, failing to 
identify any association signal for hypertension only in WTCCC emphasized the 
complexity of hypertension, and the need for having much larger sample size to 
reveal association signals for genetic marker with low effect size.  
The first two successful GWAS for BP were reported in 2009 by two large 
consortia, the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) study 115, and the Global Blood Pressure Genetic (Global BPgen) 
study.133The limited resources of case-control samples necessitated the study of 
BP primarily as a quantitative trait in these two studies. The CHARGE consortium 
included six population-based cohorts of European ancestry with a total sample 
size of 29,000 individuals, and the Global BPgen consisted of 17 cohorts with a 
total sample size of 34,000 at the discovery phase. The two consortia tested the 
association of SBP and DBP as the primary phenotypes, using a cross-sectional 
measurement with addition of a fixed value of 15/10 mmHg or 10/5 mmHg for 
individuals taking antihypertensive therapies in CHARGE and Global BPgen, 
respectively. In order to combine the results from different cohorts, imputation 
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was performed to impute the missing markers between the included cohorts, 
allowing to merge the genotypes results from different genotyping chips and 
platforms. The final association tests were performed in almost 2.5 million 
genotyped or imputed SNPs and discovered 13 loci independently associated 
with SBP or DBP at a level of genome-wide significance (p<5.0x10-8). Each study 
reported eight loci with three loci overlapping in both studies. These two studies 
have been followed by further GWASs and the results of these studies are 
summarised in Table 1-5. In addition, most of the loci reported in these two 
studies were novel except for some loci such as CYP17A1-NT5C2 and MTHFR-
NPPB, the former has been associated with a rare Mendelian form of 
hypertension, and the later lies in a region that has previously been associated 
with BP and hypertension.134 
Most of the studies in CHARGE and Global BPgen consortia were then included in 
a larger follow-up study by the ICBP consortium in 2011.107 The ICBP included 
more than 69,000 individuals in the discovery sample, followed by a replication 
in 133,000 individuals, making it the largest GWAS meta-analysis of BP to date. 
The SNPs association analyses were performed under an additive genetic model, 
which assumes that the effect conferred by an allele is increased by r-fold for 
heterozygotes and 2r-fold for homozygotes. The model was adjusted for sex, 
BMI, age, and its square (to account for the middle age plateau of DBP). Also, a 
fixed value of 15/10 mmHg was added to individuals taking antihypertensive 
treatment to account for treatment effect. The study identified 29 independent 
SNPs at 28 loci, of which 16 loci were novel and the remaining 13 loci were a 
replication of the previously reported loci in CHARGE or Global BPgen. Although 
the majority of SNPs identified by ICBP were intragenic, some loci were in gene 
desert regions or in genomic regions that has no gene encoding protein with a 
biological plausible effect on BP.  
A second study was also carried out by the ICBP consortium using MAP and PP as 
primary phenotypes with the addition of a further six studies in the consortia, 
increasing the total discovery sample size to more than 74,000 individuals.135 
The study identified four novel loci associated with PP and two loci associated 
with MAP, with one locus associated with both traits near to FIGN. The 
importance findings of this study is that three of the four loci associated with PP 
79 
 
were found to have an opposite effect in SBP and DBP, unlike the majority of BP 
variants that exerts effect in the same direction on SBP and DBP, which suggests 
the presence of genetic pathways that may differentially influence SBP and DBP. 
The study has also showed that most of MAP variants were also associated with 
both SBP and DBP, suggesting a high correlation between these three BP traits. 
Most of the GWAS for BP have taken the quantitative approach by studying BP as 
a quantitative trait, except for two studies that analysed hypertension as a 
binary trait.82,136 The first study has successfully identified a novel locus located 
in the promoter region of Uromodulin gene (UMOD), which is exclusively 
expressed in the kidney and may influence BP by a novel sodium homeostatic 
pathway.82 An alternative strategy were taken by this study in recruiting case 
and control groups by selecting individuals from the extreme of the BP 
distribution, this strategy has allowed a sharper contrast between case and 
control, and hence a smaller sample size would be required compared to a 
normal case-control study from the general population. The identified variant 
has also showed a suggestive evidence for association with SBP and DBP, with a 
consistent direction of effect with the odds of hypertension. The second study 
has used a classical case-control approach using the HYPERGENES Project, and 
identified a new locus in the promoter region of the endothelial NO synthase 
gene, which is a critical mediator for cardiovascular homeostasis and BP control 
via vascular tone regulation136 
GWAS for populations other than European descent were also performed with 
the aim of replicating the variants identified in European populations, and also 
finding new population-specific loci. The Asian Genetic Epidemiology Network 
Blood Pressure (AGEN-BP) was the largest non-European GWAS that included 
more than 30,000 individuals in the discovery stage and 20,000 for replication.137 
AGEN-BP identified six novel loci and confirmed seven loci previously reported in 
CHARGE and Global BPgen. The Continental Origins and Genetic Epidemiology 
Network (COGENT) study also performed another large GWAS using a trans-
ethnic meta-analysis and discovery sample size of 29,000 individuals of African 
American (AA) origin138 The replication sample included a mixed ethnic 
background of European and East Asian origins due to a lack of sufficient 
samples from AA. The COGENT study reported five loci associated with SBP or 
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DBP, three of which were not previously reported to be associated with BP. 
Another GWAS was also performed recently in the Chinese population and 
reported 3 novel loci, and replicated 14 previously reported loci.139 The success 
of replicating the previously reported loci for European population in the other 
population suggests that the physiologic effects of these loci may be generalized 
across populations with diverse genetic backgrounds. Yet, identifying novel loci 
also suggests that populations with different genetic background may have a 
unique genetic factors as a result of differences in allele frequencies or 
population-specific factors that interact with genes to influence BP.  
Several studies have used measured other than the single-time BP phenotypes in 
their GWAS to improve the phenotype accuracy. One study used the average of 
BP measurements across time instead of the single-visit measurement approach 
that is typically used in most of GWAS.140 This study identified 39 association 
signals at 19 loci; of them, 4 loci were novel. The study has also estimated a 20% 
improvement in statistical power with using the LTA approach over the single-
visit method (discussed in more details in the next Section 1.6.3 - p87). Another 
study has used the visit-to visit variability in BP and identified a cluster of 
genetic variants within the NLGN1 gene (3q26.31), but further replication of this 
finding is required.141 Finally, a family study of 2020 individuals used the mean 
of 24-hr BP measurements that were derived from the ABMP, and reported 
association of 24-hr DBP with a SNP in the promoter region of MTHFR and CLCN6 
genes.142 
A large scale study was performed by CHARGE, Global BPgen, and ICBP consortia 
by taking a non-standard approach to assess the gene-age interaction at GWAS 
level, in the first attempt to assess the gene-age interaction on BP using 
common variants from GWAS data.143 Unlike other GWAS that adjust for age by 
including it in the covariates, this study stratified subjects into 10-year age bins 
(20-29 years, 30-39 years …etc.) and then conducted the SNP association test 
within each age bin separately. The resulted SNP main effect estimates and 
their standard errors from all age bins were then entered into a meta-regression 
analyses through a linear regression of the SNP effect estimates onto the median 
age of each sub-group. The study was performed in a two-stage design using 
more than 99,000 individuals, and reported 20 variants using joint tests of the 
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SNP main effect and SNP-age interaction. The SNPs with the largest age-gene 
interaction in three loci (CASZ1, EHBP1L1, and GOSR2) displayed opposite 
directions of effect by increasing BP in the young and decreasing BP in the old, 
by a difference in the effect size that can reach up to 1.58 mmHg. In a 
secondary analysis, the study explored the age-specific effects by meta-
analysing the results within each age bin separately, and identified 22 distinct 
loci with evidence of age-specific effects.!An important message from this study 
is that pooling data from different studies with a wide range of age distribution 
may obscure genetic effects that are age dependent. Gene-environmental 
interaction were also assessed in two other studies with smaller sample size; in 
the first; gene-alcohol interactions were found for SNP rs10826334 near SLC16A9 
modulated by both the number of alcoholic drinks and the ounces of alcohol 
consumed per week, as SBP decreased by 3.8 mmHg in those consuming 14 
drinks/week compared to only 0.46 in non-drinkers.144 The same group also 
assessed the gene-smoking and gene-education interactions in another two 
studies145,146. However, their findings have not been replicated in any external 
samples and future work is required to validate the reported markers.!
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Table+1G5+Loci+reported+in+GWAS+for+association+with+hypertension+or+BP+traits+
#! Locus! Nearby!gene! GWAS!SNP!
Population:!
Ref! Trait! CA! CAF! β!(se)!
1! 1p36.2! CASZ1( rs880315!
EA:!115! SBP! C! 0.35! 0.89!(0.17)!
AS:!147! SBP!DBP! C! 0.59!
1.08!(0.70!–1.46)!
0.79!(0.56–1.01)!
AS:!137! DBP! C! 0.65! 0.56!(0.09)!
AS:!139!
SBP!
DBP!
HTN!
C! 0.63!
0.97!(0.16)!
0.46!(0.09)!
0.09!(0.16)!
EA:!143! SBP!MAP! T! 0.64!
J0.43!(0.08)!
J0.27!(0.05)!
EA:!140!
LTA!SBP!
LTA!MAP!
LTA!PP!
T! NR!
J0.71!(0.1)!
J0.46!(0.07)!
J0.42!(0.07)!
2! 1p36.22!
MTHFR,(
CLCN6,(
NPPA,(
NPPB(
rs17367504!
EA:!133! SBP! G! 0.14! J0.85!(0.63J1.07)!
AS:!147! SBP!DBP! A! 0.90!
0.65!(0.07–1.24)!
0.34!(0.01–0.69)!
EA:!107!
SBP!
DBP!
HTN!
G! 0.15!
J0.90!
J0.55!
J0.10!
rs5068! EA:!134!! SBP!DBP! C! 0.06!
J0.08!(0.02)!
J0.08!(0.02)!
3! 1p13.2!
SLC16A1,(
CAPZA1,(
ST7L,(
MOV10(
rs2932538a! EA:!107! SBP!DBP! G!! 0.75!
0.39!
0.24!
rs17030613!! AS:!137! DBP! C!! 0.49! 0.38!(0.07)!
rs10745332a! AS:!139!
SBP!
DBP!
HTN!
A!! 0.82!
0.96!(0.18)!
0.53!(0.1)!
0.11!(0.02)!
4! 1q32.1! MDM4( rs2169137! EA:!148! DBP! G! 0.27! J0.35!(0.07)!
5! 1q42.2! AGT( rs2004776!
EA:!149!
SBP!
DBP!
HTN!
T! NR!
0.42!(0.09)!
0.32!(0.06)!
0.08!(0.02)!
EA:!150! HTN! T! 0.24! 0.14!(0.02)!
6! 2p23.2! KCNK3( rs1275988! EA:!140! LTA!SBP!LTA!MAP! T! NR!
J0.60!(0.09)!
J0.39!(0.06)!
7! 2q11.2! FER1L5( rs7599598! EA:!140! LTA!DBP! A! NR! J0.31!(0.05)!
8! 2q24.3! FIGN( rs1446468! EA:!135!
SBP!
DBP!
MAP!
T! 0.53!
J0.50!(0.07)!
J0.26!(0.05)!
J0.34!(0.05)!
9! 2q24.3! FIGN( rs13002573! EA:!135! PP! G! 0.20! J0.31!(0.05)!
10! 2q24.3! FIGN( rs16849225! AS:!137! SBP! C! NR! 0.75!(0.11)!
11! 2q24.3! STK39( rs6749447! EA:!151! SBP! G! 0.19! 1.9!(0.6)!
12! 2q32.1! PDE1A( rs16823124! EA:!152! DBP!MAP! A! 0.30!
0.26!(0.04)!
0.27!(0.05)!
13! 3p25.3! HRH1&ATG7( rs347591! EA:!148! SBP! G! 0.36! J0.53!(0.11)!
14! 3p24.1! SLC4A7(
rs13082711! EA:!107! DBP! T! 0.78! J0.24!
rs820430! AS:!139! SBP! A! 0.32! 0.76!(0.11)!
15! 3p22.1! ULK4(
rs9815354a!
EA:!115! DBP! A! 0.17! 0.49!(0.08)!
AS:!139! DBP! A! 0.19! 0.67!
rs3774372a! EA:!107! DBP! T! 0.83! J0.37!
rs1717027a! Mix:138! DBP! T! 0.46! 0.49!(0.10)!
16! 3p21.31! MAP4(
rs319690!
EA:!135!
SBP!
DBP!
MAP!
T! 0.51!
0.42!(0.07)!
0.28!(0.05)!
0.29!(0.05)!
AS:!153! MAP! T! 0.67! 0.38!(0.20)!
AS:!154! MAP! T! 0.71! 0.26!(0.11)!
rs7651237! EA:!143! DBP! G! 0.71! 0.30!(0.07)!
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#! Locus! Nearby!gene! GWAS!SNP!
Population:!
Ref! Trait! CA! CAF! β!(se)!
MAP! 0.34!(0.05)!
17! 3p21.1! CACNA1D(( rs9810888!! AS:!139! SBP!DBP! G! 0.39!
0.53!(0.10)!!
0.39!(0.06)!
18! 3q26.1! MIR1263( rs16833934! EA:!143! DBP!MAP! G! 0.26!
J1.63!(0.29)!
J1.33!(0.27)!
19! 3q26.2! MECOM( rs419076a!
EA:!107! SBP!DBP! G! 0.47!
0.41!
0.24!
EA:!135!
SBP!
DBP!
MAP!
T! 0.44!
0.50!(0.07)!
0.30!(0.04)!
0.34!(0.04)!
20! 4q12! CHIC2( rs871606!
EA:!135! PP! T! 0.85! 0.43!(0.08)!
AS:!153! PP! T! 0.79! 0.40!(0.23)!
21! 4q21.21! FGF5(
rs16998073a!
EA:!134!! DBP! T! 0.24! 0.36!(0.12)!
AS:!147! SBP!DBP! T! 0.31!
1.51!(1.12–1.89)!
0.82!(0.59–1.05)!
AS:137! SBP!DBP! T! 0.30!
1.43!(0.20)!
0.76!(0.11)!
rs1458038a!
EA:!107! SBP!DBP! T! 0.29!
0.71!
0.45!
EA:!135!
SBP!
DBP!
MAP!
T! 0.30!
0.56!(0.08)!
0.40!(0.05)!
0.40!(0.05)!
22! 4q24! SLC39A8( rs13107325!
EA:!107! SBP!DBP! T! 0.05!
J0.98!
J0.68!
EA:!135!
SBP!
DBP!
MAP!
T! 0.12!
J0.90!(0.14)!
J0.60!(0.09)!
J0.63!(0.10)!
23! 4q25! ENPEP,(PITX2( rs6825911! AS:137! DBP! C! 0.51! 0.39!(0.07)!
24! 4q32.1!
GUCY1A3&
GUCY1B3(
(
rs13139571! EA:!107! DBP! C! 0.76! 0.26!
25! 5p13.3! NPR3&C5orf23(
rs1173771a!
EA:!107!
SBP!
DBP!
HTN!
G! 0.60!
0.50!
0.26!
0.06!
EA:!135!
SBP!
MAP!
PP!
G! 0.52!
0.51!(0.07)!
0.28!(0.05)!
0.28!(0.05)!
rs7733331a! EA:!140! LTA!SBP! T! NR! J0.55!(0.09)!
rs1173766! AS:137! SBP! C! 0.60! 0.63!(0.11)!
26! 5q33.3! EBF1( rs11953630! EA:!107! SBP!DBP! T! 0.37!
J0.41!
J0.28!
27! 6p22.2! HFE(
rs1799945!
EA:!107!
SBP!
DBP!
HTN!
G! 0.14!
0.63!
0.46!
0.10!
EA:!150! DBP! G! 0.14! 0.50!(0.12)!
EA:!148! DBP! G! 0.15! 0.41!(0.09)!
AS:!139!
SBP!
DBP!
HTN!
G! 0.04!
0.95!(0.36)!
0.88!(0.20)!
0.16!(0.04)!
rs198823! EA:!140! LTA!DBP! T! NR! J0.33!(0.06)!
28!
6p21.33!
BAG1( rs805303! EA:!107!
SBP!
DBP!
HTN!
G! 0.61!
0.38!
0.23!
0.05!
29! CYP21A2( rs2021783! AS:!139!
SBP!
DBP!
HTN!
C! 0.79!
0.68!(0.12)!
0.49!(0.07)!
0.09!(0.01)!
30! 6p21.32! HLA&DQB1( rs2854275! EA:!152! DBP! A! 0.13! J0.56!(0.10)!
31! 6p21.1! CRIP3( rs10948071! EA:!140! LTA!PP! T! NR! J0.38!(0.07)!
32! 6q22.33! RSPO3( rs13209747! Mix:!138! SBP! T! 0.19! 0.85!(0.21)!
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#! Locus! Nearby!gene! GWAS!SNP!
Population:!
Ref! Trait! CA! CAF! β!(se)!
DBP! 0.56!(0.12)!
33! 6q25.1! PLEKHG1( rs17080102! Mix:!138! SBP!DBP! C! 0.10!
J1.02!(0.25)!
J0.74!(0.15)!
34! 7p15.2! EVX1&HOXA( rs17428471! Mix:!138!
SBP!
DBP! T! 0.14!
1.20!(0.24)!
0.61!(0.14)!
35! 7p12.3! IGFBP3( rs2949837! EA:!140! LTA!PP! A! NR! 0.40!(0.07)!
36! 7q21.2! CDK6( rs2282978! EA:!152! PP! C! 0.34! 0.27!(0.05)!
37! 7q22.3! PIK3CG(
rs17477177a! EA:!135! SBP!PP! T! 0.71!
J0.55!(0.08)!
J0.42!(0.06)!
rs12705390a!
EA:!143! PP! G! 0.78! J0.42!(0.06)!
EA:!140! LTA!SBP!LTA!PP! A!
NR!
!
0.63!(0.11)!
0.59!(0.08)!
38! 7q36.1! NOS3( rs3918226!
EA:!150! DBP! T! 0.08! 0.78!(0.21)!
EA:!136! HTN! T! 0.12! OR!1.54!(1.37J1.73)!
39! 8p23.1! BLK&GATA4(
rs4841569! EA:!143! SBP!MAP! G! 0.57!
0.14!(0.31)*!
0.26!(0.21)*!
rs2898290! EA:!155! SBP! C! 0.53! NR!
40! 8q24.12! NOV( rs2071518! EA:!135! PP! T! 0.17! 0.31!(0.05)!
41! 10p12.31! CACNB2(
rs11014166!a!
EA:!115! DBP! A! 0.66! 0.37!(0.06)!
AS:!156! SBP! T! NR! −0.19!(0.69)!
rs1813353a! EA:!143!
SBP!
DBP!
MAP!
T! 0.68!
0.53!(0.29)*!
0.58!(0.19)*!
0.56!(0.20)*!
rs4373814! EA:!107!
SBP!
DBP!
HTN!
G! 0.55!
J0.37!
J0.22!
J0.05!
rs12258967! EA:!140!
LTA!SBP!
LTA!DBP!
LTA!MAP!
C! NR!
0.35!(0.06)!
0.63!(0.10)!
0.45!(0.07)!
42! 10q21.2! c10orf107(
rs1530440! EA:!134! DBP! T! 0.19! J0.44!(0.12)!
rs4590817! EA:!107!
SBP!
DBP!
HTN!
G! 0.84!
0.65!
0.42!
0.10!
rs12244842! EA:!140! LTA!DBP!LTA!MAP! T! NR!
J0.38!(0.06)!
J0.48!(0.08)!
rs7070797! EA:!140! LTA!SBP! A! NR! J0.74!(0.13)!
43! 10q22.2! VCL( rs4746172! EA:!152! DBP!MAP! C! 0.25!
0.23!(0.04)!
0.28!(0.05)!
44! 10q23.33! PLCE1( rs932764! EA:!107! SBP!HTN! G! 0.44!
0.48!
0.05!
45! 10q24.32! CYP17A1&NT5C2(
rs1004467a! EA:!115! SBP! A! 0.90! 1.05!(0.16)!
rs11191548a!
EA:!134! SBP! T! 0.92! 1.05!(0.27)!
AS:137! SBP!DBP! T! 0.74!
1.18!(0.14)!
0.58!(0.08)!
EA:!107! SBP!DBP! T! 0.91!
1.10!
0.46!
rs12413409! AS:!147! SBP!DBP! G! NR!
1.58!(1.18–1.98)!
0.76!(0.53–1.00)!
rs4409766a! AS:!139! SBP!DBP! T! 0.71!
1.24!(0.15)!
0.59!(0.09)!
rs3824755! EA:!148! SBP!PP! C! 0.10!
J0.64!(0.12)!
J0.64!(0.12) 
46! 10q25.3! ADRB1(
rs2782980! EA:!135! MAP! T! 0.20! J0.39!(0.06)!
rs7076938! EA:!148! MAP! C! 0.28! J0.39!(0.08)!
rs1801253! EA:!143! DBP!MAP! G! 0.27!
J0.29!(0.20)*!
J0.34!(0.22)*!
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#! Locus! Nearby!gene! GWAS!SNP!
Population:!
Ref! Trait! CA! CAF! β!(se)!
47! 11p15.5! LSP1&TNNT3( rs661348!
EA:!150! MAP! T! 0.57! J0.65!(0.11)!
EA:!148! SBP! C! 0.43! 0.47!(0.10)!
48! 11p15.4! ADM( rs7129220! EA:!107! SBP! G! 0.89! J0.62!
49! 11p15.1!
PLEKHA7( rs381815!
EA:!115! SBP! T! 0.26! 0.65!(0.11)!
EA:!107! SBP!DBP! T! 0.26!
0.56!
0.35!
EA:!143!
SBP!
DBP!
MAP!
T! 0.25! 0.03!(0.22)*!
PIK3C2A,(
NUCB2,(
NCR3LG1(
rs757081! EA:!152!
SBP!
MAP!
PP!
G! 0.33!
0.26!(0.05)!
0.32!(0.05)!
0.40!(0.06)!
50! 11p15.2! SOX6(
rs2014408a!
EA:!150! MAP! T! 0.21! 0.58!(0.13)!
EA:!148! SBP! C! 0.43! 0.47!(0.10)!
Mix:!138! DBP! T! 0.46! 0.45!(0.10)!
rs4757391a! AS:!139! SBP!DBP! C! 0.28!
0.88!(0.15)!
0.49!(0.09)!
51! 11q13.1! EHBP1L1( rs4601790! EA:!143! DBP!MAP! G! 0.27!
0.84!(0.21)*!
0.91!(0.22)*!
52! 11q13.1! RELA( rs3741378! EA:!152! SBP!MAP! T! 0.13!
J0.36!(0.07)!
J0.55!(0.09)!
53! 11q22.1! FLJ32810&TMEM133( rs633185! EA:!107!
SBP!
DBP!
HTN!
G! 0.28!
J0.56!
J0.33!
J0.07!
54! 11q24.3! ADAMTS8( rs11222084! EA:!135! PP! T! 0.38! 0.337!(0.05)!
55! 12q13.13! HOXC4( rs7297416! EA:!152! SBP! C! 0.30! J0.33!(0.07)!
56! 12q21.33! ATP2B1(
rs11105354a! EA:!150! HTN! G! 0.16! J0.12!(0.04)!
rs2681492a!
EA:!115!
SBP!
DBP!
HTN!
T! 0.80!
0.85!(0.13)!
0.50!(0.08)!
0.15!(0.02)!
AS:!154! MAP! T! 0.67! 0.61!(0.12)!
rs2681472a!
AS:!147! SBP!DBP! A! NR!
0.99!(0.62–1.35)!
0.43!(0.21–0.64)!
EA:!148! SBP!MAP! G! 0.17!
J0.97!(0.16)!
J0.61!(0.11)!
EA:!140!
LTA!SBP!
LTA!DBP!
LTA!MAP!
A! NR!
0.52!(0.07)!
0.95!(0.12)!
0.69!(0.08)!
rs17249754a!
AS:137! SBP!DBP! G! 0.64!
1.17!(0.13)!
0.58!(0.08)!
EA:!107!
SBP!
DBP!
HTN!
G! 0.84!
0.93!
0.52!
0.13!
AS:!139!
SBP!
DBP!
HTN!
G! 0.64!
1.03!(0.15)!
0.52!(0.08)!
0.084!(0.016)!
57! 12q24.12! SH2B3(
rs3184504a!
EA:!115! SBP!DBP! T! 0.48!
0.58!(0.10)!
0.48!(0.06)!
EA:!107! SBP!DBP! T! 0.47!
0.60!
0.45!
EA:!140! LTA!DBP!LTA!MAP! T! NR!
0.39!(0.05)!
0.45!(0.06)!
rs653178a! EA:!134! DBP! T! 0.52! J0.46!(0.05)!
58! 12q24.13! RPL6&ALDH2( rs11066280!
AS:137! SBP!DBP! T! 0.74!
1.56!(0.13)!
1.01!(0.08)!
AS:!139! SBP!DBP! T! 0.81!
0.96!(0.17)!
0.62!(0.10)!
59! 12q24.21! TBX5&TBX3( rs35444!
AS:137! DBP! A! 0.75! 0.50!(0.08)!
EA:!140! LTA!SBP! A! NR! 0.55!(0.09)!
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#! Locus! Nearby!gene! GWAS!SNP!
Population:!
Ref! Trait! CA! CAF! β!(se)!
LTA!MAP! 0.36!(0.06!
rs2384550a! EA:!115! DBP! A! 0.35! J0.35!(0.06)!
rs10850411! EA:!107! SBP!DBP! T! 0.7!
0.35!
0.25!
rs1991391a! AS:!139! DBP! G! 0.85! 0.60!(0.20)!
MED13L( rs11067763! AS:!139! SBP!DBP! A! 0.62!
0.81!(0.10)!
0.51!(0.06)!
!
60! 15q21.1! FBN1( rs1036477! EA:!152! PP! G! 0.11! J0.40!(0.08)!
61! 15q24.1! CYP1A1&ULK3(
rs6495122!
EA:!115! DBP! A! 0.42! 0.40!(0.06)!
EA:!155! DBP! A! 0.43! NR!
rs1378942!
EA:!134! DBP! C! 0.33! 0.43!(0.04)!
EA:!107! SBP!DBP! C! 0.35!
0.61!
0.42!
EA:!135!
SBP!
DBP!
MAP!
C! 0.33!
0.59!(0.07)!
0.42!(0.05)!
0.37!(0.05)!
62! 15q24.2! COX5A(
rs11072518! EA:!140! LTA!SBP!LTA!MAP! T! NR!
0.57!(0.09)!
0.43!(0.06)!
rs1133323! EA:!140! LTA!DBP! T! NR! J0.33!(0.05)!
63! 15q26.1! FURIN&FES( rs2521501!
EA:!107! SBP!DBP! T! 0.31!
0.65!
0.36!
EA:!135!
SBP!
DBP!
MAP!
T! 0.37!
0.58!(0.09)!
0.37!(0.05)!
0.34!(0.06)!
64! 16p12.3! UMOD( rs13333226! EA:!82! HT! G! NR! OR!0.87!(0.84–0.91)!
65! 16q22.1! NFAT5( rs33063! EA:!152! PP! A! 0.14! 0.34!(0.07)!
66! 17q21.31! PLCD3( rs12946454! EA:!134! SBP! T! 0.27! 0.57!(0.10)!
67! 17q21.32! GOSR2( rs17608766!
EA:!107! SBP! T! 0.86! J0.56!
EA:!143! PP! T! 0.84! J0.52!(0.32)*!
68! 17q21.33! ZNF652(
rs12940887! EA:!107! SBP!DBP! T! 0.38!
0.36!
0.27!
rs16948048! EA:!134! DBP! G! 0.37! 0.31!(0.05)!
69! 20p12.2! JAG1(
rs1327235a!
EA:!107! SBP!DBP! G! 0.46!
0.30!
0.30!
EA:!135! DBP!MAP! G! 0.58!
0.26!(0.04)!
0.26!(0.05)!
rs1887320a! AS:!139! SBP!DBP! A! 0.53!
0.78!(0.14)!
0.43!(0.08)!
70! 20q13.32!
GNAS&
EDN3( rs6015450! EA:!107!
SBP!
DBP!
HTN!
G! 0.12!
0.90!
0.56!
0.11!
C20orf174( rs6092743! EA:!140!
LTA!SBP!
LTA!DBP!
LTA!MAP!
A! NR!
0.84!(0.14)!
0.50!(0.08)!
0.64!(0.10)!
SNPs!in!the!same!locus!with!a!superscript!“a”!are!in!LD!(r!>0.80),!NR:!Not!Reported!
*!Effect!size!is!the!theoretical!SNP!effect!on!BP!in!mmHg!at!birth!(age!=0).!
SNPs!that!are!genotyped!in!this!thesis!are!underlined.!
 
87 
 
1.6.3+ Challenges+of+GWAS+for+BP+and+hypertension+
Despite the promising success of the second wave of GWAS for hypertension and 
BP traits, with findings of almost 70 loci as shown in Table 1-5, the proportion of 
phenotypic variance that is explained by all of these loci together is less than 
2.5%.107 This phenomenon of “missing heritability” is not restricted to BP traits, 
but has been observed in almost all the findings of GWAS for the complex traits. 
For instance, a classic complex trait such as height has a very large heritability 
estimate from family studies (about 80%), yet the identified loci through GWAS 
explain less than 10% of the phenotypic variance despite studies with very large 
sample sizes (>180,000 individuals).157,158 Later, a genome-wide complex trait 
analysis (GCTA) approach in unrelated individuals showed that 45% of height 
variance can be explained by the common SNPs (h2SNP) in the human genome,  
leaving more than 30% of the variance in height still unexplained.159 The GCTA 
approach was introduced by Yang et al. in 2010, and is based on estimating the 
heritability from unrelated individuals using common SNPs with the assumption 
that heritability estimates in unrelated individuals is only attributable to the 
common SNPs, while the estimation in related individuals is attributed to the 
entire genome.159  
Applying the same approach to SBP has shown that h2SNP was about 24%, which is 
approximately 50% of the heritability estimates from other twin-studies, and 
about 80% of the same study heritability estimate (h2 =30%).160 Furthermore, the 
number of independent variants with similar effect size to those reported in the 
ICBP study was estimated to be 116 (95% CI: 57-174), which can collectively 
explain around 2.2% of the phenotypic variance for BP phenotypes, compared 
with only 0.9% explained by the 29 SNPs identified by ICBP.107 These findings 
indicate that a large proportion of the heritability of BP is hidden rather than 
missing because of large number of common variants, each of which has too 
small an effect to be detected at the stringent genome-wide significance level 
using current sample sizes. Another possible explanation for this is that a typical 
GWAS does not consider the non-standard genetic contributions such as allelic 
heterogeneity, rare alleles, epistasis, parent-of-origin effects, and genetic 
variance heterogeneity, all of which can make significant contributions to the 
phenotypic variance. 
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A general trend in GWAS approaches is to increase sample sizes to enable the 
detection of variants with small effect size, especially for quantitative traits as 
they are more powered than binary traits in this setting (i.e. detection of 
variants with modest effect size). Basically, this relies on the hypothesis that if 
a part of the phenotypic variance can be explained by genetic factors, then 
increasing sample size would allow alleles with modest effect to gain statistical 
significance. Although studies with such enormous sample size offer the 
statistical power to detect larger number of variants with smaller effect size, it 
was argued that increasing the sample size may also scale the genetic 
heterogeneity in parallel, making it even harder to detect risk alleles.161,162 That 
is, increasing sample size in GWAS without unfolding heterogeneity of complex 
traits such as BP and hypertension may reduce the power of GWAS. For example, 
a case-control study of 5,000 cases and 5,000 controls with case misdiagnosis 
proportion equal to 20% has equivalent power of only 3,200 cases and 3,200 
controls without misdiagnosis cases or control.163  
A challenge for the success of most GWAS is the accuracy of phenotype, as most 
of the common disease phenotypes suffer from low resolution and 
imprecision.161 The majority of explanation and solutions of the missing 
heritability are related to the genetic factors, such as epistasis, CNV, gene-
environment interactions, or epigenetics. However, the way complex traits are 
measured, and phenotypic information is modelled is at least as important in 
GWAS as these genetic factors.164 For hypertension and BP traits, this represents 
a real challenge due to several factors that are related to the complexity of the 
disease per se and methods of measurements (discussed in Section 1.2.3.1 - 
p26). Typically, BP measurements for GWAS are based on a single-time visit; 
when more than one BP measurements are taken and the average of the last two 
measurements are used to calculate the measured BP level. Although this 
practice has proved valuable, it might be affected by several factors that can 
influence the BP measurements, and introduce additional sources of variability 
(noise) with resulting loss of statistical power to detect association signals.  
One way to strengthen the phenotype accuracy as performed by Ganesh et al. 
was to use a longitudinal phenotype data (i.e. repeated measures) of BP.140 This 
study modelled the BP phenotypes by LTA approach, in which repeated 
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measurements of BP were taken for each participant that were at least one-year 
apart and within a 15-year timespan. The LTA approach intended to reduce the 
BP measurement errors that may add another source of BP variability, and hence 
improving the phenotype accuracy and the study power. The study has identified 
39 association signals at 19 loci; of them, 4 loci were not previously discovered. 
The study has also estimated a 20% improvement in statistical power with using 
the LTA approach over the single-visit method. This improvement is a result of 
reducing the BP variability that can arise due to different factors, for instance, 
in addition to the variability in BP introduced by imprecise measurement 
techniques, BP can also vary for the same individual during the day time 
following different factors such as smoking or “white-coat” effect. Remarkably, 
it is estimated that between 15% and 20% of the power to detect a genetic 
association is reduced with increasing the variance attributable to the intra-
individual variation and measurement error up to 20%.165 
When the continuous BP measure is dichotomised into hypertension and 
normotension, it is likely that the binary phenotype may be affected by 
phenotype factors that are not very important for quantitative measures. Thus it 
is important to recognise that whilst both traits are complex polygenic traits, 
they may not be entirely similar in terms of gentic architecture and phenotypic 
confounders. Studying hypertension as a binary trait has been performed in two 
GWAS, where participants with BP of 140/90 or higher, or taking 
antihypertensive medications were classified as cases.82,136 Similar to the typical 
approach in the quantitative approach, BP measurements that are used to 
classify individuals are usually taken from a single visit. This is different to a 
clinical diagnosis of hypertension, in which a confirmation methods are required 
before providing a clinical diagnosis of hypertension. For instance, the National 
Institute for Health and Clinical Excellence 2011 guidelines advise to use ABPM 
for patients with a clinic measurement of 140/90 mmHg to confirm a clinical 
diagnosis of hypertension.34 Moreover, the prevalence of hypertension decreases 
(by almost one-half) in all populations when estimates are based on BP 
measurements taken from two or more visits compared to prevalence based on 
estimates that were taken on a single-visit.166 Thus current approach taken in 
the most typical hypertension GWAS is more likely to overestimate the 
prevalence of hypertension. Thus, the interpretation of the results of binary 
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trait studies need to consider the underlying basis of the phenotypic definition 
used. However, the two studies that used a binary trait as a phenotype have 
reported two loci in plausible biological pathways, and relied on extensive 
phenotyping characterization in selecting the cases.82,136 For instance, the BP-
extreme study has reported the UMOD locus by genotyping individuals drawn 
from the extreme of BP distribution to allow for the maximum separation 
between cases and controls.82 
Studying BP as a quantitative trait in GWAS can be compromised by the effect of 
BP-lowering medications, which may distort the physiological BP level, leading 
to substantial shrinkage in the statistical estimates (discussed in Section 1.5.1.1 
-p51).87 An appropriate adjustment was proposed by Tobin et al. by adding a 
fixed value to the observed BP in treated subjects, another method was 
proposed by Rena et al. using a refined approach by adding values based on 
antihypertensive drug class and ethnicity.87,88 In both methods, the accuracy of 
the adjustment relies on the source of subject’s medication history, which is 
typically obtained from either questionnaires or medical records. For studies 
with large sample size, it may be easier to collect this information using a 
questionnaire than obtaining the medical records for participants, due to 
inability to get an access for patients medical records. Hence, the accuracy of 
adjustment procedure would largely depend on the reliability of information 
given by the participants. Therefore, phenotypic complexity of BP represents a 
major challenge for GWAS, and further work and explorations are required to 
reduce the heterogeneity of BP phenotypes.  
Genetic studies with a family-design offer a powerful alternative for gene 
discovery, as relatives are more likely to share both the genetic background and 
environmental factors. Hence, the analysis of phenotypes among family 
members is controlled to some extent for both genetic and environmental 
factors.167 This is especially true for populations that are relatively static and 
stable, such as the Scottish population, which provides an ideal cohort to 
measure heritable and lifestyle factors for complex traits. The power of family 
studies in dissecting the genetic architecture of complex diseases relies on the 
availability of extra information that can be modelled to explain the error 
variance, leading to higher power to estimate the model parameters.168 One of 
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the largest challenges for family-based studies is the difficulty in recruiting 
family members, which is time-consuming and requires more resources 
compared to unrelated individuals. However, the presence of a pre-existing 
large scale family-based cohort such as Generation Scotland: Scottish Family 
Health Study (GS:SGHS) can overcome this issue. Furthermore, the higher rate of 
CVD and hypertension in Scotland compared to other European populations 
highlight the uniqueness of the Scottish population and the possible roles of 
genetic and environmental factors.169 
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1.7+Study+aims+
The specific aims of this study are: 
•! Critically analyse BP measurements and medication history in GS:SFHS, to 
generate highly validated BP phenotypes for epidemiological and 
genetically analyses. 
•! Conduct a detailed epidemiological analysis of BP traits and hypertension. 
•! Study the familial aggregation of hypertension, treatment, and BP 
control. 
•! Estimate heritability of BP traits. 
•! Validate SNPs previously reported in large meta-analysis of GWA studies 
of BP traits in the Scottish population. 
 
  
93 
 
 
 
 
 
 
 
 
 
2+ Materials+and+Methods+
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2.1+ Introduction+to+this+chapter+
This chapter describes the overall materials and methods of the thesis, with the 
exception of the statistical analyses, which are described separately in the 
relevant chapters. It explains the processing of DNA samples from the time they 
were received from Generation Scotland (GS) in sample plates, the genotyping, 
and the methods applied to generate high quality data for downstream analysis. 
The aim of the methods described in this chapter was to generate a homogenous 
sample with high quality data (i.e. phenotype and genotype) that are suitable 
for all subsequent analysis.  
As the GS:SFHS cohort was utilised for this study, GS has played a key role in 
providing the DNA samples and linking the genotypes with phenotypes. Figure 
2-1 depicts the overall approach of communication and the contribution of GS 
management team to this work. Communication was performed in two steps to 
maintain participant anonymity and confidentiality, as only GS management had 
the appropriate access to link DNA information to participant’s clinical data.  
The chapter starts by describing the GS:SFHS cohort and the participant 
recruitment process. It then provides a detailed explanation of the data 
collection process, including how BP was measured, and the methods to assess 
exposure to BP-lowering medications. Finally, it describes the method of SNPs 
selection for genotyping, the genotyping platforms, procedure and QC.  
2.2+Generation+Scotland++
GS is a multi-institutional, cross-disciplinary collaboration between the Scottish 
University Medical Schools and the National Health Service (NHS) in Scotland. 
The Scottish Government funded the project in 2003 to promote research into 
genetics and healthcare. GS includes three biomedical resources for study of 
common complex disease: the Scottish Family Health Study (GS:SFSH), Genetic 
Health in the 21st Century (GS:21CGH), and the Donor DNA Databank (GS:3D). 
The number of participants recruited in these three projects is over 30,000.170 
Participants were recruited from across Scotland between February 2006 and 
March 2011. Although the main recruitment is completed, the resources 
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continue to grow with every new use of the cohort. The full details of GS 
resources are available on the study website (www.generationscotland.org). 
The major study of GS is GS:SFHS, which is an extended family-structured, 
population-based, intensively phenotyped cohort study. The study has biological 
samples, socio-demographic information, and clinical data for approximately 
24,000 participants, aged between 18 and 98 years, recruited from across 
Scotland. The GS:SFHS protocol was published in 2006, and the full cohort 
profile description was published in 2013.171,172 GS:SFHS is characterized by the 
family-based recruitment procedure through grouping individuals into family 
units, and it is considered to be one of the largest family-based genetic 
epidemiology studies. The cohort includes a wide spectrum of ages, lifestyle, 
and demography. It includes breadth and depth of phenotype information that 
allows population-based genetic and epidemiological research on several 
important diseases and risks. Furthermore, participants have given consent to 
anonymously link their data with NHS datasets such as prescribing records, 
hospital attendance, cancer and death registration.171,172 The collected data are 
a combination of clinical measurements taken by trained staff, and self-reported 
data obtained from a pre-clinic questionnaire (PCQ) that was completed by each 
participant. 
 
Figure+2G1+The+overall+strategy+of+the+study.+
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2.2.1+Participants+
The participant recruitment strategy is divided into two phases based on the 
geographic location and recruitment time. The first phase of the study covers 
the period between the start of the study in 2006 and 2008. Potential 
participants, or probands, during this phase were recruited from the Glasgow 
and Tayside areas if they were aged between 35 and 65 years; the term 
“proband” here refers to the first person who invited other relatives into the 
study and does not imply affected individual, as participants were not 
ascertained via any particular disease. In the second phase (2009-2011), the 
study was extended to include Ayrshire, Arran, and North East Scotland, along 
with broadening the age range of the probands to between 18 and 65 years. In 
both phases, probands were recruited at random from lists of collaborating 
general medical practices, and were asked to provide details of at least one 
first-degree relative who was over 18 years old and would also participate in the 
study, and so on, to create a “snowball” sampling effect. This sampling method 
is approximate to general population family sample, since more than 96% of the 
UK population are registered at general medical practices. In addition to 
recruitment by invitation, volunteers were also recruited if they were over 18 
years with at least one first-degree relative. Throughout the study period, the 
methods of recruitment, identification, and approach were performed under an 
extensive public consultation exercise.173,174 
The total number of invited probands was 126,000. Of that group, only 12.3% 
responded and met the study criteria. Not all of the responders were recruited 
for practical reasons such as inability to give informed consent, or recruit 
another family member. The overall successful response rate was 5.3% (6665 
probands), plus 1,288 volunteered participants without an invitation, and 16,007 
relatives, giving a sample size of 23,960 individuals. The number of participants 
who attended the research clinics to complete and provide blood samples for 
DNA extraction was 21,476. The remaining participants who were unable to 
attend the clinic sent their PCQ with a saliva sample, for DNA extraction, by 
post (n =2,484). All participants signed the consent form and received the 
participant information leaflet prior to their enrolment. 
97 
 
In comparison with the Scottish population, the GS:SFHS sample was generally 
healthier, wealthier (39% lived in areas with above average Scottish-index of 
multiple deprivation [SIMD]), older, and included higher proportion of women 
(59%) (Table 2-1).171 Most of the participants were born in the UK or Ireland 
(96%), with the vast majority born in Scotland (87%). Although the sample 
cannot be considered a truly representative of the Scottish population, it 
includes a wide range of socio-demographic and clinical features. In addition, 
the large sample size increased the proportion of participants from all socio-
economic classes, with many or multiple disease traits. 
Table+2G1+Comparison+between+GS:SFHS+cohort+and+the+Scottish+population+
! GS:SFHS! Scottish!population!
Median!age!(years)!
Males!(years)! 47! 37!
Females!(years)! 48! 39!
Gender!(%!Male)! 41! 48!
Ethnicity!(%!White)! 99! 98!
Employment!(those!aged!up!to!75!years)!(%)!
Unemployed! 1.7! 4a!
Retired! 15.1! 12.9a!
Employed! 62.8! 58a!
Education!(%)!
Degree! 33! 20!
No!qualifications! 5! 33!
Overweight!or!obese!(BMI!>25)!(%)!
Males! 65! 68!
Females! 53! 61!
Current!smokers!(%)!
Males! 19! 25!
Females! 16! 25!
Alcohol!intake!(mean!units/week)!
Males! 15.8! 17.5!
Females! 7.1! 7.8!
Hypertension!(%)!
Males! 37.4!(Measured)
b!
14!(SelfJreported)! 35
c!
Females! 24.7!(Measured)
b!
13.2!(SelfJreported)! 31
c!
Heart!disease!(%)! Total!3.9!(SelfJreported)! !
Males! 5.6! 7.3!
Females! 2.7! 5.5!
Diabetes!(%)! Total!3.3!(selfJreported)! !
Males! 4.1! 5.7!
Females! 2.8! 4.3!
Stroke! Total!1.5!(SelfJreported)! !
Males! 1.7! 2.7!
Females! 1.3! 2.2!
a!People!aged!16J74!years!
b!Systolic!>140!or!diastolic!>90.!
c!Treated!or!untreated!hypertension.!
Table!is!reproduced!with!modification!from!171!
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2.3+Phenotypic+data+
Multiple measures and clinical tests were performed at the clinic for all the 
participants by trained clinical staff, according to rigorous standard operating 
procedures. All participants signed “broad” consent forms before any data 
collection, in addition to having an appropriate discussion about the future of 
their participation in the study. Participants were also asked to provide consent 
for linkage of their data and samples to routine datasets, such as NHS 
prescription records. Although GS:SFHS has a wide range of phenotype 
information, this thesis only focused on data related to BP. Hence, the related 
measurements and clinical assessments that were of interest to this thesis 
include BP measurements, anthropometric and demographic measures, 
treatment history provided by either PCQ or electronic-prescription records 
(EPRs), and health and lifestyle information obtained from the PCQ.  
2.3.1+Blood+pressure+phenotypes+
Blood pressure was measured twice, consecutively, with a three minutes 
interval, using Omron HEM-7051T digital BP monitor. The participants were 
asked to sit quietly for five minutes before the first reading. The readings were 
recorded in the clinical record form (available at 
http://www.generationscotland.org), along with the time at which the readings 
were taken. PP was calculated as the difference between SBP and DBP. MAP was 
calculated as 1/3 of SBP plus 2/3 of DBP. The BP phenotypes that were analysed 
in this thesis are either the observed BP values or the adjusted BP values. The 
observed BP values are calculated as the average of the two readings, for SBP 
and DBP. Likewise, the observed PP and MAP were calculated based on the 
values of the observed SBP and DBP. The adjusted BP values are the observed BP 
values plus a fixed value if individual was on BP-lowering medication when BP 
was measured. The rationale of adding a fixed value to the observed BP values 
for treated participants is explained in the next Section (2.3.1.1). 
2.3.1.1+ Adjustment+for+BPGlowering+medications+
Studying BP as a quantitative trait is a powerful method to examine the genetic 
and environmental factors, as it can overcome the issue of inconsistent 
diagnostic criteria for hypertension. However, a preliminary analysis of 
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prescriptions records for 8,238 individuals in GS:SFHS showed that about 12% of 
them were taking BP-lowering medications.171 Using the observed BP value 
without any adjustment for treated individuals can lead to substantial shrinkage 
in the estimated effect of the aetiological factors and reduce statistical 
power.87,175 This is because the outcome of primary interest, i.e. BP level 
without the medication effect, cannot be directly observed. Therefore, the 
observed BP measurements in treated individuals represent a biased distortion in 
quantitative analysis. Yet, excluding treated subjects from the analysis wastes 
important information regarding the familial components of BP variance, and 
reduces the effective sample size.175 Hence, the contribution of the treated 
subject is very important in the study, and can be lost if they were excluded, or 
obscured by the treatment effect if no adjustment was taking during the 
analysis. 
The size of the added fixed values is based on the recommendation of Tobin et 
al. by adding 15 mmHg to the observed SBP, and 10 mmHg to the observed DBP 
to account for the treatment effect.87 This method of adjustment for blood 
pressure-lowering medication was applied in several BP genetic studies such as 
ICBP.107,135,152 It was also shown that this method of adjustment restores the 
familial components of BP variance, and the adjusted BP values more closely 
reflects BP values without treatment effects.175,176 
2.3.2+Drug+exposure+
In order to adjust for the BP-lowering medication effect, participants taking 
these medications first needed to be identified. GS:SFHS has two sources that 
can be used to search for medication history; first, EPRs obtained by linking the 
participant’s information to the NHS prescription information system database. 
Second, self-reported medications (SRMs) history that can be extracted from the 
PCQ. The vast majority of the participants completed the current medication 
history Section in PCQ, EPRs were also available for smaller number of 
participants. Based on these two sources of treatment- exposure history, the 
participants were classified into two groups; first group included individuals who 
had both types of medication history data, and second group included 
individuals with medication history based on one medication history only. An 
additional complexity in the SRMs data occurred as the SRMs history was 
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differently obtained during the two phases of the study (detailed explanation in 
Section 2.3.2.3 - p101). The next section explains the methods to identify 
individual who were taking BP-lowering medication, based on each medication 
history sources.  
2.3.2.1+ Definition+of+BPGlowering+medications+
The British National Formulary (BNF 58) was used to create a database of 
medications classifications and indications.177 This database included 1694 items 
in the form of medication’s approved name, BNF code, BNF description, and 
pharmacological class. All of the medications indicated for hypertension in the 
BNF were considered as BP-lowering medications, and individuals taking any of 
these medications were eligible for the adjustment of the observed BP value by 
addition of the fixed value. 
2.3.2.2+ ElectronicGprescription+records+(EPRs)+
Using EPRs as a source to assess drug exposure can avoid the potential of recall 
bias that may occur in SRMs.178,179 However, important factors need to be 
considered carefully to avoid misclassification of participants. The first factor is 
to differentiate between participants with missing prescription records, and 
participants that were not in the prescription record because they have not 
been prescribed any medication. In other words, to be sure that missing 
individuals are such because they have not been prescribed any medication and 
not because their data were not available. To address this factor, a list of 
“eligible” participants was generated to identify the ID of participants with 
prescription records (i.e. whether they have been prescribed any medication not 
just antihypertensive drugs). The eligibility criteria were based on the 
recruitment area and date, that is all Tayside participants (area code T), and 
Glasgow participants (area code G) recruited from 2008 onwards. Individuals 
from other areas or recruited from Glasgow before 2008 were set as missing for 
prescription records because of the incomplete prescription data. 
The second factor is the definition of drug exposure, which is based on the type 
of medication and the time window. The time window refers to the period prior 
to a reference date that is reviewed to search for prescription of BP-lowering 
medication. The recruitment date was used as the reference date because it 
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was the day when BP was measured and each participant completed the PCQ. 
Several time windows were considered in studies that investigate the accuracy 
of prescription record as a source to measure drug exposure; it ranged from 30 
days to one year prior to the reference day.179-183 Although the 90 days time 
window has shown high sensitivity for medication of chronic disease, this thesis 
used a time window of 120 days prior to the day of recruitment.181,183 This was 
to have a less stringent period, and choose a value that lay between the two 
most common time windows (i.e. 90 days and 6 months). Also, a preliminary 
analysis showed that increasing the time window beyond 120 days did not 
demonstrate any additional improvement in concordance with the SRMs. 
Participants were then coded as “1” or “0” if they were taking a BP-lowering 
medications or not, respectively; this value was named as (Treatmentprescr), 
which indicates if the individual was taking a BP-lowering medication based on 
EPRs. 
2.3.2.3+ SelfGreported+medications+(SRMs)+history+
The PCQ form was sent to the participants to be completed at home, and 
participants were required to bring with them during the clinic visit along with 
any regular medications. The participants completed the PCQ before performing 
any medical assessment, with help of the research nurse to clarify any queries. 
The PCQ included questions related to demographic details, occupational 
history, lifestyle, personal and family medical history, pain, and current 
medication history. The PCQ form was slightly amended in 2009, dividing the 
study into two phases, where the period up to this revision was termed phase 1 
(n =9,016), and the period thereafter was termed phase 2 (n =11,305). One 
aspect of this revision was changing the question structure from open-ended 
questions to closed questions, in particular the part about current medication 
history. The participants were asked to write “Name of Prescribed or Bought 
Pills or other Oral Medication” in PCQ-1, and to tick the appropriate Yes or No 
box if they “regularly taking any blood pressure lowering medication” in PCQ-2. 
In order to offset this alteration in the structure of question, each PCQ-phase 
was analysed separately to identify participants who were taking BP-lowering 
medication. Subjects who have written a BP-lowering medication name in PCQ-1 
or answered “Yes” in PCQ-2 were coded as “1”, or “0” otherwise for the field 
(TreatmentQues); separate coding was constructed based on each PCQ. The two 
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PCQ forms can be accessed from the GS website 
(http://www.generationscotland.org). The following section explains the 
method of analysis in each PCQ. 
2.3.2.4+ PCQG1+
The current medication history section in this form contained four questions 
about names of the regular medications based on their dosage forms (i.e. oral, 
cream, inhaler, and injection). Participants were also asked to tick a box if they 
were not taking any medications. Because participants manually wrote their 
medication names, entries were inconsistent for medications across individuals. 
For instance, the name of the same medication can be written in several forms 
such as a generic, trade, medication name plus the strength, or a combination 
of these names. Also, the entries were not free from spelling errors or irrelevant 
symbols. Hence, the written names were first formatted in the same style to 
improve the accuracy of the retrieved information. This was performed by 
checking each participant answer to be reformatted into the correspondence 
medication approved name; for unclear answers, an attempt to correct for the 
written medication names was undertaken when it possible. Although the vast 
majority of the participant entries were retrieved, a few answers were ignored 
as they were impossible to be guessed. The result of this review was a new 
database that contained the participants ID and their answers to the current 
medication history, but in the form of the medication’s approved name. This 
database was then linked to the same database of BNF medication in Section 
2.3.2.1, and subjects taking BP-lowering medication were identified based on 
the same criteria. Participants who have completed the PCQ-1 and were 
identified to be receiving a BP-lowering medication were coded as “1”, or “0” 
otherwise for the field (TreatmentPCQ-1). 
2.3.2.5+ PCQG2++
The current medication history question has changed in this phase to be a closed 
question (i.e. yes/no). This has made the analysis straightforward as each 
subject is coded as either “1” if answered “Yes”, or “0” if answered “No” to the 
question of taking a BP-lowering medication. Yet, some participants have left 
the question unanswered and they were coded as missing “-9”. Participants who 
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have completed the PCQ-2 and were identified to be receiving a BP-lowering 
medication were coded as “1”, or “0” otherwise for the field (TreatmentPCQ-2). 
2.3.3+Anthropometric+measures+
The anthropometric measurements obtained at the recruitment visit were 
height, weight, waist, hip, and body fat composition. These measurements were 
used to calculate BMI, as weight in kilograms (kg) divided by height in meter 
squared (m2). 
2.3.4+Social+and+demographic+data+
Socio-demographic data for each participant were retrieved from the PCQ. Age 
and sex of each individual were obtained during the clinic visit, along with 
information about place of birth and ethnicity background. Furthermore, 
participants answered the same demographic questions about their parents. In 
addition, participants reported their address postcode, which was then linked to 
the SIMD 2009 report.184 SIMD is a measure of deprivation that ranks Scotland’s 
area into data zones based on seven domains and indicators, which are income, 
employment, health, education, access to service, housing, and crime.184 The 
data zones are then ranked based on their score on these seven domains. SIMD 
quintile classifies the postcodes into five quintiles, each containing 20% of the 
data zones. Areas in the first quintile (SIMD =1) are the most deprived area in 
Scotland, and areas in the fifth quintile (SIMD =5) are the least deprived in 
Scotland. 
2.3.5+Family+health+history+
The two forms of PCQ contain questions regarding previous clinical diagnoses of 
certain conditions including high blood pressure of the participants, their father, 
mother, brothers, sisters, and grandparents. The question in PCQ-1 combined 
brother and sister in one single question, meaning that the participants would 
tick the same box if they have a “brother or sister” with hypertension. This was 
slightly different in PCQ-2, where the answer for brother and sister were 
collected separately in two boxes. Also, a question about number of brothers 
and sisters were only available in PCQ-2. To overcome this discrepancy, I 
created a new field named as “sibling” that combined the information from the 
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two forms, though indicating no sibling with hypertension in PCQ-1 cannot be 
distinguished from the case where an individual has no sibling. 
2.3.6+Phenotype+Quality+Control+
Clinical and questionnaire data were only retrieved for individuals with quality 
checked genotypes, which meant that individuals without genetic information or 
those who did not pass genotype QC were excluded before this step. The 
phenotype QC aimed to check the completeness of clinical data for the 
genotyped individuals, in particular BP values, anthropometric measurements, 
and medication history, for which the procedure of collection was previously 
explained. As the availability of these three components is critical for all the 
analysis, any individual without any of these components was excluded from the 
study. Thus, the study sample will be homogenous with regards to the 
availability of genotypic and phenotypic data. The importance of these three 
components is summarized as follows: first, BP measurement is essential to do 
the quantitative analysis, as well as the qualitative analysis in which subjects 
are dichotomized into a binary trait (i.e. hypertensive or not) based on a 
specific definition. Second, presence of anthropometric measurements is 
necessary to calculate BMI and is used as a covariate in most of the subsequent 
analysis. Third, ascertainment of current medication history is essential to 
assess if the observed BP is influenced by BP-lowering medication or truly 
reflects the underlying BP (that is, the BP that treated subjects would have if 
they were not taking BP-lowering medication). Individuals were not excluded if 
they had other missing information, and will be reported as missing. Figure 2-2 
shows the flowchart for the steps of genotype and phenotype QC, starting from 
receiving the DNA until completing of the QC.  
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Figure+2G2+Flowchart+of+the+QC+procedure.+
*+Subjects+with+BP+readings,+BMI+measurements,+and+medication+history+were+considered+
as+having+a+complete+phenotypic+data.+
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2.4+Genotypic+data+
2.4.1+Extraction+and+storage+of+DNA+
The process of collection and storing of DNA for all the samples was performed 
using standard operating procedures and managed through a laboratory 
information management system. Blood samples were obtained in the research 
clinic from each consenting participant using standard venipuncture procedures 
and collected in a 9 ml Ethylenediaminetetraacetic acid (EDTA) tube. DNA 
extraction was performed using a Nucleon Kit on 9 ml of blood sample (Tepnel 
Life Science) with the BACC3 protocol. The precipitated DNA was hooked out 
and placed directly into a labelled 2.0 ml microtube (Scientific Specialties Inc) 
containing 1 ml TE buffer pH 7.5 (10 mM Tris-Cl pH 7.5, 1 mM EDTA pH 8.0). For 
postal participants and participants with insufficient blood sample, DNA was 
extracted from the provided saliva sample using an Oragene OG-250 saliva kit 
into similar microtubes by a standard protocol (DNA Genotek). Microtubes were 
incubated at room temperature for two weeks with rotation until DNA was fully 
re-suspended. To assess the quality of DNA extraction, 8 samples of every batch 
of 92 samples were electrophoresed on 1% agarose gel and quantified by 
NanoDrop (Thermo Scientific) to confirm DNA yield. The Picogreen method 
(Invitrogen) was finally used to quantify the DNA concentration in ng/µl, and 500 
µl of each DNA master stock was transferred to a deep well plate and then 
normalized to 50 ng/µl to make working stock plates. The DNA extraction 
procedure was performed at the Centre for Molecular Medicine, University of 
Edinburgh, by the GS laboratory staff. 
For this study, DNA samples were transferred in 384-well PCR plates to the 
British Heart Foundation-Glasgow Cardiovascular Research Centre, and stored at 
-4°C until genotyping. Plates were numbered from 1 to 55, and matched with 
Plates map sheet that was provided by GS. The Plates map sheet contains 
information about the ID sample of each well in each plate in the form of; Res 
ID, CRF Barcode, destination plate ID, and destination well. This plate map 
sheet was used to link the genotype information with individual phenotype data, 
and to track the sample information of each well. The plates numbered from 1 
to 54 contained 380 DNA samples in the concentration of 50 ng/µl, and 4 empty 
wells to be used as no-template controls (wells number A1, A24, P1, and P24). 
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Plate number 55 contained only 233 DNA samples, and the remaining wells were 
all empty, which gave a total of 20,753 samples that were available for 
genotyping.  
2.4.2+Genotyping+procedure+
2.4.2.1+ Genotyping+platform+
The genotyping procedure was performed using a TaqMan® OpenArray® 
Genotyping System (Applied Biosciences), which provides an automated and 
rapid qualitative detection of bi-allelic SNP. The assay relies on a fluorescence-
based polymerase chain reaction (PCR) that uses the 5` nuclease activity of the 
AmpliTaq Gold® DNA polymerase to cleave a perfectly matched probe and emit a 
signal (Figure 2-3). Each assay consists of a normal PCR primers that flank the 
target polymorphic region, in which two allele-specific TaqMan® probes are 
hybridized.185,186 The fluorescence signals for each intact probe is quenched by 
the physical proximity of the reporter and quencher dyes through fluorescence 
resonance energy transfer. During the PCR extension, the AmpliTaq Gold® DNA 
polymerase extends the normal PCR primers until reaching the TaqMan® probes, 
in which it can only cleave the hybridized probe (i.e. matched), and release the 
reporter dye. On the other hand, the mismatched probe remains intact and 
shows no fluorescence.186-188 The TaqMan® probes incorporate 3`-minor groove 
binder (MGB) technology that enhances the stability of the formed duplex DNA 
when probes are hybridized.185 This is achieved by increasing the differences in 
the melting temperature (Tm) between the perfectly matched and mismatched 
probes, which leads to improvement in genotyping accuracy. The higher Tm of 
the MGB probes is achieved without increasing probe length, which allows for 
designing of shorter probes that are more sensitive to a single base mismatch. 
The TaqMan® OpenArray® plate contains 3,072 microscopic through-holes 
(divided into subarrays of 8 x 8) that are coated with a hydrophilic material from 
inside, and can accommodate a reaction volume of 33 nl.189 The dimensions of 
plates are similar to the conventional microscope slides, and the number of 
loaded samples per plate depends on the number of assays in the plate, which 
can range from 144 samples in the 16-plex assays format to only 12 samples in 
the 256-plex Assay format (Figure 2-4). The experiments in this thesis were 
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performed using the 64-plex assays, with which up to 48 samples can be loaded 
on a single OpenArray® Genotyping plate. 
The advantage of this system is that it only requires a single enzymatic reaction 
with a simple operating procedure. The experiment can be completed within 
eight hours with TaqMan® assay reliability and a projected overall call rate of 
99%.189 The assay materials include TaqMan® assays, primers, and probes were 
designed by Applied Biosystem based on SNPs information that were selected for 
this thesis. 
2.4.2.2+ Genotyping+workflow+
The overall procedure of the experiment involved transferring the DNA sample 
to the TaqMan® OpenArray® 384-Well Sample Plate, and then to the TaqMan® 
OpenArray® Genotyping Plate (OpenArray plate), which is then placed in the 
thermal cycler before scanning the OpenArray plates to call the genotypes by 
using the appropriate software (Figure 2-5). The complete procedure that was 
followed during the genotype experiment was as following: 
1.! Preparing the Sample Information File (*.csv) for sample integration 
a.! Before starting the experiment, the sample information file was 
created that contains information about the sample ID of each well 
in each plate. Each one of the 55, 384-Well DNA Sample Plates has 
a unique sample information file, which is created based on the 
information provided by GS. This sample information file is used in 
the sample integration process that is performed when sample is 
loaded into the TaqMan® OpenArray® Genotyping by the 
OpenArray® Accufill™ System, as discussed in next steps. 
2.! Loading DNA samples and master mix into the TaqMan® OpenArray® 384-
well Plate 
a.! The 384-well PCR plate that contains the DNA samples was thawed 
to room temperature, and then centrifuged at 1600 rpm for 1 
minute. 
b.! 2.5 µl of the TaqMan® OpenArray® Master Mix was added to the 
TaqMan OpenArray 384-well sample plate. 
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c.! 2.5 µl of the DNA sample from the 384-well PCR plates was 
transferred to the same position in the TaqMan OpenArray 384-well 
sample plate, with gently mixing by pipetting up and down. 
d.! 2.5 µl of DNase-free, sterile-filtered water was added to the no-
template wells. 
e.! The TaqMan OpenArray 384-well sample plate was covered with 
the provided sealing tape, and then centrifuged for 1 minute at 
1500 rpm to eliminate bubbles. 
3.!  Prepare the TaqMan® OpenArray® Genotyping plate 
a.! The genotyping plate is stored at -20 °C until the day of the 
experiment. 
b.! The required amount of genotyping plates are removed from the 
freezer, and thawed at room temperature for 5 minutes. 
4.! Sample plate preparation for loading into OpenArray Genotyping plate 
using OpenArray® Accufill™ System 
a.! Prepare the TaqMan® OpenArray® Accessories Kit, which contains 
the genotyping case, sealing glue, and immersion fluid. 
b.! Place the genotyping case in the case rack and fill the case 
approximately 3/4 with immersion fluid. 
c.! Place the OpenArray AccuFill Loader Tips, and Plate Holder at their 
assigned locations. 
d.! Initialize the Accufill™ system for the loading operation. 
e.! To enable the sample integration option, the sample information 
file (*.csv) and the plate setup file (*.spf) were imported into the 
appropriate fields. The plate setup files were entered in the same 
order as their physical position in the plate holder. This file 
contains information on assay location within the OpenArray plate. 
The output of sample integration is the assignment of all samples 
to their respective assays in one new updated plate file. 
f.! Hold the OpenArray Plate by the edges, at the end opposite from 
the barcode, and place it into the Plate Holder. 
g.! Start the loading process 
h.! After completion of the loading, the software create a newly plate 
setup file that start by the prefix “Loaded_[plate serial 
number].spf”. This file is then copied into a USB drive to process 
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the OpenArray® Genotyping plates in the OpenArray® NT Cycler 
during the imaging step.  
5.! Seal the TaqMan OpenArray® Genotyping plates 
a.! Slide the OpenArray Genotyping plate into the genotyping case, 
guided by the grooves in the case. 
b.! Use the sealing glue to seal the genotyping case by filling the top 
of the case. 
c.! Cure the glue by placing the genotyping case in the sealing station 
for 90 seconds. 
6.! Perform thermal cycling using the Block GeneAmp® PCR System 9700 
a.! The sealed OpenArray genotyping plates were then loaded into the 
thermal cycler, by keeping the barcode face-up. 
b.! The thermal cycler can accommodates up to 8 OpenArray plates, 
and the run takes about 4 hours using this profile 
i.! 10 minutes at 93°C. 
ii.! 45 seconds at 95 °C. 
iii.! 13 seconds at 94 °C. 
iv.! 2:14 minutes at 53 °C. 
v.! Repeat steps (ii to iv) for 50 cycles. 
vi.! Hold at 4°C forever.  
7.! Image of the OpenArray® Genotyping plate by OpenArray® NT Imager 
a.! Start the OpenArray® NT Imager and wait for the system to fully 
boot up. 
b.!  Import the newly created plate setup file that corresponds to the 
OpenArray® Genotyping plate position in the machine, and repeat 
for position 2 and 3. 
c.! When the imaging is completed, a new folder is created that 
contains all the related files; 
i.! SNP plate data (*.spd) file for downstream analysis in 
TaqMan® Genotyper Software V1.3. This file is copied into 
the USP drive for later analysis and QC. 
ii.! Four images that are important to check the quality of each 
Genotyping plate; all the four images were carefully 
checked in each run. 
8.!  The experiment for each plate was tracked using the designed form. 
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Figure+2G3+Dynamics+of+allelic+discrimination+in+the+TaqMan®+genotyping+assay.+
Each+allele+has+a+specific+probe+that+carries+a+nonfluorescent+quencher+(NFQ)+at+the+3′+end,+
and+either+VIC+(green)+dye,+or+FAM+(blue)+dye+at+the+5`+end.+During+PCR+primer+extension,+
each+probe+anneals+specifically+to+its+complementary+sequence+between+the+forward+and+
reverse+primer+sites.+A+DNA+polymerase+that+possesses+5`+exonuclease+activity+is+used+in+
the+assay+to+cleave+the+hybridized+probe+that+is+perfectly+matched,+freeing+the+reporter+dye+
from+the+NFQ+and+allowing+it+to+fluorescent+signal+in+the+absence+of+its+NFQ.+However,+the+
mismatch+probe+is+not+hybridized+and+remains+intact+with+no+florescence.+In+this+figure,+a+
substantial+increase+in+VIC+dye+indicates+homozygote+for+Allele+1,+and+a+substantial+
increase+in+FAM+dye+indicates+homozygote+for+Allele+2,+and+an+equal+amount+on+VIC+and+
FAM+dyes+indicates+heterozygotes.++ +
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Figure+2G4+Layout+of+the+OpenArray+384GWell+Sample+Plate,+and+the+OpenArray+Genotyping+
Plate.+
(A)+The+384GWell+sample+plate+is+used+to+mix+the+DNA+with+the+Master+Mix+before+using+the+
AutoLoader+system+to+transfer+the+mixture+into+the+genotyping+plate.+It+is+divided+into+eight+
areasl+each+area+has+48+wells+(12+x+4).+During+the+loading+process,+the+AutoLoader+transfers+
samples+from+one+area+into+the+Genotyping+plate.+(B)+The+OpenArray+Genotyping+Plate+has+
3,072+throughGholes+divided+into+smaller+groups+of+8+x+8+subarrays+(48+subarrays).+The+
subarrays+are+addressed+by+a+capital+letter+represents+the+row+(AGD),+and+a+number+
represents+the+column+(1G12).+Within+subarrays,+each+throughGhole+is+addressed+by+a+small+
letter+(aGh)+to+represent+the+row,+and+number+(1G8)+to+represent+the+column.+For+instance,+the+
throughGhole+filled+with+red+can+be+addressed+as+A1a1.+For+the+64Gplex+format,+each+
subarray+contains+one+sample+only.+
++ +
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Figure+2G5+Genotyping+experiment+workflow.+
! !
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2.4.2.3+ Genotype+calling+
Genotype calling was performed using the TaqMan® Genotyper Software V1.3 
(Life Technologies), which uses the generated raw data from the OpenArray® NT 
Imager system in the form of (*.spd) file. The genotype-calling algorithm is 
based on the clustering strategies that combine sample with similar dye 
fluorescence intensities at each SNP to one cluster. The program then assigns a 
discreet genotype to each cluster according to its position on the plot. Samples 
are then clustered into three clusters that vary along the X-axis (homozygosity 
for Allele 1), Y-axis (homozygosity for Allele 2), or diagonal (heterozygosity). 
One feature of the TaqMan® Genotyper Software is its ability to overlay and 
analyse raw data from several genotyping plates together, to increase the 
confidence of the genotype call.190 Therefore, it is recommended to combined 
between 6 to 8 genotypes experiments in one study, a study is the technical 
name for the collection of the raw data from several OpenArray® Genotyping 
plates. For the convenient of sample tracking, each 8 OpenArray® Genotypes 
plates that originated from the same DNA sample plate were pooled into one 
study. The cluster plots for each study of each SNP were then manually checked 
to exclude samples with low genotype QC, as indicated by a call rate lower than 
80%. In addition, a manual genotype calling procedure was carried out on any 
SNP that showed clear clustering to one of the three genotype clusters, but was 
not automatically called by the program. The procedure of excluding samples 
with very poor genotyping quality can be considered as the first step of 
genotype QC. The output across all plates was exported to the appropriate 
format to be linked with phenotype data by GS management staff, before 
commencing the complete genotype QC. 
2.4.2.4+ Genotype+quality+control++
The genotype QC was performed using PLINK software after merging all the 
samples in one file.191 All the samples were pooled together to do more 
stringent QC based on a total of 60 SNPs, including 16 SNPs that shared the same 
OpenArray Genotype plate but were related to a different project. Sample QC 
was performed first to exclude samples with a genotype call rate ≤95% (using 
PLINK’s function --mind 0.05); samples with very large proportion of failed SNP 
assays may be indicative of a poor quality DNA sample, which could lead to 
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aberrant genotype calling. Based on this call rate threshold, any sample with 
more than three missing genotypes was excluded. The next step was to remove 
families with Mendelian errors ≥5% (using PLINK’s function --me 0.05 0.01); that 
is to exclude family with high proportion of Mendelian inconsistencies, which 
indicate genotyping errors if pedigree information is correct. Checking of 
Mendelian error is only possible in samples of related individuals, with pedigree 
information. This procedure aims to check that genotype transmission for each 
SNP follows Mendelian inheritance laws. For instance, two homozygous parents 
with a genotype of AA for a SNP cannot have an offspring with heterozygous or 
homozygous for the other allele (i.e. AB or BB), and this scenario will be 
highlighted as a Mendelian error in the QC. The aim of the this step is to exclude 
any family with three or more Mendelian errors, erroneous genotypes in 
individuals with less than three Mendelian errors were set as missing genotype 
(using PLINK’s function --set-me-missing 1 1). A second run of checking of 
genotypes for Mendelian inconsistency was performed using the program 
PEDSTATS (Version 0.6.12; sph.umich.edu/csg/abecasis/PedStats; Goncalo 
Abecasis; Abecasis Lab, Center for Statistical Genetics, School of Public Health, 
University of Michigan, Ann Arbor, Michigan).192 This step will be described in 
more details in the next Section (2.4.2.5), as it was followed by imputation of 
the missing genotypes. 
The QC for SNPs started by checking the SNP genotyping efficiency (the 
proportion of samples with a genotype call for each marker), to exclude SNPs 
with a high proportion of missing individuals; a threshold of 90% of call rate per 
SNP was applied in this step (using PLINK’s function --geno 0.1). The next step 
was to check the MAF using the function (using PLINK’s function --freq), and 
exclude any SNP with MAF below 1% (using PLINK’s function –maf 0.01), as 
statistical power is extremely low for rare SNPs and they are more prone to 
error.122,190,193 The final step in SNPs QC was to check the Hardy-Weinberg 
Equilibrium (HWE), as departure from this equilibrium may result from 
genotyping errors or population stratification.194 In PLINK, the HWE statistics is 
only calculated in founders (i.e. individuals for whom the paternal and maternal 
individuals are coded 0). In other word, the test considers the parents only and 
ignores the offspring to have an estimate that is free from bias, which might be 
introduced by the presence of correlated genotypes in one nuclear family. PLINK 
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outputs the HWE exact test p-value of the null hypothesis that genotype 
frequency follows the HWE expected proportions (i.e. p2, 2pq, q2); against the 
alternative hypothesis that observed genotypic proportions are significantly 
different from the expected. A threshold of p-value <0.001 was set to indicate a 
departure from HWE. 
2.4.2.5+ Pedigree+based+Imputation+
After completing the genotype QC, one more step was performed to impute the 
missing genotypes in a subset of individuals, who have a maximum of three 
missing genotypes or a maximum of three genotypes set to missing due to 
Mendelian inconsistency. Two approaches were used to impute the missing 
genotypes. The first approach was applied for individuals with genotyped 
relatives (i.e. parents or offspring) by using the genotype inference feature in 
MERLIN software (Version 1.1.2; 
sph.umich.edu/csg/abecasis/Merlin/index.html; Goncalo Abecasis; Abecasis 
Lab, Center for Statistical Genetics, School of Public Health, University of 
Michigan, Ann Arbor, Michigan).195 In this method, PEDSTATS was initially used to 
check the pedigree information and confirm that all genotypes follow Mendelian 
law of inheritance. The next step was to use the genotype inference parameter 
(--infer) that is integrated in MERLIN to estimate the missing genotypes. The 
output of this analysis is a table that contains; the most likely genotype, the 
expected number of copies for the tested allele (0, 1, or 2 if the genotyped is 
not missing; or a fractional count if the genotype is missing), and the posterior 
probabilities for the three alternative genotypes. The genotype with highest 
posterior probabilities was imputed instead of the missing genotype. The second 
approach was applied for individuals without a genotyped relative, for whom the 
genotype inference feature in MERLIN cannot be used, and the missing 
genotypes were imputed using the average coded allele frequency.  
2.5+SNP+Selection+
Two parallel methods were performed to identify SNPs to be assayed in the 
chosen genotype platform. In the first method, the National Human Genome 
Research Institute (NHGRI) catalogue of Published GWAS (updated as of July 
2012) was searched.196,197 The GWAS catalogue provides a publicly available 
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collection of SNPs identified by means of GWAS and catalogued based SNP-trait 
association with p value less than 1.0x10-05.196 The second approach was done by 
expanding the search method by snowballing from the identified GWAS, to 
include any possible studies that were not represented in the GWAS 
catalogue.The search was restricted to SNPs reported from studies of European 
ancestry, searching for these key words: “SBP”, “DBP”, “MAP”, “PP”, 
“hypertension”, or “BP”. The selected SNPs were entered in the SNAP pairwise 
LD analysis to test independent SNPs that are not in LD.198 Similarly, SNAP tool 
was used to identify proxy SNPs in complete LD with the selected SNP, to be 
used if no predesigned TaqMan assay is available for the selected SNP by Life 
Technologies. In total, 44 SNPs in 39 loci were selected for assay in the 
genotyping platform (Table 2-2)  
2.6+Ethical+approval++
All components of GS:SFHS have received ethical approval from the NHS Tayside 
Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89). 
GS:SFHS has been granted Research Tissue Bank status by the Tayside 
Committee on Medical Research Ethics (REC Reference Number: 10/S1402/20) 
providing generic ethical approval for a wide range of uses within medical 
research. !
! !
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Table+2G2+List+of+selected+SNPs+for+genotyping+
No.! GS!SNP! Locus! Main!Ref.!
Other!studies!
reported!the!
same!SNP!
Other!Studies!
reported!the!same!
locus!
1+ rs17367504+
1p36.22+
107!
133,!155! 133,!155,!147,+142,!150!2+ rs5068+ 134+
3+ rs17030613+ 1p13.2+ 137+ 133+ +4+ rs2932538+ 107! ! +
5+ rs2004776+ 1q42.2+ 150,149! ! +
6+ rs1446468+ 2q24.3+ 135! ! 137+
7+ rs13082711+ 3p24.1+ 107! ! +
8+ rs3774372+ 3q22.1+ 107! ! 115+
9+ rs319690+ 3p21.31+ 135,137+ ! +
10+ rs419076+ 3q26.2+ 107! ! +
11+ rs871606+ 4q12+ 135! ! +
12+ rs1458038+ 4q21.2+ 107! ! 133,!137+
13+ rs13107325+ 4q24+ 107! ! +
14+ rs13139571+ 4q32.1+ 107( ( +
15+ rs1173771+ 5p13.3+ 107( ( 150,+137+
16+ rs11953630+ 5q33.2+ 107( ( +
17+ rs1799945+ 6p22.2+ 107! 150! +
18+ rs805303+ 6p21.33+ 107! ! +
19+ rs12705390+ 7q22.3+ 135! ! +
20+ rs3918226+ 7q36.1+ 136! 150! +
21+ rs2071518+ 8p23.1+ 135! ! +
22+ rs4373814+
10p12.3+
107! ! +
23+ rs1813353+ 107! ! 155,!115+
24+ rs4590817+ 10q21.2+ 107! ! +25+ rs1530440+ 133+ 155! +
26+ rs932764+ 10q23.33+ 107! ! +
27+ rs11191548+ 10q24.3+ 107! ! 133,+155,+147,+137,+115+
28+ rs2782980+ 10q25.3+ 135! ! +
29+ rs661348+ 11p15.5+ 150! ! +
30+ rs7129220+ 11p15.4+ 107! ! 199+
31+ rs381815+ 11p15.1+ 107! 155,115+ 137,!150+
32+ rs633185+ 11q22.1+ 107! ! +
33+ rs11222084+ 11q24.3+ 135! ! +
34+ rs17249754+ 12q21.3+ 107! ! 115,!147,!150,!155+
35+ rs3184504+ 12q24.1+ 107! 155,+115+ +36+ rs653178+ 133+ 155! +
37+ rs10850411+ 12q24.2+ 107! ! 137,+115+
38+ rs1378942+ 15q24.1+ 107! 133,!155! 115+
39+ rs2521501+ 15q26.1+ 107! ! +
40+ rs13333226+ 16p12.3+ 82! ! +
41+ rs12940887+ 17q21.33+ 107! ! 133,!155!
42+ rs17608766+ 17q21.32+ 107! ! +
43+ rs1327235+ 20p12.2+ 107! ! +
44+ rs6015450+ 20q13.32+ 107! ! +
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3+ Quality+control+of+GS:SFHS+
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3.1+ Introduction+about+this+chapter+
This chapter describes the data cleaning procedure applied in this thesis to 
ensure high quality data were used in the subsequent analyses. This procedure 
started with performing a QC step for genotyping data, and then explored the 
primary variables in this study (i.e. BP traits). Each participant was checked for 
the availability of high quality genotypes, phenotypes, and medication history to 
be included in the final study population. 
3.2+Method+
The general methods used in this chapter are described in detail in Chapter 2. 
Briefly, inclusion and exclusion criteria for individuals in the QC procedure are 
based on the availability of three components: genotype information, clinical 
data, and medication history (Figure 2-2). Each one of these three components 
has its own inclusion/exclusion criteria. Briefly, individual’s exclusion criteria 
based on genotypes were; sample call rate ≤95%, and individuals from family 
with Mendelian errors ≥5% (see Section 2.4.2.4 -p102). The clinical data were 
then checked for completeness in individuals with complete genotypes. This was 
first accomplished by checking the availability of BP and BMI measurements; 
individuals without these values were excluded as well as those without 
medication history (see Sections 2.3.2 -p99, and Section 2.3.3 -p103). Analysis 
was performed only on participants who passed these criteria, to produce a 
sample!with a complete genotype and phenotype information. The procedure of 
SNP QC started by checking the genotype call rate, MAF, and Mendelian errors as 
described previously in Section 2.4.2.4 -p114 and Section 2.4.2.5 -p116. 
Exploratory data analysis for BP values was performed first by generating 
graphical summaries for each variable. Extreme values were then double 
checked to distinguish between those values that are genuine extreme value 
(i.e. outliers) fromincorrect values. Standard methods to remove outliers are 
based on considering any values above multiples of standard deviation (i.e. 3 SD) 
as outliers. However, this thesis used the method reported by Welch et al. to 
remove outliers based on sensible boundaries defined by representative survey 
data.200 In this method, acceptable age- and gender-specific ranges of each 
variable were derived by adding/subtracting 10% to the most extreme values in 
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the Health Survey for England (HSE). A table for these ranges was provided by 
Welch et al. for both variables of SBP and DBP.200 Graphical summaries and data 
exploratory analysis were performed using SPSS (version 22.0; SPSS Inc. Chicago, 
Illinois, USA) and ggplot2 package in R statistical package version 3.1.1.201 
3.3+Results+
3.3.1+Excluding+individuals+based+on+genotype+call+rate+
The total number of individuals with a DNA sample and available for genotyping 
was 20,753 individuals; of them, only 18,470 individuals passed the QC criteria 
and were available for subsequent analysis (Figure 3-1). The first run of QC was 
performed manually by checking the cluster plots, and then checking the 
genotype call rate for all the individuals, in which 456 individuals were excluded 
due to low genotype call rate. The second run of QC excluded a further of 1,261 
individuals based on the predefined exclusion criteria; this resulted in a total of 
19,027 individuals with high quality genotype information.  
3.3.2+Excluding+individuals+based+on+missing+phenotypes+
The total number of individuals with genotypes (n =19,027) were then checked 
for availability of phenotypes (i.e. BP and BMI), and 146 (0.7%) individuals were 
excluded because of missing BP measurement or BMI values (Figure 3-1). 
3.3.3+Excluding+individuals+based+on+medication+history++
The remaining individuals were then checked for the availability of medication 
history data in the form of either an EPRs or SRM. Of 18,881 individuals, a total 
of 411 (2.7%) individuals were excluded because of missing medication history 
(Figure 3-1). This resulted in a total of 18,470 individuals with BP 
measurements, BMI values, and at least one source for medication history. The 
total number of participants with EPRs was 13,732 individuals. The total number 
of participants who completed PCQ-1 was 8,253 individuals, of them 3,225 
individuals ticked the box of not taking any medication pills. The total number 
of participants who completed PCQ-2 was 9,918 individuals, of them 1,086 
individuals did not answer the question regarding taking BP-lowering medication 
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(i.e. not answering yes or no), which resulted in a total of 8,832 individuals with 
a valid answer for PCQ-2. 
The participants were then classified based on the number of medication history 
sources; the first group included individuals with at least one source of 
medication history (n =18,470). The second group included individuals with two 
sources of medication history (i.e. subjects with EPRs and SRMs in PCQ; 
n =12,347).  
3.3.4+QC+for+SNP+
All SNPs have MAF ≥0.05, except for rs17608766 with a MAF of 0.00691. All SNPs 
were in HWE (P >0.0001) based on founders only, and no SNPs were removed 
because of low call rate (<90%) (Table 3-1). Furthermore, GS management staff 
performed an independent validation of a subset of the genotypes. This was 
accomplished by comparing the generated genotypes in this project against 
another project that genotyped a similar 19 SNPs for 590 individuals common to 
both the two projects, providing a total of 11,210 genotypes to be cross-
validated. The discrepancy in genotypes between the two projects was reported 
to be less than 1%. 
Imputation was performed based on the family information when possible, or 
based on the average coded allele frequency for persons without other relatives. 
For the 44 SNPs related to this thesis, 13,997 individuals had complete genotype 
data without requiring any genotype imputation. Genotype imputation in the 
remaining individuals ranged from only one SNP for 3,340 individuals to six SNPs 
for 74 individuals. The proportion of the total imputed genotypes to the chip 
genotypes was less than 2%. 
3.3.5+Family+data+review+
The family structure of the participants composed of 7,025 extended families, 
which range from 1 member per family in 2,396 families to 29 members per 
family in a single pedigree. The average family size was 2.63 members per 
family, and the average number of generations per family was 1.91 (Figure 3-2).  
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Figure+3G1+Flowchart+of+QC+results+and+classification+of+individuals+based+on+the+sources+of+
medication+history.+
+ +
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Table+3G1+Summary+statistics+of+SNPs+QC+
No! Chr.! SNP! Minor!allele! Major!allele! MAF! Call!rate!
1! 1+ rs17367504! G! A! 16.2%! 99.6%!
2! 1+ rs5068! G! A! 5.05%! 99.8%!
3! 1+ rs17030613! C! A! 19.9%! 99.5%!
4! 1+ rs2932538! A! G! 24.3%! 99.3%!
5! 1+ rs2004776! T! C! 26.4%! 99.3%!
6! 2+ rs1446468! A! G! 46.6%! 98.1%!
7! 3+ rs13082711! C! T! 25.2%! 99.5%!
8! 3+ rs3774372! C! T! 15.0%! 99.8%!
9! 3+ rs319690! G! A! 32.0%! 95.6%!
10! 3+ rs419076! T! C! 48.8%! 99.5%!
11! 4+ rs871606! C! T! 10.9%! 99.8%!
12! 4+ rs1458038! T! C! 29.1%! 98.1%!
13! 4+ rs13107325! T! C! 5.55%! 94.0%!
14! 4+ rs13139571! A! C! 24.6%! 99.3%!
15! 5+ rs1173771! A! G! 39.0%! 99.3%!
16! 5+ rs11953630! T! C! 36.6%! 99.1%!
17! 6+ rs1799945! G! C! 15.1%! 98.7%!
18! 6+ rs805303! A! G! 38.1%! 99.6%!
19! 7+ rs12705390! A! G! 19.8%! 99.8%!
20! 7+ rs3918226! T! C! 8.41%! 99.1%!
21! 8+ rs2071518! T! C! 28.4%! 99.6%!
22! 10+ rs4373814! C! G! 41.7%! 99.6%!
23! 10+ rs1813353! G! A! 33.5%! 99.4%!
24! 10+ rs4590817! C! G! 17.9%! 99.6%!
25! 10+ rs1530440! T! C! 19.6%! 99.4%!
26! 10+ rs932764! G! A! 44.5%! 99.5%!
27! 10+ rs11191548! C! T! 8.19%! 99.8%!
28! 10+ rs2782980! T! C! 27.6%! 99.1%!
29! 11+ rs661348! C! T! 41.1%! 99.4%!
30! 11+ rs7129220! A! G! 12.3%! 99.8%!
31! 11+ rs381815! T! C! 29.6%! 99.6%!
32! 11+ rs633185! G! C! 27.8%! 99.6%!
33! 11+ rs11222084! T! A! 36.9%! 99.6%!
34! 12+ rs17249754! A! G! 17.3%! 99.5%!
35! 12+ rs3184504! C! T! 50.0%! 99.2%!
36! 12+ rs653178! C! T! 50.0%! 99.5%!
37! 12+ rs10850411! C! T! 31.6%! 98.6%!
38! 15+ rs1378942! C! A! 32.1%! 99.4%!
39! 15+ rs2521501! T! A! 31.2%! 99.7%!
40! 16+ rs13333226! G! A! 18.7%! 99.4%!
41+ 17+ rs17608766+ C+ T+ 0.69%+ 98.6%+
42! 17+ rs12940887! T! C! 35.7%! 99.4%!
43! 20+ rs1327235! G! A! 49.4%! 99.5%!
44! 20+ rs6015450! G! A! 12.0%! 99.2%!
Abbreviations:!Chr.:!Chromosome,!MAF:!Minor!allele!frequency,!HWE:!HardyJWeinberg!equilibrium.!
SNP!rs17608766!(in+bold) was!excluded!because!of!low!MAF!<1%.+
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Figure+3G2+Family+size+and+number+of+generations+per+pedigree+in+GS:SFHS.+
A.+shows+the+number+of+individuals+per+family+(i.e.+family+size).+Families+are+groups+in+the+
study+sharing+a+family+identity+numberl+a+family+identity+number+was+given+to+groups+where+
each+member+was+a+firstGdegree+relative+of+at+least+one+other+individual+in+the+group.+B.+
shows+the+number+of+generation+per+pedigree,+this+figure+of+generation+structure+may+
include+family+members+that+are+not+in+the+final+study+population,+but+their+presence+is+
required+to+draw+the+pedigree+(figures+were+produced+using+Pedstats+Software).+
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3.3.6+BP+values+data+check+
The quality of BP measurements was checked to identify any outliers or 
erroneous entries by two different methods. First, a data exploratory step was 
performed by drawing a graphical summary for each BP variable as shown in 
Figure 3-3 and Figure 3-4. Second, the age- and gender-specific ranges of BP 
values were compared to a reference ranges provided in HSE,200 in which all 
values of BP in GS:SFHS were within the range (Table 3-2). Hence, all the 
measurements were considered valid values without any value labelled as an 
outlier. The departure from normality for BP traits was minimal except for PP, 
as measured by skewness (0.7, 0.3, 0.4, and 1.1 for SBP, DBP, MAP, and PP, 
respectively) and kurtosis (0.9, 0.3, 0.3, and 2.2 for SBP, DBP, MAP, and PP, 
respectively). 
3.3.7+Identifying+participants+taking+BPGlowering+medications+
based+on+EPRs+
Of the individuals who passed QC (n =18,470), the EPRs contained 1,507,927 NHS 
prescriptions, for 13,732 subjects, including 4,319 items (trade names) or 1,333 
pharmacological items (approved names). The total number of prescriptions that 
contained a BP-lowering medication was 208,408 prescriptions for a total of 91 
pharmacological items, for 4,787 individuals. However, this number of 
individuals encompassed the total number of individuals who were taking a BP-
lowering medication at any time point before the reference data (i.e. 
recruitment day). The definition of BP-lowering medication exposure was 
restricted to 120 days before the reference date. Hence, searching of 
prescriptions within this period revealed 7,550 BP-lowering medication 
prescriptions for 1,965 individuals (detailed description of BP-lowering 
medication is discussed later in Section 4.4.2 -p143). 
3.3.8+Identifying+participants+taking+BPGlowering+medications+
based+on+SRMs+
The total number of participants with SRMs history was 17,085 individuals; of 
them, 8,253 individuals completed the PCQ-1, and 8,832 completed the PCQ-2. 
While the retrieved information from PCQ-2 was straightforward and simple as 
subjects answered yes/no questions, more information was retrieved from    
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PCQ-1 such as medication name and pharmacological classes. In PCQ-1, the 
number of written medications names by participants was 20,715 entries; of 
them, 2,426 medications were identified as BP-lowering medication. The 
number of participants who reported taking a BP-lowering medication was 1,334 
individuals (16.16%); 701 (52%), 449 (33.6%), 148 (11.1%), 33 (2.5%), 2 (0.2%), 
and 1 (0.07%) participants reported one, two, three, four, five, and six BP-
lowering medications, respectively. The most common reported monotherapy 
were ACEIs 184 (26.2%), beta-blockers (BBs) 182 (26%), calcium-channel blockers 
(CCBs) 118 (16.8%), and thiazides diuretics 87 (12.4%). In PCQ-2, out of the 
8,832 individuals who completed the PCQ-2, 1,517 (17.2%) had positively 
answered the question of taking a regular BP-lowering medication.  
 
Figure+3G3+Histogram+for+BP+traits+with+normal+distribution+curve+on+the+plot.+
The+vertical+axis+(yGaxis)+shows+the+frequency+of+individuals,+and+the+horizontal+axis+(xGaxis)+
shows+BP+values+in+mmHg.+Histograms+represent+A.+SBP,+B.+DBP,+C.+MAP,+and+D.+PP.+ +
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Figure+3G4+BoxGWhisker+plot+with+jitterGdots+for+BP+traits.+
Red+diamond+inside+the+box+plot+represents+the+mean.+The+red+diamonds+inside+the+box+
plots+represents+the+mean,+and+the+lines+within+the+boxes+indicate+the+median,+the+edges+of+
the+pink+boxes+are+the+first+and+third+quartiles+(the+interquartile+range+or+(IQR)),+the+
whiskers+extend+to+1.5+times+the+IQR.+BP+values+above/below+the+boxplot+are+plotted+in+
with+small+jitterGdots+to+show+data+distribution.+Boxplots+represent+A.+SBP,+B.+DBP,+C.+
MAP,+and+D.+PP.+
+ +
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Table+3G2+AgeG+and+genderGspecific+ranges+of+GS:SFHS+and+HSE+
Variable!
Age!
group!
(years)!
Men! Women!
GS:SFHS! HSE!(+/J!10%)*! GS:SFHS! HSE!(+/J!10%)*!
Min! Max! Min! Max! Min! Max! Min! Max!
SBP!
(mmHg)!
17–24! 85.5! 187.5! 68.4! 207.9! 80.0! 143.5! 52.2! 149.7!
25–34! 93.5! 180.0! 61.2! 214.5! 88.5! 181.0! 72.0! 221.1!
35–44! 85.0! 188.5! 55.8! 218.9! 87.0! 188.5! 64.8! 235.0!
45–54! 98.5! 197.0! 55.8! 242.0! 74.0! 239.0! 54.9! 269.5!
55–64! 86.5! 216.5! 63.0! 256.3! 81.5! 210.5! 72.0! 256.3!
65–74! 94.5! 213.0! 72.0! 253.0! 97.5! 217.0! 54.9! 255.2!
75+! 83.5! 224.0! 78.3! 249.7! 100.5! 217.5! 61.2! 265.1!
DBP!
(mmHg)!
17–24! 35.5! 107.5! 29.7! 128.7! 44.0! 105.5! 27.9! 127.6!
25–34! 52.0! 112.5! 36.0! 139.7! 50.5! 114.0! 30.6! 125.4!
35–44! 46.0! 122.0! 29.7! 141.9! 36.0! 119.5! 35.1! 144.1!
45–54! 55.0! 124.0! 27.9! 159.5! 42.0! 145.5! 27.9! 163.9!
55–64! 50.0! 125.5! 28.8! 157.3! 48.5! 130.0! 35.1! 167.2!
65–74! 45.5! 121.5! 35.1! 154.0! 55.5! 120.0! 34.2! 165.0!
75+! 46.5! 104.5! 33.3! 158.4! 50.0! 107.5! 34.2! 161.7!
*ageJ!and!genderJspecific!ranges!of!SBP!and!DBP!from!HSE!were!derived!from!data!reported!in!Welch!et!
al.200!HSE:!Health!Survey!of!England!
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3.4+Discussion++
This chapter described the data exploratory and QC processes used in this 
thesis. This data exploration is a critical first step in analysing data to detect 
any possible incorrect, implausible, missing, or duplicate values to ensure high 
data quality. The availability of a large health record database such as GS:SFHS 
offers a unique resource for epidemiological and medical research. However, 
primary variables need to be carefully examined before conducting analysis to 
exclude errors that may potentially affect the interpretation of the results. For 
instance, a study that compared the error rate generated by two independent 
investigators reported a rate that ranged from 2.3% up to 26.9%, with errors 
clustering in non-random fashion.202 Hence, several guidelines have reported the 
importance of data cleaning in good clinical practices.  
Quality of phenotypes, DNA samples, genotyping, and family structure of 
GS:SFHS has already been examined in other studies.171,203 The quality of 
phenotypes and clinical data of the complete cohort of GS:SFHS (n =23,960) was 
published by Smith et al.171 Several reasons can explain the difference in the 
sample size between this thesis and the complete cohort reported by Smith et 
al. First, this thesis originally started with a smaller sample size due to the 
availability of DNA samples. Second, the final study population was restricted to 
individuals with specific inclusion criteria (i.e. BP and BMI measurements along 
with medication history). Third, the full cohort has reported presence of 1,400 
singletons due to recruiting participants with registered relatives who then 
failed to participate in the study. This number increased to 2,396 singletons in 
this thesis due to exclusion of extra participants from the study. 
While Smith et al. have mainly examined the phenotype data quality, Kerr et al. 
has examined the DNA, genotyping, and pedigree quality, by genotyping 32 SNPs 
in DNA from 10,450 individuals.203 SNPs genotyping call rate ranged from 91.6% 
to 99.5%, with an average sample call rate of 96.2% for DNA samples derived 
from saliva, and an average sample call rate of 97.1% for DNA samples derived 
from blood. The quality of genotyping in this thesis has also been assessed by an 
independent investigator, who compared the genotypes of 19 SNPs for 590 
individuals that were generated by this project to the same set of SNPs and 
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individuals in another project. This has provided 11,210 genotyped to be cross-
validated and the discrepancy was found to be less than 1%.  
The primary aim of this thesis is to study whether the genetic variants that have 
been previously reported to be associated with BP and hypertension also play a 
role in the Scottish population. Hence, the first inclusion criterion was the 
presence of SNP genotypes. This would allow a consistent sample size across the 
different analyses performed in this thesis. The proportion of individuals 
excluded due to genotyping errors was about 6% compared to only 2% due to 
phenotype missing information, which is mainly due to the applied stringent 
genotype QC criteria. Mendelian errors are more likely to be a result of 
genotype errors rather than errors in the recorded pedigree, as reported by Kerr 
et al. after checking the inheritance patterns of 32 SNPs in 925 parent-child trios 
in GS:SFHS.203 Considering the total of 925 trios, only 16 trios had two or more 
Mendelian errors, and 13 of them had offspring-paternal Mendelian errors, 
indicating a maximum estimated non-paternity rate in GS:SFHS of less than 1.5% 
(13 trios out of 925 trios).203 The other possible explanations of Mendelian errors 
include sample handling errors in the clinic or laboratory, or errors in pedigree 
data collection, especially that family structures were recorded during the 
participant clinic visit without an independent verification from another source. 
A higher proportion of individuals were excluded because of missing medication 
history (2.1%) than those excluded because of missing phenotypes (0.7%). The 
importance of the presence of a medication history relies on the fact that 
studying BP as a quantitative trait is seriously compromised without proper 
adjustment for treatments (see Section 1.5.1.1 -p51).87 Hence, adjustment for 
treatment can only be performed for subjects with a reliable and complete 
medication history, and including individual with vague treatment status would 
introduce inconsistency between individuals, which may affect the precision of 
the phenotype and thence statistical power. At this stage, the source of 
medication history (i.e. EPRs or SRMs) did not influence the decision of including 
individuals, and each participant with at least one source of medication history 
was included.  
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The only reason for excluding individuals based on phenotype quality was 
missing BP measurements in about of 0.7%. BP measurements in all of the 
remaining participants were all considered within the age- and gender-specific 
ranges provided by Welch et al.200 This method was found to be more efficient 
than the traditional method of removing values above/below 3 SD, as it is based 
on sensible boundaries as defined by a representative population, while keeping 
individuals with genuine extreme values that may represent the true variation in 
the study. The distribution of BP traits were normally distributed with a slight 
skewness to the right, especially for PP. 
In conclusion, this chapter aimed to ensure the availability of high quality data 
for each participant in the final study population. Hereafter, the term of 
GS:SFHS will be used to describe the final study population that includes only 
participants with validated phenotypes and genotypes. This chapter did not 
expand to describe the baseline characteristics of participants. 
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4+ Study+of+BP+phenotypes+
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4.1+ Introduction+
4.1.1+Introduction+to+this+chapter+
This chapter describes the baseline characteristics of the study population. It 
then focuses on BP-related phenotypes, starting with the assessment of the 
prescription patterns of BP-lowering medications and the quality of SRMs history 
by comparing it with the information from EPRs. Next, the prevalence of 
hypertension, treatment, control, and awareness in GS:SFHS were calculated. 
Lastly, the influence of different risk factors on hypertension-related traits was 
evaluated using a logistic mixed model that accounts for the familial 
correlation. 
4.1.2+Pharmacoepidemiological+analysis++
Self-reported methods are prone to various types of bias, such as recall bias, 
that may influence recall accuracy. Several studies have reported different 
factors that influence medication recall accuracy in self-reported methods such 
as medication type, pattern of drug use, questionnaire design, respondent 
characteristics, and the study method of analysis.183,204,205 Typically, pharmacy 
prescription records are considered the “gold standard” of drug exposure 
information compared with self-reported information.205,206 
As shown in Chapter 3 (Sections 3.3.7 -p126, and Section 3.3.8 -p126), 
participants of GS:SFHS can be divided into two groups based on the number of 
medication history sources. While two-thirds of participants (n =12,347) have 
both SRMs history and EPRs, the vast majority of remaining participants have 
only SRMs history. In order to combine information of medication history across 
all participants, it is important to determine the quality of SRMs in GS:SFHS by 
comparing it to the information retrieved from the EPRs. For this thesis, the 
analysis was restricted to assess the reliability of reporting BP-lowering 
medication by self-reported methods.  
The availability of different sources of medication history in GS:SFHS has 
allowed different kinds of pharmacoepidemiological analysis to be performed. 
The aim of the pharmacoepidemiologic analysis is to make use of the EPRs and 
SRMs to understand the prescription patterns for BP-lowering medications in 
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GS:SFHS. Further analyses include assessment of the accuracy of SRMs history. 
Finally, the influence of changing the PCQ forms from open-ended questions in 
PCQ-1 to closed-end questions in PCQ-2 will be assessed by comparing each 
phase with the EPRs.  
4.1.3+Prevalence+of+hypertensionGrelated+health+outcomes+in+
GS:SFHS+
Sections 1.3.3 to 1.3.7 in the introduction chapter discussed the prevalence of 
hypertension and its related health outcomes globally and in the Scottish 
population. Historically, Scotland has been called the “sick man of Europe”, 
owing to the higher mortality rate compared to other western European 
countries. Although life expectancy in Scotland was comparable to other 
western countries up until 1950, it improved at a slower rate thereafter 
compared to other wealthy nations, before further faltering after 1980.207 
Basically, mortality rates from CVD, stroke and cancer were higher before 1980s, 
after which an increase in mortality rates from violent, drug-related and suicide 
deaths was observed. Relative to England, Scotland had 40% higher mortality 
rates for all causes, 60% higher mortality rates for coronary heart disease, and 
42% higher mortality rate for stroke.169 These higher mortality rates were 
observed across the socio-economic spectrum, suggesting a minimum 
contribution of socio-economic factors in explaining the mortality rates 
differences. Indeed, it was found that only a quarter of the excess mortality 
rates in Scotland could be attributed to socioeconomic, behavioural, 
anthropological or biological factors.169 The remaining excess mortality rate that 
is not explained by differences in levels of socio-economic deprivation is known 
as the “Scottish Effect”.208 These findings highlight the uniqueness of the 
Scottish population, and the importance of identifying the factors that 
contribute to the higher mortality rates compared to their English counterpart. 
In this section, the aims are to estimate the prevalence of hypertension in the 
GS:SFHS, and the extent of treatment, control, and awareness of hypertension. 
Also, the influence of some determinants in these hypertension-related 
outcomes will be examined. 
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4.2+Aims+of+this+chapter+
The aims of this chapter are to:  
(1)!describe the baseline characteristics of the study population.  
(2)!Perform a pharmacoepidemiological analysis to identify those individuals 
taking BP-lowering medications, and assess the reliability of SRMs history 
in exposure measurements of BP-lowering medication.  
(3)!Calculate the prevalence of hypertension, treatment, control, and 
awareness.  
(4)!Estimate the relationship of BP levels and prevalence of hypertension 
with socio-economic factors (as defined by SIMD quintiles).  
4.3+Methods+
4.3.1+Overview+of+the+method+
Since the EPRs were not available for all participants, the reliability of SRMs was 
performed only on the subset of individuals with this information. The SRMs 
source can be compared against the EPRs; in which, the EPRs were considered 
the “gold standard”. Because hypertension is defined based on BP 
measurements and medication history, as will be discussed in Section 4.3.2, 
participants taking BP-lowering medications were firstly identified as explained 
in Section 2.3.2. The second analysis was carried out to determine the 
prevalence of hypertension, awareness, treatment, and control of hypertension; 
and finally using a multilevel multivariate mixed model that accounts for 
familial correlation to assess the effect of socio-economic factors in 
hypertension-related indicators.!
4.3.2+Assessing+the+validity+of+the+SRMs+
The agreement between each source was evaluated using several methods, each 
of which addresses a different question regarding the concordance between the 
sources.205,209-211 Generally, comparing two methods of data collection or two 
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sources can be performed in two ways; measurement of validity or measurement 
of reliability.205 Although the terms validity and reliability can be used 
interchangeably to describe the agreement between two sources of information, 
they differ in that the validity analysis requires that one of the two sources is 
superior to the other, or one source can be described as a “gold standard”. 
Whereas, the reliability analysis assumes that the two sources are similar 
without a priori assumption that one is superior to the other. The important 
metrics of validity analysis are; sensitivity, specificity, positive predictive value 
(PPV), and negative predictive value (NPV) (Table 4-1). It is important to 
consider that the denominators of the first two measures represent the actual 
number of subjects with or without the outcome. However, the denominators of 
the last two measures (i.e. predictive values) are the number of subjects 
classified as having or not having the outcome. Hence, the predictive values 
measure the performance of classification not the validity of the test, and are 
influenced by the prevalence of the outcome which may differ between 
populations. 
The second method to assess the concordance between the two methods of data 
collection is applied when both of them are considered equivalent (i.e. neither 
of them can be considered as gold standard). In this situation, the measurement 
of reliability statistics evaluates the agreement between the two methods using 
Cohen’s Kappa coefficients (κ) statistics.209-211 Kappa is designed to improve the 
simple measure of proportional agreement between two observers (po) by 
subtracting the proportion of agreement that is expected by chance (pe) from 
the optimal agreement (1). Hence, the calculation of kappa is based on 
constructing a ratio between the chance-corrected observed agreement and the 
chance-corrected perfect agreement.212 That is, subtracting the value of the 
expected agreement by chance (pe) from both the observed agreement (po) and 
the perfect agreement with a value of (1). The kappa value can be interpreted 
as follows: poor agreement if κ <0.20, fair agreement if κ =0.21-0.40, moderate 
agreement if κ =0.41-0.60, good agreement if κ =0.61-0.80, and very good 
agreement if κ >0.80.209-211 Although the kappa statistic is quite simple and is 
increasingly reported in the literature, the value of kappa is influenced by the 
skewed distribution of the outcome or unbalanced marginal total, resulting from 
high prevalence of the outcome or systemic bias. Hence, other measures are 
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reported here to highlight the reliability results. The effect of prevalence occurs 
when the proportion of positive agreement is greatly different from the 
proportion of negative agreement, and it is expressed by the prevalence index 
(PI). In the presence of higher PI, the agreement just by chance is also higher 
and thus kappa is lower (this illustrates the first paradox of kappa).210,211 The 
effect of bias occurs when the two sources disagree on the proportion of the 
outcome, and it is expressed by the bias index (BI). In the presence of higher BI, 
large bias exists between the two sources, which leads to higher kappa. An 
adjusted kappa value has been used in some literature, known as prevalence-
adjusted bias-adjusted kappa (PABAK), which is calculated by substituting the 
positive and negative agreement values by their average to adjust for 
prevalence, and the other two disagreement values by their average to adjust 
for bias. Yet, Hoehler has criticized this value as he showed through simulation 
studies that the effect of bias and prevalence are informative and should not be 
disregarded by adjusting.213 Finally, Cicchetti and Feinstein (1990) proposed two 
indices to be presented with kappa for better describing the observed 
agreements; that are the proportion of the observed positive agreement (Ppos) 
and the proportion of the observed negative agreement (Pneg). These two indices 
are considered as analogous to sensitivity and specificity, in the scenario of no a 
priori “gold standard”.212,214 
In this thesis, the two methods of measuring the validity and reliability were 
applied as following; the EPRs (Treatmentprescr) was considered the “alloyed gold 
standard” in one analysis, and the validity of SRMs (TreatmentQues) was assessed 
by applying the method of measuring validity (i.e. sensitivity, specificity, and 
predictive values). The second analysis was performed under the assumption of 
no gold standard method and the reliability measure was used by applying kappa 
statistics. In order to compare the two PCQ phases and to examine the effect of 
questionnaire structure, the two PCQ phases were compared using the 
measurement of reliability methods. However, because the two PCQ phases 
(TreatmentPCQ-1) and (TreatmentPCQ-2) were mutually exclusive, no subjects have 
completed both of them. An indirect assessment was performed by comparing 
both of them independently against (Treatmentprescr). The contingency 2x2 
tables were constructed using SPSS (version 22.0; SPSS Inc. Chicago, Illinois, 
USA) after coding participants into “1”, “0”, or “NA” if they were taking BP-
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lowering medication, not, or not applicable, respectively ( i.e. if participant was 
coded “1 or 0” for TreatmentPCQ-1, he will be coded as “NA” for TreatmentPCQ-2). 
Hence, each participant received at least three codes for the previous four 
sources (i.e. Treatmentprescr, TreatmentQues, TreatmentPCQ-1, and TreatmentPCQ-2). 
This analysis was performed using the subset of individuals who were identified 
as hypertensive using the definition of [a mean BP value ≥ 140/90 mmHg, taking 
a BP-lowering medication based on either EPRs or SRMs, or answered “yes” to 
the question about a previous medical diagnosis of high BP]. 
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Table+4G1+Definitions+and+formulas+of+the+concordance+analysis+measures+
Notation 
   EPRs  
  Treated Not treated Total 
SRMs Treated A B g1 Not treated C D g2 
 Total f1 f2 N 
Others  m  (A + D)/2 n (C + B)/2 
Formula and definition 
Sensitivity 
The degree to which the self-reported source correctly identifies 
participants taking BP-lowering medication [ !"# ]. 
Specificity  
The degree to which the self-reported source correctly identify 
participants not taking BP-lowering medication [$"%]. 
Positive predictive 
value (PPV) 
The probability that subjects with a positive test are truly positive 
[ !&']. 
Negative predictive 
value (NPV) 
The probability that subjects with a negative test truly do not have 
the outcome $&(. 
Observed agreement 
()*) The proportion of observed agreement in both sources [ !+$,  ]. 
Expected agreement 
()-) The proportion of agreement that is expected by chance [("'∗&')+("(∗&(),%  ]. 
Cohen’s Kappa 
coefficients (κ) 
The proportion of agreement beyond that is expected by chance  
[ (12314125)(1'41251)  ]. 
Prevalence index 
(PI) 
The proportion of agreements that is due to the prevalence of the 
outcome only [1|1!4$1|,  ]. 
Bias index 
(BI) 
The proportion of disagreement between the two sources that is due 
to systemic difference (bias) [1|17−91|:  ]. 
Bias-adjusted and 
prevalence-adjusted 
Kappa (BAPAK) 
Kappa statistics after adjusting for the bias and prevalence effects  
[ 
%;< 4125'4125  ]. 
Proportion of 
positive agreement 
(Ppos) 
The observed proportion of positive agreement [ (!"#+1&# ]. 
Proportion of 
negative agreement 
(Pneg) 
The observed proportion of negative agreement [ ($"%+1&% ]. 
 !
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4.3.3+Definitions+of+hypertension+related+indicators++
Several hypertension-related indicators were evaluated for each participant: 
hypertension status, treatment, control and awareness of hypertension. The 
definition of each indicators is: 
•! Hypertension: SBP ≥140 mmHg or a DBP ≥90 mmHg, or receiving 
treatment.  
•! Treatment: taking at least one BP-lowering medication based on EPRs 
where available, or based on SRMs for the remaining participants.  
•! Controlled hypertension: taking a treatment with BP level below 140/90 
mmHg if aged <80 years, or below than 150/90 mmHg if aged ≥80 years.  
•! Awareness: self-report of a previous diagnosis of hypertension by a 
healthcare professional.  
•! BP category: the seventh report of the Joint National Committee was 
used to categorize participant based on their BP values215: 
o! Prehypertension: SBP 120-139 mmHg, or DBP 80-89 mmHg 
o! Stage-1 hypertension: SBP 140-159 mmHg, or DBP 90-99 mmHg 
o! Stage-2 hypertension: SBP ≥160 mmHg, or DBP ≥100 mmHg 
•! High-risk population: it includes the subset of participants with a 
complete medical history (i.e. SRM, EPR, and self-reported history of 
hypertension) who were defined as hypertensive based on the study 
definition and/or self-reported history of clinically diagnosed 
hypertension. 
4.3.4+Estimating+of+hypertensionGrelated+indicators+prevalence+
For descriptive analysis, continuous variables are expressed as mean ±SD, and 
categorical variables were expressed as number of subjects and percentage. 
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Baseline variables were compared using a chi-square test for categorical 
variables, and analysis of variance (ANOVA) for continuous variables; a two-
tailed p value of <0.05 was considered significant. Simple descriptive analysis 
was performed using SPSS (version 22.0; SPSS Inc. Chicago, Illinois, USA). 
The prevalence of hypertension, awareness, treatment and control are 
represented as crude proportions, and as age- and sex- standardized prevalence. 
In addition, they were stratified by different risk factors - BMI, SIMD quintiles, 
smoking status, number of parents with hypertension as reported by participants 
in the PCQ, and number of years at school. The standardization procedure was 
performed by applying a direct method using age and sex sub-groups distribution 
of mid-year 2011 census household estimates for Scotland as a standard 
population; the age sub-groups were: 18–24, 25–34, 35–44, 45–54, 55–64, 65–74, 
and +75 years (Appendix 1). The age-standardized proportion ()`) was calculated 
as follows: 
)` = ,?@?? ,??   
Where )` is the age specific rate in the age group i and :A is the standard 
population in age group i. The variance of the standardized proportion was 
estimated by: 
BCD )` = 1(,?%112?1E?1/1G?)? ,?? % 1 , 
Where HA = 1 −1)A1 
4.3.5+Assess+the+effect+of+socioGeconomic+factors+in+
hypertensionGrelated+indicators+
A multilevel mixed effect model that accounts for the family structure of the 
sample was used to examine the factors associated with selected outcome 
variables. The model can be considered as two levels where individuals were 
treated as the level one unit and families were treated as the level two unit. 
This would allow the simultaneous examination of the effects of family-level and 
individual-level variables on individual-level outcome, while controlling for the 
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correlation within family members.216 The family units were constructed to 
include members of a nuclear family only. A generalized linear-mixed model 
were applied to assess that effect of socio-economic factors in the different 
hypertension-related binary outcomes; in which, individuals were nested within 
families in the logistic-mixed model that included the hypertension-related 
indicators (i.e. hypertension status) as dependent variables after adjusting for 
age, sex, and BMI. The results are presented in tables showing odd ratios (OR) 
with 95% CI for the final models; ORs are showed relative to reference category. 
Mixed-models were estimated using R package “lme4”.217 
4.4+Results+
4.4.1+Participants+baseline+characteristics+
The baseline characteristics of the GS:SFHS final populations (n =18,470) are 
provided in Table 4-2. The final study population had a higher proportion of 
women (58.7%) than men (41.3%). The mean of age was 45.3 ± 15.0 years, and 
45.8% of the participants were middle aged (40–59 years old). A higher 
percentage of men were active smokers compared to women (18.4% and 15.8%, 
respectively), and 51.7% of GS:SFHS participants had never smoked. The average 
BMI was 26.6 ± 5.1 kg/m2, and 21.2% of the participants had a BMI of 30 kg/m2 
or more (obesity). Only 3% had a reported a history of diabetes and 4.5% 
reported a history of other cardiovascular diseases. The mean SBP and DBP were 
131.5 ± 17.8 mmHg, and 79.8 ± 10.3 mmHg, respectively. Approximately half of 
the participants (52.4%) lived in area with above average SIMD score. The high 
risk group included 5,181 (28%) individuals, and 5,071 (98%) of them were 
defined as hypertensive based on the study definition of hypertension. 
4.4.2+Pharmacoepidemiological+analysis+
For all the 13,732 individuals with EPRs, 1,956 (14.3%) individuals had at least 
one BP-lowering medication that was prescribed within the time-window of 120 
days before the recruitment day. The number of BP-lowering medication classes 
per individual ranges from a single medication in 1011 (52%) individuals to a 
maximum of five BP-lowering medications in 12 (1%) individuals (Table 4-3); the 
number of individuals taking two, three and four classes of BP-lowering 
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medication were 648 (33%), 223 (11%), and 62 (3%), respectively. The most 
commonly prescribed monotherapy class was ACEIs, followed by BBs, CCBs, and 
thiazide diuretics. In dual combination therapy, ACEIs and diuretics were the 
most common combination therapy followed by ACEIs and BBs; ACEIs & CCBs; 
and BBs & diuretics. The proportion of controlled hypertension according to the 
number of BP-lowering classes were 47%, 46%, 43%, 39%, and 50% for individuals 
taking one, two, three, four, and five BP-lowering medications, respectively. 
Furthermore, only 53% participants who were taking a single BP-lowering class 
declared a previous diagnosis of hypertension, comparing to 71%, 78%, 85%, and 
83% for the participants taking two to five medications, respectively. Similarly, 
the proportion of participants who declared other cardiovascular or diabetes is 
higher in the groups of two or more BP-lowering classes. 
The number of individuals reported taking BP-lowering medication by SRMs was 
2,851 (16.9%). Of the 8,253 individuals who completed PCQ-1, 1,334 individuals 
(16.2%) reported taking BP-lowering medication by writing the medication 
names, and of the 8,832 individuals completed PCQ-2, 1,517 (17.2%) reported 
BP-lowering medication by giving affirmative answer to the corresponding 
yes/no question. 
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Table+4G2+Baseline+characteristics+of+study+participants+
Category! All! Men! Women!
Total! 18470! 100%! 7632! 41.3%! 10838! 58.7%!
Age,!mean±SD,!years! 47.6!±!15.0! 47.0!±!15.1! 47.6!±!14.8!
BMI,!mean±SD,!kg/m2! 26.6!±!5.1! 26.9!±!4.5! 26.5!±!5.5!
Average!SBP,!mmHg! 131.6!±!17.8! 136.3!±!15.8! 128.3!±!18.3!
Average!DBP,!mmHg! 79.8!±!10.3! 81.8!±!10.4! 78.4!±!10.1!
eGFR, ml/min/1.73m2! 87.3!±!17.6! 89.9!±!17.6! 85.4!±!17.1!
Total!Cholesterol,!mmol/l! 5.1!±!1.1! 5.0!±!1.1! 5.2!±!1.1!
HDL!Cholesterol,!mmol/l! 1.5!±!0.2! 1.3!±!0.3! 1.6!±!0.4!
Glucose,!mmol/l! 4.8!±!1.1! 5.0!!±!1.2! 4.7!±!1.0!
Diabetic*! 548! 3.00%! 293! 3.80%! 255! 2.40%!
Cancer*! 397! 2.20%! 107! 1.40%! 290! 2.70%!
Other!CVD!diseases*! 831! 4.50%! 477! 6.30%! 354! 3.30%!
Age!group!(years)!
≤!39!years!old! 5734! 31.0%! 2481! 32.5%! 3253! 30.0%!
40–59!years!old! 8468! 45.8%! 3366! 44.1%! 5102! 47.1%!
≥!60!years!old! 4268! 23.1%! 1785! 23.4%! 2483! 22.9%!
Smoking!
Active! 3123! 16.9%! 1407! 18.4%! 1716! 15.8%!
ExJsmoker! 5348! 29.0%! 2299! 30.1%! 3049! 28.1%!
Never! 9549! 51.7%! 3716! 48.7%! 5833! 53.8%!
missing! 450! 2.4%! 210! 2.75%! 240! 2.20%!
BMI!categories!(kg/m2)!
≤!18.5! 292! 1.6%! 75! 1.0%! 217! 2.0%!
18.5–24.9! 7405! 40.1%! 2616! 34.3%! 4789! 44.2%!
25–29.9! 6854! 37.2%! 3391! 44.4%! 3463! 32.0%!
≥!30! 3919! 21.2%! 1550! 20.3%! 2369! 21.9%!
SIMD!quintile!
1! 2287! 12.4%! 860! 11.2%! 1247! 11.51%!
2! 2375! 12.9%! 908! 11.9%! 1467! 13.54%!
3! 2725! 14.8%! 1176! 15.4%! 1549! 14.29%!
4! 4362! 23.6%! 1831! 23.9%! 2531! 23.35%!
5! 5320! 28.8%! 2283! 29.9%! 3037! 28.02%!
Number!of!years!at!school!
≤!11!years! 6281! 34%! 2665! 37.0%! 3616! 35.16%!
11–17!years! 9392! 51%! 3707! 51.5%! 5685! 55.2%!
≥!17!years! 1825! 10%! 824! 11.5%! 1001! 9.70%!
Underlined!percentages!are!significantly!different!between!sex!
*Based!on!participant’s!selfJreport!answer!in!the!familyJhealth!history!section!of!PCQ,!data!
were!available!for!18171!individuals!only.!
 +
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Table+4G3+Frequency+of+BPGlowering+medications+classes+based+on+EPRs+
Medication!class! Totala! Female! Controlledb! HTNc! CVDc!
1! ACEIs! 281!(0.14)! 143!(0.51)! 118!(0.42)! 186!(0.68)! 40!(0.15)!
ARBs! 96!(0.05)! 45!(0.47)! 29!(0.30)! 72!(0.77)! 9!(0.10)!
BBs! 264!(0.13)! 172!(0.65)! 166!(0.63)! 70!(0.27)! 46!(0.18)!
CCBs! 163!(0.08)! 90!(0.55)! 66!(0.40)! 102!(0.65)! 21!(0.13)!
Thiazides!diuretic! 120!(0.06)! 91!(0.76)! 38!(0.32)! 80!(0.67)! 9!(0.08)!
Other!diuretics! 54!(0.03)! 45!(0.83)! 40!(0.74)! 13!(0.24)! 11!(0.20)!
Other!classes! 33!(0.02)! 25!(0.76)! 17!(0.52)! 5!(0.16)! 1!(0.03)!
Total!of!one!medication! 1011!(0.52)! 611!(0.60)! 474!(0.47)! 528!(0.53)! 137!(0.14)!
2! ACEIs!&!BBs! 84!(0.04)! 26!(0.31)! 51!(0.61)! 44!(0.55)! 47!(0.59)!
ACEIs!&!CCBs! 80!(0.04)! 30!(0.38)! 41!(0.51)! 59!(0.75)! 17!(0.22)!
ACEIs!&!diuretics! 112!(0.06)! 71!(0.63)! 52!(0.46)! 84!(0.76)! 18!(0.16)!
ARBs!&!BBs! 25!(0.01)! 16!(0.64)! 9!(0.36)! 15!(0.63)! 11!(0.46)!
ARBs!&!CCBs! 37!(0.02)! 18!(0.49)! 12!(0.32)! 30!(0.81)! 5!(0.14)!
ARBs!&!diuretics! 70!(0.04)! 47!(0.67)! 26!(0.37)! 50!(0.74)! 6!(0.09)!
BBs!&!CCBs! 45!(0.02)! 24!(0.53)! 21!(0.47)! 29!(0.64)! 16!(0.36)!
BBs!&!diuretics! 80!(0.04)! 65!(0.81)! 39!(0.49)! 57!(0.72)! 13!(0.16)!
CCBs!&!diuretics! 66!(0.03)! 45!(0.68)! 28!(0.42)! 56!(0.85)! 5!(0.08)!
Diuretics!combinations! 18!(0.01)! 16!(0.89)! 12!(0.67)! 4!(0.22)! 2!(0.11)!
Other!combination! 31!(0.02)! 22!(0.71)! 6!(0.19)! 27!(0.87)! 5!(0.16)!
Total!of!two!medications! 648!(0.33)! 380!(0.59)! 297!(0.46)! 455!(0.71)! 145!(0.23)!
3! ACEIs,!CCBs!&!diuretic! 37!(0.02)! 24!(0.63)! 18!(0.47)! 29!(0.78)! 13!(0.35)!
ACEIs,!BBs!&!CCB! 20!(0.01)! 3!(0.14)! 7!(0.33)! 15!(0.75)! 13!(0.65)!
ACEIs,!BBs!&!diuretics! 42!(0.02)! 16!(0.38)! 19!(0.45)! 32!(0.76)! 23!(0.55)!
ARBs,!BBs&!CCB! 11!(0.01)! 2!(0.18)! 2!(0.18)! 9!(0.82)! 6!(0.55)!
ARBs,!BBs!&!diuretics! 18!(0.01)! 12!(0.67)! 11!(0.61)! 11!(0.61)! 8!(0.44)!
ARBs,!CCBs!&!diuretics! 22!(0.01)! 16!(0.72)! 8!(0.35)! 19!(0.86)! 4!(0.18)!
BBs,!CCBs!&!diuretics! 28!(0.01)! 15!(0.54)! 16!(0.53)! 22!(0.79)! 6!(0.21)!
Other!3combinations! 40!(0.02)! 23!(0.58)! 15!(0.38)! 32!(0.80)! 9!(0.23)!
Total!of!three!medications! 223!(0.11)! 111!(0.5)! 96!(0.43)! 169!(0.78)! 82!(0.38)!
4! AA1Blocker,!ARBs,!BBs!&!diuretics! 5!(0)! 4!(0.80)! 2!(0.4)! 5!(1)! 1!(0.20)!
ACEIs,!AA1Blocker,!CCB!&!diuretics! 11!(0.01)! 1!(0.09)! 4!(0.36)! 10!(0.91)! 4!(0.36)!
ACEIs,!BBs,!CCBs!&!diuretics! 14!(0.01)! 4!(0.29)! 5!(0.36)! 11!(0.79)! 5!(0.36)!
ARBs,!BBs,!CCBs!&!diuretics! 6!(0)! 3!(0.50)! 4!(0.67)! 6!(1)! 4!(0.67)!
Other!combinations! 25!(0.01)! 14!(0.54)! 9!(0.35)! 20!(0.80)! 7!(0.28)!
Total!of!four!medications! 62!(0.03)! 26!(0.42)! 24!(0.39)! 52!(0.85)! 21!(0.34)!
5! ACEIs,!AA1Blocker,!BB,!CCB!&!
diuretic! 3!(0)! 1!(0.33)! 0! 3!(1)! 0!
Other!combinations! 9!(0)! 4!(0.44)! 6!(0.67)! 7!(0.78)! 6!(0.67)!
Total!of!five!medications! 12!(0.01)! 5!(0.42)! 6!(0.50)! 10!(0.83)! 6!(0.50)!
Overall!total! 1956! 1133!(0.58)! 897!(0.46)! 1214!(0.63)! 391!(0.20)!
(a)!The!numbers!in!brackets!represent!the!proportion!of!the!category!in!each!medication!regimen!(for!example,!the!
proportion!of!female!taking!ACEIs!was!143/281=0.51),!except!for!the!total!column!in!which!the!proportion!is!calculated!
using!the!overall!number!as!denominator!(1956).!(b)!Controlled!is!defined!as!having!a!BP!<140/90!mmHg!for!individuals!
aged!up!to!80!years,!or!<150!if!the!participant!was!≥!80!years.!(b)!Based!on!selfRreported!information!of!having!
hypertension!(HTN),!cardiovascular!diseases!(CVD),!or!diabetes.!!
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4.4.3+Validity+of+SRMs+
This analysis was restricted to the high risk population (n =5,181). In total 2,166 
participants self-reported taking BP-lowering medications, of them 1,624 (75.0%) 
could be confirmed with EPRs. The remaining 542 (25%) were only identified as 
taking BP-lowering medication by SRMs but without a confirmation from the 
EPRs. Using EPRs only, the number of treated hypertensive individuals was 
1,808, with 1,624 (89.2%) confirming their BP therapy in SRMs (Table 4-4). The 
sensitivity of self-reported BP-lowering medication was 90% and the specificity 
was 83%, with PPV and NPV of 75% and 64%, respectively. Asking participants to 
write their medication names as in PCQ-1 had better sensitivity (92% vs. 82%) 
and NPV (69% vs. 62%) compared to asking them to only indicate if they were 
regularly taking BP-lowering medication or not as in PCQ-2. However, the 
closed-end question in PCQ-2 showed better specificity (80% vs. 87%) and PPV 
(68% vs. 81%) compared to the open-end question in PCQ-1.  
In the second analysis where no source was considered as superior, kappa 
statistics showed a “good agreement” with a value of 71% (Ppos =82% and 
Pneg =89%) for concordance between SRMs and EPRs. Between the two PCQ 
phases, PCQ-2 showed better agreement with the EPRs than PCQ-1, with a kappa 
value of 74% (Ppos =84% and Pneg =97%), compared to 66% (Ppos =78% and Pneg =96%) 
for PCQ-1.  
Out of the 5,181 participants in the high risk population, 1,168 (22.5%) showed 
complete agreement with the three metrics of SRMs, EPRs, and self-reported 
diagnosis of hypertension (Figure 4-1); of those with complete agreement, 719 
(61.5%) participants had a BP level equal to 140 mmHg or higher. Almost half of 
the participants (2,558) were classified as hypertensive based only on BP 
criteria, as they were not on BP-lowering medication based on any medication 
history sources, and they did not report a previous clinical diagnosis of 
hypertension. The total number of participants who declared a previous 
hypertension diagnosis was 1,840 (35.5%); of which 273 participants were not on 
treatment, based on both sources, despite more than half of them having a high 
BP level (≥140 mmHg) (Figure 4-1).  
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Table+4G4+Concordance+analyses+of+the+two+medication+history+sources+in+participants+with+
BPGlowering+medication+history+sources+
 
TreatmentPrescr! !
Yes! No! Total!
TreatmentQues!
Yes!
n! 1624!
31.0%!!
[30.1–32.6%]!
542!
10.5%!!
[9.7–11.3%]!
2166!
41.8%!
[40.5–43.5%]!
%!
CI!
No!
n! 184!
3.6%!!
[3.1–4.1%]!
2831!
54.6%!!
[53.3–56.0%]!
3015!
58.2%!
[56.8–59.5%]!
%!
CI!
Total!
1808!!
34.9%!
[33.6–36.2%]!
3373!
65.1%!
[63.8–66.4%]!
5181!
Measurements1of1validity! Sensitivity! 90%! Specificity! 84%!PPV! 75%! NPV! 65%!
Measurements!of!
agreement!
)*! 86%! )-! 52%!Z! 71%! PI! 23%!
BI! 7%! PABAK 72% 
Ppos! 82%! Pneg! 89%!
Validity!analysis!by!PCQ!
PCQJ1!
TreatmentPCQ1!
Yes!
n! 673!
28.8%!!
[28.0–31.7%]!
316!
13.5%!!
[12.6–15.5%]!
1269!
54.3%!
[54.1–58.2%]!
%!
CI!
No!
n! 60!
2.6%!!
[2.0–3.3%]!
1287!
55.1%!!
[53.1–57.1%]!
1347!
57.7%!
[55.7–59.7%]!
%!
CI!
Total!!
733!
31.4%!
[29.5–33.3%]!
1603!
68.6%!
[66.7–70.5%]!
2336!
Measurements1of1validity! Sensitivity! 92%! Specificity! 80%!PPV! 68%! NPV! 69%!
Measurements!of!
agreement!
)*! 84%! )-! 53%!Z! 66%! PI! 26%!
BI! 11%! PABAK 68% 
Ppos! 78%! Pneg! 87%!
PCQJ2!
TreatmentPCQ2!
Yes!
n! 951!
33.4%!!
[31.7–35.2%]!
226!
7.9%!!
[7.0–9.0%]!
1177!
41.4%!
[39.6–43.2%]!
%!
CI!
No!
n! 124!
4.4%!!
[3.7–5.2%]!
1544!
54.3%!!
[52.4–56.1%]!
1668!
59.3%!
[57.5–61.1%]!
%!
CI!
Total!!
1075!
37.8%!
[36.0–39.6%]!
1770!
61.2%!
[60.4–64.0%]!
2845!
Measurements1of1validity! Sensitivity! 88%! Specificity! 87%!PPV! 81%! NPV! 62%!
Measurements!of!
agreement!
)*! 88%! )-! 52%!Z! 74%! PI! 21%!
BI! 4%! PABAK 75% 
Ppos! 84%! Pneg! 90%!
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Figure+4G1+Venn+diagram+of+the+status+of+highGrisk+population+in+GS+for+BP+level,+treatment+
based+on+EPRs+and+SRMs,+and+selfGreported+hypertension.+
The+green+circle+includes+participants+with+a+BP+level+that+is+140/90+mmHg+or+over,+blue+
circle+includes+participants+identified+as+taking+BPGlowering+medication+based+on+EPRs,+red+
circle+includes+participants+identified+as+taking+BPGlowering+medication+based+on+SRMs,+
purple+circle+includes+participants+indicated+that+they+have+received+a+clinical+diagnosis+of+
hypertension+by+medical+staff.++
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4.4.4+Distribution+of+BP+in+GS:SFHS+
The distribution of SBP and DBP by age groups and sex is shown in Figure 4-2. 
SBP increases with age in both men and women, with higher SBP in women only 
after the age of 75 years. The differences in mean SBP between men and women 
were statistically significant for all age groups up to the age group bin of 65–74 
years, and thereafter SBP did not show statistically significant difference 
between sexes. The mean DBP also increased with age but reached a plateau at 
55–64 years, and then decreased with increasing age. The difference in DBP 
between sexes were statistically significant in age groups bins between 25–34 
and 65–74 years, and there was no statistical difference!between men and 
women for both the youngest and oldest age group bins.  
Comparison of the observed BP level between normotensive and hypertensive 
(treated and untreated) is depicted in Figure 4-3. On average, women had a 
lower BP than men by 8/3.4 mmHg (P <0.0001) overall; and by 6.9/1.8 mmHg 
(P <0.0001) in the normotensive group. The differences between sexes were not 
statistically significant in the two hypertensive groups (i.e. treated and 
untreated). The age-adjusted prevalence of the four BP level classes showed a 
higher prevalence of normotensive class in women compared to men [36.8% (CI: 
35.6–38.0%), and 14.0% (CI:13.1–14.9%), respectively].The prevalence of the 
remaining three classes were higher in men than women (Table 4-5). 
Table+4G5+AgeGstandardized+prevalence+of+BP+classes+in+men+and+women+
BP!category! Men!%!(CI%)!
Women!
%!(CI%)!
Normotensive! 14.0!(13.1–14.9)! 36.8!(35.6–38.0)!
PreJhypertensive! 46.4!(44.7–48.0)! 34.4!(33.2–35.6)!
Stage!1! 29.5!(28.2–30.9)! 19.5!(18.5–20.6)!
Stage!2! 10.1!(9.3–11.0)! 9.3!(8.5–10.1)!
AgeJ!standardization!was!performed!by!applying!the!direct!method,!using!the!midJyear!2011!
census!household!estimates!for!Scotland!as!standard!population,!Appendix!1!
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Figure+4G2+Distribution+of+the+mean+of+SBP+and+DBP+by+sex+and+age.+
The+bar+graph+with+its+axis+title+on+right+shows+the+number+of+individuals+in+each+age+bin.++
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+
Figure+4G3+Box+plots+of+SBP+and+DBP+levels+by+sex+and+hypertensive+status.+
(A)+box+plots+show+SBP+level+in+the+overall+and+groups+of+normotensive,+treated,+and+
untreated+hypertension+groups+in+women+and+men.+(B)+box+plots+show+the+same+
information+for+DBP.+The+red+diamonds+inside+the+box+plots+represents+the+mean,+and+the+
lines+within+the+boxes+indicate+the+median,+the+edges+of+the+white+boxes+are+the+first+and+
third+quartiles+(IQR),+the+whiskers+extend+to+1.5+times+the+IQR,+values+above/below+that+
are+represented+with+dots.+
+ +
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4.4.5+Prevalence+of+hypertension++
The crude prevalence of hypertension, awareness, treatment and control are 
shown in Table 4-6. The overall crude prevalence of hypertension was 38.7%, 
with a prevalence of 47% and 33% in men and women, respectively. The crude 
prevalence table is presented here to show the numbers of individuals in each 
sub-group; however, all quoted prevalence data hereafter are age- and sex-
adjusted (Table 4-7). The overall age-and sex adjusted prevalence in GS:SFHS 
was 40.8% [CI: 39.7–41.9%]; the prevalence of hypertension was higher among 
men in every other age group below 75 years (Figure 4-4). The difference in 
prevalence between genders was large in those under 54 years. Hypertension 
prevalence increased with age in both sexes. In women, the prevalence was 
relatively low in the age groups younger than 45 years old (4.2%–15.8%), and 
then doubled in those aged 45–54 (31.6%). In men, however, the increase in 
prevalence of hypertension was steady with age; the most observed difference 
was between age bins of 35–45 and 45–54 years old. Examining the prevalence of 
hypertension across different risk factor categories showed a correlation with 
BMI, with prevalence increasing in each BMI group from 20.3% for BMI ≤18.5 up 
to 55.9% for BMI ≥30 (Table 4-7). The prevalence of hypertension among 
participants stating that none of their parents were hypertensive was 37.7%, 
compared to 44.3% and 52.6% in participants with one and two hypertensive 
parents, respectively. Furthermore, the prevalence of hypertension tended to 
be lower in the least deprived area of Scotland (SIMD =5; 38.5%), compared to 
area of the most deprived area (SIMD =1; 43.4%). Active smokers had lower 
prevalence of hypertension compared to ex-smokers or never smokers, though 
the difference was very small. Finally, hypertension was higher in people with a 
lower level of education as examined by the number of years at school. 
4.4.6+Prevalence+of+hypertension+awareness++
The overall rate of awareness was 25.3% [CI: 23.9–26.7%]; and the proportions of 
aware hypertensive increased with age in both sexes (Table 4-7). Women were 
more aware than men in every age group except for the age groups >55–74 years 
old, where awareness was similar in both men and women (Figure 4-4). The 
proportions of aware participants across the different risk factors categories had 
generally similar trends to hypertension status with some exceptions. First, 
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awareness was lower in the normal BMI group (BMI 18.5–24.9 kg/m2) compared 
to the underweight group (BMI <18.5 kg/m2). Second, there is a general trend of 
higher awareness of hypertension in the most deprived areas of Scotland (SIMD 
quintiles 1 and 2). Finally, a clear difference was observed in the proportion of 
awareness between active (21.2%) and ex-smokers or never smokers (25.7%).  
4.4.7+Prevalence+of+treated+hypertension++
The overall prevalence of treated hypertension was 31.2% [CI: 29.5–32.9%], with 
a higher prevalence of treatment in older people. Women had higher prevalence 
of treated hypertension in the younger groups, and both sexes had similar 
prevalence at the age of 55–64 years, after which men were more frequently 
treated (Figure 4-4). The prevalence of treated hypertensive was lower in the 
normal and overweight groups compared to the underweight and obese groups 
(Table 4-7). In addition, participants with one and two hypertensive parents had 
higher prevalence of treated hypertension compared to participants without any 
hypertensive parents (32.2% and 39.7% compared to 29.2%, respectively). With 
the exception of participants living in area of the fourth SIMD quintiles, areas 
with the lowest SIMD quintiles tend to have a higher prevalence of treated 
hypertension compared to areas with above average SIMD quintiles. 
4.4.8+Prevalence+of+controlled+hypertension++
The overall prevalence of controlled hypertension among treated hypertensive 
was 54.3% [CI: 46.5–62.1%], women had a higher prevalence of controlled 
hypertension up to the age group of 55–64 years old, while men started to have 
higher prevalence of controlled hypertension after 55–64 years (Figure 4-4). The 
prevalence of controlled hypertension in women sharply decreased with age; for 
instance, all the treated women younger than 24 years were controlled 
compared to only 29.5% of women older than 75 years old. This trend was less 
obvious in men with only a general trend of lower control in older groups. Lower 
BMI categories had a higher prevalence of controlled hypertension, and 
participants with both parents had hypertension had a lower controlled rate. 
Finally, participants living in the most deprived areas had a higher prevalence of 
controlled hypertension compared to those living above the average.  
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Table+4G6+Crude+prevalence+of+hypertension,+awareness,+treatment,+and+control+by+baseline+
characteristics+
Category++
Prevalence+
among+all+
participants+
Awareness+
among+
hypertensive+
Treatment+
among+
hypertensive+
Control+
among+
treated+
hypertensive+
!! N! %! n! %! n! %! n! %! n! %!
Overall+
Men! 7632! 41%! 3565! 47%! 980! 27%! 1152! 32%! 468! 41%!
Women! 10838! 59%! 3581! 33%! 1223! 34%! 1489! 42%! 698! 47%!
All! 18470! 100%! 7146! 39%! 2203! 31%! 2641! 37%! 1166! 44%!
BMI+(Kg/m2)+
≤18.5! 292! 1.60%! 39! 13%! 6! 16.0%! 13! 33%! 10! 77%!
18.5–24.9! 7404! 40%! 1762! 24%! 421! 24%! 551! 31%! 282! 51%!
25–29.9! 6854! 37%! 3014! 44%! 855! 30%! 1065! 35%! 465! 44%!
!≥30! 3920! 21%! 2331! 59%! 891! 39%! 1012! 43%! 410! 41%!
Number+of+parents+with+hypertension§+
None! 11354! 61%! 4153! 37%! 1060! 26%! 1461! 35%! 641! 44%!
One! 5855! 31%! 2378! 41%! 856! 36%! 896! 38%! 399! 45%!
Two! 1261! 0.70%! 615! 49%! 287! 47%! 284! 46%! 130! 46%!
SIMD+
1! 2287! 12%! 892! 39%! 295! 34%! 365! 41%! 202! 55%!
2! 2375! 13%! 941! 40%! 301! 34%! 368! 39%! 144! 39%!
3! 2725! 15%! 1039! 38%! 299! 29%! 374! 36%! 174! 47%!
4! 4362! 24%! 1680! 39%! 518! 31%! 649! 39%! 297! 46%!
5! 5320! 29%! 2043! 38%! 595! 30%! 673! 33%! 283! 42%!
Smoking+
Active! 3123! 17%! 1026! 33%! 262! 8%! 366! 36%! 211! 58%!
ExJsmoker! 5348! 29%! 2472! 46%! 854! 16%! 998! 40%! 412! 41%!
Never! 9549! 52%! 3474! 36%! 1070! 11%! 1208! 35%! 513! 42%!
Number+of+years+at+school+
≤11!years! 6281! 34%! 3063! 49%! 1092! 36%! 1332! 43%! 586! 44%!
11–17!years! 9392! 51%! 3153! 34%! 866! 27%! 998! 32%! 448! 45%!
≥17!years! 1825! 10%! 546! 30%! 146! 27%! 152! 28%! 67! 44%!
Awareness,!treatment,!and!control!were!assessed!among!hypertensive!participants,!control!was!
assessed!among!treated!participants.!
§!Based!on!selfJreporting!PCQ.!
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Table+4G7+AgeG+and+sexGadjusted+prevalence+of+hypertension,+awareness,+treatment,+and+
controlled+hypertension+
Category+ Prevalence+
among+all+
participants+
Awareness+
among+
hypertensive+
Treatment+
among+
hypertensive+
Control+among+
treated+
hypertensive+
%! SE! %! SE! %! SE! %! SE!
Overall*+
Men! 46.3! 0.89! 21.7! 0.64! 25.7! 0.89! 47.8! 6.17!
Women! 35.8! 0.74! 28.6! 1.17! 33.2! 1.46! 60.2! 5.08!
All! 40.8! 0.53! 25.3! 0.72! 31.2! 0.87! 54.3! 3.93!
BMI+categories+(years)+
≤18.5! 20.3! 5.06! 20.7! 11.05! 32.6! 12.2! 48.3! 16.79!
18.5–24.9! 31.0! 0.89! 18.8! 1.12! 28.9! 1.79! 64.8! 7.23!
25–29.9! 42.5! 0.92! 24.8! 1.36! 28.8! 1.35! 50.8! 7.62!
!≥30! 55.9! 1.50! 30.5! 1.41! 34.6! 1.44! 42.6! 6.87!
Number+of+parent+with+hypertension§+
None! 37.7! 0.66! 19.4! 0.82! 29.2! 1.16! 57.9! 5.84!
One! 44.3! 1.30! 30.4! 1.46! 32.2! 1.71! 56.1! 8.19!
Two! 52.6! 4.98! 45.9! 6.95! 39.7! 4.74! 48.4! 8.49!
SIMD+quintile+
1! 43.4! 1.70! 27.9! 1.84! 34.1! 2.14! 60.9! 9.00!
2! 44.0! 1.72! 25.7! 1.75! 32.6! 2.24! 58.1! 12.94!
3! 40.9! 1.72! 23.3! 1.86! 29.3! 1.93! 44.2! 6.21!
4! 40.0! 1.22! 25.4! 1.52! 33.9! 1.97! 56.3! 8.43!
5! 38.5! 1.06! 23.3! 1.55! 29.5! 2.22! 51.2! 9.74!
Smoking+
Active! 39.5! 1.82! 21.2! 1.67! 33.5! 2.35! 67.0! 8.48!
ExJsmoker! 42.0! 1.00! 25.7! 1.20! 32.5! 2.52! 51.8! 7.47!
Never! 40.2! 0.86! 25.7! 1.05! 29.8! 1.20! 53.5! 7.72!
Number+of+years+at+school+
≤11!years! 41.4! 0.88! 27.4! 2.06! 35.0! 2.80! 60.5! 10.08!
11–17!years! 39.1! 0.95! 23.4! 1.05! 28.48! 1.26! 53.4! 5.67!
≥17!years! 34.4! 2.23! 23.0! 2.64! 25.8! 3.03! 47.5! 8.76!
AgeJ!and!sexJstandardization!was!carried!out!by!applying!the!direct!method!using!the!midJ
year!2011!census!household!estimates!for!Scotland!as!standard!population.!
*the!overall!prevalence!was!only!standardized!for!age!and!stratified!by!sex.!
§!Based!on!selfJreporting!PCQ.!
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Figure+4G4+AgeG+and+sex+stratified+prevalence+of+hypertension,+awareness,+treatment,+and+
control+by+age+groups+
+ +
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4.4.9+Determinants+of+hypertension+related+indicators+
Mixed model logistic regression models were used to assess the independent 
effect of a range of risk factors with hypertension-related health outcomes after 
adjusting for age, sex, and BMI. Table 4-8 shows the OR and CI for the 
association of the tested factors with hypertension prevalence, awareness, 
treatment and control. The odds of hypertension were higher in men, 
overweight (BMI ≥25 kg/m2), participants with at least one hypertensive parent, 
and those living in the most deprived area of Scotland (SIMD quintiles 1 and 2). 
Among hypertensive participants, men were less likely to be treated than 
women [OR 0.88 (95% CI:0.78–0.98)], and no statistically significant association 
was found between treatment and BMI category. The odds of receiving 
treatment were 1.46 (95% CI:1.28–1.66) times higher in participants with one 
hypertensive parent, and 2.65 (95% CI:2.15–3.26) times higher in participants 
with two hypertensive parents compared to hypertensive participants without 
history of parental hypertension. Participants living in the least deprived area of 
Scotland were significantly less likely to be treated for hypertension compared 
to all the other regions, except for area of average SIMD. Furthermore, 
awareness among hypertensive participants was statistically higher among obese 
and subjects with parental history of hypertension and among those living in the 
most deprived areas of Scotland. Among treated participants, men were less 
likely to be controlled than women [OR 0.79 (95% CI: 0.66–0.94). Obese subjects 
were also less likely to be controlled compared to participants with normal BMI 
level, and people living in the most deprived area had higher odds of controlled 
hypertension than those living in the least deprived area.  
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Table+4G8+Multivariate+association+of+characteristics+with+hypertension,+awareness,+
treatment,+and+control+
Variable+
Hypertension+ Treatmenta+ Controlb+ Awarenessa+
OR+ (95%+CI)+ OR+ (95%+CI)+ OR+ (95%+CI)+ OR+ (95%+CI)+
P+value+ P+value+ P+value+ P+value+
Sex+
Women! 1! 1! 1! 1!
Men! 2.31+ (2.13–2.50)+ 0.88+ (0.78–0.98)+ 0.79+ (0.66–0.94)+ 0.95! (0.84–1.07)!<2ed16+ 0.03+ 0.008+ 0.41!
BMI+(kg/m2)+
Normal!
(18.5–24.9)! 1! 1! 1! 1!
Underweight!!
(≤!18.5)!
1.19! (0.79–1.80)! 1.59! (0.71–3.54)! 1.44! (0.40–5.15)! 0.71! (0.27–1.88)!
0.40! 0.26! 0.57! 0.49!
Overweight!!
(25–29.9)!
1.25+ (1.12–1.41)+ 1.08! (0.91–1.28)! 0.78! (0.61–1.01)! 1.18! (0.89–1.41)!
0.00015+ 0.39! 0.06! 0.0746!
Obese!!
(!≥!30)!
1.39+ (1.12–1.73)+ 1.30! (0.99–1.74)! 0.65+ (0.44–0.96)+ 1.44+ (1.08–1.91)+
0.0024+ 0.063! 0.03+ 0.0118+
Number+of+parents+with+hypertension+
No!parents! 1! 1! 1! 1!
one!parent!
1.45+ (1.33–1.57)+ 1.46+ (1.28–1.66)+ 0.87! (0.72–1.05)! 2.11+ (1.85–2.42)+
<2ed16+ 9.46ed09+ 0.13! <2ed16+
two!parents!
2.02+ (1.74–2.34)+ 2.65+ (2.15–3.26)+ 0.76! (0.57–1.01)! 4.09+ (3.31–5.06)+
<2ed16+ <2ed16+ 0.057! <2ed16+
SIMD+quintiles+
SIMD!5!!
(least!deprived)! 1! 1! 1! 1!
SIMD!4!
1.05! (0.94–1.16)! 1.33+ (1.14–1.56)+ 1.18! (0.94–1.49)! 1.07! (0.91–1.26)!
0.4! 0.00027+ 0.15! 0.4!
SIMD!3!
1.06! (0.94–1.19)! 1.16! (0.97–1.39)! 1.04! (0.79–1.36)! 0.96! (0.79–1.16)!
0.35! 0.11! 0.78! 0.66!
SIMD!2!
1.16+ (1.03–1.32)+ 1.34+ (1.11–1.62)+ 0.93! (0.71–1.22)! 1.11! (0.92–1.35)!
0.0187+ 0.0019+ 0.6! 0.28!
SIMD!1!
(most!deprived)!
1.16+ (1.02–1.32)+ 1.61+ (1.33–1.94)+ 1.73+ (1.31–2.28)+ 1.27+ (1.04–1.55)+
0.022+ 1.21ed06+ 0.0001+ 0.016+
a.!the!model!only!included!hypertensive!participants.!
b.!the!model!only!included!individuals!taking!BPJlowering!medication(s).!
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4.5+Discussion+
This chapter provides a descriptive analysis of BP and hypertension phenotypes 
in GS:SFHS, with assessment and validation of BP-lowering medication exposure. 
The results of this chapter provide an estimate of the quality of the BP and 
hypertension phenotype in GS:SFHS, and enable a comparison of the 
epidemiological findings in GS:SFHS to other populations. GS:SFHS included 
participants from Scotland with a wide range of socio-demographic and clinical 
features, and is considered to be one of the largest family-based genetic 
epidemiology studies. The importance of this chapter relies on the fact that 
participants will be classified as hypertensive or not based on their exposure to 
BP-lowering medication (i.e. participants taking BP-lowering medication would 
be classified as hypertensive) and their blood pressure measurements. Hence, 
assessing the quality of self-reported data that are subject to recall bias is 
essential to have an estimate of the data quality, especially for the subset of 
participants without EPRs. Several analyses were performed in this chapter to 
achieve its aims based on the available resources, as discussed in the following 
sections. 
4.5.1+Quality+of+SRMs+history+
The assessment of self-reported BP-lowering medication history used the subset 
of individuals with both medication exposure sources for 68% of GS:SFHS 
participants. The analysis showed suboptimal agreement between the two 
sources for BP-lowering medication history. The sensitivity analysis showed that 
almost 90% of all the BP-lowering medication users based on EPRs recalled their 
medications in the PCQ (i.e. sensitivity 90%), and 84% of high-risk participants 
who did not recall their medication in the PCQ were truly not on treatment 
based on EPRs (i.e. specificity 84%). Based on treatment status only and by 
considering EPRs as a superior source, self-reported history of BP-lowering 
medication would classify 10.5% of the high risk population as hypertensive 
though they were not treated by EPRs, and overestimate the exposure to BP-
lowering medication by 25%. However, some people were already classified as 
hypertensive based on their BP values. Hence, the proportion of participants 
who were classified as hypertensive only because they indicated a treatment in 
PCQ was 4.7% (i.e. represented in Figure 4-1 by area with 109 and 135 
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participants). These findings are based on the assumption that EPRs is a gold 
standard or an “alloyed gold standard”, which is typically assumed in studies 
that verify drug exposure by self-report.205 In the UK, blood pressure lowering 
therapy can only be obtained by prescription and through the pharmacy. 
Patients cannot access BP lowering drugs over the counter. Thus pharmacy refill 
data are a good indicator of antihypertensive therapy, though not an indicator of 
true drug adherence. The study of agreement or concordance between the 
medication exposure sources revealed “good agreement” with a total agreement 
between the two sources in 86% of the observations and a kappa value of 71% 
(Ppos =82% and Pneg =89%).  
The influence of the questionnaire structure in concordance showed that the 
open-ended question (PCQ-1) provided a better sensitivity to self-report BP 
lowering medication, but the closed-ended question (PCQ-2) provided a better 
agreement with EPRs. This finding may be explained by the differences in the 
nature of the two PCQ phases, especially as the procedure of assignment to the 
corresponding treatment status was different between the two PCQ. For 
instance, participants who completed PCQ-1 were assigned a treatment status 
by the investigator (i.e. myself) if they wrote at least one of the BP-lowering 
medications; whereas, participants who completed PCQ-2 were assigned to a 
treatment status based on their awareness of their medication type. In the 
latter case, a participant prescribed one of the BP-lowering medications in our 
list (e.g. doxazosin) but for a diagnosis other than hypertension (e.g. benign 
prostatic hyperplasia) would answer “No” to the question “do you regularly 
takes any BP-lowering medication?”. These participants were taking a drug with 
BP-lowering effects, but they were unaware of there medication proprieties as 
they were prescribed for an indication other than hypertension. 
The agreement of SRMs and medical records has been examined in several 
studies. Generally, several factors were identified that influence the accuracy of 
recalling a medication in self-report questionnaire including type of medication, 
frequency of drug administration, questionnaire design, and the respondent 
characteristics.183,205,206,218,219 For CVD drugs and particularly antihypertensive 
drugs, self-reported methods were considered a reliable source to assess drug 
exposure with a sensitivity ranging from 87% to 94%.179,220,221 This is in 
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accordance with findings that medication for chronic diseases or serious 
conditions that are used in a regular basis are better recalled in the 
questionnaire, and have higher agreement with pharmacy records compared to 
drug used as needed or for shorter period.179,222 Furthermore, the higher 
sensitivity of antihypertensive medications recall can be extended to a longer 
time window, as the sensitivity was only decreased by 2% (from 92% to 90%) 
when increasing the exposure time window from 6 months up to two years.221  
The influence of question structure and the questionnaire design on the recall 
accuracy was also evaluated in several studies. The method of addressing this 
matter was substantially different between these studies, with heterogeneity in 
the methodological approaches, populations studied, drugs evaluated, and in 
presentation of results. Yet, the general finding is that recalling drugs is 
improved when drug names or indications are used instead of an open-ended 
question.223 For instance, Klungel et al. has examined the impact of a specific-
indication and an open-ended question on drug recall accuracy on 372 
hypertensive subjects.204 This was performed by designing the questionnaire to 
have five specific-indication questions, including a question about BP-lowering 
medication, followed by an open-ended question to write names of medication 
not already mentioned. The sensitivity of the specific-indication question for 
antihypertensives was 90.6% compared to 16.7% for the open-ended question, 
and the general sensitivity for the specific-indication question was almost twice 
as high as for the open-ended question. For all the assessed medication classes, 
a direct recall with a specific indication had much better sensitivity (88%) 
compared to the open-ended questions (41%). 
The analysis of the concordance between SRM and EPR is very important due to 
the differences in the type of recrods of medication-exposure between 
participants. It is very important to assess the reliability and concordance of 
each source before combining all the results together, and defined participants 
as treated or not. Generally, this analysis has showed that information from the 
differernt medication-histroy sources can be combined together in GS:SFHS. A 
strength of this analysis is the large sample size of the participants. In similar 
studies, the method of assessing the agreement is usually performed by 
reporting the kappa statistics. However, kappa statistics suffers from some 
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limitations and is influenced by the prevalence of the outcome.211 Hence, the 
raw numbers and sensitivity analysis were reported here to enable a better 
interpretation of the results. Furthermore, the analysis was restricted to the 
high-risk population to reduce the number of normal participants who could 
have skewed the results by showing higher agreement (results using the total 
population is shown in Appendix 2 -p251). In the other hand, this approach has 
underestimated the specificity and NPV due to targeting the high risk 
population. A number of difficulties arise in performing the analysis that ranged 
from the study design to choosing the best methods for analysis. First, the EPRs 
were available for about two-thirds of the participants only, making the analysis 
only possible for those participants with two medication-history sources. 
Second, subjects were mutually exclusive for one of the two PCQ phases. Hence, 
a comparison between the two question structures (i.e. open-ended to closed-
ended) in the same participant was not possible, and a general approach was 
taken to compare the overall agreement between PCQ-1 and PCQ-2, with EPRs 
was taken. Third, the influence of participants’ characteristics on the recall 
accuracy was not examined in this analysis as this aimed to assess the overall 
quality of PCQ. 
4.5.2+Prevalence+of+hypertensionGrelated+health+indicators+
This analysis showed that the overall prevalence of hypertension in GS:SFHS was 
40.8%, with lower prevalence of hypertension in women (35.8%) compared to 
men (46.3%). These numbers are higher than the reported prevalence of 
hypertension in the SHeS for the years of 2008/2009, and 2010/2011; in which 
average prevalence of hypertension for the two surveys in overall, women and 
men were 32.7%, 31.7%, and 33.7%, respectively (discussed in Section 1.3.5 -
p38).66 The comparison was made with these two surveys because it covers the 
time of recruitment and data collection for GS:SFHS participants. The higher 
prevalence of hypertension in GS:SFHS compared to the Scottish population is in 
concordance with the full GS:SFHS cohort profile description reported by Smith 
et al., though their hypertension definition was based only on BP measurement 
(BP >140/90 mmHg) regardless of treatment status.171 Compared with other 
populations, the prevalence of hypertension in GS:SFHS lies well within the 
range of prevalence of hypertension (31–60%) reported in other European 
countries.224 However, it is higher than prevalence reported in the USA (29.1%) 
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and Canada (19.5%).225 Furthermore, comparing the population of GS:SFHS with 
populations of Scotland, England, USA, and Canada showed that both 
hypertension prevalence and average of BP levels by groups are higher in 
GS:SFHS (figures are shown in Appendix 3 -p252 and Appendix 4 -p253). Several 
factors may contribute to the higher prevalence of hypertension and BP levels in 
GS:SFHS compared to other populations. First, the measurements used for 
GS:SFHS are based on averaging two available readings from a single visit, 
whereas most other studies are based on averaging the second and third 
measures.225 Second, the prevalence of main risk factors of hypertension differs 
between these populations, which may largely contribute to the variation in 
hypertension prevalence. This would include differences in study design, BP 
measurement methods, and clinical systems between these countries.  
The prevalence of hypertension in GS:SFHS was higher in men, older people, 
obese, most deprived area of Scotland, less educated participants, and in non-
smokers participants. These findings are consistent with the results of several 
others studies in different countries.226 Moreover, the prevalence of 
hypertension in participants with two hypertensive parents was much higher 
than participants without any hypertensive parents, with an intermediate 
prevalence for participants with only one hypertensive parent. The multi-level 
mixed model also showed that participants with one or two hypertensive parents 
have 42% or 2 folds higher risk of having hypertension compared to participants 
without any hypertensive parents. The association of parental history of 
hypertension with BP level and development of hypertension in offspring were 
also reported in the John Hopkins Precursors Study; in which, men with both 
parents with hypertension or with one hypertensive parent were at higher risk of 
developing hypertension.42 This emphasizes the important of taking the family 
history of hypertension and reviewing of all eligible family members for 
hypertension status and treatment if required. 
The rate of hypertension awareness and treatment in GS:SFHS were 25.3% and 
31.2%, respectively; these are the lowest rates compared to the reported rates 
in other European and North American population-based studies.62,63,225,226 These 
rates are comparable to rates reported by Lloyd-Sherlock et al. in LIC and MIC.67 
For awareness, a comparison with SHeS is not possible as the rate of awareness 
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was not reported in any edition. However, the 2012/2013 survey compared the 
prevalence of doctor-diagnosed hypertension (i.e. informed from participants) 
with the survey-defined hypertension, which can be used as an approximate 
estimate of hypertension awareness as following; the prevalence of doctor-
diagnosed hypertension was 22.8% compared with 29.1% survey-defined 
hypertension, suggesting that the overall rate of awareness was 78% (22.8/29.1), 
based on the assumption that all the doctor-diagnosed hypertensive were also 
defined as hypertensive by the survey.66 Similarly, the rate of treated 
hypertension in GS:SFHS was much lower than the prevalence of treated 
hypertension reported in the SHeS of 2008/2009 and 2010/2011 (49% and 48%, 
respectively). 
The lower rate of awareness and treatment in GS:SFHS may be explained by the 
fact that almost 50% of hypertensive participants were classified as hypertensive 
based on their BP values only (Figure 4-1). In other words, their average BP level 
was 140/90 mmHg or higher, but they were not on BP-lowering medication. 
Moreover, participants were classified as hypertensive based on a single visit and 
two BP measurements, which is not the criteria for a clinical diagnosis of 
hypertension which requires multiple BP measurements on different occasions or 
using ambulatory BP monitoring.215 The rate of awareness and treatment was 
higher in women, overweight, parental history of hypertension, greater 
deprivation, and in less educated persons. This highlights that people with any 
of these risk factors are more aware of their hypertension status, and were more 
likely to seek a clinical advice, or these individuals have higher comorbidity 
levels requiring greater engagement with doctors and hence more likely to be 
diagnosed by a clinician. On the other hand, people without these risk factors 
were more likely to have undiagnosed hypertension.  
The control rate of hypertension in GS:SFHS was 54.3%, with higher rates in 
women (60%) compared to men (47.8%). This rate is slightly higher than the 
reported controlled rate in SHeS for the years of 2008/2009 (53%) and 2010/2011 
(50%).66 In contrast to the findings in SHeS, the rates of controlled hypertension 
in women in GS:SFHS were higher than men. Compared to other populations, the 
prevalence of controlled hypertension is one of the highest out of the European 
countries, but lower than observed in North American countries.47,62,63 Control 
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rate was higher in younger groups compared to older groups; for instance, all 
the treated young women (<25 years) were controlled compared to only 30% of 
women above 75 years old. This is opposite to what has been observed in other 
populations, such as Portugal, England, USA, and Canada.47,226 Controlled 
hypertension was not statistically associated with number of parents with 
hypertension, though there are a trend of lower proportion of controlled 
hypertension in participants with at least one hypertension parent. Similar to 
the pattern of awareness and treatment, control rate was higher in the most 
deprived area compared to the least deprived area. This is might be explained 
by a higher risk factor burden and hence more follow-up and treatment. This is 
especially true as a reduction in inequality of care between socio-economic 
strata have been observed in England and Scotland.227,228 Indeed, Hammouche et 
al. has reported a higher achievement of Quality and Outcome Framework (QOF) 
– indicator 4 (QOF4) (BP <150/90) in the most deprived area of Scotland 
compared to the least deprived.227 Moreover, participants in the most deprived 
area were 34% more likely to receive a lifestyle advice compared to participants 
in the least deprived area.  
An important consideration for the association between hypertension-related 
health indicators and deprivation is that these were only observational findings, 
and that more works are needed to explore these findings. Several potential 
confounders can play role in such findings, leading to differences in the 
prevalence between the most and the least deprived area of Scotland. For this 
analysis, SIMD was used as index for the deprivation status but other 
confounders such as alcohol consumption, smoking, physical activity, or BMI 
were not accounted for in this analysis. 
4.5.3+Conclusion+
This chapter has shown that SRMs history can be used as a surrogate to assess 
the exposure to BP-lowering medication in GS:SFHS participants. Although both 
sources suffer from some limitations, they can be considered the best available 
source to estimate the drug exposure history. Hypertension management 
indicators in GS:SFHS are lower than similar reported studies, with the exception 
of prevalence of controlled hypertension, which achieved a better rate 
compared to other populations. In GS:SFHS, almost half of men and a third of 
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women had hypertension based on the study definition, and only one of four 
(25%) hypertensive participants were aware of their condition. Furthermore, 
about one-third of the hypertensive participants were treated, and more than 
half of the treated hypertensives were controlled. Interestingly, participants 
with parental history of hypertension were significantly more likely to be 
treated and aware of their hypertension compared to those without any parental 
history of hypertension. Therefore, a history of hypertension should instigate a 
review of all eligible family members for hypertension status and treatment if 
required. 
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5+ Heritability+and+familial+aggregation+of+BP+and+
hypertension+
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5.1+ Introduction+to+this+chapter+
This chapter focuses on examining the familial aggregation of BP and 
hypertension traits in GS:SFHS. Such studies are performed to estimate the 
genetic determinants of a trait, and dissect the contribution of genetic and 
environmental factors. These can be performed either for single traits or as 
bivariate analysis to assess the shared genetic correlation between two traits.  
5.1.1+Familial+correlation+and+heritability+of+BP+
Familial aggregation and correlation of BP are a result of complex interactions 
between several factors that include genetic and/or shared familial 
environmental factors. Several studies have reported a higher correlation of BP 
levels between relatives than others; the Montreal adoption study reported a 
correlation coefficient of 0.38 between biological siblings, and 0.16 between 
adoptive siblings.229 The Victorian Family Heart Study, a study of health adult 
families that included 783 families enriched with monozygotic and dizygotic 
twins, demonstrated a correlation coefficient of 0.44 for non-twin siblings, 0.50 
for dizygotic siblings, 0.78 for monozygotic siblings, and 0.12 for spouse-spouse 
pairs for SBP.230 The study has also reported that the genetic factors accounted 
for 41% and 46% of the variation in SBP and DBP, respectively. The relative risk 
of developing hypertension was found to be 4.1 in men and 5.0 in women aged 
20–39, if they had two or more 1st–degree relatives diagnosed with hypertension 
before the age of 55 years.231 Furthermore, evidence for familial aggregation of 
treatment and control of hypertension were also demonstrated a significant 
siblings concordance in both treatment (OR =1.61) and control of hypertension 
(OR =1.51).232 
The general assumption in these studies is that siblings and parent-offspring 
share 50% of their genome, in addition to shared environmental factors. Under 
random mating assumption, spouses are expected to share familial 
environmental factors only without any shared genetic factors. Therefore, a 
significant correlation between siblings and parent-offspring but not between 
spouses, means that familial aggregation of the traits is primarily resulting from 
shared genetic factors. Alternatively, if the spouse correlation is significant as 
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well, then it suggests that the trait is influenced by both genetic and shared 
environmental factors. 
Estimating the heritability components of a trait is another method to quantify 
familial aggregation. Heritability can be defined as the proportion of total 
phenotypic variance explained by genetic factors (explained in more details in 
Section 1.5.3.2 –p56). For BP, several studies have estimated the heritability 
using different approaches. Generally, the difference between these studies 
relies on using different family structures (e.g. family-study or twin study), or 
different BP measurements and traits (e.g. single office BP, ambulatory BP, or 
long-term BP). For instance, family studies that used single office measurements 
reported heritability that ranged from 15–40% for SBP, 15–30% for DBP, 33–40% 
for MAP, and 18–24% for PP.233-236 However, twin studies have reported higher 
heritability estimates for BP traits in monozygotic twins that ranged from 48–
74%, and 51–72% for SPB and DBP, respectively.237 Other studies have also taken 
another approach by using ABMP instead of the office BP, knowing that ABPM is a 
better predictor for CVD end-organ damage.24,25 Heritability in these studies 
were around 70% and 68% for SBP, and 70% and 64% for DBP at day-time and 
night-time, respectively.234,238-240 These findings emphasize the multifactorial 
and complexity of BP traits, which exhibit a complex mode of inheritance.  
5.1.2+Sibling+recurrence+risk+ratio+(λS) 
λS is an alternative approach to estimate the familial aggregation of the trait by 
calculating the probability that a sibling of an affected person is also affected 
(previously discussed in Section 1.5.3.1 -p55). This measure is widely used in 
genetic studies as a supporting evidence for the role of genetic factors in the 
disease or trait, and has an important meaning in genetic counselling of the 
family of affected individuals. λS for hypertension was found to be around 1.2 – 
3.5, indicating a trait with modest genetic effects.131,241  
Typical genetic studies that estimate λS obtains the sibship or family data by 
recruiting non-randomly selected family based on certain criteria, such as 
families of affected individuals who attended the clinic. Such a way of sampling 
or ascertainment is performed to maximize the number of affected individuals 
with lower cost and effort. However, this procedure can produces a bias known 
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as “ascertainment bias”, which can alter the expected ratio of affected to 
unaffected siblings, and hence result in a potentially biased estimate of λS.242 
One way to avoid the ascertainment bias is by recruiting a random sample or a 
census of sibships from the population of sibships with at least one affected 
individual.243 This ascertainment scheme is called “complete ascertainment”, 
where every sibship with at least one affected member has an equal probability 
of being ascertained, independent of the number of affected or the total size of 
the sibship.243 Essentially, it refers to the method in which family are firstly 
ascertained and then the family members are examined for the presence of the 
disease of interest. Thus, it is not required to ascertain all the affected 
individuals in the population to achieve complete ascertainment, providing that 
every sibship in the population has an equal ascertainment probability. The 
original pedigree and participants of GS:SFHS study were not ascertained via any 
particular phenotypes, and were recruited from the general population given 
that another family member is willing to participate. Hence, no ascertainment 
correction is required for this study.243  
5.2+Chapter+aims+
The aims of this chapter are to estimate the familial aggregation of BP and 
hypertension traits by; 
(1) Estimating the familial correlation of BP traits 
(2) Calculating the univariate heritability of BP traits, and bivariate genetic 
correlation between BP traits 
(3) Calculating the λS of hypertension and hypertension treatment 
5.3+Statistical+analysis+
This study used the full sample of GS:SFHS (n =18,470), which includes 
individuals described in the previous chapters. In particular, Section 3.2 
described the method of phenotype QC. Unlike the descriptive analysis 
performed in the previous chapter, this chapter has used the adjusted BP values 
(as described in Section 2.3.1.1-p98), by adding a fixed values of 15 mmHg to 
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the measured SBP value and 10 mmHg to the observed DBP value, for 
participants taking BP-lowering medications. This follows the recommendation 
of Tobin et al. to adjust for the treatment effect for quantitative trait 
analysis.87 The means of BP traits per family was calculated only in families with 
at least three members, and data is shown as a ranked mean from the lowest to 
the highest across the families. The following sections describe the methods 
used in this chapter to assess the familial aggregation and heritability of BP and 
hypertension.  
5.3.1+Estimate+of+familial+correlation+of+BP+traits+
The family structure was assessed using two methods. The first method is based 
on graphically assessment of the familial correlation of BP and hypertension 
traits using the graphical function in PEDSTATS software.195 PEDSTATS was firstly 
used to verify the structure of each family (as performed for checking genotypes 
Mendelian inconsistency in Section 2.4.2.4 -p114), and to analyse the generic 
behaviour of the variables among the different members of the family, and to 
estimate the number of and types of available relative pairs. The second method 
is based on calculation of the familial correlation coefficients (r2) among 
different types of family pairs. This was performed by the family correlation 
(FCOR) function in S.A.G.E (Statistical Application for Genetic Epidemiology).244 
FCOR considers all pairs of relatives if both members have at least one trait in 
common, and excludes the pairs where one of the members has missing data. An 
available option in the function is to calculate two types of correlation that are 
“main type” and “subtypes”; the main type correlation does not depend on the 
sex of the pairs, for example it will only produce one correlation coefficient 
value of parent-offspring pair, by ignoring the sex of the pairs. The subtype’s 
correlation depends on the individuals’ sex, for the previous example, the 
parent-offspring main type has four subtypes; father-son, mother-son, father-
daughter, and mother-daughter. FCOR always calculates the subtype correlation 
first and has the option to calculate the main type if requested by recalculating 
the correlation coefficients by ignoring sex. FCOR can also output the Chi-square 
statistics and p-values of the test for homogeneity of correlation among 
subtypes, in which the hypothesis that all subtypes within a main type have the 
same correlation. The familial correlation values were calculated for two 
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models; the first model was not adjusted for any covariate, and the second 
model was adjusted for age, age2, sex, and BMI. The residualization values in 
the second model was calculated by the software Sequential Oligogenic Linkage 
Analysis Routines (SOLAR v. 7.2.5), as part of heritability calculation that is 
explained in more details in the next section. 
5.3.2+Calculating+the+univariate+heritability+of+BP+traits++
Univariate heritability and bivariate (genetic and environmental correlation) 
were estimated using standard quantitative genetic variance-component model 
implemented in SOLAR software (SOLAR v. 7.2.5).245 The variance-components 
model is a classical quantitative genetic model that decomposes phenotypic 
variance (σ2P) into additive genetic components (σ2G) and non-genetic 
components (i.e. environmental; σ2E), as previously explained in Section 1.5.3.2 
-p56; this model assumes that σ2P =σ2G + σ2E. Hence, the proportion of 
phenotypic variance attributable to additive genetic factors (h2) can be 
calculated as [h2 =σ2G/σ2P], and the proportion of variance attributable to 
environmental factors as [e2 =1- h2]. The heritability estimates represented here 
refers to “narrow-sense heritability”, which is concerned with the additive 
genetic component rather than all the genetic components such as dominance.  
The univariate heritability of BP traits were estimated for three models; the 
first model was not adjusted for any covariates; the second model was adjusted 
for age, sex, age2; and the third model was adjusted for the same covariates as 
the second model in addition to BMI. Including covariates in the model means 
that the model will firstly account for the effects of the covariates, and then 
estimates h2 and e2 from the remaining residual phenotypic variance (i.e. σ2P 
equals phenotypes after accounting for the effect of the covariates rather than 
the total phenotypic variance). The contribution of the genetic factors in these 
models is estimated by multiplying the heritability estimate (h2) by the total 
variance not explained by the covariates [1- Variance explained by covariates]. 
This to rescale the phenotypic variance to exclude the variance explained by 
covariates.  
A rank-based inverse-normal transformation was performed to the BP traits 
values before estimating heritability to obtain a normal distribution of the 
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residuals. The normalization feature is included in SOLAR to improve the 
normality of the traits while retaining much of the original information, as the 
inverse normalized variable will have a mean near zero and a SD near 1.0, with a 
distribution that approximates normal. !
5.3.3+Calculating+the+bivariate+genetic+correlation+for+BP+traits+
An extension to the univariate heritability analysis to encompass the 
multivariate state is possible by SOLAR. This analysis identifies the origin of 
correlations between each pair of traits (e.g. SBP and DBP), and partitions the 
correlation into additive genetic correlation (ρG), and environmental correlation 
(ρE). A value of 1 or -1 for ρG between two traits imply that all the additive 
genetic factors that influence trait X will also influence Y (i.e. complete 
pleiotropy). Similarly, a significant value of ρG that is different from both 0 and 
1 or -1 is evidence of incomplete pleiotropy (i.e. some of the phenotypic 
similarity between two traits are due to the same gene or genes). Hence, the 
phenotypic correlation (ρp) between the two traits can be dissected into genetic 
and environmental constituents. For example, ρp for SBP and DBP can be 
calculated as by this equation; 
[2(\]@∗$]@) = ℎ\]@1( 1 ℎ$]@( 1[_ +1 1 − ℎ\]@1( 1 1 − ℎ$]@( 1[a 1 
The contribution of the shared genetic factors to the phenotypic correlation 
between two traits is called the bivariate heritability, and can be calculated by 
taking the square root of both univariate heritabilities multiplied by the genetic 
correlation (i.e. the first part of the above equation).!
5.3.4+Estimate+of+sibling+recurrence+risk+of+hypertension+and+
treated+hypertension+
Sibling recurrence risk (κS) is the probability that a sibling of an affected 
individual is also affected. λS is calculated by dividing κS by the population 
prevalence of the outcome (i.e. the outcomes for this analysis are hypertension 
and treated hypertension). In this study we adopted the method proposed by 
Olson and Cordell to estimate λS in siblings of hypertensive patients compared 
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with the background population.243 This method is appropriate for a population 
cohort in which participants are not ascertained via any particular phenotypes 
and under a complete ascertainment sampling method, in which λS is assumed to 
be unbiased and consistent.243 This method is applicable here as the original 
pedigrees were not ascertained via any specific BP phenotype, leading to the 
use of the equation proposed by Olson and Cordell when proband status is 
unknown;  
bc = de f4' Gg egeh#igh# de c4' Gg egeh#igh#   ----------------------------------------- Equation (1) 
where wa is the weight given to a sibship with (a) affecteds, and ns(a) is the 
number of sibships in the population of size (s) with (a) affected. For randomly 
or completely sampled siblings such as GS:SFHS, wa is equal to (a), which 
provide an estimate of the proportion of affected among all sibling of affected 
in the sample. The denominators in the λS (i.e. population prevalence) for these 
outcomes were based on the reported prevalence in the SHeS 2010/2011 
(reported in Section 1.3.4 – p 38).  
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5.4+Results+
The number of extended-families (i.e. pedigrees) was 7,025 with an average size 
of 2.6 members per family (SD =2.02), and range from a singleton family to a 
family of 29 members. The number of available sibships was 4,616 sibships, 
which ranged from two to eight members per sibships. The full description of 
family structures was previously described in Section 3.3.5 -p122. The 
distribution of BP traits per family is showed in Figure 5-1, with mean values 
that ranged from 102–177 mmHg for SBP, 60–111 mmHg for DBP, 76–134 mmHg 
for MAP, and 31–83 mmHg for PP. 
5.4.1+Familial+correlation+of+BP+traits+
The familial correlation coefficients (r2) for the different types of family pairs 
are presented in Figure 5-2. The familial correlation coefficients are shown for 
the two types (as it presented by S.A.G.E output); that is the subtypes in Figure 
5-2A, and main types in Figure 5-2B. The correlation coefficients for all the 
possible family relative pairs including second-degree relative are listed in Table 
5-1. 
For SBP, the highest familial correlation was observed for the sister-sister pair 
(0.38), with very close correlation coefficients for the brother-brother pair 
(0.37). After adjusting for the covariates, the correlation coefficients slightly 
decreased and brother-brother pairs had the highest correlation (0.29). For DBP, 
the highest correlation coefficient was observed for brother-brother pairs in 
both models (0.36 and 0.23, for model 1 and 2, respectively). The change in 
correlation values between spouses in the two models was very small, from 0.1 
in model 1 to 0.09 in model 2. Spouse correlation was higher for both SBP and 
DBP in the unadjusted model, but reduced by half for SBP and by only 0.01 for 
DBP in the adjusted model to have a same value of 0.09. 
For MAP, the brother-brother pairs had the highest correlation coefficients in 
both models (0.38 and 0.27, for model 1 and 2, respectively). The correlation of 
spouses has slightly decreased from 0.13 in the first model to 0.09 in the second 
model. For PP, the sister-sister pairs had the highest correlation value in the 
first model (0.37), but brother-brother pair had the highest correlation value 
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after adjusting for the covariates in the second model (0.25). The correlation 
between son and both father and mother were very small and not significant in 
the first model, but after adjusting for the covariates the correlation values 
increased slightly and became significant. The highest observed correlation 
among the four BP traits for spouse pairs was for PP in the first model (0.23). 
Yet, adjusting for the covariates in the second model reduced the correlation. 
 
Figure+5G1+Mean+values+of+BP+traits+per+family.+
Red+points+represent+the+mean+values+of+(1)+SBP,+(2)+DBP,+(3)+MAP,+and+(4)+PP+for+100+
families+from+the+lower+and+100+families+from+the+upper+extreme+tails+of+the+distributions.+
Only+families+with+at+least+three+members+per+family+were+considered+in+the+distributions.+
The+vertical+lines+show+minimum+and+maximum+values+within+each+family.+
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Figure+5G2+Familial+correlation+coefficients+for+all+the+four+BP+traits.+
+(A)+The+correlation+coefficients+of+the+subtype+pairs+as+represented+by+a+pedigree+of+a+
nuclear+family.+The+correlation+coefficients+of+BP+traits+are+written+in+the+middle+of+the+
arrows+between+each+pairs,+in+the+forms+of+r+(se)+with+a+symbol+that+indicates+the+pGvalue+for+
the+correlation.+The+BP+traits+are+SBP,+DBP,+MAP,+PP+ordered+from+top+to+bottom.+(B)+
Relative+pair+plots+of+siblingGsibling,+and+parentGoffspring+with+correlation+coefficients+for+
BP+traits+(SBP,+DBP,+MAP,+and+PP,+as+ordered+from+left+to+right).+Values+for+pair+types+are+
represented+by+a+single+data+point+formed+by+plotting+the+first+sibling+or+the+parent+along+
the+xGaxis,+and+the+second+sibling+or+the+offspring+along+the+yGaxis.+For+all+plots,+the+
correlation+coefficients+are+shown+above+the+plots.+
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Table&5(1&Familial&correlation&coefficients&for&different&relative&pairs&
Pairs& #of&pairs& Model&
SBP& DBP& MAP& PP&
r& se& p" r& se& p" r& se& p" r& se& p"
Parent5
Offspring& 8077&
1& 0.19& 0.01& <0.0001& 0.15& 0.01& <0.0001& 0.20& 0.01& <0.0001& 0.06& 0.01& <0.0001&
2& 0.11& 0.01& <0.0001& 0.13& 0.01& <0.0001& 0.13& 0.01& <0.0001& 0.07& 0.01& <0.0001&
Father5
Son& 1419&
1& 0.14& 0.03& <0.0001& 0.08& 0.03& 0.003& 0.14& 0.03& <0.0001& 0.01& 0.03& 0.83&
2& 0.09& 0.03& 0.0021& 0.07& 0.03& 0.01& 0.07& 0.03& 0.0079& 0.09& 0.03& 0.0012&
Mother5
Son& 2042&
1& 0.21& 0.02& <0.0001& 0.21& 0.02& <0.0001& 0.27& 0.02& <0.0001& 50.03& 0.02& 0.17&
2& 0.13& 0.02& <0.0001& 0.17& 0.02& <0.0001& 0.17& 0.02& <0.0001& 0.05& 0.02& 0.033&
Father5
Daughter& 1718&
1& 0.19& 0.03& <0.0001& 0.13& 0.03& <0.0001& 0.17& 0.03& <0.0001& 0.12& 0.03& <0.0001&
2& 0.12& 0.03& <0.0001& 0.14& 0.03& <0.0001& 0.14& 0.03& <0.0001& 0.08& 0.03& 0.0037&
Mother5
Daughter& 2898&
1& 0.26& 0.02& <0.0001& 0.17& 0.02& <0.0001& 0.23& 0.02& <0.0001& 0.17& 0.02& <0.0001&
2& 0.13& 0.02& <0.0001& 0.12& 0.02& <0.0001& 0.13& 0.02& <0.0001& 0.11& 0.02& <0.0001&
Sibling5
Sibling& 7239&
1& 0.34& 0.01& <0.0001& 0.30& 0.01& <0.0001& 0.33& 0.01& <0.0001& 0.29& 0.01& <0.0001&
2& 0.21& 0.01& <0.0001& 0.20& 0.01& <0.0001& 0.21& 0.01& <0.0001& 0.18& 0.01& <0.0001&
Brother5
Brother& 1256&
1& 0.37& 0.03& <0.0001& 0.36& 0.03& <0.0001& 0.38& 0.03& <0.0001& 0.28& 0.03& <0.0001&
2& 0.29& 0.03& <0.0001& 0.23& 0.03& <0.0001& 0.27& 0.03& <0.0001& 0.25& 0.03& <0.0001&
Brother5
Sister& 3256&
1& 0.33& 0.02& <0.0001& 0.29& 0.02& <0.0001& 0.32& 0.02& <0.0001& 0.26& 0.02& <0.0001&
2& 0.17& 0.02& <0.0001& 0.18& 0.02& <0.0001& 0.18& 0.02& <0.0001& 0.13& 0.02& <0.0001&
Sister5
Sister& 2727&
1& 0.38& 0.02& <0.0001& 0.31& 0.02& <0.0001& 0.35& 0.02& <0.0001& 0.37& 0.02& <0.0001&
2& 0.20& 0.02& <0.0001& 0.22& 0.02& <0.0001& 0.21& 0.02& <0.0001& 0.20& 0.02& <0.0001&
Half&Sib.& 134& 1& 0.24& 0.09& 0.01& 0.19& 0.09& 0.04& 0.23& 0.09& 0.02& 0.20& 0.09& 0.03&2& 0.16& 0.09& 0.08& 0.07& 0.09& 0.43& 0.09& 0.09& 0.34& 0.21& 0.09& 0.02&
Grandp.& 654& 1& 50.05& 0.04& 0.27& 50.03& 0.04& 0.50& 50.03& 0.04& 0.50& 50.07& 0.04& 0.09&2& 0.02& 0.05& 0.72& 0.03& 0.04& 0.41& 0.03& 0.04& 0.47& 50.04& 0.05& 0.45&
Avunc.& 5288& 1& 0.09& 0.02& <0.0001& 0.08& 0.02& <0.0001& 0.11& 0.02& <0.0001& 0.00& 0.02& 0.82&2& 0.05& 0.02& 0.0014& 0.06& 0.02& 0.0001& 0.06& 0.02& <0.0001& 0.02& 0.02& 0.32&
Cousin& 1729& 1& 0.08& 0.03& 0.01& 0.14& 0.03& <0.0001& 0.12& 0.03& 0.0001& 0.03& 0.03& 0.37&2& 0.00& 0.04& 0.94& 0.03& 0.03& 0.26& 0.03& 0.03& 0.33& 0.01& 0.03& 0.77&
Spouse& 1189& 1& 0.18& 0.03& <0.0001& 0.10& 0.03& 0.0005& 0.13& 0.03& <0.0001& 0.23& 0.03& <0.0001&2& 0.09& 0.03& 0.0034& 0.09& 0.03& 0.0023& 0.09& 0.03& 0.0014& 0.06& 0.03& 0.0309&
Model&1&is&the&basic&model&that&includes&BP&without&any&covariates;&model&2&was&adjusted&for&age,&age2,&sex,&and&BMI,&(Avunc.:&avuncular),&
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5.4.2%Univariate%heritability%of%BP%traits%%
The estimated univariate heritabilities for the four BP traits in the population of 
GS:SFHS are presented in Table 5-2. The heritability estimates (h2) ranges from 
12% for PP for the unadjusted model to 35% for MAP for the second model, and 
all heritability were significant (p <0.0001). In the two models (model 2 and 3) 
that were adjusted for covariates, h2 represents the total additive genetic effect 
for the correspondence trait, which is different from the total genetic variance 
for the trait. For SBP, the additive genetic effect of genes (h2) accounts for 33% 
of the variation in SBP that is not explained by the covariates, with 29% of the 
variance being explained by the covariates. Hence, genetic factors account for 
23% of the total variance in the SBP trait. After further adjusting for BMI, the 
estimate of heritability reduced to 30% and the variance explained by adding BMI 
to covariates increased to 37%, indicating that only 19% of the total variance of 
SBP is explained by genetic components. Since BMI also has genetic components, 
this indicates that 19% of the total variance of SBP in GS:SFHS is explained by 
unknown genetic factors that contribute to SBP variance independent of the 
BMI.  
For DBP, the heritability in the second model was 34%, and in the third model 
was 31%, suggesting that genetic factors explain 28% and 22% of the total 
variance of DBP in the second and third models, respectively. Estimates for MAP 
and PP are shown in Table 5-2, and can be interpreted in the same way. 
5.4.3%Bivariate%genetic%correlation%
Table 5-3 shows the bivariate genetic correlation and heritability of BP traits. All 
correlations were positive and significant. The correlation between DBP and MAP 
showed the highest phenotypic correlation (94%), genetic correlation (93%), and 
environmental correlation (93%), with a bivariate heritability equals to 31%; 33% 
of the total phenotypic correlation between DBP and MAP is due to shared 
genetic factors. Although the phenotypic correlation between DBP and PP was 
only 10%, almost 60% of this correlation can be explained by shared genetic 
factors. All the genetic correlations were significantly different than both 0 and 
1 or -1, suggesting incomplete pleiotropy between these traits (i.e. some of the 
phenotypic similarity between two traits are due to the same gene or genes). 
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The proportions of phenotypic correlation that is explained by genetic factors 
between BMI and all the four BP traits were exactly the same (54%), despite the 
variation in the value of phenotypic correlations, which range from 36% to 10%. 
5.4.4%Sibling%Recurrence%Risk%ratio%(λS)%
The number of individuals with at least one sibling presented in the analysis was 
10,376, making a total of 4,616 sibships. Calculating the KS for hypertension was 
based on a total of 2,548 informative sibships (55%; i.e. contain at least one 
hypertensive sibling) (Table 5-4). The proportion of sibships with at least two 
hypertensive siblings was 22%. The number of hypertensive individuals was 2,938 
among a total of 5,461 siblings, resulting with an estimate of KS that equals 54% 
(2,938/5,461), and λS for hypertension was then calculated as 1.6 (0.54/0.32), 
based on the hypertensive prevalence reported in SHeS (32%). The total number 
of informative sibships for hypertension treatment was 1,030 (22%), and 78% of 
the sibships did not have any sibling who was taking any BP-lowering medication 
(Table 5-5). KS for hypertension treatment was estimated by dividing the total 
number of treated siblings 616 by the total number of informative siblings 1,883, 
resulting a KS estimate of 33%, and an estimate of λS for hypertension treatment 
was 2.04 (0.33/0.16). 
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Table%5B2%Univariate%heritability%of%BP%traits%
Model& Trait& h2& SE& P$ Var.&by&Cov.a&
Genetic&
factorsb& Covariates&
1& SBP& 0.17& 0.02& 6.95EB30& B& B& None&
2& 0.33& 0.02& 2.44EB90& 0.29& 0.23& Sex,&age,&age2&
3& 0.30& 0.02& 2.39EB78& 0.37& 0.19& Sex,&age,&age2,&BMI&
1& DBP& 0.24& 0.02& 1.74EB54& B& B& None&
2& 0.34& 0.02& 1.57EB99& 0.18& 0.28& Sex,&age,&age2&
3& 0.31& 0.02& 8.61EB85& 0.28& 0.22& Sex,&age,&age2,&BMI&
1& MAP& 0.22& 0.02& 1.09EB45& B& B& None&
2& 0.35& 0.02& 1.49EB104& 0.24& 0.27& Sex,&age,&age2&
3& 0.32& 0.02& 9.62EB90& 0.34& 0.21& Sex,&age,&age2,&BMI&
1& PP& 0.12& 0.02& 1.11EB14& B& B& None&
2& 0.24& 0.02& 7.35EB51& 0.26& 0.18& Sex,&age,&age2&
3& 0.24& 0.02& 3.02EB49& 0.27& 0.17& Sex,&age,&age2,&BMI&
a.! Var.&by&Cov&is&the&proportion&of&the&total&variance&that&is&explained&by&the&covariates&in&the&
model.&
b.! The&contribution&of&the&genetic&factors&to&the&total&variance&of&the&trait,&which&is&calculated&as:&
[(1&–&Var.&by&Cov.)&x&h2].&&
!
Table%5B3%Phenotypic,%genetic,%and%environmental%correlations%for%BMI%and%BP%traits%
Trait&pairs& ρp& ρG&(se)& ρE&(se)& Bivariate&h2*&
%&Explained&
by&shared&
genetics**&
SBP,&DBP& 0.72& 0.81&(0.02)& 0.68&(0.02)& 0.25& 0.35&
SBP,&MAP& 0.91& 0.94&(0.01)& 0.90&(0.01)& 0.30& 0.32&
SBP,&PP& 0.77& 0.78&(0.02)& 0.78&(0.01)& 0.21& 0.27&
SBP,&BMI**& 0.32& 0.41&(0.03)& 0.27&(0.02)& 0.17& 0.54&
DBP,&MAP& 0.94& 0.97&(0.01)& 0.93&(0.01)& 0.31& 0.33&
DBP,&PP& 0.10& 0.22&(0.01)& 0.06&(0.02)& 0.06& 0.59&
DBP,&BMI**& 0.35& 0.44&(0.03)& 0.30&(0.02)& 0.19& 0.54&
MAP,&PP& 0.41& 0.46&(0.04)& 0.40&(0.01)& 0.13& 0.31&
MAP,&BMI**& 0.36& 0.44&(0.03)& 0.31&(0.02)& 0.20& 0.54&
PP,&BMI**& 0.13& 0.19&(0.03)& 0.11&(0.02)& 0.07& 0.54&
*&Bivariate&h2$is&the&contribution&of&shared&genetic&factors&to&the&phenotypic&correlation&
between&two&traits,&calculated&by&this&formula&[ ℎ"#×%&'%(".*)×%√ℎ*#),&where&A&and&B&are&
trait&one&and&trait&two.&
**This&column&shows&the&proportion&of&the&phenotypic&correlation&explained&by&shared&
genetics&factors,&calculated&by&this&formula&[Bivariate&h2/&ρp].&
**The&model&included&sex,&age,&age2&as&covariates.&For&the&remaining,&models&included&
BMI&in&the&covariates&in&addition&to&sex,&age,&and&its&square.&
Abbreviations:&ρp:&phenotypic&correlation,&ρG:&genetic&correlation,&ρE:&environmental&
correlation.&
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Table%5B4%Number%of%siblings%with%hypertension%per%sibship%
&
Number&of&hypertensive&siblings&in&the&sibship&(a)&
Total&
0& 1& 2& 3& 4& 5& 6& 7&
Si
ze
&o
f&s
ib
sh
ip
&(s
)& 2& 1799& 1257&
&
& B& B& B& B& B& 3724&
3& 225& 221& 156& 99& B& B& B& B& 701&
4& 37& 36& 36& 21& 17& B& B& B& 147&
5& 7& 3& 12& 3& 2& 4& B& B& 31&
6& 0& 2& 1& 3& 3& 1& 0& B& 10&
7& 0& 0& 0& 0& 0& 0& 1& 1& 2&
8& 0& 1& 0& 0& 0& 0& 0& 0& 1&
Total& 2068& 1520& 873& 126& 22& 5& 1& 1& 4616&
Affected&
siblings1& 0& 0& 1746& 756& 264& 100& 30& 42& 2938&
Total&sibling2& 0& 1836& 2282& 864& 296& 105& 36& 42& 5461&
1&This&row&is&calculated&by&multiplying&the&number&in&total&row&by&number&of&affected&sibling&(a)&
and&number&of&affected&sibling&minus&one&(aB1),&to&represents&the&numerator&KS&(equation&1).&
2&Total&sibling&is&the&sum&of&number&of&affected&sibling&(a)&multiplied&by&the&size&of&sibship&
minum&one&(sB1)&and&number&of&affected&sibling&for&each&sibship&size.&
 
Table%5B5%Number%of%siblings%with%treated%hypertension%per%sibship.%
&
Number&of&sibling&taking&a&BPBlowering&medication&in&the&sibship&
Total&
0& 1& 2& 3& 4& 5& 6& 7&
Si
ze
&o
f&s
ib
sh
ip
&
2& 2972& 613& 139& B& B& B& B& B& 3724&
3& 494& 140& 49& 18& B& B& B& B& 701&
4& 95& 34& 11& 6& 1& B& B& B& 147&
5& 19& 3& 3& 5& 1& 0& B& B& 31&
6& 5& 2& 1& 2& 0& 0& 0& B& 10&
7& 0& 2& 0& 0& 0& 0& 0& 0& 2&
8& 1& 0& 0& 0& 0& 0& 0& 0& 1&
Total& 3586& 794& 203& 31& 2& 0& 0& 0& 4616&
Affected&
siblings1& 0& 0& 406& 186& 24& 0& 0& 0& 616&
Total&sibling2& 0& 1029& 574& 252& 28& 0& 0& 0& 1883&
1&This&row&is&calculated&by&multiplying&the&number&in&total&row&by&number&of&affected&sibling&(a)&
and&number&of&affected&sibling&minus&one&(aB1),&to&represents&the&numerator&KS&(equation&1).&
2&Total&sibling&is&the&sum&of&number&of&affected&sibling&(a)&multiplied&by&the&size&of&sibship&
minum&one&(sB1)&and&number&of&affected&sibling&for&each&sibship&size.&
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5.5%Discussion%
In this chapter, I have demonstrated the familial aggregation of BP and 
hypertension traits in GS:SFHS by using multiple measurements that assess the 
genetic components of BP. The presence of nuclear family structure with 
different relative pairs types has allowed me to carried out these analyses. The 
main findings of this study can be summarised as follows; 1) the familial 
correlation of BP traits showed higher correlation among first-degree relatives 
than other types of relative pairs; 2) heritability of BP traits ranged from 24% to 
32% with PP having the lowest heritability estimate; 3) bivariate genetic 
correlation between BP traits showed a high correlation between SBP, DBP and 
MAP (ρG: 81% to 94%), but lower correlations with PP (ρG: 22% to 78%); 4) the 
familial aggregation of hypertension and treated hypertension as a binary trait 
were 1.6 and 2.04 respectively. In addition, despite the wide variation in the 
extent of phenotypic and genotypic correlation between BMI and the four BP 
traits, the proportion of variance that is explained by shared genetic factors was 
exactly the same (54%).  
Studying familial aggregations of BP and hypertension represents an important 
aspect of genetic epidemiological studies. As heritability estimates are specific 
to the population studied, this is the first study of the Scottish population. The 
large number of families with an extended family structure is another advantage 
that provides more reliability to the estimate reported here. It must be noted 
that the direct comparison of the results of this study with other studies should 
be considered carefully due to several factors that are related to differences in 
study design, sample size, and methods of analysis (i.e. including using of 
different covariates in the adjusted model). For instance, heritability estimates 
from twin studies tend to show higher estimates of heritability than studies that 
include nuclear families. The heritability estimate per se is a population-specific 
measurement, and there were no other studies that looked at the Scottish 
population particularly, to compare my results against.  
Several studies have reported the familial correlation of BP traits, under the 
theory that relatives share genetic and environmental factors, leading to greater 
phenotypic similarity between relatives than unrelated individuals. For instance, 
siblings and parent-offspring have a kinship coefficient of 25%, but spouse pairs 
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under the assortative mating assumption share the environmental factors only. 
This was also observed in our results in which the correlation between spouse 
pairs was greater than zero and statistically significant, suggesting the influence 
of shared environmental factors. The correlations reported here are within the 
range of correlation coefficients reported in other populations, such as the 
Finnish 246, the Portuguese 247, the English 248, and the Chinese Han 249. Unlike 
most of these studies, our estimates in the different pairs of nuclear family (i.e. 
father-son, mother-son, father-daughter, and mother-daughter) were all 
statistically significant (p <0.0001), except for DBP in father-son pairs, and for 
PP in both father-son and mother-son. Adjusting for the effect of BMI has 
reduced the crude familial correlation in all of the possible relatives pairs, but 
remained significant in most relative-pairs.  
Correlation coefficients between parent-offspring pairs were generally smaller 
compared to sibling pairs, which may suggest a possible age-specific factors or 
the presence of non-additive genetic effects. This was also observed in other 
studies that calculated the narrow-sense and broad-sense heritability.250,251 In 
which, an important proportion of the trait heritability was attributed to non-
additive genetic effects, particularly for older groups. This proportion of non-
additive genetics variance may include genetic dominance effects, gene-gene 
interaction (epistasis), or gene-environment interaction factors that act in non-
additive way to produce a different correlation between parent-offspring and 
siblings pairs. Furthermore, van Dongen et al. suggested that age factor is 
unlikely to explain the non-additive effects, as they could not find evidence for 
the presence of genes that act differently in different ages.250 Alternately, this 
can be attributed to the fact that siblings are more likely to share more similar 
environments with each other than they do with their parents.  
The spouse resemblance was significant in all the BP traits in the crude model 
and before adjusting for BMI. The adjusted model showed lower correlation 
coefficients and was only significant at the nominal p value level for PP, which 
showed the maximum reduction after adjusting for BMI (from 23% to 6%). This 
may be an indication of some sort of assortative mating. Indeed, Allison et al. 
reported evidence of assortative mating for relative weight, which may 
overestimate the correlation between spouse.252 Theoretically, adjusting for BMI 
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should eliminate the effect of assortative mating based on weight, and produce 
lower correlation coefficients after adjustment, which was observed in our 
study. The significant decreases observed in PP after adjusting for BMI may be 
indicative of the important role of BMI on PP. It has been shown that BMI is an 
independent factor that is associated with decreasing arterial compliance and 
elevated PP.253 
The univariate heritability estimates reported here for BP traits were 
statistically significant and ranged from 24–32%, with PP having the lowest 
estimate and MAP having the highest estimates, which is in line with two other 
studies.233,254 These estimates were in the range of 19–45% for SBP, and 6–43% 
for DBP which are similar to other reported heritability from family-based 
studies.233,234,236,248,255 Our findings confirm the previous reported results of 
moderate influence of additive genetic factors on the variation of BP traits.  
The covariates included in the model accounted for a large proportion of the 
phenotypic variance (up to 37% in the SBP model that included BMI); hence, the 
heritability estimates were not inflated by their effects. In line with previous 
studies, the heritability estimates of BP decreased after adjustment for BMI, 
which along with the findings from the familial correlation analyses suggest the 
importance role of BMI, and that the variance in BMI explained large proportion 
of total phenotypic variation in BP. Wu et al. have suggested that this reduction 
in heritability estimates after adjusting for BMI is due to a higher influence of 
common and unique environmental factors with increasing levels of BMI.256 For 
instance, several behavioural factors that predict BP level such as unhealthy diet 
and sedentary lifestyle are more prevalent among groups of higher BMIs. In 
addition, other factors that can be considered as pure environmental factors 
such as socio-economic status may also have some genetic basis. Indeed, 
another study that also used the GS:SFHS cohort has reported a heritability of 
41% for education, 54% for intelligence, and 71% for socio-economic factors as 
represented by SIMD.257 This can also be attributed to the fact that children 
share the same environment as their parents, such as they grow up together in 
the same household. The extent to which the genetic factors of socio-economic 
might also contribute to the familial correlation of BP has not been studied in 
twin or family studies. 
187 
 
The bivariate genetic correlation analysis between BP traits indicate that they 
partly share common genetics factors, but the observed incomplete correlation 
as represented by findings that (ρG ≠ 0, 1, or -1; p <0.0001), suggest the 
presence of trait-specific set of genes (i.e. incomplete pleiotropy). Similarly, BP 
traits were greatly influenced by similar environmental factors, but each trait 
was still influenced by specific-environmental factors (ρE ≠ 0, 1, or -1; 
p <0.0001). A high genetic correlation between SBP, DBP and MAP has been 
observed in two previous studies, which reported similar findings to this 
thesis.233,254 However, this thesis found a higher genetic correlation between 
DBP and PP than one of the studies, which reported an absence of this 
correlation 233, and a higher phenotypic correlation than the other study, which 
also reported an absence of this correlation.254 Nevertheless, the correlation 
between PP and the remaining BP traits were the lowest in this thesis, 
suggesting the presence of an independent set of genes that influence PP. This is 
concordant with animal studies that shows that different loci are involved in 
regulation of steady-state (DBP) and pulsatile (PP) 258, and the absence of 
phenotypic correlation between DBP and PP in rats.259!
The bivariate correlation between BP traits and BMI has showed that the extent 
of phenotypic correlation that is explained by shared genetic factors is exactly 
the same (54%). These interesting findings may emphasize the presence of 
gene(s) that influence both BMI and BP traits by the same way. The genetic 
correlation between BP traits and BMI in our study ranged from 19–44%, with PP 
having the lowest correlation and very close estimates for SBP, DBP, and MAP. 
Our genetic correlation estimates are higher than those reported in Spanish 254, 
Atherosclerosis Risk in Communities,160 Victorian Family Heart Study,260 and 
Chinese Han population.256 Recently, two twins studies have examined the 
genetic and environmental determinates of BP and BMI in Italy and Chinese Han 
populations.256,261 The two studies have reported a significant genetic 
correlation of BMI with SBP (0.29–0.38) and DBP (0.15–0.48). The phenotypic 
correlations were largely explained by genetic factors, which were 0.82 and 0.86 
in the Chinese Han population, and 0.74 and 0.65 in the Italian population for 
SBP and DBP, respectively. These results are in line with our findings that these 
traits share some common genetic factors. However, both studies reported that 
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the proportion of genetic factors that influence both of BMI and BP traits were 
less than 8%.256,261 
Analysis of hypertension as a binary trait was performed using λS, which is the 
relative risk of the siblings of hypertensive individuals. GS:SFHS was not 
ascertained for any particular BP traits, and thus there was not any requirement 
to correct for ascertainment bias. For hypertension, the λS in GS:SFHS was 1.6, 
which is lower than the λS reported by the WTCCC for hypertension (2.5 to 3.5) 
131, but within the range reported by Caulfield et al. (1.2 to 1.7)241. Calculating 
λS based on the treatment status may provide a more accurate estimate of the 
clinically diagnosed hypertension, since individuals taking BP-lowering 
medication are more likely to receive a clinical diagnosis of hypertension than 
people defined as hypertension based on the study criteria (BP ≥140/90 mmHg, 
or taking BP-lowering medications). Especially as only 25% of the hypertensive 
participants in GS:SFHS were aware of their disease (discussed in Section 4.4.6 -
p153). The λS for treated hypertension (2.04) was higher than hypertension 
(1.60), suggesting that having a treated hypertensive sibling confers a higher risk 
of receiving a clinical diagnosis of hypertension. The importance of family 
history in identify participants at higher risk of developing the disease, or 
initiating the pharmacological therapy for chronic diseases has not been 
appreciated.262 For instance, Daniels et al. reported that having one controlled 
sibling increases the odds of the other sibling to be also controlled by 51% (95% 
CI: 25–83%). This led him to suggest that having a complete family history for 
the patients may enable the physician to switch the drug regimens in the 
uncontrolled patient to the regimen that is more effective in his sibling.232 
5.5.1%Conclusion%
In summary, this chapter has assessed the familial aggregation of BP and 
hypertension traits in the Scottish population using one of the largest family-
based studies, which include 18,471 individuals and 7,025 extended families. 
The results are generally in line with similar studies in other populations and 
confirm that genetic factors have moderate effect in explaining BP variability in 
the Scottish population. The importance of other factors such as BMI was also 
highlighted in our study, which in combination with environmental factors that 
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are usually shared within the same family or household, such as socio-economic 
factors, can explain part of the remaining variability.  
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6% SNP%association%analysis%
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6.1% Introduction%%
GWASs have identified several genetic loci that are associated with different BP 
traits including SBP, DBP, MAP, and PP as quantitative traits, and hypertension 
as a binary trait. The ICBP is the largest ever GWAS for BP and hypertension, and 
reported 29 SNPs in 28 loci with a combined genetic effect explaining 0.9% of 
the phenotypic variance in BP (details of all the GWAS for hypertension is 
discussed previously in Section 1.6.2 -p77).107 Considering the heterogeneity 
among different populations, it is essential to replicate the reported genetic 
variants in the large GWAS in independent populations. For instance, the 
association of these variants in specific population has been examined in two 
separate studies of Finnish and Chinese populations, where both studies have 
also assessed the association of genetic risk score with BP traits in their 
populations.263,264 Comparing the results of these SNPs between populations may 
provide insight about the genetic contribution in BP variability between 
populations.     
6.1.1%Aims%
The primary aims of this chapter are: (1) to validate SNPs that have been 
previously reported to be associated with BP at a genome-wide significance level 
in the GS:SFHS Scottish population, using SBP and DBP as the primary 
phenotypes; and (2) to assess the association of a genetic risk scores that is 
constructed from these variants with SBP and DBP.  
The secondary aims include: (1) evaluate the association of these SNPs with 
other BP traits including MAP and PP, and (2) to evaluate the effect of the 
association signals and variants effect size using different BP-lowering 
medication adjustment models, and (3) to compare SNPs effect sizes to those 
reported in other population. 
6.2%Methods%
6.2.1%DNA%extraction,%genotyping,%and%SNP%selection%
Chapter 2 explained in details the methods of DNA extraction (Section 2.4.1 -
p106), the genotyping procedure (Section 2.4.2 -p20), and SNP selection 
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procedure (Section 2.5 -p116). In summary, DNA samples were extracted from 
blood samples for the vast majority of the samples, and from saliva from the 
remaining postal samples. The extracted DNA was transferred to TaqMan® 
OpenArray® plate and mixed with TaqMan® OpenArray® Master Mix, following the 
manufacture-recommended protocol. The genotyping procedure was performed 
using 64-plex OpenArray® Genotyping plates, which genotypes up to 48 samples 
on a single OpenArray® Genotyping plate. The plate contained 64 SNPs, of which 
44 SNPs were related to this project and were selected based on two 
approaches. Firstly, by consulting the NHGRI catalogue of Published GWAS as of 
July 2012. Second, snowballing from the reference list of the identified studies 
and candidate-gene studies to expand the search results. Only SNPs reported in 
the large GWAS of European populations for association with BP traits or 
hypertension, and achieving a genome-significant level were selected for this 
study.  
6.2.2%BP%phenotypes%%
BP phenotypes and definition of hypertension were described previously in the 
Methods and Materials chapter (Section 2.3.1 -p98). For this chapter, the BP 
values used are the average of two BP readings, plus a fixed value of 15/10 
mmHg for individuals taking BP-lowering medication (Section 2.3.1.1 -p98). This 
is in accordance with the recommendation of Tobin et al. to add a fixed value 
for adjustment of the treatment effect.87 Hypertension was defined as having an 
average SBP of 140 mmHg or higher, an average of DBP of 90 mmHg or higher, or 
taking BP-lowering medications. For the overall group (n =18,470), definition of 
hypertension and BP adjustments were based on the information retrieved from 
EPRs primarily, and then from the SRMs for those individuals with missing EPRs, 
following the findings from the assessment of self-reported reliability in Chapter 
4 (Section 4.3.2 -p136). These BP traits for the overall group were given a 
superscript of the letter “O”. Another two classes of adjustments were 
developed from information retrieved solely from EPRs and SRMs for the group 
of individuals with these two drug exposure sources (n =12,347). In the first 
class, BP traits were based on treatment-adjustments from EPRs (represented by 
a superscript “P”). In the second class, BP traits were based on treatment-
adjustment from SRMs (represented by a superscript “Q”). The last BP traits 
class was based on a random treatment-adjustment using the same sample size 
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as group 2 (n =12,347), but a similar treatment-adjustment structure as the 
overall group (n =18,470). In this traits class, treatment-adjustment of 8,231 
individuals was based on EPRs, and the remaining 4,116 subjects were based on 
SRMs (represented by a superscript “R”). 
6.2.3%Statistical%analyses%
The population sample in this study included extended-pedigree families with 
complex familial relationships and multi-generational pedigrees. In addition, as 
described in Section 3.3.5 -p122, the sample included 2,396 singleton-families in 
which no other relatives are presented in the study. Hence, this mixture of 
related and unrelated individuals in the sample requires a statistical test that 
account for both within- and between-family information. There are several 
widely-used tests for family-based studies that test for within-family information 
only, by assessing transmission of alleles within a family without incorporating 
information of allelic association observed across families, leading to loss of 
information. Even for studies that include family data only, simulation studies 
have shown that methods that assess the total association outperformed the 
methods that assess within-family information only.265 
Several statistical methods were recently developed to account for family and 
structural population jointly using a linear mixed models (LMMs) approach, in 
which a genetic relationship matrix (GRM) is incorporated as a random-effect 
variable in the statistical model, which may also include fixed-effect variables 
such as age and sex. The contribution of the GRM to the total phenotypic 
variance of the trait is then assessed by the model, along with computing 
statistics that account for the remaining phenotypic variance. Basically, this 
approach calculates to what extent phenotypic similarity between a pair of 
individuals can be attributed to their similarity in the GRM, allowing an estimate 
of the extent to which phenotypic variance can be explained by the tested 
genetic variance. This approach was firstly proposed for samples of related 
individuals, in which the GRM can be easily constructed from the pair-wise 
kinship coefficients estimated from the pedigree.125,126 This approach was then 
extended to use a GRM that is based on information from the genomic SNP data, 
by using a marker-based kinship in the GRM instead of the pedigree-based 
kinship matrix.266-268 This approach of marker-based kinship is appropriate for 
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samples with a complex unknown family structure, in which the study has 
genotyped a large number of genomic markers to establish a reliable marker-
based kinship. Several software packages are available for fitting LMM for GWAS, 
but one example is the genome-wide efficient mixed-model association 
(GEMMA), which provides an exact estimate of the test statistics, unlike other 
approximate methods.268 
In this study, SNP association tests were performed using LMM methods to 
account for relatedness in GS:SFHS and dependent observations between family 
members. This was carried out by fitting a LMM, as implemented in GEMMA 
(http://www.xzlab.org/software.html, version 0.94). The included covariates in 
the model were sex, BMI, age, and age-squared. Adjusting for both age and age-
squared allows for the non-linear effect of age on BP. The GRM in the model was 
provided by constructing a kinship coefficient matrix based on the pedigree 
information, using the “kinship 2” package in R.269 The kinship coefficient for 
any pair of individuals is the probability that an allele chosen at random at a 
given locus is identical-by-descent. The quantitative trait association test (-
robustAssoc) function that is implemented in MERLIN software was used to 
identify the variance explained by each tested SNP.99,270 
6.2.3.1% Genetic%risk%score%
The effect of GRS on the different BP traits was estimated as follows: (1) 
individual GRS was calculated for each individual by multiplying the effect size 
reported in the reference study by the number of copies of the coded allele for 
each individual SNP. The coded allele is the allele coded 0, 1, or 2 according to 
the number of copies of the allele. This is opposed to the alternative approach, 
in which no weighting of effect is used, and each SNP allele counts equally in 
the score. Five GRS were constructed for SBP, DBP, MAP, PP, and for 
hypertension (included SNPs in each GRS and their estimated effect size as 
reported by the reference study is shown in Appendix 5 -p254). (2) The 
association test between each GRS and BP trait was performed using a two level 
linear mixed model, in which fixed effects were the adjusted covariates (sex, 
BMI, age, and its square), and the random effect was the family unit. (3) to 
visualize the relationship between each GRS and its corresponding trait, GRSs 
were categorized into six groups based on the cutpoints (± 1&2 SD), and the 
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means of BP within each category were plotted. The mean difference in BP 
levels between the GRS groups was tested using a one-way analysis of variance 
(ANOVA) - linear trend analysis. Statistical analysis was performed using SPSS 
(version 22.0; SPSS Inc. Chicago, Illinois, USA). 
6.3%Results%
6.3.1%SNPs%association%test%results%for%SBP%
The association test revealed 9 significant SNPs associated with SBP (p <0.0012), 
and another 14 SNPs were significant at nominal p value level (p <0.05) (Table 
6-1). All of the tested SNPs showed concordant direction of effect as reported by 
the reference studies, except for two SNPs that were not statistically significant 
in MECOM and CACNB2(5') (Figure 6-1). The coded allele effect sizes were also 
highly correlated with original estimated effects reported in the reference 
studies (r =0.86). Eight of the nine significant SNPs were originally reported in 
the ICBP studies, which are located in loci near to MTHFR-NPPB, FGF5, NPR3-
C5orf23, CACNB2(3'), CYP1A1-ULK3, FURIN-FES, JAG1, and GNAS-EDN3. The last 
significant SNP is located in the UMOD locus, which was originally reported for 
association with hypertension in the BP-extreme study. 
Examining the effect of the BP-treatment adjustment source by SNP association 
test has showed that only rs2521501 in FURIN-FES remained significant in all the 
adjustment models (even for the unadjusted model), and rs1458038 (FGF5) was 
significant with SBPQ and SBPR, which then became the top significant SNP in 
SBPo (Figure 6-2). The unadjusted model (SBPU) was the least correlated model 
with the reference studies in term of the direction and estimated effect size 
(r =82), compared to the other three adjusted models, which had a better 
correlation values (r =86; Figure 6-3) 
The total phenotypic variance explained by all the genotyped SNPs was 1.4%, 
with the most variance explained by SNPs reported in the ICBP study (1.1%). The 
top significant SNP with SBP (rs1458038; FGF5) explained the largest extent of 
phenotypic variance (0.1%), with a range between 0.06% to 0.09% for the 
remaining significant SNPs.
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Table&6(1&SNPs&association&results&for&SBP&
SN# SNPs# locus# Chr# A1# A2# GS:SFHS# Reference#study# Finnish#cohort#RAF$ Beta$ se$ P$value$ h2%$ Ref.$ RAF$ Beta$ se$ P$value$ RAF$ beta$ P$value$
1# rs17367504# MTHFRDNPPB# 1# G# A# 0.164# D0.80# 0.23# 0.0006# 0.06# I$ 0.15$ 70.90$ 0.09$ 8.72E722$ 0.85# D0.90# 1.0ED05#
2# rs5068$ NPPA$ 1$ G$ A$ 0.052$ 70.96$ 0.39$ 0.0137$ 0.03$ N$ 0.06$ 70.80$ 0.02$ 2.00E706$ 7$ 7$ 7$
3# rs17030613$ ST7L$ 1$ C$ A$ 0.2$ 0.30$ 0.22$ 0.1617$ 0.01$ 7$ 7$ 7$ 7$ 7$ 7$ 7$ 7$
4# rs2932538$ MOV10$ 1$ G$ A$ 0.756$ 0.29$ 0.20$ 0.1514$ 0.01$ I$ 0.75$ 0.39$ 0.06$ 1.17E709$ 0.77# 0.60# 0.0005#
5# rs2004776$ AGT$ 1$ T$ C$ 0.258$ 0.45$ 0.20$ 0.0223$ 0.03$ C2$ 0.23$ 0.42$ 0.09$ 3.80E706$ 0.19$ 0.04$ 0.8200$
6# rs1446468$ FIGN$ 2$ A$ G$ 0.463$ 70.27$ 0.17$ 0.1236$ 0.02$ 7$ 7$ 7$ 7$ 7$ 7$ 7$ 7$
7# rs13082711$ SLC4A7$ 3$ T$ C$ 0.744$ 70.20$ 0.20$ 0.3154$ 0.01$ I$ 0.78$ 70.32$ 0.07$ 1.51E706$ 0.18# D0.61# 0.0010#
8# rs3774372$ ULK4$ 3$ T$ C$ 0.851$ 70.09$ 0.24$ 0.7221$ 0.00$ I$ 0.83$ 70.07$ 0.08$ 3.90E701$ 0.21$ 0.02$ 0.9100$
9# rs319690$ MAP4$ 3$ A$ G$ 0.684$ 0.19$ 0.19$ 0.3150$ 0.01$ 7$ 7$ 7$ 7$ 7$ 7$ 7$ 7$
10# rs419076$ MECOM$ 3$ T$ C$ 0.474$ 70.02$ 0.17$ 0.8956$ 0.00$ I$ 0.47$ 0.41$ 0.06$ 1.78E713$ 7$ 7$ 7$
11# rs871606$ CHIC2$ 4$ T$ C$ 0.893$ 0.08$ 0.28$ 0.7654$ 0.00$ 7$ 7$ 7$ 7$ 7$ 7$ 7$ 7$
12# rs1458038# FGF5# 4# T# C# 0.295# 0.79# 0.19# 0.00005# 0.10# I$ 0.29$ 0.71$ 0.07$ 1.47E723$ 0.33# 0.91# 5.0ED09#
13# rs13107325$ SLC39A8$ 4$ T$ C$ 0.058$ 70.62$ 0.38$ 0.0967$ 0.01$ I$ 0.05$ 70.98$ 0.13$ 3.27E714$ 0.99# D2.36# 0.0002#
14# rs13139571$ GUCY1A37GUCY1B3$ 4$ C$ A$ 0.751$ 0.37$ 0.20$ 0.0644$ 0.02$ I$ 0.76$ 0.32$ 0.07$ 1.16E706$ 0.76# 0.65# 0.0001#
15# rs1173771# NPR3DC5orf23# 5# G# A# 0.604# 0.61# 0.18# 0.0007# 0.07# I$ 0.6$ 0.50$ 0.06$ 1.79E716$ 0.59# 1.02# 6.0ED12#
16# rs11953630$ EBF1$ 5$ T$ C$ 0.365$ 70.48$ 0.18$ 0.0071$ 0.04$ I$ 0.37$ 70.41$ 0.06$ 3.02E711$ 0.66$ 70.28$ 0.0680$
17# rs1799945$ HFE$ 6$ G$ C$ 0.158$ 0.28$ 0.24$ 0.2464$ 0.01$ I$ 0.14$ 0.63$ 0.09$ 7.69E712$ 0.1$ 0.50$ 0.0380$
18# rs805303$ BAT27BAT5$ 6$ G$ A$ 0.622$ 0.06$ 0.18$ 0.7313$ 0.00$ I$ 0.61$ 0.38$ 0.06$ 1.49E711$ 0.52$ 0.29$ 0.0470$
19# rs12705390$ PIK3CG$ 7$ A$ G$ 0.198$ 0.47$ 0.22$ 0.0299$ 0.03$ 7$ 7$ 7$ 7$ 7$ 7$ 7$ 7$
20# rs3918226$ NOS3$ 7$ T$ C$ 0.085$ 0.61$ 0.31$ 0.0528$ 0.02$ 7$ 7$ 7$ 7$ 7$ 7$ 7$ 7$
21# rs2071518$ NOV$ 8$ T$ C$ 0.281$ 0.03$ 0.19$ 0.8779$ 0.00$ 7$ 7$ 7$ 7$ 7$ 7$ 7$ 7$
22# rs4373814$ CACNB2(5')$ 10$ G$ C$ 0.579$ 0.06$ 0.18$ 0.7435$ 0.00$ I$ 0.55$ 70.37$ 0.06$ 4.81E711$ 7$ 7$ 7$
23# rs1813353# CACNB2(3')# 10# A# G# 0.661# 0.67# 0.18# 0.0002# 0.08# I$ 0.68$ 0.57$ 0.08$ 2.56E712$ 0.69# 0.42# 0.0080#
24# rs4590817$ C10orf107$ 10$ G$ C$ 0.825$ 0.52$ 0.23$ 0.0239$ 0.03$ I$ 0.84$ 0.65$ 0.09$ 3.97E712$ 0.88# 0.82# 0.0006#
197 
 
#
25# rs1530440$ c10orf107$ 10$ T$ C$ 0.191$ 70.69$ 0.22$ 0.0017$ 0.06$ 7$ 7$ 7$ 7$ 7$ 7$ 7$ 7$
26# rs932764$ PLCE1$ 10$ G$ A$ 0.431$ 0.36$ 0.18$ 0.0411$ 0.03$ I$ 0.44$ 0.48$ 0.06$ 7.10E716$ 0.57# 0.93# 2.0ED10#
27# rs11191548$ CYP17A17NT5C2$ 10$ T$ C$ 0.923$ 0.72$ 0.32$ 0.0261$ 0.03$ I$ 0.91$ 1.10$ 0.10$ 6.90E726$ 0.92# 1.52# 2.0ED08#
28# rs2782980$ ADRB1$ 10$ T$ C$ 0.267$ 70.39$ 0.20$ 0.0449$ 0.02$ 7$ 7$ 7$ 7$ 7$ 7$ 7$ 7$
29# rs661348$ LSP1/TNNT3$ 11$ C$ T$ 0.412$ 0.39$ 0.18$ 0.0268$ 0.03$ 7$ 7$ 7$ 7$ 7$ 7$ 7$ 7$
30# rs7129220$ ADM$ 11$ G$ A$ 0.874$ 70.14$ 0.26$ 0.5798$ 0.00$ I$ 0.89$ 70.62$ 0.09$ 2.97E712$ 0.22# D1.05# 3.0ED09#
31# rs381815$ PLEKHA7$ 11$ T$ C$ 0.289$ 0.38$ 0.19$ 0.0453$ 0.02$ I$ 0.26$ 0.57$ 0.09$ 5.27E711$ 0.25$ 70.22$ 0.1800$
32# rs633185$ FLJ328107
TMEM133$
11$ G$ C$ 0.271$ 70.60$ 0.19$ 0.0020$ 0.05$ I$ 0.28$ 70.56$ 0.07$ 1.21E717$ 0.71# D0.81# 4.0ED06#
33# rs11222084$ ADAMTS78$ 11$ T$ A$ 0.37$ 0.08$ 0.18$ 0.6754$ 0.00$ 7$ 7$ 7$ 7$ 7$ 7$ 7$ 7$
34# rs17249754$ ATP2B1$ 12$ G$ A$ 0.823$ 0.72$ 0.23$ 0.0016$ 0.06$ I$ 0.84$ 0.93$ 0.11$ 1.82E718$ 7$ 7$ 7$
35# rs3184504$ SH2B3,$ATXN2$ 12$ T$ C$ 0.502$ 0.28$ 0.17$ 0.1055$ 0.02$ I$ 0.47$ 0.60$ 0.07$ 3.83E718$ 7$ 7$ 7$
36# rs653178$ SH2B3$ 12$ T$ C$ 0.497$ 70.31$ 0.17$ 0.0753$ 0.02$ C1$ 0.53$ 70.74$ 0.15$ 8.50E707$ 7$ 7$ 7$
37# rs10850411$ TBX57TBX3$ 12$ T$ C$ 0.68$ 0.58$ 0.18$ 0.0015$ 0.06$ I$ 0.7$ 0.35$ 0.07$ 5.38E708$ 0.67$ 70.05$ 0.7400$
38# rs1378942# CYP1A1DULK3# 15# C# A# 0.315# 0.72# 0.19# 0.0001# 0.08# I$ 0.35$ 0.61$ 0.06$ 5.69E723$ 7$ 7$ 7$
39# rs2521501# FURINDFES# 15# T# A# 0.316# 0.73# 0.19# 0.0001# 0.09# I$ 0.31$ 0.65$ 0.07$ 5.20E719$ 0.26# 0.83# 5.0ED07#
40# rs13333226# UMOD# 16# G# A# 0.185# D0.84# 0.22# 0.0002# 0.08# S$ 0.19$ 70.49$ 7$ 2.60E705$ 0.78$ 70.21$ 0.2200$
41# rs12940887$ ZNF652$ 17$ T$ C$ 0.361$ 0.23$ 0.18$ 0.2127$ 0.01$ I$ 0.38$ 0.36$ 0.06$ 1.79E710$ 0.42$ 0.21$ 0.1600$
42# rs1327235# JAG1# 20# G# A# 0.489# 0.68# 0.17# 0.0001# 0.09# I$ 0.46$ 0.34$ 0.06$ 1.87E708$ 0.42# 0.53# 0.0003#
43# rs6015450# GNASDEDN3# 20# G# A# 0.126# 1.02# 0.26# 0.0001# 0.08# I$ 0.12$ 0.90$ 0.09$ 3.87E723$ 0.17# 1.41# 4.0ED13#
SNPs#in#bold#are#statistically#significant#(p#value#<0.0012,#for#GS:SFHS,#and#p#value#<0.0016#for#Finnish#Study).#
h2#%:#the#extent#of#phenotypic#variance#explained#by#the#SNP.#
Ref.#I:#ICBP#107,#S:#BPDextreme82,#C1:#CHARGE#115,#C2:#CHARGE#drug#target#149,#N:#NewtonDCheh#et#al.134,#Finish#Cohort#263#
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Figure'6)1'Effect'size'of'the'coded'allele'for'SBP'in'GS:SFHS.'
The'effect'sizes'of'coded'alleles'from'the'SBPO'(GS:SFHS),'Reference'and'Finnish'cohort'
studies'are'represented'by'different'coloured'markers,'as'indicated,'with'horizontal'bars'
representing'the'95%'CI.'SNP'names'are'shown'to'the'left,'and'loci'to'the'right,'with'
statistically'significant'loci'for'SBPO'underlined.''
'
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Figure!6)2!SNPs!association!with!SBP!for!the!different!adjustment!models.!
SNPs!that!exceed!the!statistic!threshold!(p<0.0012),!represented!as!red!dotted!line!in!the!figure,!for!SBP!are!in!colour!and!labelled!with!the!locus!name,!the!
remaining!non!significant!SNPs!are!in!greyscale!with!dotted!line.!Abbreviations,!SBPU:!Un)adjusted!(measured)!SBP,!SBPP:!BP)adjustment!was!based!on!
EPRs!only,!SBPQ:!BP)adjustment!was!based!on!SRMs!only,!SBPR:!BP)adjustment!was!based!on!both!sources,!SBPO:!BP)adjustment!was!based!on!both!
sources,!and!using!the!total!sample!size!in!GS:SFHS.!The!red!dotted!line!shows!the!GS:SFHS!statistical!threshold.!
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Figure'6)3'Coded'allele'effect'size'for'SBP'in'the'different'adjustment'models.'
SNP'names'are'shown'to'the'left,'and'loci'to'the'right,'with'statistically'significant'loci'for'
SBPO'underlined.''
Abbreviations,'SBPU:'Un)adjusted'(measured)'SBP,'SBPP:'BP)adjustment'was'based'on'
EPRs'only,'SBPQ:'BP)adjustment'was'based'on'SRMs'only,'SBPR:'BP)adjustment'was'
based'on'both'sources,'SBPO:'BP)adjustment'was'based'on'both'sources,'and'using'the'
total'sample'size'in'GS:SFHS.' '
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6.3.2'SNPs'association'test'results'for'DBP'
In the overall model, DBPO was found to be significantly associated with six loci 
at the Bonferroni-corrected level (p<0.0012), and with another 23 SNPs at the 
nominal p value level (Table 6-2). All the association signals were in the same 
direction as reported by the reference study, except for rs7129220 near to ADM 
(Figure 6-4). The correlation for the estimated effect size of the coded allele 
between our results and the reference study was also high (r =0.92). Of the six 
significant SNPs, five loci were reported originally by the ICBP study (FGF5, 
NPR3-C5orf23, CYP1A1-ULK3, FURIN-FES, and GNAS-EDN3), and the last one was 
originally reported by the Global BPgen study in the locus near to c10orf107. 
Studying the association signals across the different DBP adjustment models 
shows that the top significant SNP (rs1378942; CYP1A1-ULK3) has remained 
significant in all the models, only rs1173771 near to NPR3-C5orf23 has just 
reached the statistical significant threshold in the DBPQ model only (Figure 6-5). 
The correlation of the coded allele effect size and direction was the lowest in 
the unadjusted model (r =0.89), and the remaining adjustment models had 
almost similar correlation values (r =0.93) (Figure 6-6). 
The 43 genotyped SNPs explained 1.52% of the total phenotypic variance in 
DBPO, with each individual significant SNP contributing between 0.06-0.14% to 
the phenotypic variance. 
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Table&6(2&SNPs&association&results&for&DBP&
SN# SNP# locus# Chr# A1# A2# GS:SFHS# Reference#Study# Finnish#study#
A1F$ Beta$ se$ P$value$ H2$ Ref$ A1F$ Beta$ se$ P$value$ A1F$ Beta$ P$value$
1# rs17367504$ MTHFR;NPPB$ 1$ G$ A$ 0.164$ ;0.44$ 0.14$ 0.0017$ 0.05$ I$ 0.15$ ;0.55$ 0.06$ 3.55E;19$ 0.85# @0.46# 0.0002#
2# rs5068$ NPPA$ 1$ G$ A$ 0.052$ ;0.38$ 0.24$ 0.1080$ 0.01$ N$ 0.06$ ;0.08$ 0.02$ 1.00E;06$ ;$ ;$ ;$
3# rs17030613$ ST7L$ 1$ C$ A$ 0.2$ 0.26$ 0.13$ 0.0505$ 0.02$ ;$ ;$ ;$ ;$ ;$ ;$ ;$ ;$
4# rs2932538$ MOV10$ 1$ G$ A$ 0.756$ 0.22$ 0.12$ 0.0735$ 0.02$ I$ 0.75$ 0.24$ 0.04$ 9.88E;10$ 0.77# 0.32# 0.0020#
5# rs2004776$ AGT$ 1$ T$ C$ 0.258$ 0.35$ 0.12$ 0.0038$ 0.05$ C2$ 0.23$ 0.32$ 0.06$ 5.00E;08$ 0.19$ 0.09$ 0.4100$
6# rs1446468$ FIGN$ 2$ A$ G$ 0.463$ ;0.24$ 0.11$ 0.0204$ 0.03$ ;$ ;$ ;$ ;$ ;$ ;$ ;$ ;$
7# rs13082711$ SLC4A7$ 3$ T$ C$ 0.744$ ;0.03$ 0.12$ 0.8172$ 0.00$ I$ 0.78$ ;0.24$ 0.04$ 3.77E;09$ 0.18# @0.40# 0.0004#
8# rs3774372$ ULK4$ 3$ T$ C$ 0.851$ ;0.35$ 0.15$ 0.0176$ 0.03$ I$ 0.83$ ;0.37$ 0.05$ 9.02E;14$ 0.21# @0.41# 9.0E@0.5#
9# rs319690$ MAP4$ 3$ A$ G$ 0.684$ ;0.01$ 0.12$ 0.9579$ 0.00$ ;$ ;$ ;$ ;$ ;$ ;$ ;$ ;$
10# rs419076$ MECOM$ 3$ T$ C$ 0.474$ 0.07$ 0.11$ 0.5302$ 0.00$ I$ 0.47$ 0.24$ 0.03$ 2.12E;12$ ;$ ;$ ;$
11# rs871606$ CHIC2$ 4$ T$ C$ 0.893$ ;0.33$ 0.17$ 0.0483$ 0.02$ ;$ ;$ ;$ ;$ ;$ ;$ ;$ ;$
12# rs1458038# FGF5# 4$ T# C# 0.295# 0.38# 0.12# 0.0010# 0.06# I$ 0.29$ 0.46$ 0.04$ 8.46E;25$ 0.33# 0.63# 6.0E@12#
13# rs13107325$ SLC39A8$ 4$ T$ C$ 0.058$ ;0.57$ 0.23$ 0.0116$ 0.03$ I$ 0.05$ ;0.68$ 0.08$ 2.28E;17$ 0.99# @2.01# 2.0E@07#
14# rs13139571$ GUCY1A3;GUCY1B3$ 4$ C$ A$ 0.751$ 0.38$ 0.12$ 0.0018$ 0.05$ I$ 0.76$ 0.26$ 0.04$ 2.17E;10$ 0.76# 0.43# 2.0E@05#
15# rs1173771# NPR3@C5orf23# 5# G# A# 0.604# 0.37# 0.11# 0.0005# 0.07# I$ 0.6$ 0.26$ 0.04$ 9.11E;12$ 0.59# 0.37# 3.0E@05#
16# rs11953630$ EBF1$ 5$ T$ C$ 0.365$ ;0.23$ 0.11$ 0.0326$ 0.03$ I$ 0.37$ ;0.28$ 0.04$ 3.81E;13$ 0.66$ ;0.16$ 0.0720$
17# rs1799945$ HFE$ 6$ G$ C$ 0.158$ 0.30$ 0.15$ 0.0432$ 0.02$ I$ 0.14$ 0.46$ 0.06$ 1.45E;15$ 0.1$ 0.42$ 0.0040$
18# rs805303$ BAT2;BAT5$ 6$ G$ A$ 0.622$ 0.09$ 0.11$ 0.3821$ 0.01$ I$ 0.61$ 0.23$ 0.03$ 2.98E;11$ 0.52$ 0.07$ 0.4400$
19# rs12705390$ PIK3CG$ 7$ A$ G$ 0.198$ ;0.05$ 0.13$ 0.6880$ 0.00$ ;$ ;$ ;$ ;$ ;$ ;$ ;$ ;$
20# rs3918226$ NOS3$ 7$ T$ C$ 0.085$ 0.60$ 0.19$ 0.0016$ 0.05$ C1$ 0.08$ 0.78$ 0.18$ 2.20E;09$ ;$ ;$ ;$
21# rs2071518$ NOV$ 8$ T$ C$ 0.281$ ;0.25$ 0.12$ 0.0316$ 0.02$ ;$ ;$ ;$ ;$ ;$ ;$ ;$ ;$
22# rs4373814$ CACNB2(5')$ 10$ G$ C$ 0.579$ ;0.17$ 0.11$ 0.1106$ 0.02$ I$ 0.55$ ;0.22$ 0.04$ 4.36E;10$ ;$ ;$ ;$
23# rs1813353$ CACNB2(3')$ 10$ A$ G$ 0.661$ 0.33$ 0.11$ 0.0028$ 0.05$ I$ 0.68$ 0.41$ 0.05$ 2.30E;15$ 0.69# 0.36# 0.0001#
24# rs4590817$ C10orf107$ 10$ G$ C$ 0.825$ 0.37$ 0.14$ 0.0084$ 0.04$ I$ 0.84$ 0.42$ 0.06$ 1.29E;12$ 0.88$ 0.42$ 0.0030$
25# rs1530440# c10orf107# 10# T# C# 0.191# @0.48# 0.13# 0.0003# 0.08# G$ 0.19$ ;0.39$ 0.06$ 1.00E;09$ ;$ ;$ ;$
26# rs932764$ PLCE1$ 10$ G$ A$ 0.431$ 0.10$ 0.11$ 0.3531$ 0.01$ I$ 0.44$ 0.18$ 0.04$ 8.06E;07$ 0.57# 0.24# 0.0070#
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27# rs11191548$ CYP17A1;NT5C2$ 10$ T$ C$ 0.923$ 0.44$ 0.20$ 0.0254$ 0.03$ I$ 0.91$ 0.46$ 0.07$ 9.44E;13$ 0.92# 0.52# 0.0010#
28# rs2782980$ ADRB1$ 10$ T$ C$ 0.267$ ;0.31$ 0.12$ 0.0096$ 0.04$ ;$ ;$ ;$ ;$ ;$ ;$ ;$ ;$
29# rs661348$ LSP1/TNNT3$ 11$ C$ T$ 0.412$ 0.12$ 0.11$ 0.2769$ 0.01$ ;$ ;$ ;$ ;$ ;$ ;$ ;$ ;$
30# rs7129220$ ADM$ 11$ G$ A$ 0.874$ 0.12$ 0.16$ 0.4520$ 0.00$ I$ 0.89$ ;0.30$ 0.06$ 6.44E;08$ 0.22# 0.36# 0.0006#
31# rs381815$ PLEKHA7$ 11$ T$ C$ 0.289$ 0.04$ 0.12$ 0.7054$ 0.00$ I$ 0.26$ 0.35$ 0.06$ 5.34E;10$ 0.25$ ;0.01$ 0.9300$
32# rs633185$ FLJ32810;TMEM133$ 11$ G$ C$ 0.271$ ;0.35$ 0.12$ 0.0027$ 0.05$ I$ 0.28$ ;0.33$ 0.04$ 1.95E;15$ 0.71# @0.46# 1.0E@05#
33# rs11222084$ ADAMTS;8$ 11$ T$ A$ 0.37$ ;0.29$ 0.11$ 0.0087$ 0.04$ ;$ ;$ ;$ ;$ ;$ ;$ ;$ ;$
34# rs17249754$ ATP2B1$ 12$ G$ A$ 0.823$ 0.30$ 0.14$ 0.0325$ 0.03$ I$ 0.84$ 0.52$ 0.07$ 1.16E;14$ ;$ ;$ ;$
35# rs3184504$ SH2B3,$ATXN2$ 12$ T$ C$ 0.502$ 0.28$ 0.11$ 0.0076$ 0.04$ I$ 0.47$ 0.45$ 0.04$ 3.59E;25$ ;$ ;$ ;$
36# rs653178$ SH2B3$ 12$ T$ C$ 0.497$ ;0.30$ 0.11$ 0.0041$ 0.05$ G$ 0.52$ ;0.46$ 0.05$ 3.00E;18$ ;$ ;$ ;$
37# rs10850411$ TBX5;TBX3$ 12$ T$ C$ 0.68$ 0.27$ 0.11$ 0.0156$ 0.04$ I$ 0.7$ 0.25$ 0.04$ 5.43E;10$ 0.67$ ;0.02$ 0.8500$
38# rs1378942# CYP1A1@ULK3# 15# C# A# 0.315# 0.58# 0.11# 2.32E@07# 0.14# I$ 0.35$ 0.42$ 0.04$ 2.69E;26$ ;$ ;$ ;$
39# rs2521501# FURIN@FES# 15# T# A# 0.316# 0.39# 0.11# 0.0006# 0.07# I$ 0.31$ 0.36$ 0.05$ 1.89E;15$ 0.26$ 0.30$ 0.0020$
40# rs13333226$ UMOD$ 16$ G$ A$ 0.185$ ;0.41$ 0.14$ 0.0029$ 0.05$ $ 0.19$ ;0.23$ ;$ 1.50E;05$ 0.78$ ;0.18$ 0.0790$
41# rs12940887$ ZNF652$ 17$ T$ C$ 0.361$ 0.17$ 0.11$ 0.1121$ 0.02$ I$ 0.38$ 0.27$ 0.04$ 2.29E;14$ 0.42# 0.30# 0.0006#
42# rs1327235$ JAG1$ 20$ G$ A$ 0.489$ 0.33$ 0.11$ 0.0019$ 0.06$ I$ 0.46$ 0.30$ 0.04$ 1.41E;15$ 0.42# 0.38# 1.0E@05#
43# rs6015450# GNAS@EDN3# 20# G# A# 0.126# 0.61# 0.16# 0.0001# 0.08# I$ 0.12$ 0.56$ 0.06$ 5.63E;23$ 0.17# 0.80# 5.0E@12#
SNPs#in#bold#are#statistically#significant#(p#value#<0.0012,#for#GS:SFHS,#and#p#value#<0.0016#for#Finnish#Study).#
h2%#shows#the#extent#of#phenotypic#variance#explained#by#the#SNP.#
Ref.#I:#ICBP#107,#S:#BP@extreme82,#C1:#CHARGE#115,#C2:#CHARGE#drug#target#149,#N:#Newton@Cheh#et#al.134,#Finish#Cohort#263,#G:#Global#BPgen#133#
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Figure'6)4'Effect'size'of'the'coded'allele'for'DBP'in'GS:SFHS'
The'effect'sizes'of'coded'alleles'from'the'DBPO(GS:SFHS),'Reference'and'Finnish'cohort'
studies'are'represented'by'different'coloured'markers,'as'indicated,'with'horizontal'bars'
representing'the'95%'CI'confidence'intervals.'SNP'names'are'shown'in'the'left,'and'loci'in'
the'right,'with'statistically'significant'loci'for'DBPO'underlined.''
'
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Figure'6)5'SNPs'association'with'DBP'for'the'different'adjustment'models.'
SNPs'that'exceed'the'GS:SFHS'statistic'threshold'(p<0.0012),'represented'as'red'dotted'line'in'the'figure,'for'DBP'are'in'colour'and'labelled'with'the'locus'
name,'the'remaining'non'significant'SNPs'are'in'greyscale.'Abbreviations,'DBPU:'Unadjusted'(i.e.'measured)'DBP,'DBPP:'BP)adjustment'was'based'on'
EPRs'only,'DBPQ:'BP)adjustment'was'based'on'SRMs'only,'DBPR:'BP)adjustment'was'based'on'both'sources,'DBPO:'BP)adjustment'was'based'on'both'
sources,'and'using'the'total'sample'size'in'GS:SFHS.''
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Figure'6)6'Coded'allele'effect'size'for'DBP'in'the'different'adjustment'models.''
SNP'names'are'shown'to'the'left,'and'loci'to'the'right,'with'statistically'significant'loci'for'
DBPO'underlined.'
Abbreviations,'DBPU:'Unadjusted'(i.e.'measured)'DBP,'DBPP:'BP)adjustment'was'based'on'
EPRs'only,'DBPQ:'BP)adjustment'was'based'on'SRMs'only,'DBPR:'BP)adjustment'was'
based'on'both'sources,'DBPO:'BP)adjustment'was'based'on'both'sources,'and'using'the'
total'sample'size'in'GS:SFHS. '
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6.3.3'SNPs'association'test'results'for'MAP'
Testing the association of the reported GWAS SNPs for BP with MAPO has 
revealed nine significant loci at the Bonferroni corrected significance level 
(P<0.0012); all of them except rs13333226 (UMOD) were also reported by Wain 
et al. for association with MAP, plus an association with another 15 SNPs at the 
nominal p value (Table 6-3).These SNPs were located in loci near to MTHFR-
NPPB, FGF5, NPR3-C5orf23, CYP1A1-ULK3, FURIN-FES, and GNAS-EDN3. The 
remaining three loci are near to CACNB2(3'), c10orf107, and UMOD; which were 
originally reported for other BP and hypertension traits. All the tested SNPs were 
in the same direction of effect as reported by the reference study (Figure 6-7). 
The correlation of the coded allele effect size between our estimates and the 
reported effect size in the reference study was very high (r =0.93). 
The number of significant SNPs remained the same across the different 
adjustment models, as the top two SNPs in the full sample size model (MAPO) 
near to CYP1A1-ULK3 and FURIN-FES were also significant in the three smaller 
sample size models (Figure 6-8). The correlation coefficients of the estimated 
effect size from the different adjustment models with the reference study was 
similar (r =0.93) (Figure 6-9). 
The total of phenotypic variance explained by all the genotyped SNPs was 1.6%, 
and the phenotypic variance explained by the significant SNPs only was 0.5%. 
Individually, rs1378942 near to CYP1A1-ULK3 was the SNP that explained the 
largest phenotypic variance (0.13%), with other significant SNPs explaining 0.07-
0.10% each.  
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Table&6(3&SNPs&association&results&for&MAP&
SN# SNP#
locus# Chr#
A1# A2#
GS:SFHS# Reference#study#
A1F# Beta# se# P"value# H2# A1F# Beta# se# P"value#
1" rs17367504" MTHFR0NPPB" 1" G" A" 0.16" 00.50" 0.15" 0.0010" 0.07" 0.17# A0.53# 0.07# 2.00EA16#
2# rs5068# NPPA# 1# G# A# 0.05# A0.58# 0.26# 0.0221# 0.03# A# A# A# A#
3# rs17030613# ST7L# 1# C# A# 0.20# 0.24# 0.14# 0.0971# 0.02# A# A# A# A#
4# rs2932538# MOV10# 1# G# A# 0.76# 0.19# 0.13# 0.1510# 0.02# 0.74# 0.25# 0.06# 8.00EA06#
5# rs2004776# AGT# 1# T# C# 0.26# 0.31# 0.13# 0.0156# 0.05# A# A# A# A#
6# rs1446468# FIGN# 2# A# G# 0.46# A0.20# 0.11# 0.0792# 0.03# 0.53# A0.34# 0.05# 6.00EA12#
7# rs13082711# SLC4A7# 3# T# C# 0.74# A0.09# 0.13# 0.4680# 0.00# 0.80# A0.34# 0.06# 5.00EA09#
8# rs3774372# ULK4# 3# T# C# 0.85# A0.19# 0.16# 0.2300# 0.01# A# A# A# A#
9# rs319690# MAP4# 3# A# G# 0.68# 0.05# 0.13# 0.6720# 0.00# 0.51# 0.30# 0.05# 3.00EA08#
10# rs419076# MECOM# 3# T# C# 0.47# 0.05# 0.11# 0.6380# 0.00# 0.44# 0.34# 0.05# 8.00EA13#
11# rs871606# CHIC2# 4# T# C# 0.89# A0.24# 0.18# 0.1820# 0.01# A# A# A# A#
12# rs1458038" FGF5" 4" T" C" 0.30" 0.46" 0.13" 0.0003" 0.09" 0.30# 0.40# 0.05# 3.00EA14#
13# rs13107325# SLC39A8# 4# T# C# 0.06# A0.52# 0.25# 0.0335# 0.02# 0.12# A0.63# 0.10# 1.00EA10#
14# rs13139571# GUCY1A3AGUCY1B3# 4# C# A# 0.75# 0.38# 0.13# 0.0036# 0.04# 0.74# 0.29# 0.06# 3.00EA07#
15" rs1173771" NPR30C5orf23" 5" G" A" 0.60" 0.40" 0.12" 0.0006" 0.09" 0.53# 0.28# 0.05# 4.00EA09#
16# rs11953630# EBF1# 5# T# C# 0.37# A0.27# 0.12# 0.0206# 0.04# A# A# A# A#
17# rs1799945# HFE# 6# G# C# 0.16# 0.26# 0.16# 0.1030# 0.02# A# A# A# A#
18# rs805303# BAT2ABAT5# 6# G# A# 0.62# 0.09# 0.12# 0.4210# 0.00# A# A# A# A#
19# rs12705390# PIK3CG# 7# A# G# 0.20# 0.14# 0.14# 0.3280# 0.00# A# A# A# A#
20# rs3918226# NOS3# 7# T# C# 0.09# 0.51# 0.20# 0.0123# 0.04# A# A# A# A#
21# rs2071518# NOV# 8# T# C# 0.28# A0.15# 0.13# 0.2230# 0.01# A# A# A# A#
22# rs4373814# CACNB2(5')# 10# G# C# 0.58# A0.11# 0.12# 0.3480# 0.00# A# A# A# A#
23" rs1813353" CACNB2(3')" 10" A" G" 0.66" 0.44" 0.12" 0.0003" 0.07" A# A# A# A#
24# rs4590817# C10orf107# 10# G# C# 0.83# 0.37# 0.15# 0.0131# 0.04# 0.83# 0.58# 0.07# 2.00EA18#
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25" rs1530440" c10orf107" 10" T" C" 0.19" 00.53" 0.14" 0.0003" 0.08" A# A# A# A#
26# rs932764# PLCE1# 10# G# A# 0.43# 0.18# 0.12# 0.1150# 0.01# A# A# A# A#
27# rs11191548# CYP17A1ANT5C2# 10# T# C# 0.92# 0.51# 0.21# 0.0165# 0.03# A# A# A# A#
28# rs2782980# ADRB1# 10# T# C# 0.25# A0.30# 0.13# 0.0207# 0.03# 0.20# A0.34# 0.06# 2.00EA09#
29# rs661348# LSP1/TNNT3# 11# C# T# 0.41# 0.18# 0.12# 0.1240# 0.02# A# A# A# A#
30# rs7129220# ADM# 11# G# A# 0.87# 0.03# 0.17# 0.8480# 0.00# A# A# A# A#
31# rs381815# PLEKHA7# 11# T# C# 0.30# 0.15# 0.13# 0.2370# 0.01# 0.30# 0.30# 0.05# 3.00EA08#
32# rs633185# FLJ32810ATMEM133# 11# G# C# 0.27# A0.41# 0.13# 0.0014# 0.06# 0.32# A0.33# 0.05# 7.00EA10#
33# rs11222084# ADAMTSA8# 11# T# A# 0.37# A0.17# 0.12# 0.1490# 0.01# A# A# A# A#
34# rs17249754# ATP2B1# 12# G# A# 0.82# 0.42# 0.15# 0.0051# 0.04# 0.89# 0.56# 0.07# 1.00EA17#
35# rs3184504# SH2B3,#ATXN2# 12# T# C# 0.50# 0.27# 0.11# 0.0194# 0.03# A# A# A# A#
36# rs653178# SH2B3# 12# T# C# 0.50# A0.29# 0.11# 0.0115# 0.04# 0.59# A0.43# 0.00# 7.00EA20#
37# rs10850411# TBX5ATBX3# 12# T# C# 0.68# 0.33# 0.12# 0.0061# 0.05# A# A# A# A#
38" rs1378942" CYP1A10ULK3" 15" C" A" 0.32" 0.59" 0.12" 1.16E006" 0.13" 0.33# 0.39# 0.05# 2.00EA15#
39" rs2521501" FURIN0FES" 15" T" A" 0.32" 0.50" 0.12" 4.66E005" 0.09" 0.37# 0.34# 0.06# 3.00EA08#
40" rs13333226" UMOD" 16" G" A" 0.19" 00.49" 0.15" 0.0008" 0.07" A# A# A# A#
41# rs12940887# ZNF652# 17# T# C# 0.36# 0.17# 0.12# 0.1470# 0.02# 0.42# 0.25# 0.05# 2.00EA07#
42# rs1327235# JAG1# 20# G# A# 0.49# 0.36# 0.11# 0.0014# 0.08# 0.58# 0.26# 0.05# 4.00EA08#
43" rs6015450" GNAS0EDN3" 20" G" A" 0.13" 0.63" 0.17" 0.0002" 0.10" 0.07# 0.52# 0.07# 2.00EA12#
SNPs#in#bold#are#statistically#significant#(p#value#<0.0012).#
h2%#shows#the#extent#of#phenotypic#variance#explained#by#the#SNP.#
Reference#study#for#MAP#is#Wain#et#al.135"
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Figure'6)7'Effect'size'of'the'coded'allele'for'MAP'in'GS:SFHS'
Blue'circles'show'the'estimated'effect'size'in'GS:SFHS,'and'the'estimated'effect'size'of'the'
reference'study'for'the'reported'SNPs'for'association'with'MAP'are'shown'as'orange'
diamonds.'Bars'around'the'symbols'show'the'95%'CI.'SNP'names'are'shown'in'the'left,'and'
loci'in'the'right,'with'statistically'significant'loci'for'MAPO'underlined''
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Figure'6)8'SNPs'association'results'with'MAP'for'the'different'adjustment'models'
SNPs'that'exceed'the'GS:SFHS'statistic'threshold'(p<0.0012),'represented'as'red'dotted'line'in'the'figure,'for'MAP'are'in'colour'and'labelled'with'the'locus'
name,'the'remaining'non'significant'SNPs'are'in'greyscale'with'dotted'lines.'Abbreviations,'Unadjusted'(i.e.'measured)'MAP,'MAP'P:'BP)adjustment'was'
based'on'EPRs'only,'MAP'Q:'BP)adjustment'was'based'on'SRMs'only,'MAP'R:'BP)adjustment'was'based'on'both'sources,'MAP'O:'BP)adjustment'was'based'
on'both'sources,'and'using'the'total'sample'size'in'GS:SFHS.'
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Figure'6)9'Coded'allele'effect'size'for'MAP'in'the'different'adjustment'models.'
SNP'names'are'shown'to'the'left,'and'loci'to'the'right,'with'statistically'significant'loci'for'
MAPO'underlined.'
Abbreviations,'MAPU:'Unadjusted'(i.e.'measured)'MAP,'MAPP:'BP)adjustment'was'based'on'
EPRs'only,'MAPQ:'BP)adjustment'was'based'on'SRMs'only,'MAPR:'BP)adjustment'was'
based'on'both'sources,'MAPO:'BP)adjustment'was'based'on'both'sources,'and'using'the'
total'sample'size'in'GS:SFHS.'' '
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6.3.4'SNPs'association'test'for'PP'
Only rs12705390 near to PIK3CG was significant with PPO at the Bonferroni 
corrected significance level (P<0.0012); this SNP is in complete LD with 
rs17477177 that was reported by the reference study for association with PP 
(Table 6-4).The direction of effect for the coded allele was in the same 
direction as reported in the reference study, with a high correlation coefficient 
(r =0.9) for the size of the effect (Figure 6-10). In the other adjustment models, 
rs11222084 near to ADAMTS-8 was statistically significant with PPP but the 
association vanished after increasing the sample size in the overall model PPO, 
as well as with the other two adjustment models (i.e. PPR and PPQ) (Figure 
6-11). The estimated effect size across the different adjustment models with 
the reference study were very similar (r ≈ 0.73), except for the overall model 
which was highly correlated with the reference study (r =0.9) (Figure 6-12) The 
genotyped SNPs explained only 0.8% of the total phenotypic variance in PPO, 
with the only significant SNP near to PIK3CG (rs12705390) explained the highest 
proportion of the variance individually (0.07%). 
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Table&6(4&SNPs&association&results&for&PP&
SN# SNP# locus# Chr# A1# A2#
GS:SFHS# Reference#study#
A1F# Beta# se# P"value# H2# A1F# Beta# se# P"value#
1# rs17367504# MTHFRFNPPB# 1# G# A# 0.16# F0.35# 0.16# 0.03# 0.02# F# F# F# F#
2# rs5068# NPPA# 1# G# A# 0.05# F0.57# 0.27# 0.03# 0.02# F# F# F# F#
3# rs17030613# ST7L# 1# C# A# 0.20# 0.04# 0.15# 0.79# 0.00# F# F# F# F#
4# rs2932538# MOV10# 1# G# A# 0.76# 0.07# 0.14# 0.59# 0.00# F# F# F# F#
5# rs2004776# AGT# 1# T# C# 0.26# 0.10# 0.14# 0.48# 0.00# F# F# F# F#
6# rs1446468# FIGN# 2# A# G# 0.46# F0.02# 0.12# 0.88# 0.00# F# F# F# F#
7# rs13082711# SLC4A7# 3# T# C# 0.74# F0.18# 0.14# 0.20# 0.01# F# F# F# F#
8# rs3774372# ULK4# 3# T# C# 0.85# 0.26# 0.17# 0.13# 0.01# F# F# F# F#
9# rs319690# MAP4# 3# A# G# 0.68# 0.20# 0.13# 0.13# 0.01# F# F# F# F#
10# rs419076# MECOM# 3# T# C# 0.47# F0.08# 0.12# 0.49# 0.00# F# F# F# F#
11# rs871606# CHIC2# 4# T# C# 0.89# 0.40# 0.19# 0.04# 0.02# 0.85# 0.43# 0.08# 1.00EF08#
12# rs1458038# FGF5# 4# T# C# 0.30# 0.39# 0.13# 0.0034# 0.05# F# F# F# F#
13# rs13107325# SLC39A8# 4# T# C# 0.06# F0.04# 0.26# 0.88# 0.00# F# F# F# F#
14# rs13139571# GUCY1A3FGUCY1B3# 4# C# A# 0.75# F0.01# 0.14# 0.95# 0.00# F# F# F# F#
15# rs1173771# NPR3FC5orf23# 5# G# A# 0.60# 0.23# 0.12# 0.07# 0.02# 0.53# 0.28# 0.05# 5.00EF09#
16# rs11953630# EBF1# 5# T# C# 0.37# F0.26# 0.12# 0.04# 0.02# F# F# F# F#
17# rs1799945# HFE# 6# G# C# 0.16# 0.00# 0.17# 0.98# 0.00# F# F# F# F#
18# rs805303# BAT2FBAT5# 6# G# A# 0.62# F0.03# 0.12# 0.80# 0.00# F# F# F# F#
19# rs12705390*# PIK3CG# 7# A# G# 0.20# 0.52# 0.15# 0.0005# 0.07# 0.17# 0.42# 0.06# 2.27EF13#
20# rs3918226# NOS3# 7# T# C# 0.09# 0.03# 0.22# 0.91# 0.00# F# F# F# F#
21# rs2071518# NOV# 8# T# C# 0.28# 0.28# 0.13# 0.03# 0.03# 0.18# 0.31# 0.05# 4.00EF09#
22# rs4373814# CACNB2(5')# 10# G# C# 0.58# 0.23# 0.12# 0.06# 0.02# F# F# F# F#
23# rs1813353# CACNB2(3')# 10# A# G# 0.66# 0.34# 0.13# 0.01# 0.04# F# F# F# F#
24# rs4590817# C10orf107# 10# G# C# 0.83# 0.15# 0.16# 0.36# 0.01# F# F# F# F#
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#
25# rs1530440# c10orf107# 10# T# C# 0.19# F0.20# 0.15# 0.18# 0.01# F# F# F# F#
26# rs932764# PLCE1# 10# G# A# 0.43# 0.26# 0.12# 0.03# 0.03# F# F# F# F#
27# rs11191548# CYP17A1FNT5C2# 10# T# C# 0.92# 0.28# 0.22# 0.22# 0.01# 0.94# 0.53# 0.08# 8.00EF11#
28# rs2782980# ADRB1# 10# T# C# 0.27# F0.08# 0.14# 0.55# 0.00# F# F# F# F#
29# rs661348# LSP1/TNNT3# 11# C# T# 0.41# 0.27# 0.12# 0.03# 0.03# F# F# F# F#
30# rs7129220# ADM# 11# G# A# 0.87# F0.26# 0.18# 0.14# 0.01# 0.87# F0.38# 0.08# 4.00EF07#
31# rs381815# PLEKHA7# 11# T# C# 0.29# 0.34# 0.13# 0.01# 0.04# 0.3# 0.24# 0.05# 7.00EF06#
32# rs633185# FLJ32810FTMEM133# 11# G# C# 0.27# F0.25# 0.13# 0.07# 0.02# F# F# F# F#
33# rs11222084# ADAMTSF8# 11# T# A# 0.37# 0.36# 0.12# 0.0044# 0.05# 0.37# 0.34# 0.05# 2.00EF11#
34# rs17249754# ATP2B1# 12# G# A# 0.82# 0.42# 0.16# 0.01# 0.04# 0.89# 0.39# 0.06# 6.00EF10#
35# rs3184504# SH2B3,#ATXN2# 12# T# C# 0.50# 0.00# 0.12# 0.98# 0.00# F# F# F# F#
36# rs653178# SH2B3# 12# T# C# 0.50# F0.01# 0.12# 0.94# 0.00# F# F# F# F#
37# rs10850411# TBX5FTBX3# 12# T# C# 0.68# 0.31# 0.13# 0.01# 0.03# F# F# F# F#
38# rs1378942# CYP1A1FULK3# 15# C# A# 0.32# 0.13# 0.13# 0.30# 0.01# F# F# F# F#
39# rs2521501# FURINFFES# 15# T# A# 0.32# 0.34# 0.13# 0.01# 0.04# F# F# F# F#
40# rs13333226# UMOD# 16# G# A# 0.19# F0.43# 0.16# 0.01# 0.04# F# F# F# F#
41# rs12940887# ZNF652# 17# T# C# 0.36# 0.05# 0.13# 0.67# 0.00# F# F# F# F#
42# rs1327235# JAG1# 20# G# A# 0.49# 0.36# 0.12# 0.0028# 0.05# F# F# F# F#
43# rs6015450# GNASFEDN3# 20# G# A# 0.13# 0.40# 0.18# 0.03# 0.03# 0.07# 0.35# 0.07# 2.00EF06#
*#SNP#in#bold#is#statistically#significant#(p#value#<0.0012),#which#is#in#a#complete#LD#with#SNP#rs17477177#reported#by#Wain#LV#et#al.#for#association#with#PP.#
h2%#shows#the#extent#of#phenotypic#variance#explained#by#the#SNP.#
Reference#study#is#135#
 
216 
 
!
Figure!6)10!Effect!size!of!the!coded!allele!for!PP!in!GS:SFHS!
Blue!circles!show!the!estimated!effect!size!in!GS:SFHS,!and!the!estimated!effect!size!of!the!
reference!study!for!the!reported!SNPs!for!association!with!PP!are!shown!as!orange!
diamonds.!Bars!around!the!symbols!show!the!95%!CI.!SNP!names!are!shown!in!the!left,!and!
loci!in!the!right,!with!statistically!significant!loci!for!PPO!underlined.
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Figure'6)11'SNPs'association'results'with'PP'for'the'different'adjustment'models.'
SNPs'that'exceeds'the'GS:SFHS'statistic'threshold'(p<0.0012),'represented'as'red'dotted'line'in'the'figure,'for'PP'are'in'colour'and'labelled'with'the'locus'
name,'the'remaining'non'significant'SNPs'are'in'greyscale'with'dotted'lines.'Abbreviations,'PPU:'Unadjusted'(i.e.'measured)'PP,'PPP:'BP)adjustment'was'
based'on'EPRs'only,'PPQ:'BP)adjustment'was'based'on'SRMs'only,'PPR:'BP)adjustment'was'based'on'both'sources,'PPO:'BP)adjustment'was'based'on'
both'sources,'and'using'the'total'sample'size'in'GS:SFHS.''
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Figure'6)12'Coded'allele'effect'size'for'PP'in'the'different'adjustment'models.'
SNP'names'are'shown'to'the'left,'and'loci'to'the'right,'with'statistically'significant'loci'for'
PPO'underlined.'
Abbreviations,'PPU:'Unadjusted'(i.e.'measured)'PP,'PPP:'BP)adjustment'was'based'on'EPRs'
only,'PPQ:'BP)adjustment'was'based'on'SRMs'only,'PPR:'BP)adjustment'was'based'on'both'
sources,'PPO:'BP)adjustment'was'based'on'both'sources,'and'using'the'total'sample'size'in'
GS:SFHS.! '
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6.3.5'Association'of'genetic'risk'scores'with'BP'traits'
All the four GRSs were significantly associated with the four BP traits, except for 
the GRS of PP that was significantly associated with SBP and PP only (Table 6-5). 
Effect size of the different GRS ranged from 0.29-1.33 mmHg, with DBP GRS 
having the highest effect size on SBP level, as each one unit increases in GRS of 
DBP increases SBP level by 1.33 mmHg (95% CI: 1.13–1.53 mmHg). Classifying 
individuals based on their GRS (i.e. ±1&2 SD) and plotting the deviation from the 
mean of BP showed that difference between the group with highest GRS and the 
group with the lowest GRS can reach up to 7.2 mmHg in SBP. Subjects in the 
highest SBP GRS group had a mean of SBP that is above the population’s mean by 
3 mmHg, and subjects in the lowest SBP GRS group had a mean of SBP that the 
below the population’s mean by 4.5 mmHg. Similar findings were observed for 
the other BP traits (Figure 6-13 & Figure 6-14). All the four GRSs showed a 
significant linear trend for higher mean BP levels with higher GRS groups 
(p<7.5x10-10). !
Hypertension GRS was also associated with higher prevalence of hypertension, as 
represented by a prevalence of 44% in the fourth quartile compared to 34% in 
the first quartile (Figure 6-15). This was also observed with the prvelance of 
treatment and awareness across the GRS quartiles were the fourth quartile had 
higher prevalence of trerated hypertension and awareness (Figure 6-16 & Figure 
6-17). For controlled hypertension, the prevalence of controlled hypertension 
were lower in the third and fourth quartiles of GRS (Figure 6-18), but a linear 
trend of assocaition was not statically significant. 
  
220 
 
 
 
Table'6)5'Association'of'the'GRS'with'BP'traits'
!
!
!
GRS!
SBP!level! DBP!level! MAP!level! PP!level!
β!
(95%!CI)! P4value!
β!!
(95%!CI)! P!4value!
β!!
(95%!CI)! P4value!
β!!
(95%!CI)! P4value!
SBP! 0.85!(0.7240.97)! 8.67E439!
0.56!
(0.4740.64)! 3.07E440!
0.65!
(0.5640.74)! 2.09E445!
0.29!
(0.2040.38)! 7.62E411!
DBP! 1.33!(1.1341.53)! 2.21E438!
0.91!
(0.7841.04)! 3.40E443!
1.05!
(0.9141.19)! 4.43E447!
0.42!
(0.2840.56)! 2.86E409!
MAP! 1.18!(0.9741.40)! 8.51E427!
0.80!
(0.6640.94)! 1.04E429!
0.93!
(0.4841.08)! 1.64E432!
0.38!
(0.2340.53)! 6.11E407!
PP! 1.00!(0.6041.39)! 7.86E407!
0.21!
(40.054
0.46)!
0.11! 0.47!(0.1940.75)! 0.01!
0.79!
(0.5241.06)! 1.28E408!
Columns!represent!the!BP!traits,!and!rows!represent!the!GRS!
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Figure'6)13'GRS'for'SBP'and'DBP.'
The'top'figure'shows'the'deviation'in'SBP'(mmHg)'from'the'mean'SBP,'and'the'bottom'
figure'shows'the'deviation'in'DBP'(mmHg)'from'the'mean'DBP,'represented'by'the'solid'
line'and'symbols.'The'dotted'lines'and'whiskers'above'and'below'the'solid'line'represent'
the'upper'and'lower'95%'CI,'respectively.'The'shaded'bars'show'sample'size'for'each'GRS'
category.'The'p'values'for'slope'across'GRS'were'highly'significant'for'linear'trends:'
3.99x10)28,'and'3.84x10)33'for'SBP'versus'SBP'GRS,'and'DBP'versus'DBP'GRS,'respectively.''
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Figure'6)14'GRS'for'MAP'and'PP'
The'top'figure'shows'the'deviation'in'MAP'(mmHg)'from'the'mean'MAP,'and'the'bottom'
figure'shows'the'deviation'in'PP'(mmHg)'from'the'mean'PP,'represented'by'the'solid'line'
and'symbols.'The'dotted'lines'and'whiskers'above'and'below'the'solid'line'represent'the'
upper'and'lower'95%'confidence'interval,'respectively.'The'shaded'bars'show'sample'size'
for'each'GRS'category.'The'p'values'for'slope'across'GRS'were'all'highly'significant'for'
linear'trends:'1.80x10)21,'and'7.56x10)10'for'MAP'versus'MAP'GRS,'and'PP'versus'PP'GRS,'
respectively.''
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Figure'6)15'Prevalence'of'hypertension'by'GRS'Quartiles.'
Markers'shows'the'prevalence'of'hypertension'in'each'GRS'quartiles'with'95%'CI_'
horizontal'line'shows'the'p'value'for'linear'trend.'
 
Figure'6)16'Hypertension'treatment'by'GRS'Quartiles.'
Markers'shows'the'prevalence'of'hypertension'in'each'GRS'quartiles'with'95%'CI_'
horizontal'line'shows'the'p'value'for'linear'trend.' '
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Figure'6)17'Hypertension'controlled'by'GRS'Quartiles'
Markers'shows'the'prevalence'of'hypertension'in'each'GRS'quartiles'with'95%'CI_'
horizontal'line'shows'the'p'value'for'linear'trend.'
 
Figure'6)18'Hypertension'awareness'by'GRS'Quartiles'
Markers'shows'the'prevalence'of'hypertension'in'each'GRS'quartiles'with'95%'CI_'
horizontal'line'shows'the'p'value'for'linear'trend.'
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6.4'Discussion'
The association of the previously identified SNPs in the large GWAS of BP was 
tested in one of the largest national family-based cohorts. We replicated the 
association for 11 SNPs at a stringent Bonferroni-corrected significance level, 
with directional consistency for almost all SNPs with the reported allele effect 
size and direction. The replicated SNPs at the Bonferroni-corrected significance 
level were nine SNPs for SBP (MTHFR-NPPB, FGF5, NPR3-C5orf23, CACNB2(3'), 
CYP1A1-ULK3, FURIN-FES, JAG1, GNAS-EDN3, and UMOD), six SNPs for DBP 
(FGF5, NPR3-C5orf23, CYP1A1-ULK3, FURIN-FES, GNAS-EDN3, and c10orf107), 
nine SNPs for MAP (MTHFR-NPPB, FGF5, NPR3-C5orf23, CYP1A1-ULK3, FURIN-
FES, GNAS-EDN3, CACNB2(3'), c10orf107, and UMOD), and one SNP with PP 
(PIK3GG). For some of these loci, the associations identified in this study were 
not found with the primary BP traits reported in the reference study. For 
example, a significant association for the UMOD locus with SBP and MAP was 
found, which has not been reported previously. Assessing the effect of BP-
treatment adjustment source on the association analyses has showed only a 
minimal impact of treatment exposure source compared to the effect of 
increasing sample size. The association of GRSs with BP traits were all 
statistically significant, with a linear trend of having higher BP levels in people 
of the highest extreme GRS.  
6.4.1'SNP'association'with'BP'traits'
The association of rs17367504 (MTHFR-NPPB) with SBP was first reported by the 
Global BPgen consortium for association with SBP, and then validated by the 
ICBP study which found a further significant association with DBP and 
hypertension.107,133 This SNP is located in an intron of the MTHFR 
(methylnetetrahydrofolate reductase) gene in a region with many plausible 
candidate genes including MTHFR, CLCN6, NPPA, NPPB and AGTRAP. The 
precursors for the hormone atrial- and B-type natriuretic peptides (ANP, BNP) 
encoded by NPPA and NPPB is located near to this region, which contains rs5068 
(modestly correlated [r =0.26] with rs17367504) that was also found to be 
associated with plasma ANP, BNP, and BP.134 In this study, rs5068 was associated 
with SBP, MAP, and PP at the nominal p value only. Population-based studies 
have also showed that genetically determined increased circulating 
226 
 
concentration of ANP and BNP are associated with lower BP, and reduced risk of 
hypertension than genetic variants exhibiting lower peptide concentrations.271 
Interestingly, the findings of these GWAS were also corroborated by revealing 
the underlying molecular mechanisms by which a single base pair change in the 
NPPA gene (rs5068) prevents the binding of MicroRna-425 in subjects carrying 
the G allele and results in higher ANP levels.272 This is consistent with the 
hypothesis that the risk allele reduces ANP levels, and hence increases BP level. 
Furthermore, abnormality in the natriuretic peptide system has been associated 
with obesity, type 2 diabetes mellitus, glucose intolerance and essential 
hypertension.271  
SNP rs1458038 lies 3.4 kb upstream of FGF5 (fibroblast growth factor 5), which is 
a member of the fibroblast growth factor (FGF) family that stimulates cell 
growth and proliferation in multiple cell types, including cardiomyocytes and 
has been associated with angiogenesis in the heart.133 The locus was first 
reported in Global BPgen for association with DBP and rs16998073, which is in 
complete LD with the genotyped SNP in this study. The two ICBP studies have 
also confirmed the association with SBP, DBP, and MAP.107,135 Studies in the East 
Asian populations have replicated the association of this variant with BP 
traits.137,147 In this thesis, this variant was associated with three BP traits: SBP, 
DBP, and MAP, with the strongest association signal for SBP. It was also the 
variant with the highest variance explained individually (h2 =0.1%, for SBP). In 
the Pharmacogenomic Evaluation of Antihypertensive Responses Study, the 
association of this SNP has reached a nominal significance level (p <0.05) for 
association with better response to atenolol and hydrochlorothiazide therapies, 
with genotype effects in opposite directions as individuals with the risk allele for 
hypertension (T) responded better to atenolol than hydrochlorothiazide.273 This 
represents one of the very few GWAS SNPs that has showed some 
pharmacogenetic effects. 
The second locus found was to be associated with three BP traits (SBP, DBP, and 
MAP) in this study is located near NPR3 (rs1173771). This SNP was first reported 
by the ICBP study for association with SBP, DBP and HTN in the European 
populations, and then replicated in the second ICBP study for association with 
SBP, MAP and PP.107,135 This association were also reported in other populations, 
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such as East Asian and African American populations.137,274 This locus encodes 
the natriuretic peptide clearance receptor (NPR-C), in which knockout mice 
exhibit reduced clearance of circulating natriuretic peptides and lower BP.107 
The family of natriuretic peptides elicit a number of vascular, renal, and 
endocrine effects that are important in the maintenance of BP and extracellular 
fluid volume. These effects are mediated by specific binding of the peptides to 
cell surface receptors in the vasculature, kidney, adrenal, and brain. 
SNP rs12705390 was the only significant SNP associated with PP in our study. 
This SNP is in complete LD with SNP rs17477177 reported by the ICBP study for 
association with PP, and the same SNP genotyped in this study was recently 
reported for association with LTA-SBP and LTA-PP by Ganesh et al.135,140 This 
variant is located 94 kb upstream of PIK3CG that encodes the phosphoinositide-
3-kinase, catalytic, γ polypeptide protein (PI3Kγ). This protein phosphorylates 
phosphoinositides and modulates extracellular signals, including those elicited 
by E-cadherin–mediated cell–cell adhesion, which plays an important role in 
maintenance of the structural and functional integrity of epithelia.38 Another 
association for PP was found for rs11222084 near to ADAMTS8, but this 
association was only significant for PPP and only at nominal p-values for the full 
model (PPO) (p-value =0.0044). This locus was also reported in the ICBP study for 
association with PP, and is located 1.6 kb downstream of ADAMTS8, which is 
highly expressed in macrophage-rich areas of human atherosclerotic plaques and 
may affect extracellular matrix remodeling.135 
The locus CACNB2 that contains SNP rs1813353 was first identified by the 
CHARGE study for association with DBP. The CHARGE study reported the 
association with rs11014166, which is in complete LD with rs1813353 (r =1).133 
The ICBP then validated the association and reported an association with SBP 
and hypertension.107 Furthermore, the ICBP identified another independent SNP 
at the same locus, rs4373814, which was also genotyped in GS:SFHS but showed 
no significant association with any BP traits. The LTA study has lately reported 
the association of rs12258967 (r =0.69, with rs1813353) with SBP, DBP, and 
MAP.140 This locus was also replicated in the Chinese population.156 CACNB2 
encodes the β2-subunit of a voltage-gated calcium channel, and is expressed in 
the cardiovascular tissue and a loss-of-function missense mutation in CACNB2 
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was identified in affected individuals with Brugada syndrome.275 Variants in the 
promoter of CACNB2 have shown evidence of pharmacogenetic effects in the 
INVEST-GENES cohort, as Caucasian patients taking CCBs (verapamil) who were 
homozygotes for the minor allele had increased risk of adverse cardiovascular 
outcomes relative to patients with AA, or AG genotypes.276 This finding was also 
validated in Hispanic patients in the same study, and supported by an in vitro 
functional study that showed a significant increase in luciferase activity 
associated with the G allele, suggesting an increase in transcriptional activity 
compared to the A allele. However, the study did not replicate their findings in 
an independent sample. 
SNP rs1530440 near to C10orf107 was also replicated in GS for association with 
DBP and MAP. This SNP was first identified in the Global BPgen for association 
with DBP only, and then replicated in the ICBP SNPs along with another SNP that 
is in moderate LD with the Global BPgen (rs4590817, r =0.59).107,133 Two other 
SNPs that are in moderate LD were also reported in the LTA study for association 
with LTA-DBP, LTA-MAP, and LTA-SBP.140 These SNPs are located in 10q21, which 
is intronic and belongs to cluster of SNPs in C10orf107, an open reading frame of 
unknown function. This region has no clear neighbouring candidate genes of 
functional implication in BP.  
The second SNP in this study that was found to be associated with three BP 
traits was rs1378942, in 15q24.1. This SNP was even associated with DBP and 
MAP in all the three differently adjusted models for BP-treatment exposure 
source models, using a smaller sample size (n =12,347). This locus was 
replicated in the two ICBP studies for association with SBP, DBP, and MAP, after 
it was first identified by the CHARGE study for association with DBP only. 
CHARGE reported the association with rs6495122 (r =0.70, versus 
rs1378942).107,115,135 These SNPs cluster are located in the intron region of CSK 
(c-sre tyrosine kinase), and nearby genes include CYP1A2 (cytochrome P450 
enzyme), LMAN1L (lectin mannose- binding1 like) and ARID3B (encoding AT-rich 
interacting domain protein). CYP1A2 is one of the major CYPs in human liver 
that are responsible for drug and xenobiotic chemical metabolisms, such as 
caffeine, theophylline, propranolol, and verapamil. A study in 553 young White 
individuals showed that the risk of hypertension associated with coffee intake 
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varied according to CYP1A2 genotypes, with individuals carrying the allele with 
lower enzyme activity having higher risk of hypertension.277 The association of 
CYP1A2 variants with hypertension was also found to be modified by smoking 
status, as smoking is a well-known CYP1A2 inducer. The three CYP1A2 variants, 
including rs1378942, were associated with hypertension in non-smokers only, 
and higher CYP1A2 activity was linearly associated with lower BP after quitting 
smoking.278 In non-smokers, these variants were associated with higher reported 
caffeine intake, lower odds of hypertension and lower BP. This study has applied 
a Mendelian randomization approach to provide some evidence that caffeine 
intake is a modifiable factor for the observed association between CYP1A2 
variants and BP.278 It must be noted that care is required when interpreting the 
results from Mendelian randomization studies when the direct product of the 
gene is not explored, as several conditions are needed to infer causality in 
observational epidemiology.279,280 
The third SNP that has showed an association with three BP traits was rs2521501 
near to FURIN, which was firstly identified by the ICBP study for association with 
SBP and DBP, and then replicated in the second ICBP study with additional 
association with MAP.107,135 In this study, rs2521501 is the only SNP that was 
statistically significant with all the different treatment adjustment models for 
SBP, and with rs1378942 for MAP. Variants in FURIN were also found to be 
significantly associated with metabolic syndrome in Japanese individuals.281 A 
very recent genome-wide expression quantitative trait loci study has also 
reported an independent variant in the FURIN locus associating a lower 
expression of FURIN with increased BP, possibly by increasing systemic vascular 
resistance.282 Rs2521501is 11kb downstream of FURIN, an enzyme that belong to 
the proprotein convertase subtilisin/kexin (PCSK) family, a type 1 membrane-
bound protease that processes latent precursor proteins into their biologically 
active protein and peptides, and encodes a type-1 membrane bound protease 
that is expressed in many tissues including neuroendocrine, liver, gut, and brain. 
FURIN was also found to be able to convert the (pro)renin receptor (PRR) into its 
active and soluble forms in the plasma.283 Although, the importance of PRR in 
hypertension has been documented in different studies, the physiological roles 
of the PRR remain undetermined because the construction of PRR knockout mice 
has not been successful.284  
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UMOD is one locus that was identified from a GWAS using a dichotomous 
hypertension trait; this study used the BP-extreme approach to allow the 
maximum phenotypic separation between cases and control, and reported 
rs13333226, located in the promoter region of UMOD.82 The BP-extreme study 
reported a suggestive association with SBP and DBP, with a direction of effect 
that is consistent with the odds of hypertension. A statistically significant 
association for this SNP with any BP quantitative trait has not been replicated by 
other studies. However, in this thesis a statistically significant association for 
rs13333226 is observed with quantitative BP traits (i.e. SBP and MAP). Another 
variant that is in complete LD with this SNP (rs4293393) was also found to be 
associated with serum creatinine concentration, uromodulin concentrations, and 
chronic kidney disease, with a stronger association at older age.285,286 Yet, the 
association with hypertension was shown to be independent of renal function, 
suggesting a possible pleiotropic effect.82 Functional studies in UMOD knockout 
mice showed that UMOD regulates sodium uptake in the thick ascending limb of 
the loop of Henle by modulating the effect of tumour necrosis factor-α on 
NKCC2A expression, making UMOD an important determinant of BP.287 
Significantly, a clear differences was observed in the BP level between UMOD 
knockout mice and wildtype, in that the knockout mice had significantly lower 
BP and were insensitive to salt-induced changes in BP. On the other hand, UMOD 
overexpression in transgenic mice let to salt-sensitive hypertension.288 These 
findings highlight the importance of UMOD as a therapeutic target for lowering 
BP and preserving renal function. 
The SNP rs1327235, was only associated with SBP in our study. This SNP was first 
identified by the ICBP study for association with SBP and DBP, but then 
conversely, in the second ICBP study an association was found only for MAP and 
DBP, but not with SBP.135 An association was also identified in an Asian 
population with both SBP and DBP.139 The SNP is located near to JAG1 (Jagged 1) 
that encodes one of five cell surface ligands in the highly conserved Notch 
signalling pathway, which play a critical role in cellular fate determination and 
is active throughout development and across many organ systems.289 Mutations 
in JAG1 have been associated with several disorders such as the multi-system 
dominant disorder Alagille syndrome, which has cholestatic, skeletal, cardiac, 
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ocular, and facial characteristics and includes renal involvement with 
hypertension.289 
The last SNP that was found to be associated with three BP traits (SBP, DBP, and 
MAP) was rs6015450, which is located in an intergenic region near to endothelin-
3 (EDN3). This SNP was firstly identified by the ICBP study for association with 
SBP, DBP, and hypertension, and was also associated with MAP in the second 
ICBP study.107,135 The LTA study has also reported the association of another 
variant rs6092743 that is in moderate LD (r =0.59, versus rs6015450) with SBP, 
DBP, and MAP.140 EDN3 is a strong candidate for BP regulation, as the 
endothelins are widely expressed vasoactive peptides that exert proliferative, 
inflammatory, and fibrotic changes in blood vessels and other organs involved in 
the regulation of vascular tone and BP.107 GNAS encodes the α-subunit of the 
heterotrimeric G-protein that mediates signal transduction at the β1 and β2 
adrenergic receptors, influencing heart rate and smooth muscle tone. This 
genomic region also harbours a variant with pharmacogenetic effect, as SNP 
rs2273359 was found to influence BP response to hydrochlorothiazide, in which 
carriers of the minor allele G demonstrated consistently greater BP response to 
hydrochlorothiazide than the CC homozygotes (lower BP by 7/5 mm Hg).290 
However, the variant with the pharmacogenetic effect is not in LD with the two 
BP-associated variants (r2 = 0.003, 189 kb apart). All these variants are 
intergenic and are unlikely to be the functional variant, suggesting that they 
may be in LD with undiscovered functional variants that influence gene 
expression or protein structure.  
All the significant variants for SBP and DBP in our study were also significant in 
the Finnish study, except for the association of rs13333226 in UMOD with SBP 
and DBP, and for the association of rs2521501 in FURIN-FES with DBP.263 Several 
other loci were significant only in the Finnish Study, which has replicated 22 loci 
out of the 32 tested variants. This discrepancy maybe due the difference in 
sample size between the two studies, as the Finnish Study was larger by more 
than 14,000 subjects. Also, population-specific genetic factors may play roles as 
demonstrated by finding significant association with UMOD in GS:SFHS only. It is 
impoartant to note that SNPs effect sizes in our study were compared aginst the 
effect sizes of the combined phase (i.e. joint phase) in the references study, as 
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the estimated effect size of the discovery phase would be inflated due to 
winner’s curse.  
6.4.2'Influence'of'phenotype'measurement'errors'on'association'
signal'
In the second aim of this study, the influence of BP-treatment exposure source 
on the SNP association signals was assessed by constructing three models; the 
same sample was used in the three models to eliminate any effect of sample 
size, while keeping the random model to mimic the phenotypic noise in the 
overall model. To the best of our knowledge, there is no study that assessed the 
effect of BP-treatment exposure source in the genetic association signals using a 
real dataset. Several studies have assessed the concordance between SRMs 
history and clinical data, and showed a good concordance for antihypertensive 
medication particularly, and for medication of chronic use generally (discussed 
in Section 4.5.1 -p160). However, assessing if the association signals can be 
distorted by incorrect treatment adjustment in some individuals as a result of 
incorrect classification (i.e. treated\not treated) has never been done 
previously. Generally, this analysis demonstrated that SBP and DBP were more 
sensitive to treatment adjustment errors than MAP, which was the least affected 
with the same replicated SNPs in the two models.!
A summary of the concordance results is revisited here to enable a better 
understanding of the results (discussed in Section 4.5.1 -p160). The concordance 
between the two treatment-exposure sources at the full sample level was found 
to be 94% (kappa statistics =78%, Appendix 2 -p251). For 13.1% of individuals, 
the two adjustments were similar and there was no difference in their 
classification (i.e. treated or not) between the two sources. Hence, adding a 
fixed value of 15/10 mmHg to their observed BP levels was justified by the two 
treatment-exposure sources. For participants with discordant treatment status, 
however, care is needed in interpreting the results as it depends on whether one 
source can be considered as superior or not. Generally, EPRs are considered a 
superior source to measure medication exposures, especially if participants have 
no access to BP-lowering medication without obtaining a prescription. Thus, the 
self-reported method had incorrectly classified 4.4% of the sample as treated, 
leading to unnecessarily adjustment in these subjects, and missed 1.5% of the 
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sample in which no adjustment was made. In total, the misclassification or 
phenotypic errors introduced to the BP phenotypes by adjusting the treatment 
based on self-reported methods was about 6%. 
This study reinforces the findings from other studies of the importance of having 
accurate phenotypic characterisation, particularly for complex traits such as BP 
that are sensitive to several factors. BP phenotypes derived from treatment 
adjustment on the basis of EPRs can be considered more accurate than those 
adjusted on the basis of SRMs. Hence, finding an association signal with SBPP 
that is not replicated in SBPQ would imply that phenotypic noise introduced by 
BP adjustment in SBPQ has altered the statistical power, and the similar concept 
can be applied to the remaining BP traits. For SBP, FGF5 and FURIN-FES were 
significant with SBPQ, but only FURIN-FES remained significant when using SBPP. 
Similarly, CYP1A1-ULK3 and FURIN-FES were significant with DBPQ, but only 
CYP1A1-ULK3 remained significant with DBPP. For MAP, however, the same two 
loci (CYP1A1-ULK3 and FURIN-FES) remained significant in both MAPP and MAPQ. 
For PP, ADAMTS8 was found significant only with PPP. These observation implies 
that MAP was more robust to the effect of phenotypic noise as introduced by the 
different adjustment sources. Moreover, FURIN-FES was found significant even 
with unadjusted MAP that was calculated from the observed BP values, 
supporting the finding that MAP is less impacted by the treatment status.  
This analysis has shown that MAP may provides a better phenotype for genetic 
association analysis than SBP and DBP, as it was least affected by the phenotypic 
errors introduced by treatment adjustment. In addition, using MAP as a 
phenotype has captured all the significant SNPs that were also found to be 
associated with SBP, DBP, or both of them; with the exception of one SNP that 
was associated with SBP only (rs1327235, near to JAG1). These findings were 
consistent with previous results in the two ICBP studies, in which the first ICBP 
study reported the association of 29 SNPs with SBP, DBP or both; and the second 
ICBP study reported a further 8 new loci that were associated with PP and 
MAP.107,135 Importantly, of the 22 SNPs that were associated with both of SBP 
and DBP in the first ICBP, the second ICBP has replicated the association with 
MAP for 18 SNPs. For the remaining four SNPs, three of them (MOV10, BAT2-
BAT5, CACNB2(5')) were not even significant with any of SBP or DBP, and the 
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fourth SNP near to ZNF652 was found significant with DBP only in the second 
ICBP (Appendix 6 - p255). Furthermore, a significant association with MAP was 
also reported with SLC4A7 that was associated with DBP only in the first ICBP. 
These findings emphasize that SNPs reported for association with MAP are more 
likely to reflect physiological pathways related to both SBP and DBP [and are 
less likely to be influenced by slight phenotypic errors].  
The four BP traits (SBP, DBP, MAP, and PP) that were examined in this analysis 
represent different components of BP that specifically reflect distinctive 
hemodynamic factors (discussed in more details in Section1.2.2 -p24). From a 
clinical point of view, it was determined that using a combination of two 
components (SBP and DBP, or MAP and PP) provided a better prediction values 
for CVD than using a single component.20,291 In addition, the combination of SBP 
and DBP has a superior prediction for CVD risk, but the combination of MAP and 
PP provide greater insight into hemodynamics of altered arterial stiffness versus 
impaired peripheral resistance. Unlike the traditional components of BP (SBP 
and DBP), MAP represents a physiological component of BP that reflect the 
product of CO and peripheral resistance minus central venous pressure.20,291 
Furthermore, MAP is highly correlated with both SBP and DBP, with a phenotypic 
correlation of 91% and 94% in this study, similar to the reported correlation in 
other studies (Table 5-3 -p182).233 
6.4.3'SNPs'with'potential'pharmacogenetic'effects'
A simulation study performed by Masca et al has showed that methods that 
adjust for BP treatment by adding a fixed value could be biased for genetic 
variants that affect the level of response, leading to false positives or false 
negatives depending on the direction of the pharmacogenetic effect.292 For 
instance, a genetic variant that influences treatment efficacy could yield 
spurious association with BP, or, conversely, a genetic variant that truly 
influences BP could be masked if it is also involved in a pharmacogenetic 
interaction. In the other hand, Mascal et al has also suggested that inference 
about the presence of such interaction could be made by comparing the effect 
size estimate from the measured BP (i.e. the unadjusted model) and the model 
adjusted by adding a fixed value. 292 Hence, the presence of the such interaction 
can be assessed in this thesis by comparing the unadjusted model to the 
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adjusted model (for instance SBPU to SBPR). The random model is chosen here as 
it represents a model with the average effect size of the treatment adjustment. 
Based on Mosac et al simulation study, SNPs with large different in effect size 
between the two models (i.e. adjusted and unadjusted) have potential 
pharmacogenetic effects. 
The top five SNPs with the largest discripincy in the effect size between the two 
models are in loci near to SLC39A8, GNAS-EDN3, MTHFR-NPPB, AGT, and 
C10orf107. The SLC39A8 was reported to be associated with SBP, DBP, HDL, and 
BMI, which shows that this variant may has a pleiotropic effects or influence a 
common pathway that impact these traits.107,293-294 The!GNAS-EDN3 locus has 
been previously reported to have a pharmacogenetic effects, as it was found to 
be associated with BP response to hydrochlorothiazide in black hypertensives.290 
The SNP near to MTHFR-NPPB is pharmocogenetically interesting SNP, 
considering its adjacency to the NPPA/NPPB genes and the concurrent possible 
association with diuretics treatment in particular. The SNP near to AGT is also 
interested for possible pharmacogenetic interaction as the RAAS is a drug target 
for multiple class of antihypertensive drug classes. In the other extrem, the 
bottom five loci with the lowest discripincy between the two models were in 
loci near to SH2B3 (2 SNPs), BAT2-BAT5, CYP17A1-NT5C2, and NOV. These 
variants can be assumed to have a minimial possible pharmacogenetic 
interaction. This exploration of the potential role of pharmacogenetic 
interaction should be further confirmed by biological and clinical evidences. For 
instance, by performeing a clinical trail to assess the presence of such 
pharmacogenetic interaction.   
6.4.4'Impacts'of'genetic'risk'scores'on'BP'traits'
Testing the aggregate association of combined SNPs with the phenotype may 
provide a better prediction for the risk to the disease than a single SNP, as each 
SNP individually is likely to confer a low effect size. The present analysis 
examined the association of four GRSs with the four quantitative BP traits and 
hypertension prevalence, and showed that GRS is positively associated with BP 
level and hypertension prevalence, with an average effect of 0.8 mmHg increase 
per one standard deviation in the significant GRS across the different BP traits. 
The four GRSs were weighted according to previously reported effect estimates, 
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and based on SNPs that showed significant association with each trait only. The 
DBP GRS (i.e. GRS that included significant SNPs for DBP and their weighted 
effect size for DBP) showed the highest effect size for the four BP traits, even 
higher effect size than the match GRS for each trait. For instance, SBP level 
increased only 0.85 mmHg (95%CI: 0.72–0.97) with each one unit of SBP GRS, but 
increased 1.38 mmHg (95%CI: 1.13–1.53) with each one unit of DBP GRS.  
Several studies have assessed the association of the GRS with BP traits, either 
within the same GWAS such as the CHARGE and ICBP studies, or as a separate 
study that aim to replicate the findings of GWAS. The CHARGE Consortium 
assessed the conjoint effect of the top ten SNPs in their study, and showed that 
the variation explained by them was 1%, and that higher GRS was associated 
with higher BP level, which can reach up to 5 mmHg and 3 mmHg for SBP and 
DBP, respectively.115 The ICBP study constructed a GRS based on a higher 
number of SNP (29 SNPs), and observed a strong association with both of SBP and 
DBP in European and non-European ancestry groups (i.e. East-Asian, South Asian, 
and African).107 Furthermore, individuals in the top decile of the GRS had a 
higher prevalence of hypertension (29%) compared with those in the bottom 
decile (16%), and those in the top quintiles had higher SBP and DBP levels by 4.6 
mmHg and 3.0 mmHg, respectively. These GRS were positively associated with 
left ventricular wall thickness, stroke, and coronary artery diseases, but no 
kidney disease or kidney function. In this thesis, higher prevalence of treated 
hypertension and awareness were even observed in those with GRS of the 4 
quartiles. The awareness and treated hypertension may represent a clinically 
diagnosed hypertension that is more strict difention than the study definition of 
hypertension. In the other hand, controlled hypertension has not shown a trend 
in the similar direction of the other indices. This study is the first to assess the 
impact of the GRS on the prevalence of awareness, treatment, and controlled 
hypertension.  
Other studies with smaller sample sizes have also examined the impact of GRS in 
specific-population samples. A longitudinal study of Swedish individuals 
demonstrated a positive association of GRS (based on 29 SNPs) with higher BP 
and incidence of hypertension independently from traditional risk factors; 
however, the result of discrimination analysis does not show any improvement in 
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the prediction of incident hypertension on top of traditional risk factors.295 
Another study in a Finnish population conducted by Havulinna et al. concluded 
that the two GRSs based on the 29 SNPs were strongly associated with risk of 
incident coronary artery disease, stroke and composite CVD.263 These findings 
were also confirmed recently in the Swedish population by findings that GRS was 
independently associated with ischemic stroke in three Swedish case-control 
studies.296 However, both studies reported that GRS did not improve CVD risk 
discrimination over and above the traditional risk factors. A very recent study in 
the Korean population has also reached to the same conclusion, although they 
only used four SNPs in their GRS.297  
While these studies have demonstrated a modest improvement in risk 
discrimination for GRS over the traditional risk factors, the importance of such 
factor should not be disregarded as it has been shown that modest increments in 
BP level, even if based on a single BP measurement, are associated with 
substantial increases in CVD risk.3,5,6 Moreover, individuals with higher GRS are 
consistently exposed to the impact of these genetic variants over their life time, 
meaning that even a small increase in BP may translate into comparatively large 
effect when compounded over a life time. An important factor that needs to be 
considered is the fact that a risk scoring system such as the Framingham Risk 
Score is limited to a specific time-period (between 10 to 30 years), as risk 
factors included in the scores change over time. However, a risk score based on 
GRS is a lifetime score that is invariant over time.  
An important limitation in the application of GRS in this study, and most similar 
studies so far, is not considering any possible interaction between the included 
genetic variants themselves, and/or other factors such as demographic or 
environmental factors. Furthermore, the included variants are from GWAS, 
which often discovers SNPs in genomic regions that have no clear physiological 
impact on BP. Hence, including genetic variants that are identified from newer 
GWAS or pathway-based analysis could improve the prediction of GRS. In 
addition, further studies are required to clarify whether different scores are 
need in different populations, or the need to account for any confounders 
before applying the GRS!
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7' General'discussion'and'conclusion'
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The studies comprising this PhD thesis provide a unique insight into the genetic 
and epidemiological features of hypertension, through a large family-based 
cohort study (GS:SFHS). High BP is the leading risk factor for mortality 
worldwide, responsible for 13% of deaths globally. While more and more people 
are being treated for hypertension, the numbers of people with uncontrolled BP 
remain largely unchanged, and many people still remain undiagnosed. The 
diagnosis, treatment and follow-up of hypertensive patients is a core part of 
primary care workload and successful management of hypertension requires an 
engaged partnership between clinicians and their patients. Hypertension 
epidemiology in terms of prevalence, awareness, treatment and control is 
conducted through health surveys or cohort studies of unrelated individuals, and 
interventions are delivered on an individual basis. The family-design and 
population-based sampling approach taken in GS:SFHS allows investigation of 
genes, environment, and hypertension epidemiology with a valid inference to 
the population. 
The strengths of GS:SFHS include participants that were recruited from across 
Scotland, which has a high prevalence of common diseases such as coronary 
heart disease, stroke, cancer, and diabetes. Even compared to other UK 
countries, Scotland had a higher rate of mortality that is partially explained by 
baseline risk factors. 169 Furthermore, the population in Scotland is relatively 
static and stable, providing an ideal population to measure heritable and 
lifestyle factors for complex traits. Although GS:SFHS cannot be considered truly 
representative of the Scottish population, it includes a large sample size with a 
wide range of socio-economic and clinical features. Furthermore, the 
availability of clinical, self-reported, and prescription data has allowed an 
assessment of management trends of hypertension in this cohort, which can be 
generalized to the Scottish population. While the family-based nature of the 
cohort represents one of the important strengths of GS:SFHS, the availability of 
high-quality DNA samples make it a good candidate for future exome and whole-
genome sequencing analysis. The current study can serve as a first step to 
evaluate the genotypic and phenotypic features of GS:SFHS in relation to BP, 
and inform selection of individuals or families to undergo further detailed 
genomic analysis, such as whole-genome sequencing.  
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A significant variation in hypertension management trends were observed 
between countries and populations, which may reflect different population-
specific factors that may contribute to such variation including genetic, 
environmental, public-health policy, and socio-economic factors. Knowing the 
presence of such variation between populations and countries necessitates a 
cautious interpretation of studies from other populations, and also that each 
population should be independently examined to identify factors playing a role 
in this population. Nevertheless, the importance of lowering BP by either 
pharmacological or non-pharmacological approaches have consistently been 
demonstrated in all populations, such that a 10 mmHg reduction in SBP is 
associated with a 22% reduction in CHD and a 41% reduction in stroke.70 On the 
other hand, even a small incremental increase of 2 mmHg can increase the risk 
of stroke by 10% and CHD by 7%.5 It is therefore important to assess even the 
factors that impose a small effect size, such as common genetic variants. 
A family-cohort design of related individuals with adjustment for family-
clustering would likely account for important residual or unmeasured 
confounding factors, which could bias both the main effect and the interaction 
estimate.167 However, this cannot be ruled out in observational studies as a 
result of differential recall or ascertainment bias. Furthermore, the statistical 
power for gene discovery is likely to be higher in studies containing extended-
pedigree, as they represent a more homogenous sample. Member of families are 
more likely to share both genetic background and environmental factors 
exposure, and hence analysis of phenotypes can be modelled by genetic and 
environmental factors. For genetic background, a polygenic component can be 
modelled based on the genetic background that can be derived as a function of 
the degree of relationship. For instance, monozygotic twins share the extreme 
of genetic background, suggesting that phenotypic variation is to due to 
epigenetic, environmental, or interaction factors. The extent of shared 
background decreases as kinship coefficient decreases, leaving the remaining 
variability to environmental factors. Similarly, close-relatives tend to have more 
homogeneous environmental factors, as they are more likely to be living in the 
same house with similar socioeconomic status, and may share similar lifestyle 
habits such as diet, physical activity, smoking, and alcohol consumption. Whilst 
strictly controlling for these factors as in animal studies is not possible, the 
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residual noise variance is lower in family studies comparing to population studies 
with unrelated individuals. This degree of nature control for both genetic 
background and environmental factors enhances the power to detect novel 
associations as a result of reducing the residual noise variance.167 
The family-based design is typically assumed to be less powerful for genetic 
association studies than a population-based design, because the addition of a 
non-independent subject to the sample is considered not equal to one whole 
extra unrelated person, but only adds a fraction of information depending on the 
degree of familial correlation.167 However, other studies have showed that the 
opposite might actually be true, as the power to detect an effect can be 
increased by including relatives and conducting a multi-level analysis to 
accommodate familial correlation.168 Even the addition of an identical twin that 
has perfectly correlated genotype, phenotype, and residuals cannot be 
considered a redundant duplication, as neither complex phenotypes nor 
residuals are identical in any pair of twins. A critical determinant of study power 
is error variance, where the power to estimate all model parameters is 
increased as the unexplained error variance decreases. For family data, a higher 
proportion of the error variance can be explained by the extra information that 
is not available in unrelated individuals.168 
Family data can offer a deeper level of genotype QC, especially with respect to 
the detection of Mendelian errors. This can also be an important step to detect 
and possibly resolve any sample mix-ups. Moreover, a particular advantage that 
was also applied in this study is to impute the missing genotypes, by inferring 
the most likely genotypes based on the observation in other genotyped relatives. 
This is performed based on information at other markers and family relationship. 
In this study, the imputation was limited to a subset of SNPs that were not 
recalled for technical reasons. However, this approach can be extended to 
impute the genotype of relatives that were not actually genotyped in the study 
with available phenotypes, leading to more efficient and powerful statistical 
test.298 
This study was able to determine the familial risk of hypertension in Scotland, 
showing that subjects with one or two hypertensive parents have 42% or 95% 
higher risk of having hypertension, respectively, compared to participants 
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without any hypertensive parents. Whilst the rates of hypertension awareness 
and treatment in GS:SFHS were, respectively, 25.3% and 31.2%, the rate of 
treated hypertension in GS:SFHS was much lower than the rate of treated 
hypertension reported in the SHeS of 2008/2009 and 2010/2011 (49% and 48%, 
respectively). The rate of controlled hypertension in GS:SFHS was 54.3%, with 
higher rates in women (60%) compared to men (47.8%). Furthermore, parental 
history was inversely associated with control rate, such that participants with 
two hypertensive parents had a lower rate of controlled hypertension. These 
findings open up avenues for further research into implementing hypertension 
care in the community, using family as a unit of intervention, and assessing if 
this can improve awareness and ultimately improve the level of controlled BP 
across the country. 
The availability of self-reported medication and pharmacy refill records allowed 
an assessment of phenotypic accuracy when the hypertension phenotype is 
based on a history of taking antihypertensive therapy. Interestingly, around 10% 
of the hypertensive population reported taking antihypertensive therapy without 
any corroborative evidence from pharmacy data. As all hypertensive drugs in 
Scotland are obtained through pharmacies from primary care prescriptions, it is 
unlikely that these subjects were sourcing their antihypertensive drugs from 
elsewhere. Thus, this indicates the misclassification rate, if SRM was used to 
classify subjects as hypertensive, can be high and indicates the importance of 
corroborating SRM history with other records. Assessment of the SRMs reliability 
before performing epidemiological and genetic analysis allowed an approximate 
estimation of the phenotypic errors. For instance, 4.7% of hypertensive subjects 
were classified as hypertensive only because they have reported taking BP-
lowering medication in SRMs, with no confirmation in EPRs. In quantitative 
analyses, the proportion of participants who were incorrectly exposed/not 
exposed to treatment adjustment was 6%. To the best of our knowledge, these 
findings have not been previously reported for BP-lowering medications, as most 
BP genetic studies had only one source of medication history, and do not assess 
the reliability of treatment status. 
An important step in this study concerned the quality of data available in the 
GS:SFHS, with a range of procedures undertaken to ensure high quality data was 
243 
 
used in the analysis. Amending the PCQ structure with the introduction of some 
questions in the middle of the study recruitment period raised several 
challenges to optimally merge all the information. This led to losing some 
information, due to the inability to combine participants’ answers between the 
two phases. The other challenge was in transforming the inconsistent 
medication names that were hand-written by participants into standard 
medication names to retrieve the participant SRMs in PCQ-1. The availability of 
EPRs and SRMs has allowed a critical step to assess the reliability of reporting 
BP-lowering medications, and the chance to increase sample size to include 
those participants without EPRs in the familial and genetic analyses. Assessing 
the adherence to BP-lowering medication would be possible given the presence 
of these two sources of information; however, the amount of prescribed 
medication (i.e. prescribed pill count) was not available in all the prescriptions, 
and thus it was not possible to calculate the frequency of prescriptions. 
The clinical and health implications of the epidemiological part of this thesis can 
be summarized in as follows: First, although the SHeS has shown some 
improvement in the management trends of hypertension, this study indicates 
significantly more improvement is still needed in the detection and treatment of 
hypertension. Second, the rate of awareness, treatment, and controlled 
hypertension were significantly lower in the least deprived area of Scotland. 
This was in accordance with report from other studies that participants from 
more deprived areas received at least equivalent and sometimes higher quality 
of care for hypertension than those from less deprived areas.227 Hence, further 
work is needed to raise awareness in the least deprived areas about the risk of 
undiagnosed hypertension, as these individuals may make fewer visits for 
doctors and hence have a lower chance of getting their BP reviewed. Third, 
participants with parental history of hypertension were significantly more likely 
to be treated and aware of their hypertension and less likely to be controlled 
compared to those without any parental history of hypertension. Though, for 
controlled hypertension the association was not statistically signifincant.  
Therefore, a history of hypertension should instigate a review of all eligible 
family members for hypertension status and treatment, if required.  
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Several statistical methods were used in this study to assess the familial 
aggregation of hypertension and BP traits. Firstly, the familial influences on the 
hypertension prevalence and treatment were assessed by reporting λS of 1.6, 
and of 2.04, respectively. These values were calculated using a counting method 
that is assumed to be unbiased and consistent when applied to samples that are 
not ascertained via any particular phenotype.243 Secondly, the familial 
correlation of BP traits was much higher among first-degree relatives than other 
types of relatives, with higher correlation between siblings than parent-
offspring, reflecting the level of shared genetics. Thirdly, the heritability of BP 
traits ranged from 24% to 32%, which is within the range reported in other 
populations. The familial aggregation of hypertension and BP can be attributed 
to shared environmental and genetic factors. These two factors can be 
intimately connected and it is difficult to partition their independent influences, 
as some of the environmental factors such as obesity and sodium intake have a 
heritable component themselves. For instance, the bivariate analysis between 
BP traits and BMI showed that shared genetic factors explain 54% of the 
phenotypic correlation. Lastly, the genetic correlation between the different BP 
traits suggests that SBP, DBP, and MAP share common genetic factors, but the 
observed incomplete pleiotropy indicates the presence of an independent set of 
gene(s) controlling each BP components. Interestingly, PP showed the lowest 
correlation with the three remaining BP traits, suggesting that PP may be 
influenced by a different set of genes.  
SNPs association tests were performed using an emerging method that is based 
on LMM approach, to test for association in the presence of sample structure. 
LMM methods perform a total association test that includes both within-family 
and between-family effects, and hence they offer a comprehensive approach 
that has been found to substantially outperform other typical family-based 
statistical methods.265 However, as this study only genotyped a small number of 
markers, pedigree data were used in constructing the GRM rather than genetic 
data. This was done by calculating theoretical pair-wise kinship coefficients 
between each two individuals. Hence, the accuracy of the constructed GRM 
relies on the quality of pedigree records, and is therefore sensitive to errors. An 
alternative approach that is usually applied in large GWAS of unrelated 
individuals with a high density of genotyped markers is to construct GRM on the 
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basis of genotyped markers, rather than being fixed at their known theoretical 
values, as implemented in software such as GCTA.299 The marker-based GRM can 
overcome issues of incomplete pedigree, inbreeding, selection, and drift. 
However, comparing a model fitted with marker-based GRM to a model fitted 
with pedigree-based GRM has showed comparable results.125 Estimating the 
impact of the pedigree-based GRM in our study is not possible without having a 
large number of markers to obtain accurate estimates of both population 
structure and relative kinship within the sample. 
The association of 43 SNPs in 38 loci that were reported in large GWAS meta-
analysis of BP was assessed in GS:FHS, showing 11 SNPs were significantly 
associated with at least one BP trait at a stringent Bonferroni corrected 
significance level (p<0.0012), and 36 SNPs at a nominal p-value (p<0.05). Almost 
all the SNPs showed directional consistency with the reported allele effect size 
and direction in the reference study. SNPs that were statistically significant 
were in loci near the following genes: MTHFR-NPPB, FGF5, NPR3-C5orf23, 
PIK3CG, CACNB2(3’), C10orf107, CYP1A1-ULK3, FURIN-FES, UMOD, JAG1, and 
GNAS-EDN3. All the significant SNPs were associated with the primary traits as 
reported in the reference study, with the exception of the UMOD locus 
(rs13333226) which was found significantly associated with SBP and MAP. The 
UMOD locus (rs13333226) was reported for association with hypertension with 
only a suggestive association with SBP and DBP.82 The total variance explained 
by all the 43 genotyped SNPs was 1.4%, 1.5%, 1.6%, and 0.8% for SBP, DBP, MAP, 
and PP, respectively. Considering the heritability estimates from the family-
based analysis, these common variants on average explained less than 0.05 of BP 
heritability [e.g. 0.014/0.30 (h2)]. Therefore, this study has showed that the 
proportion of h2 that is explained by BP SNPs identified by large GWAS was 
approximately 5%. This is much lower than the proportion of 80% for SBP 
reported by Vattikuti et al. based on more than 400,000 markers.160 
Consequently, this discrepancy between the two numbers is a result of the 
difference in number of markers that were used to estimate the h2SNP, 
supporting the theory that several markers are yet to be discovered for BP 
traits.107 
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The problem of missing heritability has attained much focus in the field of 
complex traits genetics, for which proposed reasons include, rare variants in 
novel pathways that are undetectable by the traditional GWAS approach; many 
more variants with smaller effect size that need even larger sample sizes to 
capture the variants; poor modelling of the genetic effects by ignoring the 
epistasis factors; structural variants such as CNVs that are poorly captured by 
existing genotyping platforms; over-estimated heritability in the family-based 
studies; and inadequate accounting for shared environment among family 
members.159 GWAS with larger sample sizes and a wider range of allele 
frequency continue to detect additional variants, and this implies that variants 
detected so far represent only a small fraction of those that influence a given 
trait. The ICBP study predicted that there are potentially 116 variants yet to be 
discovered with similar effect size to those identified so far.107 The phenotypic 
variance explained by these variants is only 2.2%. Hence, dissecting the genetic 
architecture of complex traits is a challenging process that requires larger 
sample size, better phenotyping, consideration of non-genetic risk factors, 
focused study designs, and an integration of multiple sources of phenotypic and 
genetic information.300 
Given the complexity of traits, such as BP, and the shortcomings of GWAS to 
explain much of the phenotypic variance, this has resulted in great interest in 
exploring the role of rare variants. This is also made possible by the increased 
affordability of exome- and whole-genome sequencing. However, this is more 
challenging as association studies that focus on rare variants (MAF <1%) require 
even larger sample sizes than that currently used in the largest GWASs. 
Essentially, finding rare variants with large effect size do not equate to 
explaining a large proportion of phenotypic variance at the population level. It is 
important to reiterate that complex diseases are more likely to have highly 
polygenic architecture that is consistent with the following features: (a) rare 
cases clustered within families with likely Mendelian forms of the disease, (b) a 
majority of cases at population level with little or no family history, (c) two 
different cases may carry different sets of risk alleles (genetic heterogeneity). 
Hence, dissecting the genetic architecture of such complex traits requires a 
combination of large-scale GWAS and more targeted approaches at both the 
population- and family-level to identify the remaining genetic variants. 
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Phenotypic accuracy represents a major challenge for most genetic studies, and 
can impact the effect size of genetic association or even the proportion of 
phenotypic variance explained by the findings of GWAS.81,85 Heritability 
estimates can also be influenced by measurements errors, as it was found that 
heritability of more accurate BP phenotypes, using approaches such as LTA or 
ABPM, resulted in higher heritability estimates.239,301,301 Combining individuals 
based on a broad clinical definition such as hypertension can average the effect 
size across them, while in fact they may have distinct underlying casual 
variants. Preferably, individuals should be classified into smaller groups on the 
basis of related phenotypes to reduce the chances of genetic heterogeneity. 
Advancement in high throughput “omics” technology can provide phenotypes 
that are closer to the level of gene action “endophenotypes” such as gene 
transcription, microRNA levels, proteomics, and metabolomics. For instance, the 
effects of a mutation that alters transcription factor binding can be clearly 
observed at the level of gene expression but may not be detected at the level of 
disease risk.81 Another way to improve the phenotype is to combine multiple 
phenotypic information for the same subjects and adopt a multivariate approach 
by jointly modelling multiple traits, or by stratifying the phenotype by the 
values of another phenotype, similar to what has been done in stratifying type 2 
diabetes cases based on their BMI values.303,304 
The impact of BP-lowering medications on quantitative genetic studies has been 
demonstrated in several studies.87 However, no previous study has examined the 
impact of using SRMs or EPRs as a basis for adjustment of treatment on subjects 
taking BP-lowering medications. Although the pharmacoepidemiological analyses 
have showed good concordance between the SRMs and EPRs, the effect of 
treatment-exposure source was observed in the SNPs association signals, 
especially for SBP and DBP. Interestingly, MAP was the least impacted BP trait 
with overlapping findings in the phenotypes generated by both SRMs and EPRs. 
This may imply that MAP is a more robust BP phenotype that is less impacted by 
the BP-lowering treatment. Further studies are required to explore if MAP 
represent a better phenotype for genetic association studies than both of SBP 
and DBP. The question of whether MAP provides a better phenotype than both of 
SBP and DBP, or it simply reflects different physiological pathways require 
further work. Using MAP only for dissecting the genetic architecture of BP can: 
248 
 
(1) capture genetic variants that show strong association with both SBP and DBP, 
(2) provide better phenotype quality that are less impacted by BP-lowering 
medications, and (3) reduce the multiple testing penalty (i.e. testing the 
association of SNP with one phenotype instead of two phenotypes). Importantly, 
MAP is one component of BP that represents a physiological (rather than 
traditional) component of BP, and corresponds to the product of CO and PVR 
minus central venous pressure. In this study, MAP was highly correlated with 
both SBP and DBP (ρp of 0.91 and 0.94, respectively), and the genetic 
correlation was even higher (ρG of 0.94 and 0.97, respectively). 
This thesis was limited by some factors due to the available resources; first, the 
BP values used are based on two measurements at a single time-point. This is 
clearly not the optimal BP phenotype, as discussed in this thesis. Second, 
changing the PCQ structure in the middle of the study has limited the use of 
some information. Third, the findings of this study may not be applicable to 
other populations, particularly of non-European ancestry, as this study was 
restricted to the Scottish population. Fourth, although the cohort recruited in 
the study can be considered the largest family-based available, the sample size 
is still not adequate to detect low frequency variants of modest effect reported 
in previous GWAS, even at nominal p <0.05. 
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Appendix'1:'2011'Mid)year'household'population'estimates'for'Scotland'by'age'and'sex.'
Age$group$(years)$ Men$ Women$
18!–!24! 252,000! 253,100!
25!–!34! 337,900! 332,300!
35!–!44! 335,500! 365,380!
45!–!54! 370,270! 405,150!
55!–!64! 319,520! 337,250!
65!–!74! 221,450! 253,430!
75+! 152,370! 231,530!
Total! 1,989,010! 2,178,140!
Data%are%reproduced%from%http://www.gov.scot/Publications/2012/09/8038/1%%
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Appendix'2'Concordance'of'BP)lowering'medication'in'the'total'population'
 
TreatmentPrescr! !
Yes! No! Total!
TreatmentQues!
Yes!
1624!
13.1%!!
[12.5%–13.7%]!
542!
4.4%!!
[4.5%–4.7%]!
2166!
17.5%!
[16.9%–18.2%]!
No!
184!
1.5%!!
[1.3%–1.7%]!
9997!
81%!!
[80.3%–81.6%]!
10181!
82.5%!
[81.8%–83.1%]!
Total!
1808!
14.6%!
[14.0%–15.3%]!
10540!
85.4%!
[84.7%–86.0%]!
12,347!
Measurements*of*validity* Sensitivity* 90%* Specificity* 95%*PPV! 75%! NPV! 85%!
Measurements!of!
reliability!!
23! 94%! 24! 73%!5! 78%! PI! 68%!
BI! 3%! PABAK 88% 
Ppos! 82%! Pneg! 96%!
TreatmentPCQ1!
Yes!
673!
11.7%!!
[10.9%–12.5%]!
316!
5.54%!!
[4.9%–6.1%]!
989!
17.3%!
[16.3%–18.3%]!
No!
60!
1.1%!!
[0.8%–1.3%]!
4678!
81.6%!!
[80.6%–82.6%]!
4738!
82.7%!
[81.7%–83.7%]!
Total!!
733!
12.8%!
[11.7%–13.7%]!
4994!
87.2%!
[86.3%–88.0%]!
5727!
Measurements*of*validity* Sensitivity* 92%* Specificity* 94%*PPV! 75%! NPV! 85%!
Measurements!of!
reliability!!
23! 93%! 24! 74%!5! 74%! PI! 70%!
BI! 4%! PABAK 87% 
Ppos! 78%! Pneg! 96%!
TreatmentPCQ2!
Yes!
951!
14.3%!!
[13.5%–15.2%]!
226!
3.4%!!
[3%–3.8%]!
1177!
17.8!
[16.7%–18.7%]!
No!
124!
1.9%!!
[1.6%–2.2%]!
5319!
80.4%!!
[79.4%–81.3%]!
5443!
82.2%!
[81.3%–83.1%]!
Total!!
1075!
16.2%!
[15.4%–17.2%]!
5545!
83.8%!
[82.9%–84.6%]!
6,620!
Measurements*of*validity* Sensitivity* 88%* Specificity* 96%*PPV! 81%! NPV! 84%!
Measurements!of!
reliability!!
23! 95%! 24! 72%!5! 81%! PI! 66%!
BI! 2%! PABAK 89% 
Ppos! 84%! Pneg! 97%!
' '
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Appendix'3'Average'of'BP'in'men'by'age'groups'in'GS:SFHS,'Scotland,'England,'USA,'and'
Canada.'
Left!vertical!axis!shows!the!average!of!SBP!and!DBP!by!each!age!groups,!the!right!vertical!axis!
shows!the!percentage!of!participants!fall!in!each!age!groups!as!represented!by!the!bar!chart.!
'
'
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Appendix'4'Average'of'BP'in'women'by'age'groups'in'GS:SFHS,'Scotland,'England,'USA,'
and'Canada.'
Left!vertical!axis!shows!the!average!of!SBP!and!DBP!by!each!age!groups,!the!right!vertical!axis!
shows!the!percentage!of!participants!fall!in!each!age!groups!as!represented!by!the!bar!chart.!
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Appendix'5'SNPs'included'in'each'GRS,'and'effect'size'as'reported'by'the'reference'study'
SN! SNP! CA! Chr.! SBP1! DBP1! MAP2! PP2! HTN!
1! rs17367504! G! 1! 40.90! 40.55! 40.53! 4! 40.10!
2! rs5068! G! 1! 4! 4! 4! 4! 4!
3! rs17030613! C! 1! 4! 4! 4! 4! 4!
4! rs2932538! G! 1! 0.39! 0.24! 0.25! 4! 0.05!
5! rs2004776! T! 1! 4! 4! 4! 4! 4!
6! rs1446468! A! 2! 4! 4! 40.34! 4! 4!
7! rs13082711! T! 3! 40.32! 40.24! 40.34! 4! 40.03!
8! rs3774372! T! 3! 4! 40.37! 4! 4! 4!
9! rs319690! A! 3! 4! 4! 0.30! 4! 4!
10! rs419076! T! 3! 0.41! 0.24! 0.34! 4! 0.03!
11! rs871606! T! 4! 4! 4! 4! 0.43! 4!
12! rs1458038! T! 4! 0.71! 0.46! 0.40! 4! 0.07!
13! rs13107325! T! 4! 40.98! 40.68! 40.63! 4! 40.10!
14! rs13139571! C! 4! 0.32! 0.26! 0.29! 4! 0.04!
15! rs1173771! G! 5! 0.50! 0.26! 0.28! 0.28! 0.06!
16! rs11953630! T! 5! 40.41! 40.28! 4! 4! 40.05!
17! rs1799945! G! 6! 0.63! 0.46! 4! 4! 0.09!
18! rs805303! G! 6! 0.38! 0.23! 4! 4! 0.05!
19! rs12705390! A! 7! 4! 4! 4! 4! 4!
20! rs3918226! T! 7! 4! 4! 4! 4! 4!
21! rs2071518! T! 8! 4! 4! 4! 0.31! 4!
22! rs4373814! G! 10! 40.37! 40.22! 4! 4! 40.05!
23! rs1813353! A! 10! 0.57! 0.41! 4! 4! 0.08!
24! rs4590817! G! 10! 0.65! 0.42! 0.58! 4! 0.10!
25! rs1530440! T! 10! 4! 4! 4! 4! 4!
26! rs932764! G! 10! 0.48! 0.18! 4! 4! 0.06!
27! rs11191548! T! 10! 1.10! 0.46! 4! 0.53! 0.10!
28! rs2782980! T! 10! 4! 4! 0.34! 4! 4!
29! rs661348! C! 11! 4! 4! 4! 4! 4!
30! rs7129220! G! 11! 40.62! 40.30! 4! 40.38! 40.04!
31! rs381815! T! 11! 0.57! 0.35! 0.30! 0.24! 0.06!
32! rs633185! G! 11! 40.56! 40.33! 40.33! 4! 40.07!
33! rs11222084! T! 11! 4! 4! 4! 0.34! 4!
34! rs17249754! G! 12! 0.93! 0.52! 0.56! 0.39! 0.13!
35! rs3184504! T! 12! 0.60! 0.45! 4! 4! 0.06!
36! rs653178! T! 12! 4! 4! 40.43! 4! 4!
37! rs10850411! T! 12! 0.35! 0.25! 4! 4! 0.05!
38! rs1378942! C! 15! 0.61! 0.42! 0.39! 4! 0.07!
39! rs2521501! T! 15! 0.65! 0.36! 0.34! 4! 0.06!
40! rs13333226! G! 16! 4! 4! 4! 4! 40.14!
41! rs12940887! T! 17! 0.36! 0.27! 0.25! 4! 0.05!
42! rs1327235! G! 20! 0.34! 0.30! 0.26! 4! 0.03!
43! rs6015450! G! 20! 0.90! 0.56! 0.52! 0.35! 0.11!
Total!number!of!SNPs!included!in!the!GRS! 27! 28! 21! 9! 28!
Abbreviation,!Ch;!chromosome,!CA;!coded!allele.!SNP!effect!size!is!reported!in!the!reference!study,!for!
SBP!and!DBP!from!ICBP1&(ref&107),&and&for&MAP&and&PP&from&ICBP2&(ref.&135!
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!
Appendix!6!Reported!association!results!for!SBP,!DBP!and!MAP!from!the!two!ICBP!studies.!
Nearby'genes' SNP' Ch' CA'
ICBP1' ICBP'2'
CAF'
SBP' DBP'
CAF'
SBP' DBP' MAP'
β (se) p8value' β (se) p8value' β (se) p8value! β (se) p8value! β (se) p8value!
MTHFR&'NPPB' rs17367504' 1' G' 0.15' 80.9(0.09)' 8.72E&22' 80.55(0.06)' 3.55E&19' 0.17' 80.83(0.09)' 1.38E&18' 80.52(0.06)' 5.81E&18' 80.53(0.07)' 2.18E&16'
MOV10' rs2932538' 1' G' 0.75' 0.39(0.06)' 1.17E&09' 0.24(0.04)' 9.88E&10' 0.83' 0.42(0.08)' 2.72E807' 0.24(0.05)' 5.24E807' 0.25(0.06)' 8.25E806'
SLC4A7' rs13082711' 3' T' 0.78' 80.32(0.07)' 1.51E806' 80.24(0.04)' 3.77E&09' 0.80' 80.38(0.08)' 5.28E806' 80.32(0.05)' 4.37E&09' 80.34(0.06)' 4.62E&09'
ULK4' rs3774372' 3' T' 0.83' 80.07(0.08)' 0.39' 80.37(0.05)' 9.02E&14' 0.72' 0.07(0.09)' 4.26E801' 80.26(0.05)' 1.17E806' 80.14(0.06)' 2.77E802'
MECOM' rs419076' 3' T' 0.47' 0.41(0.06)' 1.78E&13' 0.24(0.03)' 2.12E&12' 0.44' 0.5(0.07)' 4.09E&13' 0.3(0.04)' 1.11E&11' 0.34(0.05)' 8.11E&13'
FGF5' rs1458038' 4' T' 0.29' 0.71(0.07)' 1.47E&23' 0.46(0.04)' 8.46E&25' 0.3' 0.58(0.08)' 9.42E&14' 0.4(0.05)' 1.71E&15' 0.4(0.05)' 2.88E&14'
SLC39A8' rs13107325' 4' T' 0.05' 80.98(0.13)' 3.27E&14' 80.68(0.08)' 2.28E&17' 0.12' 80.9(0.14)' 2.16E&10' 80.6(0.09)' 2.11E&11' 80.63(0.1)' 1.30E&10'
GUCY1A3&'GUCY1B3' rs13139571' 4' C' 0.76' 0.32(0.07)' 1.16E806' 0.26(0.04)' 2.17E&10' 0.77' 0.44(0.08)' 5.60E808' 0.3(0.05)' 2.97E&10' 0.29(0.06)' 2.69E807'
NPR3&C5orf23' rs1173771' 5' G' 0.60' 0.5(0.06)' 1.79E&16' 0.26(0.04)' 9.11E&12' 0.53' 0.52(0.07)' 1.39E&13' 0.23(0.05)' 3.57E807' 0.28(0.05)' 3.51E&09'
EBF1' rs11953630' 5' T' 0.37' 80.41(0.06)' 3.02E&11' 80.28(0.04)' 3.81E&13' 0.34' 80.48(0.07)' 1.86E&11' 80.31(0.05)' 3.44E&11' 80.33(0.05)' 1.51E&11'
HFE' rs1799945' 6' G' 0.14' 0.63(0.09)' 7.69E&12' 0.46(0.06)' 1.45E&15' 0.18' 0.59(0.1)' 2.04E&09' 0.43(0.06)' 8.05E&12' 0.47(0.07)' 6.55E&12'
BAT2&BAT5' rs805303' 6' G' 0.61' 0.38(0.06)' 1.49E&11' 0.23(0.03)' 2.98E&11' 0.58' 0.31(0.07)' 8.52E806' 0.12(0.04)' 2.66E803' 0.15(0.05)' 1.45E803'
CACNB2(5')' rs4373814' 10' G' 0.55' 80.37(0.06)' 4.81E&11' 80.22(0.03)' 4.36E&10' 0.41' 80.28(0.07)' 8.60E805' 80.16(0.04)' 1.83E804' 80.18(0.05)' 3.01E804'
CACNB2(3')' rs1813353' 10' T' 0.68' 0.57(0.08)' 2.56E&12' 0.41(0.05)' 2.30E&15' 0.65' 0.5(0.08)' 2.77E&11' 0.35(0.05)' 5.38E&13' 0.4(0.05)' 7.01E&15'
C10orf107' rs4590817' 10' G' 0.84' 0.65(0.09)' 3.97E&12' 0.42(0.06)' 1.29E&12' 0.83' 0.79(0.1)' 9.24E&17' 0.51(0.06)' 5.01E&17' 0.58(0.07)' 2.14E&18'
PLCE&1' rs932764' 10' G' 0.44' 0.48(0.06)' 7.10E&16' 0.18(0.04)' 8.06E807' 0.43' 0.42(0.07)' 1.28E&09' 0.15(0.05)' 1.00E803' 0.2(0.05)' 2.22E805'
CYP17A1&'NT5C3' rs11191548' 10' T' 0.91' 1.10(0.1)' 6.90E&26' 0.46(0.06)' 9.44E&13' 0.94' 1.06(0.12)' 1.44E&18' 0.56(0.08)' 6.35E&13' 0.65(0.08)' 2.19E&15'
ADM' rs7129220' 11' G' 0.89' 80.62(0.09)' 2.97E&12' 80.3(0.06)' 6.44E808' 0.87' 80.68(0.11)' 1.21E&09' 80.26(0.07)' 3.13E804' 80.33(0.08)' 2.07E805'
PLEKHA7' rs381815' 11' T' 0.26' 0.57(0.09)' 5.27E&11' 0.35(0.06)' 5.34E&10' 0.30' 0.57(0.08)' 2.16E&13' 0.34(0.05)' 9.98E&12' 0.3(0.05)' 2.75E&08'
FLJ32810&'TMEM34' rs633185' 11' G' 0.28' 80.56(0.07)' 1.21E&17' 80.33(0.04)' 1.95E&15' 0.32' 80.5(0.08)' 6.89E&11' 80.29(0.05)' 4.09E&09' 80.33(0.05)' 6.58E&10'
ATP2B1' rs17249754' 12' G' 0.84' 0.93(0.11)' 1.82E&18' 0.52(0.07)' 1.16E&14' 0.89' 0.91(0.09)' 6.02E&22' 0.46(0.06)' 3.08E&14' 0.56(0.07)' 1.21E&17'
ATXN2' rs3184504' 12' T' 0.47' 0.6(0.07)' 3.83E&18' 0.45(0.04)' 3.59E&25' 0.41' 0.56(0.07)' 9.92E&16' 0.44(0.04)' 7.22E&23' 0.41(0.05)' 3.64E&18'
TBX5&TBX3' rs10850411' 12' T' 0.70' 0.35(0.07)' 5.38E808' 0.25(0.04)' 5.43E&10' 0.72' 0.38(0.08)' 8.47E807' 0.25(0.05)' 2.56E&08' 0.25(0.05)' 4.44E806'
CSK' rs1378942' 15' C' 0.35' 0.61(0.06)' 5.69E&23' 0.42(0.04)' 2.69E&26' 0.33' 0.59(0.07)' 7.96E&17' 0.42(0.05)' 4.38E&20' 0.39(0.05)' 1.63E&15'
FES' rs2521501' 15' G' 0.31' 0.65(0.07)' 5.20E&19' 0.36(0.05)' 1.89E&15' 0.63' 0.58(0.09)' 1.16E&10' 0.37(0.05)' 1.01E&12' 0.34(0.06)' 2.88E&08'
GOSR2' rs17608766' 17' T' 0.86' 80.56(0.09)' 1.13E&10' 80.13(0.05)' 0.02' 0.91' 80.73(0.1)' 4.68E&13' 80.2(0.07)' 2.28E803' 80.36(0.07)' 1.94E807'
ZNF652' rs12940887' 17' T' 0.38' 0.36(0.06)' 1.79E&10' 0.27(0.04)' 2.29E&14' 0.42' 0.28(0.07)' 9.03E805' 0.26(0.05)' 1.36E&08' 0.25(0.05)' 2.47E807'
JAG1' rs1327235' 20' G' 0.46' 0.34(0.06)' 1.87E&08' 0.3(0.04)' 1.41E&15' 0.12' 0.35(0.07)' 5.11E807' 0.26(0.04)' 1.44E&10' 0.26(0.05)' 4.35E&08'
GNAS&'EDN3' rs6015450' 20' G' 0.12' 0.9(0.09)' 3.87E&23' 0.56(0.06)' 5.63E&23' 0.07' 0.85(0.11)' 5.94E&15' 0.51(0.07)' 4.39E&13' 0.52(0.07)' 1.58E&12'
Statisically'significant'SNPs'are'in'bold.''Abbreviation,'Ch;'chromosome,'CA;'coded'allele,'CAF:'coded'allele'frequency.'ICBP1'(ref'107),'ICBP2'(ref'135).'
Cells'are'highlighted'in'colour'as'following:'green'for'SNPs'associated'with'both'SBP'and'DBP,'blue'for'SNP'associated'with'SBP'only,'orange'for'SNP'associated'with'DBP'only,'red'for'association'that'was'not'replicated'in'the'
second'ICBP.'
256 
 
References((
1. Lim, S.S., Vos, T., Flaxman, A.D., Danaei, G., Shibuya, K., Adair-Rohani, H., 
AlMazroa, M.A., Amann, M., Anderson, H.R., Andrews, K.G., et al. (2012). A 
comparative risk assessment of burden of disease and injury attributable to 67 
risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic 
analysis for the Global Burden of Disease Study 2010. The Lancet 380, 2224–
2260. 
2. Lawes, C.M.M., Vander Hoorn, S., Rodgers, A., International Society of 
Hypertension (2008). Global burden of blood-pressure-related disease, 2001. 
Lancet 371, 1513–1518. 
3. Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., and 
He, J. (2005). Global burden of hypertension: analysis of worldwide data. Lancet 
365, 217–223. 
4. World Health Organization (WHO) (2013). A Global Brief on Hypertension: 
Silent Killer, Global Public Health Crisis. Available from: 
http://www.thehealthwell.info/node/466541 [Accessed: February 2016]. 
5. Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R., Prospective 
Studies Collaboration (2002). Age-specific relevance of usual blood pressure to 
vascular mortality: a meta-analysis of individual data for one million adults in 61 
prospective studies. The Lancet 360, 1903–1913. 
6. Vasan, R.S., Larson, M.G., Leip, E.P., Evans, J.C., O’Donnell, C.J., Kannel, 
W.B., and Levy, D. (2001). Impact of high-normal blood pressure on the risk of 
cardiovascular disease. N. Engl. J. Med. 345, 1291–1297. 
7. Lifton, R.P., Gharavi, A.G., and Geller, D.S. (2001). Molecular Mechanisms of 
Human Hypertension. Cell 104, 545–556. 
8. Oparil, S., Zaman, M.A., and Calhoun, D.A. (2003). Pathogenesis of 
hypertension. Ann. Intern. Med. 139, 761–776. 
9. Beevers, G., Lip, G.Y., and O'Brien, E. (2001). ABC of hypertension: The 
pathophysiology of hypertension. BMJ 322, 912–916. 
10. Atlas, S.A. (2007). The renin-angiotensin aldosterone system: 
pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 13, 9–
20. 
11. Riet, Te, L., van Esch, J.H.M., Roks, A.J.M., van den Meiracker, A.H., and 
Danser, A.H.J. (2015). Hypertension: renin-angiotensin-aldosterone system 
alterations. Circ. Res. 116, 960–975. 
12. Mu, S., Shimosawa, T., Ogura, S., Wang, H., Uetake, Y., Kawakami-Mori, F., 
Marumo, T., Yatomi, Y., Geller, D.S., Tanaka, H., et al. (2011). Epigenetic 
modulation of the renal [beta]-adrenergic-WNK4 pathway in salt-sensitive 
hypertension. Nat Med 17, 573–580. 
13. Coffman, T.M. (2011). Under pressure: the search for the essential 
257 
 
mechanisms of hypertension. Nat Med 17, 1402–1409. 
14. Dharmashankar, K., and Widlansky, M.E. (2010). Vascular Endothelial 
Function and Hypertension: Insights and Directions. Curr. Hypertens. Rep. 12, 
448–455. 
15. Sesso, H.D., Stampfer, M.J., Rosner, B., Hennekens, C.H., Gaziano, J.M., 
Manson, J.E., and Glynn, R.J. (2000). Systolic and diastolic blood pressure, pulse 
pressure, and mean arterial pressure as predictors of cardiovascular disease risk 
in Men. Hypertension 36, 801–807. 
16. Strandberg, T.E., and Pitkala, K. (2003). What is the most important 
component of blood pressure: systolic, diastolic or pulse pressure? Curr. Opin. 
Nephrol. Hypertens. 12, 293–297. 
17. García-Donaire, J.A., and Ruilope, L.M. (2010). Systolic Pressure, Diastolic 
Pressure, or Pulse Pressure as a Cardiovascular Risk Factor in Renal Disease. 
Curr. Hypertens. Rep. 12, 307–312. 
18. MACMAHON, S. (1990). Blood pressure, stroke, and coronary heart disease 
*1Part 1, prolonged differences in blood pressure: prospective observational 
studies corrected for the regression dilution bias. The Lancet 335, 765–774. 
19. Kannel, W.B., Gordon, T., and Schwartz, M.J. (1971). Systolic versus 
diastolic blood pressure and risk of coronary heart disease. Am. J. Cardio. 27, 
335–346. 
20. Franklin, S.S., Larson, M.G., Khan, S.A., Wong, N.D., Leip, E.P., Kannel, 
W.B., and Levy, D. (2001). Does the relation of blood pressure to coronary heart 
disease risk change with aging? The Framingham Heart Study. Circulation 103, 
1245–1249. 
21. Domanski, M., Mitchell, G., Pfeffer, M., Neaton, J.D., Norman, J., Svendsen, 
K., Grimm, R., Cohen, J., Stamler, J., MRFIT Research Group (2002). Pulse 
pressure and cardiovascular disease-related mortality: follow-up study of the 
Multiple Risk Factor Intervention Trial (MRFIT). JAMA 287, 2677–2683. 
22. Franklin, S.S., Lopez, V.A., Wong, N.D., Mitchell, G.F., Larson, M.G., Vasan, 
R.S., and Levy, D. (2009). Single versus combined blood pressure components 
and risk for cardiovascular disease: the Framingham Heart Study. Circulation 
119, 243–250. 
23. Mancia, G., Fagard, R., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., 
De Backer, G., Dominiczak, A., Galderisi, M., Grobbee, D.E., et al. (2013). 2013 
ESH/ESC guidelines for the management of arterial hypertension: the Task Force 
for the Management of Arterial Hypertension of the European Society of 
Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart 
J. 34, 2159–2219. 
24. Bliziotis, I.A., Destounis, A., and Stergiou, G.S. (2012). Home versus 
ambulatory and office blood pressure in predicting target organ damage in 
hypertension. J Hypertens 30, 1289–1299. 
25. Stergiou, G.S., and Bliziotis, I.A. (2011). Home blood pressure monitoring in 
258 
 
the diagnosis and treatment of hypertension: a systematic review. Am. J. 
Hypertens. 24, 123–134. 
26. Beevers, G., Lip, G.Y.H., and O'Brien, E. (2001). Blood pressure 
measurement. BMJ 322, 981–985. 
27. Sebo, P., Pechère-Bertschi, A., Herrmann, F.R., Haller, D.M., and Bovier, P. 
(2014). Blood pressure measurements are unreliable to diagnose hypertension in 
primary care. J Hypertens 32, 509–517. 
28. Jones, D.W., Appel, L.J., Sheps, S.G., Roccella, E.J., and Lenfant, C. (2003). 
Measuring blood pressure accurately: new and persistent challenges. JAMA 289, 
1027–1030. 
29. Handler, J. (2009). The importance of accurate blood pressure 
measurement. Perm J 13, 51–54. 
30. PLATT, R. (1959). The nature of essential hypertension. The Lancet 2, 55–57. 
31. Zanchetti A. (1986). Platt versus Pickering: an episode in recent medical 
history. By J. D. Swales, editor. An essay review. Medical History 30, 94-96. 
32. Oldham, P.D., Pickering, G., Fraser Roberts, J.A., and Sowry, G.S.C. (1960). 
THE NATURE OF ESSENTIAL HYPERTENSION. The Lancet 275, 1085–1093. 
33. National Clinical Guideline Centre The clinical management of primary 
hypertension in adults. Avilable online: 
https://www.nice.org.uk/guidance/cg127 
34. Krause, T., Lovibond, K., Caulfield, M., McCormack, T., and Williams, B. 
(2011). Management of hypertension: summary of NICE guidance. BMJ 343, 
d4891–d4891. 
35. National Institute of Health (2003). JNC 7 express: The seventh report of the 
Joint National Committee on prevention, detection, evaluation, and treatment 
of high blood pressure (Maryland: National Institutes of Health). 
36. James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, 
C., Handler, J., Lackland, D.T., LeFevre, M.L., MacKenzie, T.D., Ogedegbe, O., 
et al. (2014). 2014 evidence-based guideline for the management of high blood 
pressure in adults: report from the panel members appointed to the Eighth Joint 
National Committee (JNC 8). JAMA 311, 507–520. 
37. Padmanabhan, S., Newton-Cheh, C., and Dominiczak, A.F. (2012). Genetic 
basis of blood pressure and hypertension. Trends in Genetics 28, 397–408. 
38. Padmanabhan, S., Caulfield, M., and Dominiczak, A.F. (2015). Genetic and 
Molecular Aspects of Hypertension. Circ. Res. 116, 937–959. 
39. Coffman, T.M., and Crowley, S.D. (2014). The inextricable role of the kidney 
in hypertension. J. Clin. Invest. 124, 2341–2347. 
40. Munroe, P.B., Barnes, M.R., and Caulfield, M.J. (2013). Advances in blood 
pressure genomics. Circ. Res. 112, 1365–1379. 
259 
 
41. Wilson, P.W.F., D'Agostino, R.B., Sullivan, L., Parise, H., and Kannel, W.B. 
(2002). Overweight and obesity as determinants of cardiovascular risk: the 
Framingham experience. Arch. Intern. Med. 162, 1867–1872. 
42. Wang, N.-Y., Young, J.H., Meoni, L.A., Ford, D.E., Erlinger, T.P., and Klag, 
M.J. (2008). Blood Pressure Change and Risk of Hypertension Associated With 
Parental Hypertension: The Johns Hopkins Precursors Study. Arch. Intern. Med. 
168, 643–648. 
43. Carson, A.P., Howard, G., Burke, G.L., Shea, S., Levitan, E.B., and Muntner, 
P. (2011). Ethnic Differences in Hypertension Incidence Among Middle-Aged and 
Older Adults The Multi-Ethnic Study of Atherosclerosis. Hypertension 57, 1101–
1107. 
44. Adrogué, H.J., and Madias, N.E. (2007). Sodium and Potassium in the 
Pathogenesis of Hypertension. N. Engl. J. Med. 356, 1966–1978. 
45. Carretero, O.A., and Oparil, S. (2000). Essential Hypertension : Part I: 
Definition and Etiology. Circulation 101, 329–335. 
46. Cheng, S., Xanthakis, V., Sullivan, L.M., and Vasan, R.S. (2012). Blood 
pressure tracking over the adult life course: patterns and correlates in the 
Framingham heart study. Hypertension 60, 1393–1399. 
47. Falaschetti, E., Gillespie, C., Robitaille, C., McAlister, F.A., and Johansen, 
H. (2013). Hypertension prevalence, awareness, treatment and control in 
national surveys from England, the USA and Canada, and correlation with stroke 
and ischaemic heart disease mortality: a cross-sectional study. BMJ Open 3, 
e003423–e003423. 
48. Berenson, G.S., Chen, W., DasMahapatra, P., Fernandez, C., Giles, T., Xu, 
J., and Srinivasan, S.R. (2011). Stimulus response of blood pressure in black and 
white young individuals helps explain racial divergence in adult cardiovascular 
disease: The Bogalusa Heart Study. J Am Soc Hypertens 5, 230–238. 
49. Wang, X., Poole, J.C., Treiber, F.A., Harshfield, G.A., Hanevold, C.D., and 
Snieder, H. (2006). Ethnic and gender differences in ambulatory blood pressure 
trajectories: results from a 15-year longitudinal study in youth and young adults. 
Circulation 114, 2780–2787. 
50. Jones, D.W., and Hall, J.E. (2006). Racial and ethnic differences in blood 
pressure: biology and sociology. Circulation 114, 2757–2759. 
51. Lane, D., Beevers, D.G., and Lip, G.Y.H. (2002). Ethnic differences in blood 
pressure and the prevalence of hypertension in England. J Hum Hypertens 16, 
267–273. 
52. DeMarco, V.G., Aroor, A.R., and Sowers, J.R. (2014). The pathophysiology of 
hypertension in patients with obesity. Nat Rev Endocrinol 10, 364–376. 
53. Schmieder, R.E., and Messerli, F.H. (1993). Does obesity influence early 
target organ damage in hypertensive patients? Circulation 87, 1482–1488. 
54. Jordan, J., Yumuk, V., Schlaich, M., Nilsson, P.M., Zahorska-Markiewicz, B., 
260 
 
Grassi, G., Schmieder, R.E., Engeli, S., and Finer, N. (2012). Joint statement of 
the European Association for the Study of Obesity and the European Society of 
Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens 
30, 1047–1055. 
55. Sacks, F.M., Svetkey, L.P., Vollmer, W.M., Appel, L.J., Bray, G.A., Harsha, 
D., Obarzanek, E., Conlin, P.R., Miller, E.R., Simons-Morton, D.G., et al. (2001). 
Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches 
to Stop Hypertension (DASH) Diet. N. Engl. J. Med. 344, 3–10. 
56. He, F.J., and MacGregor, G.A. (2003). How Far Should Salt Intake Be 
Reduced? Hypertension 42, 1093–1099. 
57. Xin, X., He, J., Frontini, M.G., Ogden, L.G., Motsamai, O.I., and Whelton, 
P.K. (2001). Effects of Alcohol Reduction on Blood Pressure A Meta-Analysis of 
Randomized Controlled Trials. Hypertension 38, 1112–1117. 
58. Lawlor, D.A., Nordestgaard, B.G., Benn, M., Zuccolo, L., Tybjaerg-Hansen, 
A., and Smith, G.D. (2013). Exploring causal associations between alcohol and 
coronary heart disease risk factors: findings from a Mendelian randomization 
study in the Copenhagen General Population Study. Eur. Heart J. 34, 2519–2528. 
59. Chen, L., Davey Smith, G., Harbord, R.M., and Lewis, S.J. (2008). Alcohol 
Intake and Blood Pressure: A Systematic Review Implementing a Mendelian 
Randomization Approach. PloS Med. 5, e52. 
60. Balijepalli, C., sch, C.L.O., Bramlage, P., Erbel, R., Humphries, K.H., ckel, 
K.-H.J.O., and Moebus, S. (2013). Percentile distribution of blood pressure 
readings in 35683 men and women aged 18 to 99 years. J Hum Hypertens 28, 
193–200. 
61. Danaei, G., Finucane, M.M., Lin, J.K., Singh, G.M., Paciorek, C.J., Cowan, 
M.J., Farzadfar, F., Stevens, G.A., Lim, S.S., Riley, L.M., et al. (2011). National, 
regional, and global trends in systolic blood pressure since 1980: systematic 
analysis of health examination surveys and epidemiological studies with 786 
country-years and 5·4 million participants. Lancet 377, 568–577. 
62. Pereira, M., Lunet, N., Azevedo, A., and Barros, H. (2009). Differences in 
prevalence, awareness, treatment and control of hypertension between 
developing and developed countries. J Hypertens 27, 963–975. 
63. Wolf-Maier, K., Cooper, R.S., Kramer, H., Banegas, J.R., Giampaoli, S., 
Joffres, M.R., Poulter, N., Primatesta, P., Stegmayr, B., and Thamm, M. (2004). 
Hypertension Treatment and Control in Five European Countries, Canada, and 
the United States. Hypertension 43, 10–17. 
64. Hertz, R.P., Unger, A.N., Cornell, J.A., and Saunders, E. (2005). Racial 
Disparities in Hypertension Prevalence, Awareness, and Management. Arch. 
Intern. Med. 165, 2098–2104. 
65. Chow, C.K., Teo, K.K., Rangarajan, S., Islam, S., Gupta, R., Avezum, A., 
Bahonar, A., Chifamba, J., Dagenais, G., Diaz, R., et al. (2013). Prevalence, 
Awareness, Treatment, and Control of Hypertension in Rural and Urban 
Communities in High-, Middle-, and Low-Income Countries. JAMA 310, 959–968. 
261 
 
66. Rutherford, L., Hinchliffe, S., Sharp, C., Bromley, C., Dowling, S., Gray, L., 
Hughes, T., Leyland, A.H., McNeill, G., and Marcinkiewicz, A. The Scottish 
Health Survey 2013: Volume 1: Main Report. Avilable online: 
http://www.gov.scot/Publications/2014/12/9982 
67. Lloyd-Sherlock, P., Beard, J., Minicuci, N., Ebrahim, S., and Chatterji, S. 
(2014). Hypertension among older adults in low- and middle-income countries: 
prevalence, awareness and control. Int J Epidemiol 43, 116–128. 
68. Falaschetti, E., Mindell, J., Knott, C., and Poulter, N. (2014). Hypertension 
management in England: a serial cross-sectional study from 1994 to 2011. The 
Lancet 383, 1912–1919. 
69. Dickinson, H.O., Mason, J.M., Nicolson, D.J., Campbell, F., Beyer, F.R., 
Cook, J.V., Williams, B., and Ford, G.A. (2006). Lifestyle interventions to reduce 
raised blood pressure: a systematic review of randomized controlled trials. J 
Hypertens 24, 215–233. 
70. Law, M.R., Morris, J.K., and Wald, N.J. (2009). Use of blood pressure 
lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 
randomised trials in the context of expectations from prospective 
epidemiological studies. BMJ 338, b1665–b1665. 
71. Gaziano, T.A., Bitton, A., Anand, S., Weinstein, M.C., and Hypertension, 
F.T.I.S.O. (2009). The global cost of nonoptimal blood pressure. J Hypertens 27, 
1472–1477. 
72. Di Cesare, M., Bennett, J.E., Best, N., Stevens, G.A., Danaei, G., and Ezzati, 
M. (2013). The contributions of risk factor trends to cardiometabolic mortality 
decline in 26 industrialized countries. Int J Epidemiol 42, 838–848. 
73. Whelton, P.K., He, J., Appel, L.J., Cutler, J.A., Havas, S., Kotchen, T.A., 
Roccella, E.J., Stout, R., Vallbona, C., Winston, M.C., et al. (2002). Primary 
Prevention of Hypertension: Clinical and Public Health Advisory From the 
National High Blood Pressure Education Program. JAMA 288, 1882–1888. 
74. Burton, P.R., Tobin, M.D., and Hopper, J.L. (2005). Key concepts in genetic 
epidemiology. Lancet 366, 941–951. 
75. Alghamdi, J., and Padmanabhan, S. (2014). Fundamentals of Complex Trait 
Genetics and Association Studies. In Handbook of Pharmacogenomics and 
Stratified Medicine, (Elsevier), pp. 235–257. 
76. Lander, E.S. (2011). Initial impact of the sequencing of the human genome. 
Nature 470, 187–197. 
77. Karlsson, E.K., Kwiatkowski, D.P., and Sabeti, P.C. (2014). Natural selection 
and infectious disease in human populations. Nat. Rev. Genet. 15, 379–393. 
78. Frazer, K.A., Murray, S.S., Schork, N.J., and Topol, E.J. (2009). Human 
genetic variation and its contribution to complex traits. Nat. Rev. Genet. 10, 
241–251. 
79. Burton, P.R., Bowden, J.M., and Tobin, M.D. (2008). Epidemiology and 
262 
 
Genetic Epidemiology. In Handbook of Statistical Genetics, (Chichester: John 
Wiley & Sons, Ltd), pp. 1109–1140. 
80. Plomin, R., Haworth, C.M.A., and Davis, O.S.P. (2011). Common disorders 
are quantitative traits. Nat. Rev. Genet. 10, 872–878. 
81. Almasy, L. (2012). The role of phenotype in gene discovery in the whole 
genome sequencing era. Hum. Genet. 131, 1533–1540. 
82. Padmanabhan, S., Melander, O., Johnson, T., Di Blasio, A.M., Lee, W.K., 
Gentilini, D., Hastie, C.E., Menni, C., Monti, M.C., Delles, C., et al. (2010). 
Genome-wide association study of blood pressure extremes identifies variant 
near UMOD associated with hypertension. PLoS Genet. 6, e1001177. 
83. Green, A.E., Munafò, M.R., DeYoung, C.G., Fossella, J.A., Fan, J., and Gray, 
J.R. (2008). Using genetic data in cognitive neuroscience: from growing pains to 
genuine insights. Nat. Rev. Neurosci. 9, 710–720. 
84. Zheng, G., and Tian, X. (2005). The impact of diagnostic error on testing 
genetic association in case-control studies. Statist. Med. 24, 869–882. 
85. Liao, J., Li, X., Wong, T.Y., Wang, J.J., Khor, C.-C., Tai, E.S., Aung, T., 
Teo, Y.Y., and Cheng, C.-Y. (2014). Impact of measurement error on testing 
genetic association with quantitative traits. 9, e87044. 
86. Wojczynski, M.K., and Tiwari, H.K. (2008). Definition of Phenotype. In 
Genetic Dissection of Complex Traits, (Academic Press), pp. 75–105. 
87. Tobin, M.D., Sheehan, N.A., Scurrah, K.J., and Burton, P.R. (2005). 
Adjusting for treatment effects in studies of quantitative traits: 
antihypertensive therapy and systolic blood pressure. Statist. Med. 24, 2911–
2935. 
88. Rana, B.K., Dhamija, A., Panizzon, M.S., Spoon, K.M., Vasilopoulos, T., 
Franz, C.E., Grant, M.D., Jacobson, K.C., Kim, K., Lyons, M.J., et al. (2014). 
Imputing Observed Blood Pressure for Antihypertensive Treatment: Impact on 
Population and Genetic Analyses. Am. J. Hypertens. 27, hpt271–hpt837. 
89. Ott, J., Kamatani, Y., and Lathrop, M. (2011). Family-based designs for 
genome-wide association studies. Nat. Rev. Genet. 12, 465–474. 
90. Laird, N.M., and Lange, C. (2006). Family-based designs in the age of large-
scale gene-association studies. Nat. Rev. Genet. 7, 385–394. 
91. Clerget-Darpoux, F., and Elston, R.C. (2007). Are linkage analysis and the 
collection of family data dead? Prospects for family studies in the age of 
genome-wide association. Hum Hered 64, 91–96. 
92. Lange, E.M., Sun, J., Lange, L.A., Zheng, S.L., Duggan, D., Carpten, J.D., 
Grönberg, H., Isaacs, W.B., Xu, J., and Chang, B.-L. (2008). Family-based 
samples can play an important role in genetic association studies. Cancer 
Epidemiol. Biomarkers Prev. 17, 2208–2214. 
93. Price, A.L., Zaitlen, N.A., Reich, D., and Patterson, N. (2010). New 
263 
 
approaches to population stratification in genome-wide association studies. Nat. 
Rev. Genet. 11, 459–463. 
94. Kong, A., Steinthorsdottir, V., Masson, G., Thorleifsson, G., Sulem, P., 
Besenbacher, S., Jonasdottir, A., Sigurdsson, A., Kristinsson, K.T., Jonasdottir, 
A., et al. (2009). Parental origin of sequence variants associated with complex 
diseases. Nature 462, 868–874. 
95. Mott, R., Yuan, W., Kaisaki, P., Gan, X., Cleak, J., and Edwards, A. (2014). 
The architecture of parent-of-origin effects in mice. Cell 156, 332–342. 
96. Veltman, J.A., and Brunner, H.G. (2012). De novo mutations in human 
genetic disease. Nat. Rev. Genet. 13, 565–575. 
97. Benyamin, B., Visscher, P.M., and McRae, A.F. (2009). Family-based genome-
wide association studies. Pharmacogenomics 10, 181–190. 
98. Gordon, D., Heath, S.C., and Ott, J. (1999). True pedigree errors more 
frequent than apparent errors for single nucleotide polymorphisms. Hum Hered 
49, 65–70. 
99. Chen, W.-M., and Abecasis, G.R. (2007). Family-based association tests for 
genomewide association scans. Am. J. Hum. Genet. 81, 913–926. 
100. Visscher, P.M., Andrew, T., and Nyholt, D.R. (2008). Genome-wide 
association studies of quantitative traits with related individuals: little (power) 
lost but much to be gained. Eur. J. Hum. Genet. 16, 387–390. 
101. Sahana, G., Guldbrandtsen, B., Janss, L., and Lund, M.S. (2010). 
Comparison of association mapping methods in a complex pedigreed population. 
Genet. Epidemiol. 34, 455–462. 
102. Khoury, M.J., Beaty, T.H., and KUNG-YEE, L. (1988). CAN FAMILIAL 
AGGREGATION OF DISEASE BE EXPLAINED BY FAMILIAL AGGREGATION OF 
ENVIRONMENTAL RISK FACTORS? Am. J. Epidemiol. 127, 674–683. 
103. Risch, N. (1990). Linkage strategies for genetically complex traits. II. The 
power of affected relative pairs. Am. J. Hum. Genet. 46, 229–241. 
104. Matthews, A.G., Finkelstein, D.M., and Betensky, R.A. (2008). Analysis of 
familial aggregation studies with complex ascertainment schemes. Statist. Med. 
27, 5076–5092. 
105. Tenesa, A., and Haley, C.S. (2013). The heritability of human disease: 
estimation, uses and abuses. Nat. Rev. Genet. 14, 139–149. 
106. Sham, P.C., and Cherny, S.S. (2011). Genetic Architecture of Complex 
Diseases. In Analysis of Complex Disease Association Studies, (Elsevier), pp. 1–
13. 
107. Ehret, G.B., Munroe, P.B., Rice, K.M., Bochud, M., Johnson, A.D., 
Chasman, D.I., Smith, A.V., Tobin, M.D., Verwoert, G.C., Hwang, S.-J., et al. 
(2011). Genetic variants in novel pathways influence blood pressure and 
cardiovascular disease risk. Nature 478, 103–109. 
264 
 
108. Ehret, G.B., and Caulfield, M.J. (2013). Genes for blood pressure: an 
opportunity to understand hypertension. Eur. Heart J. 0, 4551–455. 
109. Kotchen, T.A., Kotchen, J.M., Grim, C.E., George, V., Kaldunski, M.L., 
Cowley, A.W., Hamet, P., and Chelius, T.H. (2000). Genetic Determinants of 
Hypertension Identification of Candidate Phenotypes. Hypertension 36, 7–13. 
110. HAVLIK, R.J., GARRISON, R.J., FEINLEIB, M., Kannel, W.B., CASTELLI, W.P., 
and MCNAMARA, P.M. (1979). BLOOD PRESSURE AGGREGATION IN FAMILIES. Am. 
J. Epidemiol. 110, 304–312. 
111. Kupper, N., Willemsen, G., RIESE, H., Posthuma, D., Boomsma, D.I., and De 
Geus, E.J.C. (2005). Heritability of daytime ambulatory blood pressure in an 
extended twin design. Hypertension 45, 80–85. 
112. Usher, C.L., and McCarroll, S.A. (2015). Complex and multi-allelic copy 
number variation in human disease. Briefings in Functional Genomics 14, elv028–
elv338. 
113. Zhang, D., Qian, Y., Akula, N., Alliey-Rodriguez, N., Tang, J., Bipolar 
Genome Study, Gershon, E.S., and Liu, C. (2011). Accuracy of CNV Detection 
from GWAS Data. PLoS ONE 6, e14511. 
114. Solovieff, N., Cotsapas, C., Lee, P.H., Purcell, S.M., and Smoller, J.W. 
(2013). Pleiotropy in complex traits: challenges and strategies. Nat. Rev. Genet. 
14, 483–495. 
115. Levy, D., Ehret, G.B., Rice, K., Verwoert, G.C., Launer, L.J., Dehghan, A., 
Glazer, N.L., Morrison, A.C., Johnson, A.D., Aspelund, T., et al. (2009). 
Genome-wide association study of blood pressure and hypertension. Nat. Genet.  
41, 677–687. 
116. Hindorff, L.A., Sethupathy, P., Junkins, H.A., Ramos, E.M., Mehta, J.P., 
Collins, F.S., and Manolio, T.A. (2009). Potential etiologic and functional 
implications of genome-wide association loci for human diseases and traits. 
Proc. Natl. Acad. Sci. U.S.A. 106, 9362–9367. 
117. ENCODE Project Consortium (2012). An integrated encyclopedia of DNA 
elements in the human genome. Nature 489, 57–74. 
118. Schork, A.J., Thompson, W.K., Pham, P., Torkamani, A., Roddey, J.C., 
Sullivan, P.F., Kelsoe, J.R., O'donovan, M.C., Furberg, H., Tobacco, T., et al. 
(2013). All SNPs Are Not Created Equal: Genome-Wide Association Studies Reveal 
a Consistent Pattern of Enrichment among Functionally Annotated SNPs. PLoS 
Genet. 9, e1003449. 
119. Maurano, M.T., Humbert, R., Rynes, E., Thurman, R.E., Haugen, E., Wang, 
H., Reynolds, A.P., Sandstrom, R., Qu, H., Brody, J., et al. (2012). Systematic 
localization of common disease-associated variation in regulatory DNA. Science 
337, 1190–1195. 
120. Anderson, C.A., Pettersson, F.H., Clarke, G.M., Cardon, L.R., Morris, A.P., 
and Zondervan, K.T. (2010). Data quality control in genetic case-control 
association studies. Nat Protoc 5, 1564–1573. 
265 
 
121. Weale, M.E. (2010). Quality Control for Genome-Wide Association Studies. 
In Genetic Variation: Methods and Protocols, R.M. Barnes, and G. Breen, eds. 
(Totowa, NJ: Humana Press), pp. 341–372. 
122. Turner, S., Armstrong, L.L., Bradford, Y., Carlson, C.S., Crawford, D.C., 
Crenshaw, A.T., de Andrade, M., Doheny, K.F., Haines, J.L., Hayes, G., et al. 
(2001). Quality Control Procedures for Genome-Wide Association Studies. In 
Current Protocols in Human Genetics, (Hoboken, NJ, USA: John Wiley & Sons, 
Inc.), pp. 1.19.1–1.19.18. 
123. Laurie, C.C., Doheny, K.F., Mirel, D.B., Pugh, E.W., Bierut, L.J., Bhangale, 
T., Boehm, F., Caporaso, N.E., Cornelis, M.C., Edenberg, H.J., et al. (2010). 
Quality control and quality assurance in genotypic data for genome-wide 
association studies. Genet. Epidemiol. 34, 591–602. 
124. Sham, P.C., and Purcell, S.M. (2014). Statistical power and significance 
testing in large-scale genetic studies. Nat. Rev. Genet. 15, 335–346. 
125. Yu, J., Pressoir, G., Briggs, W.H., Vroh Bi, I., Yamasaki, M., Doebley, J.F., 
McMullen, M.D., Gaut, B.S., Nielsen, D.M., Holland, J.B., et al. (2005). A unified 
mixed-model method for association mapping that accounts for multiple levels 
of relatedness. Nat. Genet. 38, 203–208. 
126. Aulchenko, Y.S., de Koning, D.J., and Haley, C. (2007). Genomewide Rapid 
Association Using Mixed Model and Regression: A Fast and Simple Method For 
Genomewide Pedigree-Based Quantitative Trait Loci Association Analysis. 
Genetics 177, 577–585. 
127. Yang, J., Zaitlen, N.A., Goddard, M.E., Visscher, P.M., and Price, A.L. 
(2014). Advantages and pitfalls in the application of mixed-model association 
methods. Nat. Genet. 46, 100–106. 
128. Luft, F.C. (2001). Twins in Cardiovascular Genetic Research. Hypertension 
37, 350–356. 
129. Tobin, M.D., Tomaszewski, M., Braund, P.S., Hajat, C., Raleigh, S.M., 
Palmer, T.M., Caulfield, M., Burton, P.R., and Samani, N.J. (2008). Common 
variants in genes underlying monogenic hypertension and hypotension and blood 
pressure in the general population. Hypertension 51, 1658–1664. 
130. Baysal, B.E. (2008). Clinical and molecular progress in hereditary 
paraganglioma. J. Med. Genet. 45, 689–694. 
131. Burton, P.R., Clayton, D.G., Cardon, L.R., Duncanson, A., Kwiatkowski, 
D.P., Mccarthy, M.I., Barrett, J.C., Donnelly, P., Marchini, J.L., Morris, A.P., et 
al. (2007). Genome-wide association study of 14,000 cases of seven common 
diseases and 3,000 shared controls. Nature 447, 661–678. 
132. Levy, D., Larson, M.G., Benjamin, E.J., Newton-Cheh, C., Wang, T.J., 
Hwang, S.-J., Vasan, R.S., and Mitchell, G.F. (2007). Framingham Heart Study 
100K Project: genome-wide associations for blood pressure and arterial stiffness. 
BMC Med. Genet. 8, 1–11. 
133. Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M.D., Bochud, M., Coin, 
266 
 
L., Najjar, S.S., Zhao, J.H., Heath, S.C., Eyheramendy, S., et al. (2009). 
Genome-wide association study identifies eight loci associated with blood 
pressure. Nat. Genet. 41, 666–676. 
134. Newton-Cheh, C., Larson, M.G., Vasan, R.S., Levy, D., Bloch, K.D., Surti, 
A., Guiducci, C., Kathiresan, S., Benjamin, E.J., Struck, J., et al. (2009). 
Association of common variants in NPPA and NPPB with circulating natriuretic 
peptides and blood pressure. Nat. Genet. 41, 348–353. 
135. Wain, L.V., Verwoert, G.C., O'reilly, P.F., Shi, G., Johnson, T., Johnson, 
A.D., Bochud, M., Rice, K.M., Henneman, P., Smith, A.V., et al. (2011). 
Genome-wide association study identifies six new loci influencing pulse pressure 
and mean arterial pressure. Nat. Genet. 43, 1005–1011. 
136. Salvi, E., Kutalik, Z., Glorioso, N., Benaglio, P., Frau, F., Kuznetsova, T., 
Arima, H., Hoggart, C., Tichet, J., Nikitin, Y.P., et al. (2012). Genomewide 
association study using a high-density single nucleotide polymorphism array and 
case-control design identifies a novel essential hypertension susceptibility locus 
in the promoter region of endothelial NO synthase. Hypertension 59, 248–255. 
137. Kato, N., Takeuchi, F., Tabara, Y., Kelly, T.N., Go, M.J., Sim, X., Tay, 
W.T., Chen, C.-H., Zhang, Y., Yamamoto, K., et al. (2011). Meta-analysis of 
genome-wide association studies identifies common variants associated with 
blood pressure variation in east Asians. Nat. Genet. 43, 531–538. 
138. Franceschini, N., Fox, E., Zhang, Z., Edwards, T.L., Nalls, M.A., Sung, Y.J., 
Tayo, B.O., Sun, Y.V., Gottesman, O., Adeyemo, A., et al. (2013). Genome-wide 
association analysis of blood-pressure traits in African-ancestry individuals 
reveals common associated genes in African and non-African populations. Am. J. 
Hum. Genet. 93, 545–554. 
139. Lu, X., Wang, L., Lin, X., Huang, J., Charles Gu, C., He, M., Shen, H., He, 
J., Zhu, J., Li, H., et al. (2015). Genome-wide association study in Chinese 
identifies novel loci for blood pressure and hypertension. Hum. Mol. Genet. 24, 
865–874. 
140. Ganesh, S.K., Chasman, D.I., Larson, M.G., Guo, X., Verwoert, G., Bis, 
J.C., Gu, X., Smith, A.V., Yang, M.-L., Zhang, Y., et al. (2014). Effects of Long-
Term Averaging of Quantitative Blood Pressure Traits on the Detection of 
Genetic Associations. Am. J. Hum. Genet. 95, 49–65. 
141. Yadav, S., Cotlarciuc, I., Munroe, P.B., Khan, M.S., Nalls, M.A., Bevan, S., 
Cheng, Y.-C., Chen, W.-M., Malik, R., McCarthy, N.S., et al. (2013). Genome-
wide analysis of blood pressure variability and ischemic stroke. Stroke 44, 2703–
2709. 
142. Tomaszewski, M., Debiec, R., Braund, P.S., Nelson, C.P., Hardwick, R., 
Christofidou, P., Denniff, M., Codd, V., Rafelt, S., Van Der Harst, P., et al. 
(2010). Genetic Architecture of Ambulatory Blood Pressure in the General 
Population: Insights From Cardiovascular Gene-Centric Array. Hypertension 56, 
1069–1076. 
143. Simino, J., Shi, G., Bis, J.C., Chasman, D.I., Ehret, G.B., Gu, X., Guo, X., 
Hwang, S.-J., Sijbrands, E., Smith, A.V., et al. (2014). Gene-age interactions in 
267 
 
blood pressure regulation: a large-scale investigation with the CHARGE, Global 
BPgen, and ICBP Consortia. Am. J. Hum. Genet. 95, 24–38. 
144. Simino, J., Sung, Y.J., Kume, R., Schwander, K., and Rao, D.C. (2013). 
Gene-alcohol interactions identify several novel blood pressure loci including a 
promising locus near SLC16A9. Front Genet 4, 277. 
145. Sung, Y.J., las Fuentes, de, L., Schwander, K.L., Simino, J., and Rao, D.C. 
(2015). Gene-smoking interactions identify several novel blood pressure loci in 
the Framingham Heart Study. Am. J. Hypertens. 28, 343–354. 
146. Basson, J., Sung, Y.J., Schwander, K., Kume, R., Simino, J., las Fuentes, 
de, L., and Rao, D. (2014). Gene-education interactions identify novel blood 
pressure Loci in the Framingham Heart Study. Am. J. Hypertens. 27, 431–444. 
147. Takeuchi, F., Isono, M., Katsuya, T., Yamamoto, K., Yokota, M., Sugiyama, 
T., Nabika, T., Fujioka, A., Ohnaka, K., Asano, H., et al. (2010). Blood Pressure 
and Hypertension Are Associated With 7 Loci in the Japanese Population. 
Circulation 121, 2302–2309. 
148. Ganesh, S.K., Tragante, V., Guo, W., Guo, Y., Lanktree, M.B., Smith, E.N., 
Johnson, T., Castillo, B.A., Barnard, J., Baumert, J., et al. (2013). Loci 
influencing blood pressure identified using a cardiovascular gene-centric array.  
Hum. Mol. Genet. 22, 1663–1678. 
149. Johnson, A.D., Newton-Cheh, C., Chasman, D.I., Ehret, G.B., Johnson, T., 
Rose, L., Rice, K., Verwoert, G.C., Launer, L.J., Gudnason, V., et al. (2011). 
Association of hypertension drug target genes with blood pressure and 
hypertension in 86,588 individuals. Hypertension 57, 903–910. 
150. Johnson, T., Gaunt, T.R., Newhouse, S.J., Padmanabhan, S., Tomaszewski, 
M., Kumari, M., Morris, R.W., Tzoulaki, I., O'Brien, E.T., Poulter, N.R., et al. 
(2011). Blood Pressure Loci Identified with a Gene-Centric Array. Am. J. Hum. 
Genet. 89, 688–700. 
151. Wang, Y., O’connell, J.R., McArdle, P.F., Wade, J.B., Dorff, S.E., Shah, 
S.J., Shi, X., Pan, L., Rampersaud, E., Shen, H., et al. (2009). Whole-genome 
association study identifies STK39 as a hypertension susceptibility gene. Proc. 
Natl. Acad. Sci. U.S.A. 106, 226–231. 
152. Tragante, V., Barnes, M.R., Ganesh, S.K., Lanktree, M.B., Guo, W., 
Franceschini, N., Smith, E.N., Johnson, T., Holmes, M.V., Padmanabhan, S., et 
al. (2014). Gene-centric meta-analysis in 87,736 individuals of European 
ancestry identifies multiple blood-pressure-related loci. Am. J. Hum. Genet. 94, 
349–360. 
153. Hong, K.-W., Min, H., Heo, B.-M., Joo, S.E., Kim, S.S., and Kim, Y. (2012). 
Recapitulation of genome-wide association studies on pulse pressure and mean 
arterial pressure in the Korean population. J. Hum. Genet. 57, 391–393. 
154. Kelly, T.N., Takeuchi, F., Tabara, Y., Edwards, T.L., Kim, Y.J., Chen, P., 
Li, H., Wu, Y., Yang, C.-F., Zhang, Y., et al. (2013). Genome-wide association 
study meta-analysis reveals transethnic replication of mean arterial and pulse 
pressure loci. Hypertension 62, 853–859. 
268 
 
155. Ho, J.E., Levy, D., Rose, L., Johnson, A.D., Ridker, P.M., and Chasman, D.I. 
(2011). Discovery and replication of novel blood pressure genetic loci in the 
Womenʼs Genome Health Study. J Hypertens 29, 62–69. 
156. Lin, Y., Lai, X., Chen, B., Xu, Y., Huang, B., Chen, Z., Zhu, S., Yao, J., 
Jiang, Q., Huang, H., et al. (2011). Genetic variations in CYP17A1, CACNB2 and 
PLEKHA7 are associated with blood pressure and/or hypertension in she ethnic 
minority of China. Atherosclerosis 219, 709–714. 
157. Lango Allen, H., Estrada, K., Lettre, G., Berndt, S.I., Weedon, M.N., 
Rivadeneira, F., Willer, C.J., Jackson, A.U., Vedantam, S., Raychaudhuri, S., et 
al. (2010). Hundreds of variants clustered in genomic loci and biological 
pathways affect human height. Nature 467, 832–838. 
158. Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., 
Hunter, D.J., Mccarthy, M.I., Ramos, E.M., Cardon, L.R., Chakravarti, A., et al. 
(2009). Finding the missing heritability of complex diseases. Nature 461, 747–
753. 
159. Yang, J., Benyamin, B., McEvoy, B.P., Gordon, S., Henders, A.K., Nyholt, 
D.R., Madden, P.A., Heath, A.C., Martin, N.G., Montgomery, G.W., et al. (2010). 
Common SNPs explain a large proportion of the heritability for human height. 
Nat. Genet. 42, 565–569. 
160. Vattikuti, S., Guo, J., and Chow, C.C. (2012). Heritability and genetic 
correlations explained by common SNPs for metabolic syndrome traits. PLoS 
Genet. 8, e1002637. 
161. MacRae, C.A., and Vasan, R.S. (2011). Next-generation genome-wide 
association studies: time to focus on phenotype? Circ Cardiovasc Genet 4, 334–
336. 
162. Kulminski, A.M., Culminskaya, I., Arbeev, K.G., Arbeeva, L., Ukraintseva, 
S.V., Stallard, E., Wu, D., and Yashin, A.I. (2015). Birth Cohort, Age, and Sex 
Strongly Modulate Effects of Lipid Risk Alleles Identified in Genome-Wide 
Association Studies. PLoS ONE 10, e0136319. 
163. Wray, N.R., Lee, S.H., and Kendler, K.S. (2012). Impact of diagnostic 
misclassification on estimation of genetic correlations using genome-wide 
genotypes. Eur. J. Hum. Genet. 20, 668–674. 
164. van der Sluis, S., Verhage, M., Posthuma, D., and Dolan, C.V. (2010). 
Phenotypic complexity, measurement bias, and poor phenotypic resolution 
contribute to the missing heritability problem in genetic association studies. PLoS 
ONE 5, e13929. 
165. Chasman, D.I., Paré, G., and Ridker, P.M. (2009). Population-based 
genomewide genetic analysis of common clinical chemistry analytes. Clin. Chem. 
55, 39–51. 
166. Bovet, P., Gervasoni, J.-P., Ross, A.G., Mkamba, M., Mtasiwa, D.M., 
Lengeler, C., Burnier, M., and Paccaud, F. (2003). Assessing the prevalence of 
hypertension in populations: are we doing it right? J Hypertens 21, 509–517. 
269 
 
167. Borecki, I.B., and Province, M.A. (2008). Genetic and genomic discovery 
using family studies. Circulation 118, 1057–1063. 
168. Krull, J.L. (2007). Using multilevel analyses with sibling data to increase 
analytic power: an illustration and simulation study. Dev Psychol 43, 602–619. 
169. McCartney, G., Russ, T.C., Walsh, D., Lewsey, J., Smith, M., Davey Smith, 
G., Stamatakis, E., and Batty, G.D. (2014). Explaining the excess mortality in 
Scotland compared with England: pooling of 18 cohort studies. J Epidemiol 
Community Health 69, jech–2014–204185–27. 
170. Generation Scotland. Available online: http://www.generationscotland.org 
171. Smith, B.H., Campbell, A., Linksted, P., Fitzpatrick, B., Jackson, C., Kerr, 
S.M., Deary, I.J., MacIntyre, D.J., Campbell, H., McGilchrist, M., et al. (2013). 
Cohort Profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). 
The study, its participants and their potential for genetic research on health and 
illness. Int J Epidemiol 42, 689–700. 
172. Smith, B.H., Campbell, H., Blackwood, D., Connell, J., Connor, M., Deary, 
I.J., Dominiczak, A.F., Fitzpatrick, B., Ford, I., Jackson, C., et al. (2006). 
Generation Scotland: the Scottish Family Health Study; a new resource for 
researching genes and heritability. BMC Med. Genet. 7, 1–9. 
173. Haddow, G., Cunningham-Burley, S., Bruce, A., and Parry, S. (2008). 
Generation Scotland: consulting publics and specialists at an early stage in a 
genetic database's development. Critical Public Health 18, 139–149. 
174. Haddow, G., Cunningham-Burley, S., Bruce, A., and Parry, S. (2004). 
Generation Scotland Preliminary Consultation Exercise 2003–04: Public and 
Stakeholder Views from Focus Groups and Interviews. Avilable online: 
http://www.innogen.ac.uk/working-papers/537 
175. Cui, J.S., Hopper, J.L., and Harrap, S.B. (2003). Antihypertensive 
Treatments Obscure Familial Contributions to Blood Pressure Variation. 
Hypertension 41, 207–210. 
176. Hunt, S.C., Ellison, R.C., Atwood, L.D., Pankow, J.S., Province, M.A., and 
Leppert, M.F. (2002). Genome scans for blood pressure and hypertension: the 
National Heart, Lung, and Blood Institute Family Heart Study. Hypertension 40, 
1–6. 
177. Joint Formulary Committee British National Formulary. Avilable online: 
https://www.medicinescomplete.com/mc/bnf/current/ 
178. Paganini-Hill, A., Paganini-Hill, A., ROSS, R.K., and Ross, R.K. (1982). 
Reliability of recall of drug usage and other health-related information. Am. J. 
Epidemiol. 116, 114–122. 
179. Monster, T.B.M., Janssen, W.M.T., De Jong, P.E., de Jong-van den Berg, 
L.T.W., PREVEND Study Group Prevention of REnal and Vascular ENT Stage 
Disease (2002). Pharmacy data in epidemiological studies: an easy to obtain and 
reliable tool. Pharmacoepidemiol Drug Saf 11, 379–384. 
270 
 
180. Haapea, M., Miettunen, J., Lindeman, S., Joukamaa, M., and Koponen, H. 
(2010). Agreement between self-reported and pharmacy data on medication use 
in the Northern Finland 1966 Birth Cohort. Int J Methods Psychiatr Res 19, 88–96. 
181. Lau, H.S., Lau, H.S., de Boer, A., de Boer, A., Beuning, K.S., Beuning, K.S., 
Porsius, A., and Porsius, A. (1997). Validation of pharmacy records in drug 
exposure assessment. J Clin Epidemiol 50, 619–625. 
182. Haukka, J., Haukka, J., Suvisaari, J., Suvisaari, J., Tuulio-Henriksson, A., 
Tuulio-Henriksson, A., Lönnqvist, J., and Lönnqvist, J. (2007). High concordance 
between self-reported medication and official prescription database 
information. Eur. J. Clin. Pharmacol. 63, 1069–1074. 
183. Nielsen, M.W., Nielsen, M.W., Søndergaard, B., Søndergaard, B., Kjøller, 
M., Kjøller, M., Hansen, E.H., and Hansen, E.H. (2008). Agreement between 
self-reported data on medicine use and prescription records vary according to 
method of analysis and therapeutic group. J Clin Epidemiol 61, 919–924. 
184. Scottish Executive Scottish Index of Multiple Deprivation: 2009 General 
Report. Avilable online: 
http://www.gov.scot/resource/doc/289599/0088642.pdf 
185. Kutyavin, I.V., Kutyavin, I.V., Afonina, I.A., Afonina, I.A., Mills, A., Mills, 
A., Gorn, V.V., Gorn, V.V., Lukhtanov, E.A., Lukhtanov, E.A., et al. (2000). 3'-
minor groove binder-DNA probes increase sequence specificity at PCR extension 
temperatures. Nucleic Acids Res. 28, 655–661. 
186. Livak, K.J., and Livak, K.J. (1999). Allelic discrimination using fluorogenic 
probes and the 5' nuclease assay. Genet. Anal. 14, 143–149. 
187. Livak, K.J., Flood, S.J., Marmaro, J., Giusti, W., and Deetz, K. (1995). 
Oligonucleotides with fluorescent dyes at opposite ends provide a quenched 
probe system useful for detecting PCR product and nucleic acid hybridization. 
PCR Methods Appl. 4, 357–362. 
188. Kim, S., and Misra, A. (2007). SNP Genotyping: Technologies and Biomedical 
Applications. Annu. Rev. Biomed. Eng. 9, 289–320. 
189. Ragoussis, J. (2009). Genotyping technologies for genetic research. Annu 
Rev Genomics Hum Genet 10, 117–133. 
190. Teo, Y.Y. (2008). Common statistical issues in genome-wide association 
studies: a review on power, data quality control, genotype calling and 
population structure. Curr. Opin. Lipidol. 19, 133–143. 
191. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R., 
Bender, D., Maller, J., Sklar, P., de Bakker, P.I.W., Daly, M.J., et al. (2007). 
PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage 
Analyses. Am. J. Hum. Genet. 81, 559–575. 
192. Abecasis, G.R., Cherny, S.S., Cookson, W.O., and Cardon, L.R. (2001). 
Merlin—rapid analysis of dense genetic maps using sparse gene flow trees. Nat. 
Genet. 30, 97–101. 
271 
 
193. Smith, J.G., and Newton-Cheh, C. (2009). Genome-Wide Association Study 
in Humans. In Ischemic Stroke in Mice and Rats, (Totowa, NJ: Humana Press), 
pp. 231–258. 
194. Wittke-Thompson, J.K., Pluzhnikov, A., and Cox, N.J. (2005). Rational 
inferences about departures from Hardy-Weinberg equilibrium. Am. J. Hum. 
Genet. 76, 967–986. 
195. Wigginton, J.E., Wigginton, J.E., and Abecasis, G.R. (2005). PEDSTATS: 
descriptive statistics, graphics and quality assessment for gene mapping data. 
Bioinformatics 21, 3445–3447. 
196. Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., 
Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014). The NHGRI GWAS 
Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, 
D1001–D1006. 
197. Hindorff, L.A., H, J., Absher, D., Hall, P., Klemm, A., and Manolio, T.A. A 
Catalog of Published Genome-Wide Association Studies. Avilable online: 
http://www.ebi.ac.uk/gwas/ 
198. Johnson, A.D., Handsaker, R.E., Pulit, S.L., Nizzari, M.M., O'donnell, C.J., 
and de Bakker, P.I.W. (2008). SNAP: a web-based tool for identification and 
annotation of proxy SNPs using HapMap. Bioinformatics 24, 2938–2939. 
199. Adeyemo, A., Gerry, N., Chen, G., Herbert, A., Doumatey, A., Huang, H., 
Zhou, J., Lashley, K., Chen, Y., Christman, M., et al. (2009). A Genome-Wide 
Association Study of Hypertension and Blood Pressure in African Americans. PLoS 
Genet. 5, e1000564. 
200. Welch, C., Petersen, I., Walters, K., Morris, R.W., Nazareth, I., Kalaitzaki, 
E., White, I.R., Marston, L., and Carpenter, J. (2012). Two-stage method to 
remove population- and individual-level outliers from longitudinal data in a 
primary care database. Pharmacoepidemiol Drug Saf 21, 725–732. 
201. Wickham, H. (2009). ggplot2: Elegant Graphics for Data Analysis (New York: 
Springer). 
202. Goldberg, S.I., Niemierko, A., and Turchin, A. (2008). Analysis of data 
errors in clinical research databases. AMIA Annu Symp Proc 2008, 242–246. 
203. Kerr, S.M., Campbell, A., Murphy, L., Hayward, C., Jackson, C., Wain, L.V., 
Tobin, M.D., Dominiczak, A., Morris, A., Smith, B.H., et al. (2013). Pedigree and 
genotyping quality analyses of over 10,000 DNA samples from the Generation 
Scotland: Scottish Family Health Study. BMC Med. Genet. 14, 1–7. 
204. Klungel, O.H., de Boer, A., Paes, A.H., Herings, R.M., Seidell, J.C., and 
Bakker, A. (2000). Influence of question structure on the recall of self-reported 
drug use. J Clin Epidemiol 53, 273–277. 
205. West, S.L., Ritchey, M.E., and Poole, C. (2013). Validity of 
Pharmacoepidemiologic Drug and Diagnosis Data. In Textbook of 
Pharmacoepidemiology, (Chichester, UK: John Wiley & Sons Ltd), pp. 203–227. 
272 
 
206. Schneeweiss, S., and Avorn, J. (2005). A review of uses of health care 
utilization databases for epidemiologic research on therapeutics. J Clin 
Epidemiol 58, 323–337. 
207. McCartney, G., Walsh, D., Whyte, B., and Collins, C. (2012). Has Scotland 
always been the “sick man” of Europe? An observational study from 1855 to 
2006. Eur J Public Health 22, 756–760. 
208. Hanlon, P., Lawder, R.S., Buchanan, D., Redpath, A., Walsh, D., Wood, R., 
Bain, M., Brewster, D.H., and Chalmers, J. (2005). Why is mortality higher in 
Scotland than in England and Wales? Decreasing influence of socioeconomic 
deprivation between 1981 and 2001 supports the existence of a “Scottish 
Effect.” Journal of Public Health 27, 199–204. 
209. Landis, J.R., and Koch, G.G. (1977). The measurement of observer 
agreement for categorical data. Biometrics 33, 159–174. 
210. Byrt, T., Bishop, J., and Carlin, J.B. (1993). Bias, prevalence and kappa. J 
Clin Epidemiol 46, 423–429. 
211. Sim, J., and Wright, C.C. (2005). The kappa statistic in reliability studies: 
use, interpretation, and sample size requirements. Phys Ther 85, 257–268. 
212. Feinstein, A.R., and Cicchetti, D.V. (1990). High agreement but low kappa: 
I. The problems of two paradoxes. J Clin Epidemiol 43, 543–549. 
213. Hoehler, F.K. (2000). Bias and prevalence effects on kappa viewed in terms 
of sensitivity and specificity. J Clin Epidemiol 53, 499–503. 
214. Cicchetti, D.V., and Feinstein, A.R. (1990). High agreement but low kappa: 
II. Resolving the paradoxes. J Clin Epidemiol 43, 551–558. 
215. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., 
Izzo, J.L., Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T., et al. (2003). 
Seventh report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206–1252. 
216. Diez-Roux, A.V. (2000). Multilevel Analysis in Public Health Research. Annu. 
Rev. Public. Health. 21, 171–192. 
217. Bates, D., Maechler, M., Ben Bolker, and Walker, S. (2014). lme4: Linear 
mixed-effects models using Eigen and S4. R package version 1.1-7. 
218. Richardson, K., Kenny, R.A., Peklar, J., and Bennett, K. (2013). Agreement 
between patient interview data on prescription medication use and pharmacy 
records in those aged older than 50 years varied by therapeutic group and 
reporting of indicated health conditions. J Clin Epidemiol 66, 1308–1316. 
219. Caskie, G.I.L., Willis, S.L., Warner Schaie, K., and Zanjani, F.A.K. (2005). 
Congruence of medication information from a brown bag data collection and 
pharmacy records: findings from the Seattle longitudinal study. Exp Aging Res 
32, 79–103. 
220. Klungel, O.H., de Boer, A., Paes, A.H.P., Herings, R.M.C., Seidell, J.C., and 
273 
 
Bakker, A. (1999). Agreement between self-reported antihypertensive drug use 
and pharmacy records in a population-based study in The Netherlands. Pharm 
World Sci 21, 217–220. 
221. Boudreau, D.M., Daling, J.R., Malone, K.E., Gardner, J.S., Blough, D.K., 
and Heckbert, S.R. (2004). A validation study of patient interview data and 
pharmacy records for antihypertensive, statin, and antidepressant medication 
use among older women. Am. J. Epidemiol. 159, 308–317. 
222. Caskie, G.I.L., and Willis, S.L. (2004). Congruence of self-reported 
medications with pharmacy prescription records in low-income older adults. 
Gerontologist 44, 176–185. 
223. Gama, H., Correia, S., and Lunet, N. (2009). Questionnaire design and the 
recall of pharmacological treatments: a systematic review. Pharmacoepidemiol 
Drug Saf 18, 175–187. 
224. Wolf-Maier, K., Cooper, R.S., Banegas, J.R., Giampaoli, S., Hense, H.-W., 
Joffres, M., Kastarinen, M., Poulter, N., Primatesta, P., Rodríguez-Artalejo, F., 
et al. (2003). Hypertension Prevalence and Blood Pressure Levels in 6 European 
Countries, Canada, and the United States. JAMA 289, 2363–2369. 
225. Joffres, M.R., Campbell, N.R.C., Manns, B., and Tu, K. (2007). Estimate of 
the benefits of a population-based reduction in dietary sodium additives on 
hypertension and its related health care costs in Canada. Can J Cardiol 23, 437–
443. 
226. Polonia, J., Martins, L., Pinto, F., and Nazare, J. (2014). Prevalence, 
awareness, treatment and control of hypertension and salt intake in Portugal: 
changes over a decade. The PHYSA study. J Hypertens 32, 1211–1221. 
227. Hammouche, S., and Holland, R. (2011). Does quality of care for 
hypertension in primary care vary with postcode area deprivation? An 
observational study. BMC Health Services Research 11, 297. 
228. Ashworth, M., Medina, J., and Morgan, M. (2008). Effect of social 
deprivation on blood pressure monitoring and control in England: a survey of 
data from the quality and outcomes framework. BMJ 337, a2030. 
229. MONGEAU, J.G., BIRON, P., and Sing, C.F. (2009). The Influence of 
Genetics and Household Environment upon the Variability of Normal Blood 
Pressure: The Montreal Adoption Survey. Clinical and Experimental 
Hypertension. Part a: Theory and Practice 8, 653–660. 
230. Harrap, S.B., Stebbing, M., Hopper, J.L., Hoang, H.N., and Giles, G.G. 
(2000). Familial patterns of covariation for cardiovascular risk factors in adults: 
The Victorian Family Heart Study. Am. J. Epidemiol. 152, 704–715. 
231. Hunt, S.C., Williams, R.R., and Barlow, G.K. (1986). A comparison of 
positive family history definitions for defining risk of future disease. J Chronic 
Dis 39, 809–821. 
232. Daniels, P.R., Kardia, S.L.R., Hanis, C.L., Brown, C.A., Hutchinson, R., 
Boerwinkle, E., Turner, S.T., Genetic Epidemiology Network of Arteriopathy 
274 
 
study (2004). Familial aggregation of hypertension treatment and control in the 
Genetic Epidemiology Network of Arteriopathy (GENOA) study. Am. J. Med. 116, 
676–681. 
233. van Rijn, M.J.E., Schut, A.F.C., Aulchenko, Y.S., Deinum, J., Sayed-
Tabatabaei, F.A., Yazdanpanah, M., Isaacs, A., Axenovich, T.I., Zorkoltseva, 
I.V., Zillikens, M.C., et al. (2007). Heritability of blood pressure traits and the 
genetic contribution to blood pressure variance explained by four blood-
pressure-related genes. J Hypertens 25, 565–570. 
234. Alwan, H., Ehret, G., Ponte, B., Pruijm, M., Ackermann, D., Guessous, I., 
Staessen, J.A., Asayama, K., Kutalik, Z., Vuistiner, P., et al. (2015). Heritability 
of ambulatory and office blood pressure in the Swiss population. J Hypertens 33, 
2061–2067. 
235. Mitchell, G.F., Destefano, A.L., Larson, M.G., Benjamin, E.J., Chen, M.-H., 
Vasan, R.S., Vita, J.A., and Levy, D. (2005). Heritability and a genome-wide 
linkage scan for arterial stiffness, wave reflection, and mean arterial pressure: 
the Framingham Heart Study. Circulation 112, 194–199. 
236. Fava, C., Burri, P., Almgren, P., Groop, L., Hulthén, U.L., and Melander, O. 
(2004). Heritability of ambulatory and office blood pressure phenotypes in 
Swedish families. J Hypertens 22, 1717–1721. 
237. Wang, X., and Snieder, H. (2013). Familial Aggregation of Blood Pressure. In 
Pediatric Hypertension, (Totowa, NJ: Humana Press), pp. 195–209. 
238. Wang, X., Ding, X., Su, S., Yan, W., Harshfield, G., Treiber, F., and 
Snieder, H. (2009). Genetic influences on daytime and night-time blood 
pressure: similarities and differences. J Hypertens 27, 2358–2364. 
239. Kupper, N., Willemsen, G., Riese, H., Posthuma, D., Boomsma, D.I., and de 
Geus, E.J.C. (2004). Heritability of Daytime Ambulatory Blood Pressure in an 
Extended Twin Design. Hypertension 45, 80–85. 
240. Bochud, M. (2011). Estimating Heritability from Nuclear Family and 
Pedigree Data. In Methods in Molecular Biology, (Totowa, NJ: Humana Press), 
pp. 171–186. 
241. Caulfield, M., Munroe, P., Pembroke, J., Samani, N., Dominiczak, A., 
Brown, M., Benjamin, N., Webster, J., Ratcliffe, P., O'Shea, S., et al. (2003). 
Genome-wide mapping of human loci for essential hypertension. Lancet 361, 
2118–2123. 
242. Wang, X., and Zhang, H. (2001). Ascertainment in Genetics Studies. In 
Encyclopedia of Life Sciences. John Wiley & Sons, Ltd, Chichester. Available 
online: http://www.els.net/. 
243. Olson, J.M., and Cordell, H.J. (2000). Ascertainment bias in the estimation 
of sibling genetic risk parameters. Genet. Epidemiol. 18, 217–235. 
244. S.A.G.E (2012). Statistical Analysis for Genetic Epidemiology. 
245. Almasy, L., and Blangero, J. (1998). Multipoint quantitative-trait linkage 
275 
 
analysis in general pedigrees. Am. J. Hum. Genet. 62, 1198–1211. 
246. Fermino, R.C., Seabra, A., Garganta, R., and Maia, J.A.R. (2009). Genetic 
factors in familial aggregation of blood pressure of Portuguese nuclear families. 
Arq. Bras. Cardiol. 92, 199–204. 
247. Fuentes, R.M., Notkola, I.L., Shemeikka, S., Tuomilehto, J., and Nissinen, 
A. (2000). Familial aggregation of blood pressure: a population-based family 
study in eastern Finland. J Hum Hypertens 14, 441–445. 
248. Saunders, C.L., and Gulliford, M.C. (2006). Heritabilities and shared 
environmental effects were estimated from household clustering in national 
health survey data. J Clin Epidemiol 59, 1191–1198. 
249. Hu, Y., He, L., Wu, Y., Ma, G., Li, L., and Hu, Y. (2013). Familial 
correlation and aggregation of body mass index and blood pressure in Chinese 
Han population. BMC Public Health 13, 686. 
250. van Dongen, J., Willemsen, G., Chen, W.-M., De Geus, E.J.C., and 
Boomsma, D.I. (2013). Heritability of metabolic syndrome traits in a large 
population-based sample. J. Lipid Res. 54, 2914–2923. 
251. Pilia, G., Chen, W., Scuteri, A., Orru, M., Albai, G., Dei, M., Lai, S., Usala, 
G., Lai, M., Loi, P., et al. (2005). Heritability of Cardiovascular and Personality 
Traits in 6,148 Sardinians. PLoS Genet. preprint, e132. 
252. Allison, D.B., Neale, M.C., Kezis, M.I., Alfonso, V.C., Heshka, S., and 
Heymsfield, S.B. (1996). Assortative mating for relative weight: Genetic 
implications. Behav Genet 26, 103–111. 
253. Kwagyan, J., Tabe, C.E., Xu, S., Maqbool, A.R., Gordeuk, V.R., and 
Randall, O.S. (2005). The impact of body mass index on pulse pressure in 
obesity. J Hypertens 23, 619–624. 
254. Jelenkovic, A., Poveda, A., and Rebato, E. (2010). A statistical 
investigation into the sharing of common genetic factors between blood pressure 
and obesity phenotypes in nuclear families from the Greater Bilbao (Spain). J 
Hypertens 28, 723–731. 
255. Biino, G., Parati, G., Concas, M.P., Adamo, M., Angius, A., Vaccargiu, S., 
and Pirastu, M. (2013). Environmental and genetic contribution to hypertension 
prevalence: data from an epidemiological survey on Sardinian genetic isolates. 
PLoS ONE 8, e59612. 
256. Wu, T., Snieder, H., Li, L., Cao, W., Zhan, S., Lv, J., Gao, W., Wang, X., 
Ding, X., and Hu, Y. (2011). Genetic and environmental influences on blood 
pressure and body mass index in Han Chinese: a twin study. Hypertension 
Research 34, 173–179. 
257. Marioni, R.E., Davies, G., Hayward, C., Liewald, D., Kerr, S.M., Campbell, 
A., Luciano, M., Smith, B.H., Padmanabhan, S., Hocking, L.J., et al. (2014). 
Molecular genetic contributions to socioeconomic status and intelligence. 
Intelligence 44, 26–32. 
276 
 
258. Dubay, C., Vincent, M., Samani, N.J., Hilbert, P., Kaiser, M.A., Beressi, 
J.P., Kotelevtsev, Y., Beckmann, J.S., Soubrier, F., and Sassard, J. (1993). 
Genetic determinants of diastolic and pulse pressure map to different loci in 
Lyon hypertensive rats. Nat. Genet. 3, 354–357. 
259. Llamas, B., Lau, C., Cupples, W.A., Rainville, M.-L., Souzeau, E., and 
Deschepper, C.F. (2006). Genetic determinants of systolic and pulse pressure in 
an intercross between normotensive inbred rats. Hypertension 48, 921–926. 
260. Cui, J., Hopper, J.L., and Harrap, S.B. (2002). Genes and Family 
Environment Explain Correlations Between Blood Pressure and Body Mass Index. 
Hypertension 40, 7–12. 
261. Tarnoki, A.D., Tarnoki, D.L., Bogl, L.H., Medda, E., Fagnani, C., Nisticò, L., 
Stazi, M.A., Brescianini, S., Lucatelli, P., Boatta, E., et al. (2013). Association of 
body mass index with arterial stiffness and blood pressure components: a twin 
study. Atherosclerosis 229, 388–395. 
262. Guttmacher, A.E., Collins, F.S., and Carmona, R.H. (2004). The Family 
History — More Important Than Ever. N. Engl. J. Med. 351, 2333–2336. 
263. Havulinna, A.S., Kettunen, J., Ukkola, O., Osmond, C., Eriksson, J.G., 
Kesäniemi, Y.A., Jula, A., Peltonen, L., Kontula, K., Salomaa, V., et al. (2013). 
A blood pressure genetic risk score is a significant predictor of incident 
cardiovascular events in 32 669 individuals. Hypertension 61, 987–994. 
264. Lu, X., Huang, J., Wang, L., Chen, S., Yang, X., Li, J., Cao, J., Chen, J., Li, 
Y., Zhao, L., et al. (2015). Genetic Predisposition to Higher Blood Pressure 
Increases Risk of Incident Hypertension and Cardiovascular Diseases in Chinese. 
Hypertension 66, 786–792. 
265. Manichaikul, A., Chen, W.-M., Williams, K., Wong, Q., Sale, M.M., Pankow, 
J.S., Tsai, M.Y., Rotter, J.I., Rich, S.S., and Mychaleckyj, J.C. (2012). Analysis 
of family- and population-based samples in cohort genome-wide association 
studies. Hum. Genet. 131, 275–287. 
266. Zhang, Z., Ersoz, E., Lai, C.-Q., Todhunter, R.J., Tiwari, H.K., Gore, M.A., 
Bradbury, P.J., Yu, J., Arnett, D.K., Ordovas, J.M., et al. (2010). Mixed linear 
model approach adapted for genome-wide association studies. Nat. Genet. 42, 
355–360. 
267. Kang, H.M., Sul, J.H., Service, S.K., Zaitlen, N.A., Kong, S.-Y., Freimer, 
N.B., Sabatti, C., and Eskin, E. (2010). Variance component model to account 
for sample structure in genome-wide association studies. Nat. Genet. 42, 348–
354. 
268. Zhou, X., and Stephens, M. (2012). Genome-wide efficient mixed-model 
analysis for association studies. Nat. Genet. 44, 821–824. 
269. Sinnwell, J.P., Therneau, T.M., and Schaid, D.J. (2014). The kinship2 R 
package for pedigree data. Hum Hered 78, 91–93. 
270. Chen, W.-M., Manichaikul, A., and Rich, S.S. (2009). A Generalized Family-
Based Association Test for Dichotomous Traits. Am. J. Hum. Genet. 85, 364–376. 
277 
 
271. Zois, N.E., Bartels, E.D., Hunter, I., Kousholt, B.S., Olsen, L.H., and 
Goetze, J.P. (2014). Natriuretic peptides in cardiometabolic regulation and 
disease. Nat Rev Cardiol 11, 403–412. 
272. Arora, P., Wu, C., Khan, A.M., Bloch, D.B., Davis-Dusenbery, B.N., 
Ghorbani, A., Spagnolli, E., Martinez, A., Ryan, A., Tainsh, L.T., et al. (2013). 
Atrial natriuretic peptide is negatively regulated by microRNA-425. J. Clin. 
Invest. 123, 3378–3382. 
273. Gong, Y., McDonough, C.W., Wang, Z., Hou, W., Cooper-Dehoff, R.M., 
Langaee, T.Y., Beitelshees, A.L., Chapman, A.B., Gums, J.G., Bailey, K.R., et 
al. (2012). Hypertension Susceptibility Loci and Blood Pressure Response to 
Antihypertensives: Results From the Pharmacogenomic Evaluation of 
Antihypertensive Responses Study. Circ Cardiovasc Genet 5, 686–691. 
274. Zhu, X., Young, J.H., Fox, E., Keating, B.J., Franceschini, N., Kang, S., 
Tayo, B., Adeyemo, A., Sun, Y.V., Li, Y., et al. (2011). Combined admixture 
mapping and association analysis identifies a novel blood pressure genetic locus 
on 5p13: contributions from the CARe consortium.  Hum. Mol. Genet. 20, 2285–
2295. 
275. Antzelevitch, C., Pollevick, G.D., Cordeiro, J.M., Casis, O., Sanguinetti, 
M.C., Aizawa, Y., Guerchicoff, A., Pfeiffer, R., Oliva, A., Wollnik, B., et al. 
(2007). Loss-of-function mutations in the cardiac calcium channel underlie a 
new clinical entity characterized by ST-segment elevation, short QT intervals, 
and sudden cardiac death. Circulation 115, 442–449. 
276. Niu, Y., Gong, Y., Langaee, T.Y., Davis, H.M., Elewa, H., Beitelshees, A.L., 
Moss, J.I., Cooper-Dehoff, R.M., Pepine, C.J., and Johnson, J.A. (2010). Genetic 
variation in the beta2 subunit of the voltage-gated calcium channel and 
pharmacogenetic association with adverse cardiovascular outcomes in the 
INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-
GENES). Circ Cardiovasc Genet 3, 548–555. 
277. Palatini, P., Ceolotto, G., Ragazzo, F., Dorigatti, F., Saladini, F., 
Papparella, I., Mos, L., Zanata, G., and Santonastaso, M. (2009). CYP1A2 
genotype modifies the association between coffee intake and the risk of 
hypertension. J Hypertens 27, 1594–1601. 
278. Guessous, I., Dobrinas, M., Kutalik, Z., Pruijm, M., Ehret, G., Maillard, M., 
Bergmann, S., Beckmann, J.S., Cusi, D., Rizzi, F., et al. (2012). Caffeine intake 
and CYP1A2 variants associated with high caffeine intake protect non-smokers 
from hypertension.  Hum. Mol. Genet. 21, 3283–3292. 
279. Bochud, M., Chiolero, A., Elston, R.C., and Paccaud, F. (2008). A cautionary 
note on the use of Mendelian randomization to infer causation in observational 
epidemiology. Int J Epidemiol 37, 414–416. 
280. Guessous, I., Eap, C.B., and Bochud, M. (2014). Blood Pressure in Relation 
to Coffee and Caffeine Consumption. Curr. Hypertens. Rep. 16, 1–9. 
281. Ueyama, C., Horibe, H., Yamase, Y., Fujimaki, T., Oguri, M., Kato, K., 
Arai, M., Watanabe, S., Murohara, T., and Yamada, Y. (2015). Association of 
FURIN and ZPR1 polymorphisms with metabolic syndrome. Biomed Rep 3, 641–
278 
 
647. 
282. Turpeinen, H., Seppälä, I., Lyytikäinen, L.-P., Raitoharju, E., Hutri-
Kähönen, N., Levula, M., Oksala, N., Waldenberger, M., Klopp, N., Illig, T., et 
al. (2015). A genome-wide expression quantitative trait loci analysis of 
proprotein convertase subtilisin/kexin enzymes identifies a novel regulatory 
gene variant for FURIN expression and blood pressure. Hum. Genet. 134, 627–
636. 
283. Cousin, C., Bracquart, D., Contrepas, A., Corvol, P., Muller, L., and 
Nguyen, G. (2009). Soluble form of the (pro)renin receptor generated by 
intracellular cleavage by furin is secreted in plasma. Hypertension 53, 1077–
1082. 
284. Ichihara, A., Sakoda, M., Kurauchi-Mito, A., Narita, T., Kinouchi, K., 
Murohashi-Bokuda, K., and Itoh, H. (2010). Possible roles of human (pro)renin 
receptor suggested by recent clinical and experimental findings. Hypertension 
Research 33, 177–180. 
285. Gudbjartsson, D.F., Holm, H., Indridason, O.S., Thorleifsson, G., 
Edvardsson, V., Sulem, P., de Vegt, F., d'Ancona, F.C.H., Heijer, den, M., 
Wetzels, J.F.M., et al. (2010). Association of variants at UMOD with chronic 
kidney disease and kidney stones-role of age and comorbid diseases. PLoS 
Genet. 6, e1001039. 
286. Köttgen, A., Hwang, S.-J., Larson, M.G., Van Eyk, J.E., Fu, Q., Benjamin, 
E.J., Dehghan, A., Glazer, N.L., Kao, W.H.L., Harris, T.B., et al. (2010). 
Uromodulin levels associate with a common UMOD variant and risk for incident 
CKD. J. Am. Soc. Nephrol. 21, 337–344. 
287. Graham, L.A., Padmanabhan, S., Fraser, N.J., Kumar, S., Bates, J.M., Raffi, 
H.S., Welsh, P., Beattie, W., Hao, S., Leh, S., et al. (2014). Validation of 
uromodulin as a candidate gene for human essential hypertension. Hypertension 
63, 551–558. 
288. Trudu, M., Janas, S., Lanzani, C., Debaix, H., Schaeffer, C., Ikehata, M., 
Citterio, L., Demaretz, S., Trevisani, F., Ristagno, G., et al. (2013). Common 
noncoding UMOD gene variants induce salt-sensitive hypertension and kidney 
damage by increasing uromodulin expression. Nat Med 19, 1655–1660. 
289. Grochowski, C.M., Loomes, K.M., and Spinner, N.B. (2016). Jagged1 (JAG1): 
Structure, expression, and disease associations. Gene 576, 381–384. 
290. Turner, S.T., Boerwinkle, E., O’connell, J.R., Bailey, K.R., Gong, Y., 
Chapman, A.B., McDonough, C.W., Beitelshees, A.L., Schwartz, G.L., Gums, 
J.G., et al. (2013). Genomic association analysis of common variants influencing 
antihypertensive response to hydrochlorothiazide. Hypertension 62, 391–397. 
291. Franklin, S.S., Gustin, W., Wong, N.D., Larson, M.G., Weber, M.A., Kannel, 
W.B., and Levy, D. (1997). Hemodynamic patterns of age-related changes in 
blood pressure. The Framingham Heart Study. Circulation 96, 308–315. 
292. Masca, N., Sheehan, N.A., and Tobin, M.D. (2010). Pharmacogenetic 
interactions and their potential effects on genetic analyses of blood pressure. 
279 
 
Statist. Med. 30, 769–783. 
293. Global Lipids Genetics Consortium, Willer, C.J., Schmidt, E.M., Sengupta, 
S., Peloso, G.M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., Buchkovich, 
M.L., et al. (2013). Discovery and refinement of loci associated with lipid levels. 
Nat Genet 45, 1274–1283. 
294. Speliotes, E.K., Willer, C.J., Berndt, S.I., Monda, K.L., Thorleifsson, G., 
Jackson, A.U., Lango Allen, H., Lindgren, C.M., Luan, J., Mägi, R., et al. (2010). 
Association analyses of 249,796 individuals reveal 18 new loci associated with 
body mass index. Nat Genet 42, 937–948. 
295. Fava, C., Sjögren, M., Montagnana, M., Danese, E., Almgren, P., Engström, 
G., Nilsson, P., Hedblad, B., Guidi, G.C., Minuz, P., et al. (2013). Prediction of 
blood pressure changes over time and incidence of hypertension by a genetic 
risk score in Swedes. Hypertension 61, 319–326. 
296. Fava, C., Sjögren, M., Olsson, S., Lövkvist, H., Jood, K., Engström, G., 
Hedblad, B., Norrving, B., Jern, C., Lindgren, A., et al. (2015). A genetic risk 
score for hypertension associates with the risk of ischemic stroke in a Swedish 
case-control study. Eur. J. Hum. Genet. 23, 969–974. 
297. Lim, N.-K., Lee, J.-Y., Lee, J.-Y., Park, H.-Y., and Cho, M.-C. (2015). The 
Role of Genetic Risk Score in Predicting the Risk of Hypertension in the Korean 
population: Korean Genome and Epidemiology Study. PLoS ONE 10, e0131603. 
298. Visscher, P.M., and Duffy, D.L. (2006). The value of relatives with 
phenotypes but missing genotypes in association studies for quantitative traits. 
Genet. Epidemiol. 30, 30–36. 
299. Yang, J., Lee, S.H., Goddard, M.E., and Visscher, P.M. (2011). GCTA: A Tool 
for Genome-wide Complex Trait Analysis. Am. J. Hum. Genet. 88, 76–82. 
300. Robinson, M.R., Wray, N.R., and Visscher, P.M. (2014). Explaining 
additional genetic variation in complex traits. Trends in Genetics 30, 124–132. 
301. Bochud, M., Bovet, P., Elston, R.C., Paccaud, F., Falconnet, C., Maillard, 
M., Shamlaye, C., and Burnier, M. (2005). High heritability of ambulatory blood 
pressure in families of East African descent. Hypertension 45, 445–450. 
302. Hottenga, J.-J., Boomsma, D.I., Kupper, N., Posthuma, D., Snieder, H., 
Willemsen, G., and De Geus, E.J.C. (2005). Heritability and Stability of Resting 
Blood Pressure. Twin Res Hum Genet 8, 499–508. 
303. O'reilly, P.F., Hoggart, C.J., Pomyen, Y., Calboli, F.C.F., Elliott, P., 
Järvelin, M.-R., and Coin, L.J.M. (2012). MultiPhen: joint model of multiple 
phenotypes can increase discovery in GWAS. PLoS ONE 7, e34861. 
304. Perry, J.R.B., Voight, B.F., Yengo, L., Amin, N., Dupuis, J., Ganser, M., 
Grallert, H., Navarro, P., Li, M., Qi, L., et al. (2012). Stratifying Type 2 Diabetes 
Cases by BMI Identifies Genetic Risk Variants in LAMA1 and Enrichment for Risk 
Variants in Lean Compared to Obese Cases. PLoS Genet. 8, e1002741. 
 
